0000950170-24-073330.txt : 20240614 0000950170-24-073330.hdr.sgml : 20240614 20240614071805 ACCESSION NUMBER: 0000950170-24-073330 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20240430 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: enGene Holdings Inc. CENTRAL INDEX KEY: 0001980845 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41854 FILM NUMBER: 241043142 BUSINESS ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 BUSINESS PHONE: (514) 332-4888 MAIL ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 10-Q 1 engn-20240430.htm 10-Q 10-Q
falseQ2000198084500-0000000UnlimitedUnlimitedUnlimitedUnlimitedhttp://engene.com/20240430#ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitieshttp://engene.com/20240430#ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitieshttp://engene.com/20240430#ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesUnlimitedUnlimited30001980845engn:ClassASecondTrancheMemberengn:ClassARedeemableConvertiblePreferredSharesMember2013-07-262013-07-260001980845engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember2023-01-3100019808452024-01-310001980845engn:ClassCRedeemableConvertiblePreferredSharesMember2023-04-300001980845us-gaap:EmployeeStockOptionMember2023-11-012024-04-3000019808452022-11-012023-10-310001980845engn:Rule10B51TradingPlanMemberengn:AnthonyCheungMember2024-04-190001980845us-gaap:ResearchAndDevelopmentExpenseMember2020-04-102020-04-100001980845engn:TermLoanMember2024-04-300001980845engn:AmendedLoanAgreementMember2023-12-222023-12-220001980845us-gaap:EmployeeStockOptionMember2024-02-012024-04-300001980845us-gaap:CommonStockMember2023-04-300001980845engn:OldEngenesShareOptionHoldersMember2023-10-310001980845us-gaap:LeaseholdImprovementsMember2023-10-310001980845us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-11-012024-04-300001980845us-gaap:RetainedEarningsMember2023-11-012024-01-310001980845engn:Series2ClassCRedeemableConvertiblePreferredMember2024-04-300001980845us-gaap:RetainedEarningsMember2022-11-012023-01-310001980845engn:AmendedLoanAgreementMemberengn:TermLoanMember2024-04-300001980845us-gaap:SoftwareDevelopmentMember2023-10-310001980845engn:TwoZeroTwoThreeFinancingMember2023-06-300001980845engn:AmendedLoanAgreementMemberengn:TermLoanMemberengn:TrancheThreeAdvanceMember2023-12-220001980845engn:OfficeAndLabSpaceMember2023-04-012023-04-300001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2023-02-012023-04-300001980845us-gaap:RetainedEarningsMember2023-10-310001980845engn:ClassBRedeemableConvertiblePreferredSharesMember2023-01-310001980845engn:ClassCInitialClosingMemberengn:Series3ClassCRedeemableConvertiblePreferredMember2021-06-302021-06-300001980845engn:OfficeAndLabSpaceMember2022-10-012022-10-310001980845engn:LoanAndSecurityAgreementsMemberus-gaap:SeriesCPreferredStockMemberengn:OldHerculesWarrantsMember2022-06-300001980845engn:ClassCWarrantsMember2021-06-300001980845engn:AnthonyCheungMemberengn:Rule10B51TradingPlanOneMember2024-04-190001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2021-12-302021-12-300001980845us-gaap:RetainedEarningsMember2024-01-310001980845engn:CeoTransitionAgreementMember2024-02-132024-02-130001980845us-gaap:EmployeeStockOptionMember2024-02-012024-04-300001980845engn:OfficeSpaceMember2024-01-012024-01-010001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2024-04-300001980845engn:ClassBThirdTrancheMemberengn:ClassBRedeemableConvertiblePreferredSharesMember2015-01-060001980845us-gaap:RetainedEarningsMember2023-04-300001980845srt:MaximumMemberengn:TheOldPlansMemberus-gaap:EmployeeStockOptionMember2018-07-052018-07-050001980845us-gaap:EmployeeStockOptionMember2023-02-012023-04-300001980845us-gaap:GeneralAndAdministrativeExpenseMember2023-02-012023-04-300001980845us-gaap:RetainedEarningsMember2024-04-300001980845us-gaap:ComputerEquipmentMember2023-10-310001980845us-gaap:RetainedEarningsMember2022-10-310001980845engn:OldHerculesWarrantsMember2024-04-300001980845engn:AmendedLoanAgreementMemberengn:TermLoanMemberengn:TrancheThreeAdvanceMember2023-12-222023-12-220001980845engn:ClassBRedeemableConvertiblePreferredSharesMember2023-04-300001980845engn:IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMemberengn:AmendedLoanAgreementMemberengn:TermLoanMember2023-12-222023-12-220001980845engn:SharesReservedForFutureIssuanceUnderTheEquityPlansMember2024-04-300001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2024-02-012024-04-300001980845engn:MergerAgreementMember2023-10-312023-10-310001980845engn:FEACMember2023-05-162023-05-160001980845us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-300001980845engn:TwentyTwentyTwoNotesMember2022-11-012023-04-300001980845us-gaap:WarrantMember2023-11-012024-04-3000019808452022-10-310001980845engn:PIPEFinancingMember2023-10-310001980845engn:TermLoanMember2023-10-310001980845engn:LoanAndSecurityAgreementMemberengn:TrancheOneMemberengn:HerculesCapitalMember2021-12-300001980845engn:FEACMember2023-10-310001980845engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember2023-11-012024-04-300001980845engn:CeoTransitionAgreementMembersrt:ChiefExecutiveOfficerMember2024-02-132024-02-130001980845engn:OldEngeneShareholdersMember2024-04-300001980845us-gaap:WarrantMember2022-11-012023-04-300001980845us-gaap:EmployeeStockOptionMember2022-11-012023-10-310001980845engn:ClassBThirdTrancheMemberengn:ClassBRedeemableConvertiblePreferredSharesMember2015-01-062015-01-060001980845us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-02-012024-04-300001980845us-gaap:ComputerEquipmentMember2024-04-3000019808452024-04-300001980845engn:TwoThousandTwentyFourSubscriptionAgreementsMember2023-11-012024-04-300001980845us-gaap:EquipmentMember2023-10-310001980845engn:TheOldPlansMember2024-04-300001980845engn:OldEngenesWarrantHoldersMember2023-10-310001980845us-gaap:EmployeeStockOptionMember2023-10-310001980845engn:TwoZeroTwoThreePlanMemberus-gaap:EmployeeStockOptionMember2023-11-012024-04-300001980845engn:Series1ClassCRedeemableConvertiblePreferredMember2024-04-300001980845engn:ClassBSecondTrancheMemberengn:ClassBRedeemableConvertiblePreferredSharesMember2015-01-060001980845engn:AprilTwoZeroTwoThreeNotesMember2023-11-012024-04-3000019808452020-09-012020-09-300001980845engn:ClassARedeemableConvertiblePreferredSharesMember2023-01-310001980845engn:ClassARedeemableConvertiblePreferredSharesMember2022-10-310001980845us-gaap:CommonStockMember2023-11-012024-04-300001980845us-gaap:AdditionalPaidInCapitalMember2023-11-012024-01-310001980845engn:Series4ClassCRedeemableConvertiblePreferredMember2024-04-300001980845us-gaap:ResearchAndDevelopmentExpenseMember2022-11-012023-04-300001980845engn:AprilTwoZeroTwoThreeNotesMember2023-04-012023-04-3000019808452024-06-110001980845us-gaap:AdditionalPaidInCapitalMember2024-04-3000019808452023-07-072023-07-070001980845engn:EvergreenProvisionMemberengn:TwoZeroTwoThreePlanMemberus-gaap:SubsequentEventMember2024-05-152024-05-150001980845engn:ConvertibleNotesMember2024-04-300001980845us-gaap:ResearchAndDevelopmentExpenseMember2023-11-012024-04-300001980845us-gaap:RetainedEarningsMember2023-01-310001980845engn:PreferredShareWarrantsMember2024-04-300001980845engn:ClassCSecondTrancheMember2021-06-300001980845us-gaap:EmployeeStockOptionMember2023-11-012024-04-300001980845us-gaap:CommonStockMember2024-01-310001980845us-gaap:RetainedEarningsMember2024-02-012024-04-300001980845engn:TwentyTwentyTwoNotesMember2022-11-012023-01-310001980845engn:PIPEFinancingMemberengn:FEACMember2022-11-012023-10-310001980845engn:PIPEFinancingMember2022-11-012023-10-310001980845engn:BdcNotesMember2023-02-012023-04-300001980845engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember2022-10-310001980845us-gaap:CommonStockMember2023-10-310001980845engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMemberengn:AmendedLoanAgreementMemberengn:TermLoanMember2023-12-222023-12-220001980845engn:TheOldPlansMember2022-11-012023-10-310001980845us-gaap:EquipmentMember2024-04-3000019808452023-11-012024-04-300001980845engn:SubscriptionAgreementsMemberus-gaap:PrivatePlacementMember2024-02-130001980845us-gaap:WarrantMember2023-02-012023-04-300001980845us-gaap:CommonStockMember2023-02-012023-04-300001980845engn:TwoZeroTwoThreePlanMember2023-10-310001980845engn:AprilTwoZeroTwoThreeNotesMember2023-05-162023-05-160001980845us-gaap:EmployeeStockOptionMember2024-04-300001980845engn:LoanAndSecurityAgreementsMemberengn:OldHerculesWarrantsMember2023-11-012024-04-300001980845engn:OldEngenesShareOptionHoldersMember2024-04-300001980845engn:WarrantToPurchaseCommonStockMember2023-10-310001980845engn:FEACMember2023-01-310001980845engn:ClassCWarrantsMember2021-06-302021-06-300001980845us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-310001980845engn:TheOldPlansMember2023-10-310001980845us-gaap:GeneralAndAdministrativeExpenseMember2022-11-012023-04-300001980845engn:AmendedLoanAgreementMemberengn:TrancheOneAdvanceMemberengn:TermLoanMember2023-12-222023-12-220001980845engn:TwoZeroTwoThreeFinancingMember2023-05-160001980845engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember2023-02-012023-04-300001980845engn:MayTwoThousandTwoThreeNotesMember2023-05-012023-05-310001980845engn:ForbionGrowthSponsorFeacIBVMember2023-06-012023-06-300001980845engn:TwoThousandTwentyFourSubscriptionAgreementsMemberus-gaap:PrivatePlacementMember2024-02-132024-02-1300019808452023-11-012024-01-310001980845us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMember2018-07-052018-07-050001980845engn:ClassBInitialClosingMemberengn:ClassBRedeemableConvertiblePreferredSharesMember2015-01-062015-01-060001980845engn:Series3ClassCRedeemableConvertiblePreferredMember2024-04-300001980845engn:TheOldPlansMemberus-gaap:EmployeeStockOptionMembersrt:MinimumMember2018-07-052018-07-050001980845engn:AmendedLoanAgreementMemberengn:TermLoanMember2023-12-222023-12-220001980845engn:ClassAInitialClosingMemberengn:ClassARedeemableConvertiblePreferredSharesMember2013-07-260001980845engn:FEACMember2024-04-300001980845us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-3100019808452020-04-102020-04-100001980845engn:ClassBSecondTrancheMemberengn:ClassBRedeemableConvertiblePreferredSharesMember2015-01-062015-01-060001980845engn:AmendedLoanAgreementMemberengn:IfInterimMilestoneAchievedAndNoDefaultMemberengn:TermLoanMember2023-12-222023-12-2200019808452023-10-310001980845us-gaap:GeneralAndAdministrativeExpenseMember2024-02-012024-04-300001980845us-gaap:RedeemableConvertiblePreferredStockMember2022-11-012023-04-300001980845us-gaap:RedeemableConvertiblePreferredStockMember2024-02-012024-04-300001980845us-gaap:WarrantMember2023-11-012024-04-300001980845engn:LoanAndSecurityAgreementsMemberus-gaap:SeriesCPreferredStockMemberengn:OldHerculesWarrantsMember2024-04-300001980845engn:ClassBInitialClosingMemberengn:ClassBRedeemableConvertiblePreferredSharesMember2015-01-0600019808452022-11-012023-04-300001980845us-gaap:NonvotingCommonStockMember2024-04-300001980845engn:AmendedLoanAgreementMemberengn:TrancheOneAdvanceMemberengn:TermLoanMember2023-12-220001980845engn:AmendedLoanAgreementMemberengn:TermLoanMember2024-02-012024-04-300001980845engn:OfficeSpaceMember2024-01-010001980845srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-11-012024-04-300001980845engn:TrancheTwoMemberengn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2022-06-152022-06-150001980845us-gaap:EmployeeStockOptionMember2023-07-072023-07-070001980845engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember2022-11-012023-01-310001980845engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember2023-04-300001980845engn:NewLaboratoryAndOfficeSpaceMember2022-12-292022-12-290001980845engn:AmendedLoanAgreementMemberengn:WallStreetJournalMemberengn:TermLoanMember2023-12-222023-12-2200019808452023-07-070001980845us-gaap:AdditionalPaidInCapitalMember2024-01-310001980845engn:AprilTwentyTwentyThreeNotesMember2023-04-040001980845engn:OfficeAndLabSpaceMember2022-10-310001980845engn:OfficeAndLabSpaceMember2021-11-012021-11-300001980845engn:TwoThousandTwentyFourSubscriptionAgreementsMember2024-02-132024-02-130001980845engn:LoanAndSecurityAgreementMemberengn:TrancheThreeMemberengn:HerculesCapitalMember2022-12-150001980845engn:ClassCSecondTrancheMember2021-06-302021-06-300001980845engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMemberengn:AmendedLoanAgreementMemberengn:TermLoanMember2023-12-220001980845engn:PhaseIClinicalTrialMember2020-04-100001980845engn:TwoThousandTwentyFourSubscriptionAgreementsMemberus-gaap:PrivatePlacementMember2024-02-130001980845us-gaap:FairValueMeasurementsRecurringMember2023-10-310001980845engn:TwoZeroTwoThreeFinancingMember2023-05-310001980845engn:TwentyTwentyTwoNotesMember2023-02-012023-04-300001980845engn:FEACMember2022-11-012023-10-310001980845us-gaap:GeneralAndAdministrativeExpenseMember2023-11-012024-04-300001980845engn:WarrantToPurchaseCommonStockMember2024-04-300001980845engn:AprilTwentyTwentyThreeNotesMember2023-02-012023-04-300001980845engn:ClassARedeemableConvertiblePreferredSharesMember2023-04-300001980845engn:MergerAgreementMember2023-11-012024-04-300001980845us-gaap:CommonStockMember2024-04-300001980845us-gaap:RetainedEarningsMember2023-02-012023-04-300001980845us-gaap:CommonStockMember2023-01-310001980845engn:PreferredShareWarrantLiabillitiesMember2023-11-012024-04-300001980845us-gaap:EmployeeStockOptionMember2022-11-012023-04-300001980845engn:ClassASecondTrancheMemberengn:ClassARedeemableConvertiblePreferredSharesMember2013-07-2600019808452021-06-302021-06-3000019808452023-04-300001980845engn:SharesReservedForFutureIssuanceUnderTheEquityPlansMember2023-10-310001980845engn:CommonSharesIssuedToPipeInvestorsMember2024-04-300001980845engn:OfficeAndLabSpaceMember2023-11-012024-01-310001980845engn:FeacShareholdersMember2024-04-300001980845engn:OldEngenesEquityAndConvertibleNoteHolderMember2023-10-310001980845engn:ClassBRedeemableConvertiblePreferredSharesMember2022-10-310001980845us-gaap:RedeemableConvertiblePreferredStockMember2023-11-012024-04-3000019808452024-02-012024-04-300001980845us-gaap:EmployeeStockOptionMember2022-11-012023-04-300001980845engn:TwoZeroTwoThreePlanMember2022-11-012023-10-310001980845engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember2022-11-012023-04-300001980845engn:AmendedLoanAgreementMemberengn:TermLoanMember2023-11-012024-04-300001980845engn:TwoZeroTwoThreePlanMember2024-04-300001980845engn:OfficeAndLabSpaceMember2021-11-300001980845engn:CashWarrantExercisesMember2023-11-012024-04-300001980845engn:TwoZeroTwoThreePlanMember2024-01-0100019808452023-01-310001980845srt:MaximumMemberengn:AmendedLoanAgreementMemberengn:WallStreetJournalMemberengn:TermLoanMember2023-12-222023-12-220001980845engn:CashlessWarrantExercisesMember2023-11-012024-04-300001980845engn:TwentyTwentyTwoNotesMember2022-11-012023-10-310001980845us-gaap:LeaseholdImprovementsMember2024-04-300001980845engn:TrancheTwoMemberengn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2022-06-150001980845engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember2024-02-012024-04-300001980845us-gaap:AdditionalPaidInCapitalMember2023-01-310001980845us-gaap:WarrantMember2024-02-012024-04-300001980845engn:TwoZeroTwoThreePlanMember2024-02-012024-04-300001980845engn:ClassCRedeemableConvertiblePreferredSharesMember2022-10-310001980845engn:AnthonyCheungMember2024-04-192024-04-190001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2023-11-012024-04-300001980845engn:TwentyTwentyTwoNotesMember2021-11-012022-10-310001980845engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember2023-02-012023-04-300001980845engn:ClassAInitialClosingMemberengn:ClassARedeemableConvertiblePreferredSharesMember2013-07-262013-07-260001980845engn:TwoZeroTwoThreeFinancingMemberengn:ForbionGrowthSponsorFeacIBVMember2023-06-300001980845engn:TwoThousandTwentyFourPipeInvestorsMember2024-02-132024-02-130001980845engn:BdcNotesMember2020-09-300001980845us-gaap:SoftwareDevelopmentMember2024-04-300001980845engn:TheOldPlansMember2023-11-012024-04-300001980845engn:ClassCInitialClosingMemberengn:Series3ClassCRedeemableConvertiblePreferredMember2021-06-300001980845us-gaap:NonvotingCommonStockMember2023-07-070001980845engn:TwoZeroTwoThreePlanMembersrt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-11-012024-04-300001980845us-gaap:AdditionalPaidInCapitalMember2023-02-012023-04-300001980845engn:PriorLoanAgreementMemberengn:AppliedToRefinanceOfAmountOutstandingMemberengn:TermLoanMember2023-12-222023-12-220001980845engn:FEACMember2023-05-160001980845us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-300001980845us-gaap:FurnitureAndFixturesMember2023-10-310001980845us-gaap:AdditionalPaidInCapitalMember2024-02-012024-04-300001980845engn:LoanAndSecurityAgreementMember2024-04-300001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2023-10-310001980845us-gaap:CommonStockMember2022-11-012023-01-310001980845engn:BdcNotesMember2022-11-012023-04-300001980845engn:NewLaboratoryAndOfficeSpaceMember2022-12-290001980845us-gaap:ResearchAndDevelopmentExpenseMember2023-02-012023-04-300001980845us-gaap:EmployeeStockOptionMember2023-02-012023-04-300001980845us-gaap:CommonStockMember2022-10-310001980845engn:LoanAndSecurityAgreementMemberus-gaap:PrimeRateMemberengn:HerculesCapitalMember2021-12-302021-12-300001980845engn:ClassCRedeemableConvertiblePreferredSharesMember2023-01-310001980845us-gaap:EmployeeStockOptionMember2023-07-070001980845us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2023-11-012024-04-300001980845us-gaap:AdditionalPaidInCapitalMember2023-04-300001980845engn:TwentyTwentyTwoNotesMember2022-10-310001980845us-gaap:RedeemableConvertiblePreferredStockMember2023-02-012023-04-3000019808452023-02-012023-04-300001980845engn:MayTwoThousandTwoThreeNotesMember2023-05-162023-05-160001980845us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-310001980845us-gaap:CommonStockMember2024-02-012024-04-300001980845us-gaap:FairValueMeasurementsRecurringMember2024-04-300001980845us-gaap:AdditionalPaidInCapitalMember2022-11-012023-01-310001980845us-gaap:AdditionalPaidInCapitalMember2023-10-3100019808452022-11-012023-01-310001980845srt:MaximumMemberengn:TheOldPlansMember2018-07-052018-07-050001980845engn:Series3ClassCRedeemableConvertiblePreferredMember2021-06-300001980845us-gaap:AdditionalPaidInCapitalMember2022-10-310001980845engn:ClassB1RedeemableConvertiblePreferredSharesMember2015-09-102015-09-100001980845engn:SubscriptionAgreementsMemberus-gaap:PrivatePlacementMember2024-02-132024-02-130001980845engn:AmendedLoanAgreementMemberengn:TrancheOneAdvanceMemberengn:TermLoanMemberengn:HerculesWarrantsMember2023-11-012024-04-300001980845engn:AmendedLoanAgreementMember2023-12-220001980845engn:AprilTwentyTwentyThreeNotesMembersrt:MinimumMember2023-04-040001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2022-11-012023-04-300001980845srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-02-012024-04-300001980845engn:AmendedLoanAgreementMemberengn:TrancheOneAdvanceMemberengn:TermLoanMemberengn:HerculesWarrantsMember2024-04-300001980845us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-310001980845engn:AmendedLoanAgreementMemberengn:FEACMember2024-04-300001980845us-gaap:FurnitureAndFixturesMember2024-04-300001980845engn:ClassB1RedeemableConvertiblePreferredSharesMember2015-09-100001980845us-gaap:ResearchAndDevelopmentExpenseMember2024-02-012024-04-300001980845engn:FEACMember2023-11-012024-04-300001980845engn:BdcNotesMember2020-09-012020-09-3000019808452021-06-300001980845engn:AprilTwentyTwentyThreeNotesMember2023-04-042023-04-040001980845engn:LoanAndSecurityAgreementMemberengn:HerculesCapitalMember2021-12-300001980845engn:PhaseIiClinicalTrialMember2020-04-10xbrli:pureiso4217:CADutr:sqftutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:CADxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _________________

Commission File Number: 001-41854

 

enGene Holdings Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

British Columbia, Canada

N/A

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

4868 Rue Levy, Suite 220

Saint-Laurent, QC, Canada

H4R 2P1

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (514) 332-4888

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Shares

 

ENGN

 

The Nasdaq Stock Market LLC

Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per share

 

ENGNW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of June 12, 2024, the registrant had 44,166,159 Common Shares, with no par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

Page

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

2

 

 

 

 

 

 

PART I.

FINANCIAL INFORMATION

4

 

 

 

Item 1.

Financial Statements (Unaudited)

4

 

Condensed Consolidated Balance Sheets as of April 30, 2024 and October 31, 2023

4

 

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Six Months Ended April 30, 2024 and 2023

5

 

Condensed Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders’ Deficit for the Three and Six Months Ended April 30, 2024 and 2023

6

 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended April 30, 2024 and 2023

7

 

Notes to the Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

29

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

42

Item 4.

Controls and Procedures

43

 

 

 

PART II.

OTHER INFORMATION

45

 

 

 

Item 1.

Legal Proceedings

45

Item 1A.

Risk Factors

45

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

46

Item 3.

Omitted

46

Item 4.

Omitted

46

Item 5.

Other Information

46

Item 6.

Exhibits

46

Signatures

48

 

1


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q may constitute “forward-looking statements” within the meaning of U.S. securities laws and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). enGene’s forward-looking statements include, but are not limited to, statements regarding enGene’s management teams’ expectations, hopes, beliefs, intentions, goals or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “appear,” “approximate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “would” and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report on Form 10-Q may include, for example, statements about:

the ability of enGene to recognize the anticipated benefits of the business combination between FEAC, the Company and Old enGene and related transactions ("Business Combination"), which may be affected by, among other things, competition and the ability of the combined business to grow and manage growth profitably;
enGene’s financial performance following the Business Combination, including financial projections and business metrics and any underlying assumptions thereunder;
the ability to maintain the listing of the Company's common shares ("Common Shares") and warrants to purchase Common Shares ("Warrants") on Nasdaq or another national securities exchange;
enGene’s success in recruiting and retaining, or changes required in, officers, key personnel or directors following the completion of the Business Combination;
enGene’s plans and ability to execute product development, manufacturing process development, preclinical and clinical development efforts successfully and on anticipated timelines;
enGene’s ability to design, initiate and successfully complete clinical trials and other studies for its product candidates and its plans and expectations regarding its ongoing or planned clinical trials;
enGene’s plans and ability to obtain and maintain marketing approval from the U.S. Food and Drug Administration and other regulatory authorities, including the European Medicines Agency, for its product candidates;
enGene’s plans and ability to commercialize its product candidates, if approved by applicable regulatory authorities;
the degree of market acceptance of enGene’s product candidates, if approved, and the availability of third-party coverage and reimbursement;
the ability of enGene’s external contract manufacturers to support the manufacturing, release testing, stability analysis, clinical labeling and packaging of enGene’s products;
enGene’s future financial performance and the sufficiency of enGene’s cash and cash equivalents to fund its operations;
the outcome of any known and unknown litigation and regulatory proceedings, including any legal proceedings that may be instituted against enGene or any of its directors or officers following the Business Combination; and
enGene’s ability to implement and maintain effective internal controls.

All forward looking-statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include:

enGene is able to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials and acquire technologies complementary to, or necessary for, its programs;
enGene is able to enroll a cohort of patients in the Phase 2 LEGEND trial to assess EG-70’s efficacy and safety between the BCG-naïve patient population and the BCG-exposed patient population and enroll an additional cohort of patients in the Phase 2 LEGEND trial to assess EG-70’s efficacy and safety in patients with BCG-unresponsive, papillary-only Ta/T1 disease to evaluate EG-70's ultimate potential as a monotherapy in first line patients and expanding EG-70’s opportunity;
enGene is able to file a Biologics License Application mid-2026 with the FDA for approval to market EG-70 in the United States as a monotherapy to treat BCG-unresponsive NMIBC;
EG-70’s product profile can be integrated seamlessly into community urology clinics where the vast majority of NMIBC patients are treated;

2


 

enGene is able to retain commercial rights to EG-70 in the United States and commercialize EG-70 independently, while selectively partnering outside of the United States;
enGene is able to execute the “pipeline-in-a-product” development strategy for EG-70; and
enGene is able to utilize the DDX gene delivery platform to develop effective, new agents for the delivery of genetic medicines to mucosal tissues.

You should not place undue reliance on these forward-looking statements which speak only as of the date hereof. The forward-looking statements contained in this Quarterly Report on Form 10-Q are based primarily on current expectations and projections about future events and trends that may affect our business, financial condition and operating results. The following uncertainties and factors, among other things (including those described in “Risk Factors” in our Annual Report on Form 10-K and elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (“SEC”)), could affect future performance and actual results to differ materially and adversely from those expressed in, anticipated or implied by forward-looking statements:

the risk that the Business Combination disrupts current plans and operations of enGene as a result of consummation of the Reverse Recapitalization;
the ability to recognize the anticipated benefits of the Business Combination;
risks applicable to enGene’s business, including the extensive regulation of all aspects of enGene’s business, competition from other existing or newly developed products and treatments;
risks associated with the protection of intellectual property, enGene’s ability to raise additional capital to fund its produce development activity, and its ability to maintain key relationships and to attract and retain talented personnel;
the possibility that enGene may be adversely affected by changes in domestic and foreign business, market, financial, political, geopolitical, legal conditions and laws and regulations;
the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect enGene or the expected benefits of the Business Combination; or
other risks and uncertainties set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K and elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the SEC.

In addition, statements that “we believe” and similar statements reflect beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

3


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

ENGENE HOLDINGS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

(Unaudited)

 

 

 

April 30,
2024

 

 

October 31,
2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

264,810

 

 

$

81,521

 

Restricted certificate of deposit

 

 

75

 

 

 

76

 

Investment tax credits receivable

 

 

1,213

 

 

 

2,343

 

Prepaid and other current assets

 

 

3,511

 

 

 

1,500

 

Total current assets

 

 

269,609

 

 

 

85,440

 

Property and equipment, net

 

 

1,107

 

 

 

589

 

Operating lease right of use asset

 

 

1,837

 

 

 

 

Other assets

 

 

975

 

 

 

930

 

Total assets

 

$

273,528

 

 

$

86,959

 

Liabilities, redeemable convertible preferred shares and shareholders’
   equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

211

 

 

$

1,156

 

Accrued expenses and other current liabilities

 

 

5,667

 

 

 

3,539

 

Operating lease liabilities, current

 

 

421

 

 

 

 

Current portion of notes payable

 

 

 

 

 

562

 

Total current liabilities

 

 

6,299

 

 

 

5,257

 

Note payable, net of current portion

 

 

22,730

 

 

 

9,216

 

Operating lease liabilities, net of current portion

 

 

1,533

 

 

 

 

Total liabilities

 

 

30,562

 

 

 

14,473

 

Shareholders’ equity :

 

 

 

 

 

 

Preferred shares, no par value; unlimited shares authorized, no shares issued
   and outstanding as of April 30, 2024 and October 31, 2023.

 

 

 

 

 

 

Common shares, no par value; unlimited shares authorized, 44,158,587 and 23,197,976 
   shares issued and outstanding as of April 30, 2024 and October 31, 2023, respectively.

 

 

453,405

 

 

 

259,373

 

Additional paid-in capital

 

 

15,860

 

 

 

13,717

 

Accumulated other comprehensive loss

 

 

(1,016

)

 

 

(1,016

)

Accumulated deficit

 

 

(225,283

)

 

 

(199,588

)

Total shareholders’ equity

 

 

242,966

 

 

 

72,486

 

Total liabilities, redeemable convertible preferred shares and shareholders’ equity

 

$

273,528

 

 

$

86,959

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


 

ENGENE HOLDINGS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

(Unaudited)

 

 

 

For the three months ended April 30,

 

 

For the six months ended April 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

9,855

 

 

$

3,215

 

 

$

15,493

 

 

$

6,886

 

General and administrative

 

 

7,455

 

 

 

1,522

 

 

 

12,590

 

 

 

2,484

 

Total operating expenses

 

 

17,310

 

 

 

4,737

 

 

 

28,083

 

 

 

9,370

 

Loss from operations

 

 

17,310

 

 

 

4,737

 

 

 

28,083

 

 

 

9,370

 

Other (income) expense, net:

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of convertible debentures embedded derivative liabilities

 

 

 

 

 

(625

)

 

 

 

 

 

(318

)

Change in fair value of warrant liabilities

 

 

 

 

 

341

 

 

 

 

 

 

1,526

 

Interest income

 

 

(2,984

)

 

 

(149

)

 

 

(4,009

)

 

 

(316

)

Interest expense

 

 

728

 

 

 

1,177

 

 

 

1,291

 

 

 

2,352

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

366

 

 

 

 

Other expense, net

 

 

(91

)

 

 

(199

)

 

 

(27

)

 

 

86

 

Total other (income) expense, net

 

 

(2,347

)

 

 

545

 

 

 

(2,379

)

 

 

3,330

 

Net loss before provision for income taxes

 

 

14,963

 

 

 

5,282

 

 

 

25,704

 

 

 

12,700

 

Provision for (benefit from) income taxes

 

 

21

 

 

 

 

 

 

(9

)

 

 

 

Net loss and comprehensive loss

 

$

14,984

 

 

$

5,282

 

 

$

25,695

 

 

$

12,700

 

Deemed dividend attributable to redeemable convertible
   preferred shareholders

 

 

 

 

 

1,175

 

 

 

 

 

 

2,389

 

Net loss attributable to common shareholders, basic and
   diluted

 

$

14,984

 

 

$

6,457

 

 

$

25,695

 

 

$

15,089

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share of common shares, basic and diluted (retrospectively restated to reflect Reverse Recapitalization – see Note 1 and Note 3)

 

$

0.38

 

 

$

9.30

 

 

$

0.82

 

 

$

22.19

 

Weighted-average common shares outstanding, basic and diluted (retrospectively restated to reflect Reverse Recapitalization – see Note 1 and Note 3)

 

 

39,443,768

 

 

 

694,497

 

 

 

31,186,238

 

 

 

680,003

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

ENGENE HOLDINGS INC.

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (DEFICIT)

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

(Unaudited)

 

Class A Redeemable
Convertible Preferred
Shares*

 

Class B Redeemable
Convertible Preferred
Shares*

 

Class C Redeemable
Convertible Preferred
Shares*

 

 

 

Common
Shares*

 

Additional
Paid in

 

Accumulated
Other
Comprehensive

 

Accumulated

 

Total
Shareholders’

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

 

 

Shares

 

Amount

 

Capital

 

Loss

 

Deficit

 

Deficit

 

Balance at October 31, 2022

 

266,696

 

$

1,899

 

 

156,036

 

$

1,554

 

 

5,560,607

 

$

49,665

 

 

 

 

665,767

 

$

16,390

 

$

7,683

 

$

(1,016

)

$

(99,671

)

$

(76,614

)

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,804

 

 

6

 

 

(6

)

 

 

 

 

 

 

Share-based compensation
   expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20

 

 

 

 

 

 

20

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,418

)

 

(7,418

)

Balance at January 31, 2023

 

266,696

 

$

1,899

 

 

156,036

 

$

1,554

 

 

5,560,607

 

$

49,665

 

 

 

 

667,571

 

$

16,396

 

$

7,697

 

$

(1,016

)

$

(107,089

)

$

(84,012

)

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

18,258

 

 

27

 

 

(10

)

 

 

 

 

 

17

 

Issuance of common shares upon cashless exercise of options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15,494

 

 

11

 

 

(11

)

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

39

 

 

 

 

 

 

39

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,282

)

 

(5,282

)

Balance at April 30, 2023

 

266,696

 

$

1,899

 

 

156,036

 

$

1,554

 

 

5,560,607

 

$

49,665

 

 

 

 

701,323

 

$

16,434

 

$

7,715

 

$

(1,016

)

$

(112,371

)

$

(89,238

)

 

Class A Redeemable
Convertible Preferred
Shares*

 

Class B Redeemable
Convertible Preferred
Shares*

 

Class C Redeemable
Convertible Preferred
Shares*

 

 

 

Common
Shares*

 

Additional
Paid in

 

Accumulated
Other
Comprehensive

 

Accumulated

 

Total
Shareholders’

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

 

 

Shares

 

Amount

 

Capital

 

Loss

 

Deficit

 

Equity

 

Balance at October 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23,197,976

 

$

259,373

 

$

13,717

 

$

(1,016

)

$

(199,588

)

$

72,486

 

Share-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

291

 

 

 

 

 

 

291

 

Issuance of warrants in connection with Amended Term Loan

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

319

 

 

 

 

 

 

319

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,711

)

 

(10,711

)

Balance at January 31, 2024

 

 

$

 

 

 

$

 

 

 

$

 

 

 

 

23,197,976

 

$

259,373

 

$

14,327

 

$

(1,016

)

$

(210,299

)

$

62,385

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

56,974

 

 

207

 

 

(156

)

 

 

 

 

 

51

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,917

 

 

 

 

 

 

1,917

 

Issuance of common shares in connection with PIPE Financing, net of issuance costs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20,000,000

 

 

187,614

 

 

 

 

 

 

 

 

187,614

 

Issuance of common shares upon exercise of warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

520,282

 

 

6,114

 

 

(131

)

 

 

 

 

 

5,983

 

Issuance of common shares upon cashless exercise of warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

383,355

 

 

97

 

 

(97

)

 

 

 

 

 

-

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(14,984

)

 

(14,984

)

Balance at April 30, 2024

 

 

$

 

 

 

$

 

 

 

$

 

 

 

 

44,158,587

 

$

453,405

 

$

15,860

 

$

(1,016

)

$

(225,283

)

$

242,966

 

 

*- The shares have been retrospectively restated to reflect exchange of shares upon the close of the Reverse Recapitalization. See Notes 1 and 3.

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


 

ENGENE HOLDINGS INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA

(Unaudited)

 

 

For the six months ended April 30,

 

 

2024

 

 

2023

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(25,695

)

 

$

(12,700

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Non-cash interest expense

 

 

372

 

 

 

1,663

 

Loss on extinguishment of debt

 

 

366

 

 

 

 

Change in fair value of warrant liabilities

 

 

 

 

 

1,526

 

Change in fair value of convertible debenture embedded derivative liabilities

 

 

 

 

 

(318

)

Debt issuance costs expensed upon issuance of debt recorded at the fair value option

 

 

 

 

 

132

 

Non-cash lease expense

 

 

67

 

 

 

 

Unrealized foreign currency losses

 

 

8

 

 

 

22

 

Share-based compensation expense

 

 

2,208

 

 

 

59

 

Depreciation of property and equipment

 

 

158

 

 

 

83

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Investment tax credit receivable

 

 

1,130

 

 

 

(722

)

Prepaid expenses and other assets

 

 

(2,057

)

 

 

(190

)

Accounts payable

 

 

(689

)

 

 

2,049

 

Accrued expenses and other liabilities

 

 

2,565

 

 

 

(2,271

)

Lease liabilities

 

 

35

 

 

 

 

Net cash used in operating activities

 

 

(21,532

)

 

 

(10,667

)

Investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

(685

)

 

 

(23

)

Net cash used in investing activities

 

 

(685

)

 

 

(23

)

Financing activities

 

 

 

 

 

 

Proceeds from the 2024 PIPE Financing

 

 

200,000

 

 

 

 

Payments of issuance costs associated with the 2024 PIPE Financing

 

 

(12,386

)

 

 

 

Proceeds from exercise of common share warrants

 

 

5,983

 

 

 

 

Proceeds from exercise of stock options

 

 

51

 

 

 

17

 

Proceeds from issuance of term loan

 

 

22,500

 

 

 

 

Repayments of term loan principal

 

 

(9,445

)

 

 

 

Payments of debt issuance costs associated with term loan

 

 

(585

)

 

 

 

Proceeds from issuance of April 2023 Notes

 

 

 

 

 

8,000

 

Payment of issuance costs associated with April 2023 Notes

 

 

 

 

 

(132

)

Payment of Reverse Recapitalization and PIPE Financing costs

 

 

(613

)

 

 

(132

)

Net cash provided by financing activities

 

 

205,505

 

 

 

7,753

 

Effect of exchange rate changes on cash and cash equivalents

 

 

1

 

 

 

1

 

Net increase in cash and cash equivalents

 

 

183,289

 

 

 

(2,936

)

Cash and cash equivalents at beginning of period

 

 

81,521

 

 

 

20,434

 

Cash and cash equivalents at end of period

 

$

264,810

 

 

$

17,498

 

Supplemental cash flow information:

 

 

 

 

 

 

Cash paid for interest

 

$

867

 

 

$

676

 

Supplemental non-cash investing and financing activities

 

 

 

 

 

 

Warrant value issued as part of Amended Term Loan

 

 

319

 

 

 

 

Right of Use Assets obtained in exchange for lease liabilities

 

 

1,904

 

 

 

 

Reverse Recapitalization and PIPE Financing transaction costs included within accrued expenses and accounts payable

 

 

 

 

 

1,167

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

(Unaudited)

1.
Description of Business

enGene Holdings Inc. (together with its consolidated subsidiaries “enGene” or the “Company”) formed in connection with the Merger Agreement (as defined below) was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. enGene Inc., its wholly owned subsidiary since October 31, 2023 (now known as “enGene Inc.” or “Old enGene”), is a biopharmaceutical company located in Montreal, Quebec, Canada, and incorporated pursuant to the Canada Business Corporations Act on November 9, 1999.

The Company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients, and its head office is located in Montreal, Quebec, Canada. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or “DDX”, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Merger with Forbion European Acquisition Corp.

Forbion European Acquisition Corporation (“FEAC”) was a special purpose acquisition company (“SPAC”), incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the “Closing Date”), the Company, FEAC, and enGene Inc., consummated the merger (the “Reverse Recapitalization”) pursuant to a business combination agreement, dated as of May 16, 2023 (the “Merger Agreement”).

The transaction was accounted for as a “reverse recapitalization” in accordance with accounting principles generally accepted in the United States (“GAAP”). Under this method of accounting, FEAC was treated as the “acquired” company for financial reporting purposes. This determination is primarily based on the fact that subsequent to the Reverse Recapitalization, senior management of Old enGene continued as senior management of the combined company; Old enGene identified a majority of the members of the board of directors of the combined company; the name of the combined company is enGene Holdings Inc. and it utilized Old enGene’s current headquarters, and Old enGene’s operations comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Company is considered to be a continuation of Old enGene, with the net identifiable assets of FEAC deemed to have been acquired by Old enGene in exchange for Old enGene common shares accompanied by a recapitalization, with no goodwill or intangible assets recorded. The number of redeemable convertible preferred shares, number of common shares, net loss per common share, the number of warrants to purchase common shares, and the number of stock options and the related exercise prices of the stock options issued and outstanding prior to the Reverse Recapitalization, have been retrospectively restated to reflect an exchange ratio of approximately 0.18048 (the “Exchange Ratio”) established in the Merger Agreement. Operations prior to the Reverse Recapitalization are those of Old enGene.

As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its ordinary shares and warrants on the Nasdaq Global Market under the symbols “ENGN” and “ENGNW,” respectively, commencing trading on November 1, 2023, with Old enGene, a subsidiary of the Company, continuing the existing business operations.

Liquidity and Going Concern

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.

The Company’s interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.

As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for developing non-viral gene therapies and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. The Company has not yet commercialized any product candidates and does not expect to generate revenue from sales of any product candidates or from other sources for several

8


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

years, if at all. The Company will need substantial additional funding to support its continuing operations and pursue its development strategy.

The Company has incurred a net loss of $15.0 million and $25.7 million for the three and six months ended April 30, 2024, respectively, and negative cash flows from operating activities of $21.5 million for the six months ended April 30, 2024, and, as of that date, has an accumulated deficit of $225.3 million. To date, the Company has not generated any revenues and has financed its liquidity needs primarily through the 2024 PIPE financing, the Reverse Recapitalization and the PIPE financing conducted by the Company as part of the Reverse Recapitalization (the "PIPE Financing"), debt and convertible debentures, and issuance of redeemable convertible preferred shares and warrants.

The Company’s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of outstanding loans. As of the issuance date of these condensed consolidated financial statements, the Company expects that its existing cash and cash equivalents as of April 30, 2024 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements. Effective from the first quarter interim condensed consolidated financial statements, the Company has ceased its disclosure of the existence of a material uncertainty that raised substantial doubt about the Company’s ability to continue as a going concern due to the proceeds received from the 2024 PIPE Financing.

2.
Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated annual financial statements for the years ended October 31, 2023 and 2022 and notes thereto, as found in our Annual Report on Form 10-K for the year ended October 31, 2023. These interim condensed consolidated financial statements should be read in conjunction with the consolidated annual financial statements. Since the date of those annual financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated balance sheet at October 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These interim financial statements include the accounts of the Company and its wholly owned subsidiaries, enGene, Inc. and enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements as of October, 31 2023 and 2022 and for the years ended October 31, 2023, and 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of April 30, 2024, the condensed consolidated statements of operations for the three and six months ended April 30, 2024 and 2023, the condensed consolidated statement of redeemable convertible preferred shares and shareholders' equity (deficit) for the three and six months ended April 30, 2024 and 2023, and condensed consolidated statements of cash flows for the six months ended April 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended April 30, 2024 and 2023 are unaudited. The results for the three and six months ended April 30, 2024 and 2023, are not necessarily indicative of results to be expected for the year ending October 31, 2024, any other interim periods, or any future year or period.

Recently Adopted Accounting Pronouncements

There have been no changes from the financial statements for the year ended October 31, 2023.

3.
Reverse Recapitalization

On October 31, 2023 (the "Closing Date”), FEAC, Old enGene, and the Company consummated the merger pursuant to the Merger Agreement, dated as of May 16, 2023. As a result of the Reverse Recapitalization, the Company became a publicly traded company, with Old enGene, a subsidiary of the Company, continuing the existing business operations.

 

At the effective time of the Reverse Recapitalization:

9


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

each outstanding common share of Old enGene was exchanged for common shares of the Company at the Exchange Ratio;
each of Old enGene’s redeemable convertible preferred shares outstanding immediately prior to the close of the Reverse Recapitalization was exchanged for shares of the Company’s common shares based on the same Exchange Ratio, with no dividends or distributions being declared or paid on Old enGene’s redeemable convertible preferred shares;
the 2022 Notes and May 2023 Notes (each as defined in Note 9) of Old enGene’s existing convertible notes outstanding immediately prior to the close of the Reverse Recapitalization were converted to Old enGene common shares at the conversion ratio in place at the time of conversion and were exchanged for shares of the Company at the Exchange Ratio;
each outstanding option to purchase old enGene common shares became fully vested and converted into an option to purchase a number of common shares of the Company equal to the number of common shares of old enGene subject to such option multiplied by the Exchange Ratio, rounded down to the nearest whole share, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio, rounded up to the nearest whole cent;
all of Old enGene’s outstanding warrants exercisable for common shares of Old enGene were exchanged for warrants exercisable for the Company’s common shares using the Exchange Ratio, with the warrants maintaining the same terms and conditions;
all of Old enGene’s existing outstanding Class C warrants outstanding at the time of the Reverse Recapitalization were terminated; and
all outstanding shares of FEAC being 3,670,927 shares, held by Forbion Growth Sponsor FEAC I B.V. ("FEAC Sponsor") and shareholders were converted into the same number of the Company’s common shares, and outstanding FEAC warrants of 5,029,444 held by FEAC warrant holders were converted into the same number of warrants to purchase one of the Company’s common shares.

 

Upon the close of the Reverse Recapitalization, 13,091,608 common shares of the Company were issued to Old enGene’s equity and convertible note holders, 2,679,432 common share warrants of the Company were issued to Old enGene’s warrant holders, and 2,706,941 common share options of the Company were issued to Old enGene’s share option holders.

 

In connection with the Merger Agreement, FEAC, the Company, and investors under the PIPE Financing (the "PIPE Investors") entered into Subscription Agreements pursuant to which, the PIPE Investors agreed to purchase the Company’s shares and warrants for an aggregate commitment amount of $56.9 million. As part of the PIPE Financing, the Company issued 6,435,441 of the Company’s common shares and 2,702,791 warrants to purchase the Company’s common shares for an aggregate purchase price equal to $56.9 million on October 31, 2023. The common shares and warrants issued as part of the PIPE Financing were determined to be equity classified. The proceeds were allocated between the common shares and warrants on a relative fair value basis, taking into consideration the quoted market price of the FEAC common shares and warrants on the close of the market on October 31, 2023, resulting in $56.1 million being allocated to the common shares and $0.8 million being allocated to the warrants. In connection with the Merger Agreement, FEAC, the FEAC Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A. and the other holders of Class B shares in the capital of FEAC ("FEAC Class B Shares"), Old enGene, the Company and the other parties named therein entered into the side letter agreements, pursuant to which the FEAC Sponsor agreed to surrender and in effect issue to PIPE Investors FEAC Class B Shares and FEAC private placement warrants, immediately prior to the closing of the Reverse Recapitalization. Immediately following the Reverse Recapitalization and the PIPE Financing, the Company had 23,197,976 common shares and 10,411,641 warrants outstanding.

 

On October 31, 2023, as part of the close of the Reverse Recapitalization, the Company received proceeds of $7.4 million from the FEAC trust account, net of the redemption payment to FEAC’s public shareholders and cash paid from the trust for FEAC expenses. Additionally, the Company received proceeds of approximately $56.9 million from the PIPE Financing. Upon the closing of the Reverse Recapitalization and PIPE Financing, the Company incurred $6.0 million in transaction costs, which was withheld from the proceeds received. The Company incurred a total of $11.1 million of transaction costs associated with the Reverse Recapitalization and PIPE Financing, of which $5.1 million was previously deferred by the Company and netted against the proceeds upon close. The transaction costs were allocated to the common shares and warrants on a relative fair value basis and netted against the proceeds upon close.

 

10


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

The following table summarizes the elements of the net proceeds from the Reverse Recapitalization and PIPE Financing transaction as of October 31, 2023:

 

 

Recapitalization

 

Cash – FEAC’s Trust Account and Cash (net of redemptions
   and cash paid for FEAC expenses prior to close)

 

$

7,363

 

Cash – PIPE Financing

 

 

56,892

 

Less transaction costs withheld from cash proceeds on Closing
   Date

 

 

(6,024

)

Cash proceeds received from the Reverse Recapitalization and
   PIPE Financing on Closing Date

 

$

58,231

 

Less transaction costs previously deferred and netted against
   proceeds

 

 

(5,086

)

Net cash proceeds from the Reverse Recapitalization and PIPE
   Financing

 

 

53,145

 

 

The total transaction costs of $11.1 million were related to third-party legal, accounting services and other professional services used to consummate the Reverse Recapitalization and the PIPE Financing incurred by Old enGene. These transaction costs are allocated between common shares and additional paid-in capital, based on the relative fair value of the common shares and warrants issued upon the close of the Reverse Recapitalization, on the Company’s consolidated balance sheet as the Company’s common shares have no par value.

The following table summarizes the number of common shares outstanding immediately following the consummation of the Reverse Recapitalization and PIPE Financing transaction:

 

 

Number
of Shares

 

Old enGene Shareholders (Excluding Convertible Notes)

 

 

6,711,786

 

FEAC Shareholders, including sponsor's and shareholder with
   non-redemption agreement

 

 

3,670,927

 

Convertible Notes - Common Shares issued

 

 

6,379,822

 

Common Shares issued to PIPE Investors

 

 

6,435,441

 

Total Common Shares outstanding immediately after the
   Reverse Recapitalization and PIPE Financing

 

 

23,197,976

 

 

4.
Fair Value Measurements

The Company did not have any financial assets or liabilities that required fair value measurement on a recurring basis as of April 30, 2024 or October 31, 2023.

During the three and six months ended April 30, 2024 and during the year ended October 31, 2023, there were no transfers or reclassifications between fair value measure levels of liabilities. The carrying values of all financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.

During the three and six months ended April 30, 2023, and as of April 30, 2023, the Company had the following instruments which were measured at fair value.

April 2023 Notes

The Company elected the fair value option of accounting for the April 2023 Notes (see Note 8). The Company recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be the total cash proceeds received of $8.0 million. No change in fair value was recorded on the April 2023 Notes during the three and six months ended April 30, 2023, given the close proximity between the issuance date of the notes and the period end.

11


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

Convertible Debentures Embedded Derivative Liabilities

Prior to the Reverse Recapitalization, the Company’s convertible debentures contained equity conversion options, and certain repayment features, that have been identified as a single compound embedded derivative requiring bifurcation from the host contract for the convertible debentures for which the fair value has not been elected. The Company estimated the fair value of the convertible debenture embedded derivative liabilities on issuance using a probability weighted scenario expected return model. The estimated probability and timing of underlying events triggering the conversion and liquidity repayment features and probability of exercise of the extension features within the convertible debentures as well as discount rates, volatility and share prices are inputs used to determine the estimated fair value of the embedded derivative.

Upon the close of the Reverse Recapitalization the 2022 Notes were converted and exchanged for common shares of the Company, resulting in an extinguishment of the 2022 Notes and related embedded derivative liability. Further the BDC Note (as defined below) was repaid in full. Refer to Note 3 and Note 9.

The following table provides a summary of the change in the estimated fair value of the Company’s convertible debentures embedded derivative liabilities for three and six months ended April 30, 2023.

 

 

Total

 

Balance as of October 31, 2022

 

$

3,791

 

Change in fair value of convertible debenture embedded
   derivative liabilities

 

 

307

 

Foreign exchange (gain)/loss

 

 

5

 

Balance as of January 31, 2023

 

 

4,103

 

Change in fair value of convertible debenture embedded
   derivative liabilities

 

 

(625

)

Foreign exchange (gain)/loss

 

 

(4

)

Balance as of April 30, 2023

 

$

3,474

 

 

Warrant Liabilities

Prior to the consummation of the Reverse Recapitalization, Old enGene issued warrants to purchase redeemable convertible preferred shares as part of the issuance of certain redeemable convertible preferred shares, convertible debentures, and the term loan (the “Preferred Share Warrants”). Upon the close of the Reverse Recapitalization, the Preferred Share Warrants were surrendered for no consideration and the fair value was determined to be zero. The Company estimated the fair value of its Preferred Share Warrant liabilities using a Modified Black-Scholes option-pricing model, which included assumptions that are based on the individual characteristics of the Preferred Share Warrants on the valuation date, and assumptions related to the fair value of the underlying redeemable convertible preferred shares, expected volatility, expected life, dividends, risk-free interest rate and discount for lack of marketability (“DLOM”). Due to the nature of these inputs, the Preferred Share Warrants are considered a Level 3 liability.

The weighted average expected life of the Preferred Share Warrants was estimated based on the weighting of scenarios considering the probability of different terms up to the contractual term of 10 years in light of the expected timing of a future exit event, which includes a SPAC transaction. The Company determines the expected volatility based on an analysis of reported data for a group of guideline companies that have issued instruments with substantially similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The risk-free interest rate is determined by reference to the Canadian treasury yield curve in effect at the time of measurement of the warrant liabilities for time periods approximately equal to the weighted average expected life of the warrants. The Company has not paid, and did not anticipate paying, cash dividends on its redeemable convertible preferred shares; therefore, the expected dividend yield is assumed to be zero.

Because there was no public market for the underlying redeemable convertible preferred shares, the Company determined their fair value based on third-party valuations. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company’s various securities of its capital structure using an option pricing method, or “OPM”, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of redeemable convertible preferred shares include volatility, DLOM, and the expected timing of a future liquidity event such as an IPO, SPAC transaction or sale of the Company, in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios.

12


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

In addition to considering the results of these valuations, the Company considered various objective and subjective factors to determine the fair value of the Company's preferred shares as of each valuation date, including the prices at which the Company sold redeemable convertible preferred in the most recent transactions, external market conditions, the progress of the Company's research and development programs, the Company's financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company's redeemable convertible preferred shares, among other factors.

The following table provides a summary of the change in the estimated fair value of the Company’s warrant liabilities for the three and six months ended April 30, 2023:

 

 

Total

 

Balance as of October 31, 2022

 

$

11,456

 

Change in fair value of warrant liabilities

 

 

1,185

 

Foreign exchange (gain)/loss

 

 

217

 

Balance as of January 31, 2023

 

 

12,858

 

Change in fair value of warrant liabilities

 

 

341

 

Foreign exchange (gain)/loss

 

 

(196

)

Balance as of April 30, 2023

 

$

13,003

 

 

5.
Property and Equipment, Net

As of April 30, 2024, and October 31, 2023, property and equipment consisted of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Lab equipment

 

$

2,167

 

 

$

1,779

 

Computer equipment

 

 

287

 

 

 

269

 

Computer software

 

 

146

 

 

 

70

 

Office furniture

 

 

177

 

 

 

69

 

Leasehold improvements

 

 

215

 

 

 

129

 

Property and equipment

 

 

2,992

 

 

 

2,316

 

Less: Accumulated depreciation and amortization

 

 

1,885

 

 

 

1,727

 

Property and equipment, net

 

$

1,107

 

 

$

589

 

 

Depreciation and amortization expense related to property and equipment was $78 and $37 for the three months ended April 30, 2024 and 2023, respectively. Depreciation and amortization expense related to property and equipment was $158 and $83 for the six months ended April 30, 2024 and 2023, respectively.

6.
Accrued Expenses and Other Current Liabilities

As of April 30, 2024, and October 31, 2023, accrued expenses and other current liabilities consisted of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Accrued research and development expenses

 

$

2,427

 

 

$

759

 

Professional fees

 

 

1,427

 

 

 

1,708

 

Employee compensation and related benefits

 

 

1,511

 

 

 

814

 

Accrued income tax payable

 

 

30

 

 

 

39

 

Other

 

 

272

 

 

 

219

 

Total accrued expenses and other current liabilities

 

$

5,667

 

 

$

3,539

 

 

13


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

7.
License Agreement and Clinical Research Organization

License Agreement – Nature Technology Corporation

On April 10, 2020, the Company entered into a Non-Exclusive License Agreement (the “License Agreement”) with Nature Technology Corporation (“NTC”) whereby the Company licenses certain rights to the technology of radiopharmaceutical products from NTC for commercialization. Under the terms of the License Agreement, NTC granted to the Company and its affiliates a non-exclusive, royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can voluntarily terminate the license agreement with prior notice to NTC.

The Company paid NTC an initial, upfront fee of $50 which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $50 annual maintenance fee. The Company is also required to make a payment to NTC of $50 upon assigning the License Agreement to a third party.

The License Agreement provides for a one-time payment of $50 for the first dose of a milestone product, as defined in the License Agreement, in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well as a one-time payment of $450 upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a milestone product, has not yet been achieved as of the period ended April 30, 2024. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by the Company, its affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country.

In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (“GMP”) lot of a product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.

During each of the three and six months ended April 30, 2024 and 2023, the Company incurred $13 and $25, respectively of expenses related to the annual maintenance fee under the License Agreement, which is recorded within research and development expenses.

8.
Notes Payable

2021 Loan and Security Agreement

On December 30, 2021, the Company entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. (“Hercules” or the “Lender”) for the issuance of a term loan facility with an aggregate principal amount of up to $20.0 million (the “Prior Term Loan”). The Prior Loan Agreement provided for (i) an initial term loan advance of $7.0 million, which closed on December 30, 2021, (ii) subject to the achievement of certain clinical milestones (“Clinical Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $4.0 million from the achievement of the Clinical Milestone through June 15, 2022, which was drawn in June 2022, and (iii) subject to the achievement of certain financial milestones (“Financial Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $9.0 million from achievement of the Financial Milestone through December 15, 2022, which was not achieved. The Company is required to pay an end of term fee (“Prior Term Loan End of Term Charge”) equal to 6.35% of the aggregate principal amount of the Prior Term Loan advances upon repayment.

The Prior Term Loans were scheduled to mature on July 1, 2025, with no option for extension (the “Prior Term Loan Maturity Date”).

The Prior Term Loan accrued interest at an annual rate equal to the greater of (i) 8.25% plus the prime rate of interest as reported in the Wall Street Journal minus 3.25% and (ii) 8.25% provided, that, from and after the date the Company achieves the financial milestone, as defined within the agreement, the reference to 8.25% in clauses (i) and (ii) is reduced to 8.15%. Borrowings under the

14


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

Prior Term Loan are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the Prior Term Loan are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. At the Company’s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the closing date of the last draw down; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the closing date of the last draw down, but on or prior to twenty-four months following the closing date of the last draw down; and 1.0% of the principal amount outstanding at any time thereafter but prior to the Maturity Date.

In connection with the Prior Term Loan, the Company granted Hercules a security interest senior to any current and future debts and to any security interest, in all of the Company’s right, title, and interest in, to and under all of the Company’s property and other assets, and certain equity interests and accounts of Old enGene, subject to limited exceptions including the Borrower’s intellectual property. The Prior Loan Agreement also contains certain events of default, representations, warranties and non-financial covenants of the Company.

The debt discount and issuance costs under the Prior Term Loan were accreted to the principal amount of debt and being amortized from the date of issuance through the Maturity Date to interest expense using the effective-interest rate method. The effective interest rate of the outstanding debt under the Prior Loan Agreement was approximately 18.3% as of October 31, 2023.

The Company borrowed $11.0 million under the Prior Loan Agreement and incurred $1.1 million of debt discount and issuance costs inclusive of facilities fees, legal fees, Prior Term Loan End of Term Charge and initial fair value of the warrants under the Prior Term Loan.

Old Hercules Warrants

Under the Prior Loan Agreement, the Company agreed to issue to Hercules warrants (the “Old Hercules Warrants”) to purchase a number of shares of Old enGene’s redeemable convertible preferred shares at the exercise price equal to 2.5% of the aggregate amount of the Prior Term Loans that are funded, as such amounts are funded. On the first tranche closing, Old enGene issued a warrant to purchase 84,714 Class C Preferred Shares which were determined to have a fair value of $34 upon issuance. On the second tranche closing, in June 2022, Old enGene issued an additional warrant to purchase 48,978 Class C Preferred Shares which were determined to have a fair value of $23 upon issuance. The fair value of the Old Hercules Warrant values were initially recorded as a discount to the Prior Term Loan principal balance and are being amortized to interest expense using the effective interest method over the life of the Prior Term Loan.

The Old Hercules Warrants were initially exercisable for a period of ten years from the date of the issuance of each warrant at a per-share exercise price equal to $2.632 Canadian dollars, subject to certain adjustments as specified in the warrants. In addition, the Company has granted to the holders of the Old Hercules Warrants certain registration rights on a pari passu basis with the holders of outstanding preferred shares and warrants to purchase preferred shares.

The Company accounted for the warrants as a liability prior to the consummation of the Reverse Recapitalization since they were indexed to Old enGene’s redeemable convertible preferred shares that were classified as temporary equity. The Company remeasured the fair value of the warrants at each reporting date with changes being recorded as a change in the fair value of the warrant liabilities.

Upon the close of the Reverse Recapitalization, the Old Hercules Warrants, along with all other warrants to purchase shares of Old enGene's redeemable convertible preferred shares, were surrendered for no consideration.

 

Amended Loan and Security Agreement

On December 22, 2023 (the "Hercules Closing Date"), the Company entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement”), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the "Lenders”). The Amended Loan Agreement amends and restates in its entirety the Prior Loan Agreement with Hercules dated December 30, 2021.

The Amended Loan Agreement provides for a term loan facility of up to $50.0 million available in multiple tranches (the "Term Loan”), as follows: (i) an initial term loan advance (the "Tranche 1 Advance”) that was made on the Tranche 1 Advance closing of $22.5 million, approximately $8.6 million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the "Interim Milestone”), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical

15


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

evaluation of EG-70 in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances to us in an aggregate principal amount of up to $7.5 million from the date of achievement of the Interim Milestone through the earlier of (x) 60 days following the achievement of the Interim Milestone and (y) March 31, 2025, and (iii) an uncommitted tranche subject to the Lenders’ investment committee approval and satisfaction of certain other conditions precedent (including payment of a 0.75% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (defined below) that the Lenders make additional term loan advances to the Company in an aggregate principal amount of up to $20.0 million. The Company is required to pay upon the earlier of January 1, 2028 ( the “Maturity Date”) or payment in full of the Term Loans, an end of term fee equal to 5.50% of the aggregate principal amount of the Term Loans (the "End of Term Charge"). The Company is also required to pay on July 1, 2025 or, if earlier, the date the Company prepays the Term Loans, $0.7 million representing the Prior Term Loan End of Term Charge (the Prior Term Loan End of Term Charge and End of Term Charge, collectively the "End of Term Charges").

The Term Loans mature on January 1, 2028, with no option for extension.

The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the Wall Street Journal plus 0.75% (capped at 9.75%) and (b) 9.25%. The Term Loan also bears additional payment-in-kind interest at an annual rate of 1.15%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement are repayable in monthly interest-only payments through the "Amortization Date”, which is either: (x) July 1, 2025 or (y) if the Interim Milestone is achieved and there has been no default, January 1, 2026, or (z) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, July 1, 2026. After the Amortization Date, the outstanding Term Loans and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. The effective interest rate of the Term Loan was 12.38% as of April 30, 2024.

At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) 1.0% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.

In connection with the Amended Loan Agreement, the Borrowers granted Hercules a security interest senior to any current and future debts and to any security interest in all of the Borrowers’ right, title, and interest in, to and under all of the Company’s property and other assets, subject to limited exceptions including the Borrowers’ intellectual property.

The Amended Loan Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict the Borrowers’ ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement also contains certain events of default and representations, warranties and non-financial covenants of the Borrowers. The Borrowers have been in compliance with the financial covenants since inception of the Term Loan.

The Company accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan. As a result of the extinguishment, the Company recorded a loss of $0.4 million as a component within other income and expense in the Company's consolidated statement of operations during the three and six months ended April 30, 2024, which represented the difference between the reacquisition price of the debt, including fees and the initial fair value of the warrants paid directly to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.

As of April 30, 2024, the Company had borrowed $22.5 million under the Amended Loan Agreement and incurred $2.1 million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan.

Hercules Common Share Warrants

In connection with the Amended Loan Agreement, the Company also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of the Company’s common shares, as shall be equal to 2% of the aggregate principal amount of such Term Loan advance divided by the Warrants per share exercise price of $7.21 (which exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary

16


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

adjustments under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of seven years from issuance.

Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is 138,696. On the Hercules Closing Date, the Company issued to the Lenders 62,413 Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans (the "Closing Date Warrants”). The Closing Date Warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815. Upon entering into the Amended Loan Agreement, $0.3 million of the total $22.5 million Tranche 1 Advance was allocated to the warrants, on a relative fair value basis, and recorded within additional paid in capital.

Subsequently issued Hercules Common Share Warrants shall be substantially in the form of the Closing Date Warrants. Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and resultant underlying common shares of the Company that could be issued is 138,696 (i.e. 2% of the $50.0 million total commitment amount divided by the exercise price of $7.21 price specified in the Closing Date Warrant), assuming no adjustments are made under the terms of the Hercules Common Share Warrants and further assuming the full amount of Term Loans are drawn.

As of April 30, 2024 and October 31, 2023, the carrying value of the term loans consisted of the following:

 

 

April 30, 2024

 

 

October 31, 2023

 

Note payable, including End of Term Charge

 

$

24,530

 

 

$

10,144

 

Debt discount, net of accretion

 

 

(1,974

)

 

 

(474

)

Accrued interest

 

 

174

 

 

 

108

 

Note payable, net of discount

 

$

22,730

 

 

$

9,778

 

 

As of October 31, 2023, the Company classified $0.6 million of the note payable as current, which represents the principal payments due and amortization of the debt discount between October 31, 2023 and the date the Prior Term Loan was amended in December 2023, as the debt was refinanced on a long-term basis in the subsequent period.

 

During the three months ended April 30, 2024 and 2023, the Company recognized $0.7 million and $0.4 million of interest expense, respectively, related to the term loans, of which $0.1 million and $0.1 million was related to the amortization of the debt discounts, respectively. During the six months ended April 30, 2024 and 2023, the Company recognized $1.3 million and $0.9 million of interest expense, respectively, related to the term loans, of which $0.3 million and $0.2 million was related to the amortization of the debt discounts, respectively.

Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and paid in kind interest are as follows as of April 30, 2024:

 

 

Note Principal
Payments

 

2024

 

$

 

2025

 

 

3,285

 

2026

 

 

8,254

 

2027

 

 

9,047

 

2028

 

 

4,617

 

Total principal payments, including End of Term Charge

 

 

25,203

 

 

As of April 30, 2024, based on borrowing rates available to the Company for loans with similar terms and consideration of the Company’s credit risk, the carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value.

 

17


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

April 2023 Notes

On April 4, 2023, Old enGene entered into a note purchase agreement (the “April 2023 Notes”) for a principal amount of $8.0 million with Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Quebec), L.P., Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Fond de solidarité des travailleurs du Québec (F.T.Q.), and Forbion Capital Fund III Cooperatief U.A. (collectively the “April 2023 Investors”). The April 2023 Notes had an interest free period of 45 days from the date of issuance, and commencing on the 46th day, began to accrue interest at a rate of 15% per annum. The April 2023 Notes were classified as current as they matured on the earlier of (i) July 31, 2023; or (ii) the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $20.0 million. Upon the completion of the 2023 Financing (as defined below) in May 2023, Old enGene issued convertible debentures and warrants of Old enGene to the April 2023 Note investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, as repayment of the April 2023 Notes.

The Company elected the fair value option of accounting for the April 2023 Notes. The Company recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be $8.0 million. Given the short period of time that the April 2023 Notes were outstanding, no change in fair value was recorded during the three months ended April 30, 2023. The April 2023 Notes were extinguished in May 2023 as part of the issuance of the May 2023 Notes (see Note 9).

9.
Convertible Debentures

Old enGene had issued convertible debentures to various investors. There was no outstanding principal, accrued interest, and unamortized deferred financing costs of the convertible debentures recorded on the balance sheet as of April 30, 2024 and October 31, 2023, as the convertible debentures were converted and exchanged for common shares of the Company or repaid upon the closing of the Reverse Recapitalization. Refer to Note 3.

BDC Notes

In September 2020, Old enGene issued a convertible debenture to the Business Development Bank of Canada (“BDC”) in the amount of $2.2 million (the “BDC Notes”). The debt bears interest at rate of 8% per annum and had an initial maturity date of September 28, 2023. In December 2021 Old enGene amended the agreement which resulted in the maturity date extending to September 29, 2025. The BDC Notes were convertible at the option of the holder into Old enGene's Class B redeemable convertible preferred shares at a price of 80% of the price paid per share in qualified financing, as defined within the BDC convertible debenture agreement. The issuance of the Prior Term Loan in 2021 met the definition of a qualified financing per the BDC convertible debenture agreement. As the conversion option was not exercised upon the issuance of the Prior Term Loan, the conversion rights upon a qualified financing were waived. There were optional conversion options that existed if Old enGene is in default, or in the event of certain liquidation events, as defined within the BDC Notes, which allow for conversion of the BDC Note into the most senior share outstanding at the time of the event. If a liquidation event, as defined within the BDC Note agreement, and which included a SPAC transaction, is consummated after a qualified financing, and optional conversion is not elected, the Company is required to pay the investor in cash, the outstanding principal and the accrued but unpaid interest and in addition an amount equal to 20% of the principal.

Upon issuance of the BDC Notes, Old enGene identified embedded derivatives related to the equity conversion features and liquidity event repayment features which required bifurcation as a single compound derivative instrument. Old enGene estimated the fair value of the embedded derivative liabilities upon issuance at $0.2 million. Old enGene remeasured the fair value of the embedded derivatives in effect at each reporting period, with the subsequent changes in the fair value of the derivative being recognized in changes in fair value of derivatives within the Company’s consolidated statements of operations and comprehensive loss. During the three and six months ended April 30, 2023, Old enGene recorded a change in fair value on the convertible debentures embedded derivative liability associated with the BDC Note of $0.2 million and $0.1 million, respectively. Total interest expense for the BDC Notes, including the amortization of debt discounts, was $60 and $0.1 million for the three and six months ended April 30, 2023. As part of the issuance of the BDC Notes, Old enGene incurred an aggregate of $36 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the BDC Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. Upon the close of the Reverse Recapitalization the Company repaid the BDC Note, resulting in full settlement of the note.

18


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

2022 Notes

During the year ended October 31, 2022, Old enGene issued convertible debentures for an aggregate amount of $18.4 million on October 20, 2022 (the “2022 Notes”). The 2022 Notes had an initial maturity that is the later of (i) three years from the date of issuance; or (ii) the maturity date of the Prior Term Loan (see Note 8). The 2022 Notes bear interest at 10% per annum commencing on the date of issuance. The 2022 Notes are automatically convertible into common shares or redeemable convertible preferred shares of Old enGene upon certain events. Upon the close of the Reverse Recapitalization, the 2022 Notes were converted into 2,081,359 common shares of the Company.

Upon issuance of the 2022 Notes, Old enGene identified embedded derivatives related to the equity conversion features which required bifurcation as a single compound derivative instrument. Old enGene estimated the fair value of the embedded derivative liabilities upon issuance at $3.5 million. During the three and six months ended April 30, 2023, the Company recorded a loss on the change in fair value associated of 2022 Notes embedded derivative liability of $0.8 million and $0.4 million, respectively. Total interest expense for the 2022 Notes, including the amortization of debt discounts, of $0.6 million and $1.3 million was recorded for the three and six months ended April 30, 2023. As part of the issuance of the 2022 Notes, the Company incurred an aggregate of $44 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the 2022 Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred.

On October 31, 2023 upon the close of the Reverse Recapitalization, the 2022 Notes were converted into 2,081,359 common shares of the Company. The Company accounted for the conversion as an extinguishment and recorded a loss on extinguishment of $3.1 million, relating to the difference between the fair value of the common shares issued and the carrying value of the 2022 Notes and fair value of the embedded derivative liability at the time of conversion.

 

May 2023 Notes

On May 16, 2023, concurrently with the execution and delivery of the Merger Agreement, Old enGene entered into agreements pursuant to which it agreed to issue new convertible notes and warrants (i) for cash in an aggregate principal amount of $30.0 million and (ii) in repayment of the April 2023 Notes in an aggregate amount of $8.0 million (collectively, the "May 2023 Notes” and, together with the warrants purchased concurrently, the "2023 Financing”; the 2023 Financing together with the Amended 2022 Financing, the "Convertible Bridge Financing”).

The 2023 Financing occurred in two separate issuances with $28.0 million issued in May 2023 for $20.0 million in cash and $8.0 million in repayment of the April 2023 Notes, and an additional $10.0 million issued in June 2023 for $10.0 million in cash, of which Forbion Growth Sponsor FEAC I B.V. funded an aggregate amount of $20.0 million of the total $38.0 million. The May 2023 Notes issued as part of the 2023 Financing, if not converted, have an initial maturity date of October 20, 2025 and are to accrue interest at 10% per annum, which is payable upon maturity.

The warrants issued as part of the 2023 Financing were for the purchase of common shares of Old enGene. The 2023 Warrants were only to become exercisable upon the completion of the merger. Upon the close of the Reverse Recapitalization, the 2023 Warrants were exchanged for 2,679,432 warrants of the Company and have the same terms as the public warrants issued upon the FEAC initial public offering, with an exercise price of $11.50, and which will expire five years after the completion of the merger.

The warrants issued as part of the 2023 Financing were concluded to be liability classified upon issuance, as they failed the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s own stock as prescribed by ASC 815. The terms of the warrants initially required the Company to issue a variable number of shares until the PIPE Financing was executed, at which time the number of warrants became fixed. The 2023 Warrants were initially and subsequently measured at fair value with any changes in fair value recorded as a component of other income and expense within the change in fair value of warrant liabilities. Refer to Note 3. Upon the execution of the PIPE Financing and consummation of the Reverse Recapitalization, the warrants were reclassified to equity as the number of warrants became fixed and it was determined that the warrants met the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s own stock as prescribed by ASC 815.

10.
Redeemable Convertible Preferred Shares

As of October 31, 2022, Old enGene’s Articles of Amendment had an unlimited number of authorized shares of each class of redeemable convertible preferred shares.

19


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

Class A Redeemable Convertible Preferred Shares

On July 26, 2013, Old enGene entered into a subscription agreement (the “Class A Agreement”) with multiple investors, whereby Old enGene agreed to sell to the investors an initial aggregate amount of 610,333 Class A redeemable convertible preferred shares at a price of $1.5929 ($1.63845 CAD) per share for total aggregate proceeds of $1.0 million (the “Class A Initial Closing”). Included within the Class A Agreement were three additional future tranche obligations (the “Class A Second Tranche,” “Class A Third Tranche” and “Class A Fourth Tranche”) for Old enGene to issue and sell shares of Class A redeemable convertible preferred shares upon the achievement of certain milestone events. Only the Class A Second Tranche closed under the Class A Agreement. The Class A Second Tranche obligated Old enGene to sell and the Class A Investors to purchase 1,830,999 shares of Class A redeemable convertible preferred shares at a price of $1.56967 ($1.63845 CAD) per share for total proceeds of $2.9 million, upon the establishment of the Company’s headquarters in Montreal Quebec and completion of experiments required to bolster a patent application for dually-derivatized chitosan (the “Second Closing Milestone Event”), which occurred in 2013. Additionally, upon completing the Class A redeemable convertible preferred share financing, convertible notes of Old enGene held by multiple investors converted into Class A redeemable convertible preferred shares.

Class B Redeemable Convertible Preferred Shares

On January 6, 2015, Old enGene entered into a subscription agreement (the “Class B Agreement”) with multiple investors, where Old enGene agreed to sell to the investors an initial aggregate amount of 2,758,221 Class B redeemable convertible preferred shares at a price of $1.85032 ($2.17532 CAD) per share for total proceeds of $5.1 million (the “Class B Initial Closing”). Included within the Class B Agreement were two additional closings (the “Class B Second Tranche,” and the “Class B Third Tranche,” respectively) which obligated Old enGene to sell and Class B investors to purchase additional Class B redeemable convertible preferred shares upon certain events. The Class B Second Tranche obligated Old enGene to sell and the Class B Investors to purchase 1,838,815 Class B Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $3.0 million and the Class B Third Tranche obligated Old enGene to sell and the Class B Investors to purchase 1,608,963 Class B Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $2.6 million. The Class B Second Tranche and Class B Third Tranche closed on March 1, 2017.

Class B-1 Redeemable Convertible Preferred Shares

On September 10, 2015, Old enGene entered into a Subscription Agreement (the Class “B-1 Agreement”), in which Old enGene was to issue 1,523,809 Class B-1 redeemable convertible preferred shares for a purchase price of $1.64367 ($2.17532 CAD) per share, resulting in aggregate proceeds of $2.5 million. During the year ended October 31, 2020, the Class B-1 redeemable convertible preferred shares converted to common shares on a 1:1 basis. Therefore, as of each of the years ended October 31, 2020, October 31, 2021, and October 31, 2022, no shares of the Class B-1 redeemable convertible preferred shares remained outstanding. The Company has presented these shares within temporary equity as of October 31, 2019 within the consolidated statements of redeemable convertible preferred shares and shareholder deficit, as they contained the same redemption features as the Class B redeemable convertible preferred shares (further described above). Upon conversion to common shares, the carrying value of the Class B-1 redeemable convertible preferred shares was reclassified to additional paid in capital within shareholders’ deficit.

Class C Redeemable Convertible Preferred Shares

The Class C redeemable convertible preferred shares are issuable in series, of which an unlimited number are designated as Series 1 Class C redeemable convertible preferred shares with an issue price per share of $1.5929 ($1.63845 CAD); an unlimited number are designated as Series 2 Class C redeemable convertible preferred shares with an issue price per share of $1.85032 ($2.175315 CAD); an unlimited number are designated as Series 3 Class C redeemable convertible preferred shares with an issue price per share of $2.12376 ($2.6320 CAD); and an unlimited number are designated as Series 4 Class C redeemable convertible preferred shares that is reserved for the potential conversion of the BDC Notes, and will each have an issue price per share of $1.69901 ($2.10559 CAD).

On June 30, 2021, Old enGene entered into a subscription agreement (the “Class C Agreement”) with multiple investors, where Old enGene agreed to sell to the Investors an initial aggregate amount of 3,662,813 Series 3 Class C redeemable convertible preferred shares (the “Series 3 Class C Shares”) at a price of $2.12376 ($2.6320 CAD) per share for total proceeds of $7.8 million (the “Class C Initial Closing”). Included within the Class C Agreement was one additional closing (the “Class C Second Tranche”) which obligated Old enGene to sell and Class C investors to purchase additional Class C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class C Second Tranche obligated Old enGene to sell and the Class C investors to purchase 3,662,810 Series 3 Class C Shares at a price of $2.13192 ($2.6320 CAD) per share for total proceeds of $7.8 million. The Class C Second Tranche closed on October 29, 2021.

20


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

As part of each of the Class C Initial Closing and Class C Second Tranche, each Class C investor received 3,662,813 and 3,662,810 warrants, respectively, to purchase Class C redeemable convertible preferred shares (the “Class C Warrants”), resulting in an aggregate issued amount of 7,325,623 Class C Warrants. The Class C Warrants have an exercise price of $2.12376 ($2.6320 CAD) per share and a term of 10 years. The Class C Warrants were determined to be liabilities. The Company estimated the fair value of the warrant liabilities upon issuance and remeasured the fair value of the warrant liabilities at each reporting period, with the subsequent changes in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabilities within the Company’s consolidated statements of operations and comprehensive loss. Upon the completion of the Reverse Recapitalization, all existing Class C Warrants of Old enGene were extinguished.

Under the terms of the Class C Agreement, certain convertible notes held by various Class C investors and other investors were exchanged for an aggregate amount of 16,464,646 Class B redeemable convertible preferred shares. Additionally, upon entering into the Class C Agreement, Old enGene also entered into a share exchange agreement (the “Share Exchange Agreement”) with the Class A investors and the Class B investors. As part of the Share Exchange Agreement, certain of the Class A redeemable convertible preferred shares issued to Class A investors were exchanged for Series 1 Class C redeemable convertible preferred shares and certain of the Class B redeemable convertible preferred shares issued to the Class B investors were exchanged for Series 2 Class C redeemable convertible preferred shares. This exchange resulted in the derecognition of Class A and B redeemable convertible preferred shares and the recognition of Class C redeemable convertible preferred shares at the fair value of the Class C redeemable convertible preferred shares. The difference between the carrying value of the Class A and Class B redeemable convertible preferred shares and the fair value of the Class C redeemable convertible preferred shares for which they converted into was recorded within additional paid in capital and no gain or loss on extinguishment was recorded within the consolidated statements of operations and comprehensive loss. Further, the February 2020 Warrants, June 2020 Warrants, and 2021 Warrants, which consisted of warrants to purchase Old enGene's Class B redeemable convertible preferred shares and were issued as part of the convertible debentures were cancelled and replaced by the terms of the Class C Warrants. The aggregate amount of outstanding warrants of 10,242,130 from the February 2020 Warrants, the June 2020 Warrants, and the 2021 Warrants converted into 10,242,130 Class C Warrants, which have an exercise price of $2.12376 ($2.6320 CAD) per share and a term expiring on February 14, 2030. Immediately prior to conversion, the warrants were marked to fair value, with the change in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabilities within the Company’s consolidated statements of operations and comprehensive loss.

Upon issuance of each series of Class A, Class B, and Class C Preferred Shares, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features.

Conversion of Redeemable Convertible Preferred Shares

Pursuant to the terms of the Merger Agreement, upon the consummation of the Reverse Recapitalization, each share of Old enGene’s redeemable convertible preferred shares issued and outstanding immediately prior to the close was exchanged for common shares of the Company using the Exchange Ratio of approximately 0.18048. A retrospective adjustment has been applied to all periods presented to reflect the Reverse Recapitalization. Refer to Note 3 for additional discussion.

Undesignated Preferred Shares

The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue an unlimited number of preferred shares with no par value. The preferred shares are currently undesignated.

11.
Common Shares

The Company has an unlimited number of Common Shares authorized shares for issuance, with no par value. As of April 30, 2024 and October 31, 2023, there were 44,158,587 and 23,197,976 Common Shares outstanding, respectively.

The holders of the Common Shares are entitled to one vote per Common Share held on all matters submitted to a vote of shareholders. Common shareholders are entitled to receive dividends, as may be declared by the board of directors, or the "Board", if any, subject to the preferential dividend rights of preferred shares. Through April 30, 2024, no cash dividends had been declared or paid.

On February 13, 2024, the Company entered into subscription agreements (collectively, the "2024 Subscription Agreements”) with the investors named therein, for the private placement (the "2024 PIPE Financing") of 20,000,000 common shares of the Company,

21


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

at a price of $10.00 per share. The aggregate gross proceeds from the 2024 PIPE Financing was $200 million, before deducting offering expenses of $12.4 million. The 2024 PIPE Financing closed on February 20, 2024.

Warrants to purchase Common Shares

As of April 30, 2024 and October 31, 2023, the Company had 8,511,968 and 10,411,641 warrants to purchase Common Shares outstanding, respectively.

Of the warrants to purchase Common Shares outstanding as of April 30, 2024, 8,449,555 have the same terms as the FEAC public warrants issued in connection with FEAC’s IPO, and have an exercise price of $11.50, and are exercisable beginning 30 days after the completion of the Reverse Recapitalization and which will expire on October 31, 2028, or five years after the completion of the Reverse Recapitalization. Through April 30, 2024, 383,355 common shares have been issued as a result of the exercise of 1,379,391 warrants on a cashless basis and 520,282 common shares have been issued through cash exercises of warrants for proceeds totaling $6.0 million.

The number of Common Shares to be issued upon the cashless exercise is equal to the quotient obtained by dividing (x) the product of the number of shares underlying the warrants, multiplied by the excess of the “Fair Market Value” over the warrant exercise price of $11.50 by (y) the Fair Market Value. The Fair Market Value is the volume weighted average price of the shares for the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Company’s Warrant Agent from the holder or its broker or intermediary. The warrants had a cashless exercise period until such time as the registration statement under the Securities Act with respect to the enGene Common Shares underlying the enGene Warrants was declared effective, which occurred on March 5, 2024. The Company may elect to call in the warrants for a redemption if the share price of the Company reaches redemption trigger price of $18.00.

The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815.

The additional 62,413 of the warrants to purchase Common Shares outstanding as of April 30, 2024, were issued as part of the Amended Term Loan on December 22, 2023, have an exercise price of $7.21, and are exercisable at any time beginning on December 22, 2023 expiring on December 22, 2030, or seven years from the issuance date. The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815.

As of April 30, 2024, and October 31, 2023, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the Company's 2023 Plan ( as defined below):

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Warrants to purchase Common Shares

 

 

8,511,968

 

 

 

10,411,641

 

Options to purchase Common Shares

 

 

3,981,433

 

 

 

2,706,941

 

Remaining shares reserved for future issuance under
   the 2023 Plan

 

 

3,222,703

 

 

 

2,607,943

 

Total

 

 

15,716,104

 

 

 

15,726,525

 

 

12.
Share-Based Compensation

Pursuant to the terms of the Reverse Recapitalization, upon the Closing Date, each outstanding option to purchase Old enGene’s common shares issued under the Old Plan’s was exchanged for an option to purchase common shares of the Company, and the number of shares and exercise price of each granted option was adjusted using the exchange ratio of approximately 0.18048. Further, the currency of all exercise prices of the options issued under the Old Plans were converted from CAD to USD using the exchange rate in effect on the day immediately prior to the Closing Date. A retrospective adjustment has been applied to the number of options and exercise price of stock options for all periods presented to reflect the Reverse Recapitalization as discussed further in Note 3.

22


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

The Old Plans

Old enGene had an employee share option plan (the “ESOP”) and an equity incentive plan (the “EIP”) (collectively, the “ Old Plans”) which was adopted by the Board of Directors, and approved by the shareholders, effective July 5, 2018.

Under the Old Plans, options to purchase non-voting common shares of Old enGene’s shares may be granted to directors, officers, employees, consultants and members of the scientific advisory board. The Old Plans provide for the issuance of stock options up to a maximum of 15% of the aggregate issued and outstanding common shares and non-voting common shares of Old enGene calculated on an as converted and fully diluted basis. The Old Plans were administered by Old enGene’s Board of Directors. Old enGene’s Board of Directors determined the number of options to be granted, the vesting period and the exercise price of new options. It was Old enGene’s policy to establish the exercise price at an amount that approximates the fair value of the underlying shares on the date of grant as determined by Old enGene’s Board of Directors. The options vest in accordance with the vesting terms determined for each grant by Old enGene’s Board of Directors. The vesting terms of Old enGene’s granted stock options with service only conditions are typically 100% vesting immediately upon grant date, or over a three- or four-year service period. Upon the consummation of the Reverse Recapitalization, the Company recognized stock based compensation expense of $0.4 million associated with the acceleration of the vesting for the outstanding awards with service only vesting conditions under the Old Plan. As of April 30, 2024, no unrecognized compensation cost remains for the outstanding awards granted under the Old Plan with service only vesting conditions.

 

On July 7, 2023, the Board of Directors approved the reservation of an additional 1,046,764 non-voting common shares for issuance under the Company’s employee equity incentive plan, revising the number of shares reserved from 1,775,729 to 2,822,493. Also on July 7, 2023, the Company granted 1,046,764 options to employees at an exercise price of $5.87 CAD ($4.24 USD). These options are not exercisable unless and until the completion of the Reverse Recapitalization and there is an effective registration statement for the shares underlying such granted options and will terminate automatically in the event of the termination of the Merger Agreement. The Company has valued these awards at the grant date using Black-Scholes pricing model in which the fair value of the stock on the grant date was equal to the exercise price of the award. The expected term has been determined using management’s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers. Upon the grant date, 794,643 of the issued options were fully vested, and the remaining 252,121 options will vest over varying terms up to four years on a pro rata basis. The Company recognizes compensation expense when achievement of the performance condition is deemed probable using an accelerated attribution method, as if each vesting tranche was treated as an individual award. During the year ended October 31, 2023, $2.6 million of stock based compensation expense was recorded associated with the 1,046,764 stock options granted in July 2023 because the Reverse Recapitalization was completed and the Company determined that the filing of the registration statement was probable to occur.

Upon the consummation of the Reverse Recapitalization on October 31, 2023, all options outstanding under the Old Plans were exchanged for 2,706,941 shares options to purchase common shares of the Company based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement. Further, all exercise prices were adjusted by the Exchange Ratio and the currency of the exercise prices was changed from CAD to USD based on the exchange rate in effect on October 30, 2023, the day immediately before the consummation of the Reverse Recapitalization. No incremental compensation cost was recorded as a result of the change in underlying common shares from Old enGene to the Company, or as a result of the change of the exercise prices to reflect the adjustment for the Exchange Ratio and the change in currency from CAD to USD, as it was concluded that the fair value of the awards immediately before and immediately after the modifications did not change. No options remain available for grant under the Old Plans as of October 31, 2023.

The 2023 Plan

On October 31, 2023, upon the completion of the Reverse Recapitalization, the shareholders approved and the Company adopted the enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which superseded the Old Plans. The 2023 Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Stock Units, Stock Appreciation Rights, or SARs, and other share-based awards including performance awards and share bonus awards.

23


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

The number of shares initially reserved for issuance under the 2023 Plan is 2,607,943 Common Shares, plus 2,706,941 common shares subject to the outstanding grants under the Old Plans, and shall automatically increase on January 1 of each calendar year beginning in 2024 by a number of shares equal to the lesser of 1,946,226 million Common Shares and such lesser number as may be determined by the Board. The Common Shares authorized under the 2023 Plan increased by 1,946,225 on January 1, 2024. As of April 30, 2024, the total number of Common Shares reserved for issuance under the 2023 Plan is 7,261,110, and there are 5,929,643 shares remaining for issuance.

The 2023 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board. The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the Common Shares on the date of grant and the term of stock option may not be greater than ten years. Common Shares that are expired terminated, surrendered or cancelled under the 2023 Plan without having been fully exercised will be available for future awards.

On May 15, 2024, the shareholders of the Company approved changes to the 2023 Plan. See Note 18 for additional information.

Stock Options

The assumptions that the Company used to determine the grant-date fair value of stock options during the three and six months ended April 30, 2024 and 2023 are summarized below:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Expected term (in years)

 

5.75 - 6.08

 

 

6.08

 

 

5.75 - 6.08

 

 

6.08

 

Expected volatility

 

78.30 - 78.92%

 

 

 

81.39

%

 

78.24 - 78.92%

 

 

 

81.39

%

Risk-free interest rate

 

4.27 - 4.66%

 

 

 

3.56

%

 

4.27 - 4.66%

 

 

 

3.56

%

Expected dividend yield

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of common shares and exercise price of options (USD)

 

$ 14.80 - 17.80

 

 

 

1.55

 

 

$ 7.66 - 17.80

 

 

 

1.55

 

Fair value of common shares and exercise price of options (CAD)

 

N/A

 

 

$

2.11

 

 

N/A

 

 

$

2.11

 

 

The following table summarizes the Company’s stock option activity:

 

 

Number of
Shares

 

 

Weighted-
Average
Exercise
Price (USD)

 

 

Weighted-
Average
Remaining
Contractual
Term (in years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding as of October 31, 2023

 

 

2,706,941

 

 

$

2.40

 

 

 

8.1

 

 

$

52,192

 

Granted

 

 

1,331,700

 

 

 

12.49

 

 

 

 

 

 

 

Exercised

 

 

(56,974

)

 

 

0.89

 

 

 

 

 

 

 

Forfeited or expired

 

 

(234

)

 

 

0.89

 

 

 

 

 

 

 

Outstanding as of April 30, 2024

 

 

3,981,433

 

 

$

5.69

 

 

8.4

 

 

$

41,181

 

Vested and exercisable as of April 30, 2024

 

 

2,434,737

 

 

$

2.10

 

 

7.6

 

 

$

33,597

 

Options unvested as of April 30, 2024

 

 

1,546,696

 

 

$

11.35

 

 

9.7

 

 

$

7,584

 

 

The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company’s common share as of each reporting period.

The weighted-average grant-date fair value per share of share options granted during the three and six months ended April 30, 2024 was $11.60 and $8.87, respectively. The weighted-average grant date fair value per share of share options granted during the three and six months ended April 30, 2023 was $1.50.

24


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

CEO Modification

 

On February 13, 2024, the Company entered into a Transition and Modified Employment Agreement (the "Transition Agreement") with the Company's Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement dated November 8, 2023 (the “Amended Employment Agreement”). Under the terms of the Amended Employment Agreement the CEO will be entitled to:

(i)
twelve months of continued health insurance benefits;
(ii)
payment of a prorated portion of his 2024 target annual bonus;
(iii)
acceleration and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination; and
(iv)
extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of the CEO’s vested equity awards extend beyond the respective applicable term thereof.

 

The Transition Agreement further provides that, in the event the CEO resigns upon the appointment by the Company of a new chief executive officer, the CEO will be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of resignation (the “Consulting Period”) in exchange for a monthly fee of $25,000 for the initial six-month Consulting Period, and $500 per hour thereafter, provided that the CEO need not devote more than fifteen (15) hours per week to providing such transition services.

 

As a result of the Transition Agreement, the 1,216,266 stock option awards issued to the CEO were modified to allow for an extended exercise period described above. The modification resulted in an incremental share-based compensation expense of $1.0 million which was recorded upon the effective date of the Transition Agreement.

 

Pursuant to the Amended Employment Agreement, (a) upon the termination of Mr. Hanson’s employment by the Company without Cause (as defined in the Amended Employment Agreement) or by Mr. Hanson for Good Reason (as defined in the Amended Employment Agreement), in addition to the above severance benefits, Mr. Hanson will also be entitled to 12 months’ base salary continuation or, if such even occurs during a change of control period (as described in the Amended Employment Agreement), 18 months’ base salary continuation.

Share-based Compensation Expense

Share-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss was as follows:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Research and development

 

$

337

 

 

$

7

 

 

$

530

 

 

$

12

 

General and administrative

 

 

1,580

 

 

32

 

 

 

1,678

 

 

47

 

Total share-based compensation expense

 

$

1,917

 

 

$

39

 

 

$

2,208

 

 

$

59

 

 

As of April 30, 2024, there was $11.3 million of unrecognized compensation, which is expected to be recognized over a weighted-average period of 3.60 years.

25


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

13.
Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the Reverse Recapitalization:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

14,984

 

 

$

5,282

 

 

$

25,695

 

 

$

12,700

 

Deemed dividend attributable to redeemable convertible
   preferred shareholders

 

 

 

 

 

1,175

 

 

 

 

 

 

2,389

 

Net loss attributable to common shareholders, basic and
   diluted

 

$

14,984

 

 

$

6,457

 

 

$

25,695

 

 

$

15,089

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares used in net
   loss per share, basic and diluted

 

 

39,443,768

 

 

 

694,497

 

 

 

31,186,238

 

 

 

680,003

 

Net loss per common share, basic and diluted

 

$

0.38

 

 

$

9.30

 

 

$

0.82

 

 

$

22.19

 

 

The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders for the three and six months ended April 30, 2024 and 2023 because including them would have had an anti-dilutive effect:

 

 

Three and Six Months Ended April 30,

 

 

2024

 

 

2023

 

Redeemable convertible preferred shares

 

 

 

 

 

5,983,339

 

Warrants to purchase redeemable convertible preferred shares

 

 

 

 

 

3,194,756

 

Warrants to purchase common shares

 

 

8,511,968

 

 

 

 

Options to purchase common shares

 

 

3,981,433

 

 

 

1,620,599

 

Total

 

 

12,493,401

 

 

 

10,798,694

 

 

14.
Income Taxes

During the three months ended April 30, 2024 and 2023, the Company recorded $21 thousand and zero, respectively, in income tax provision. During the six months ended April 30, 2024 and 2023, the Company recorded $9 thousand and zero, respectively, in income tax benefit.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of April 30, 2024, the Company has maintained a full valuation allowance against its remaining net deferred tax assets.

15.
Leases

The Company’s leases are comprised of operating leases for office and lab space.

In November 2021, the Company entered into an office and lab space lease approximating 9,360 of rentable square feet for designated office and lab spaces located at 7171 Frederick-Banting, City of Montreal, judicial district of Montreal, Province of Quebec. The leased commenced in November 2021 and had an initial term of 12 months that would have expired on October 31, 2022, and includes options to renew for consecutive twelve-month periods upon landlord consent at new lease rates. As the Company has elected

26


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

to not recognize leases with a lease term of 12 months or less on the balance sheet, this was considered a short-term lease, and no operating lease right of use assets and liabilities were recognized. In October 2022, the Company entered into a lease amendment to extend the lease for an additional term of six months through April 2023, with an option to extend the lease through September 2023. In April 2023, the Company extended the lease through September 2023. The lease was further extended through November 5, 2023, at which time the Company vacated the lease.

On December 29, 2022, the Company signed a lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for 10 years, beginning on the commencement date, and requires an annual initial base rent of $36.50 CAD per square foot, which is subject to annual increases of 2%. The lease commenced in November 2023. Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $1.4 million.

On January 1, 2024, the Company entered into a lease agreement, in which the Company is sub-leasing approximately 6,450 square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $0.5 million under the initial term of the lease, which is set to expire on December 30, 2026 and does not have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $0.4 million.

During the three and six months ended April 30, 2024 and 2023, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Lease Cost:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease cost

 

 

119

 

 

 

 

 

 

209

 

 

 

 

Variable operating lease cost

 

 

 

 

 

16

 

 

 

24

 

 

 

32

 

Short-term operating lease cost

 

 

 

 

 

106

 

 

 

 

 

 

212

 

Total operating lease cost

 

 

119

 

 

 

122

 

 

 

233

 

 

 

244

 

 

Maturities of the Company's operating lease liabilities as of April 30, 2024 are as follows:

 

2024 (remaining)

 

 

223

 

2025

 

 

456

 

2026

 

 

468

 

2027

 

 

327

 

2028

 

 

303

 

Thereafter

 

 

1,722

 

Total

 

 

3,499

 

Less: Interest

 

 

(1,545

)

Total Lease liability

 

 

1,954

 

 

16.
Commitments and Contingencies

Legal Proceedings

From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of April 30, 2024, and October 31, 2023, there were no matters which would have a material impact on the Company’s financial results.

Purchase and Other Obligations

The Company enters into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.

27


ENGENE HOLDINGS INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)

17.
Related Party Transactions

During the three and six months ended April 30, 2024 the Company had the following transactions with related parties:

 

On February 20, 2024, the Company completed the 2024 PIPE Financing, which provided for the private placement of 20,000,000 Common Shares, at a price of $10.00 per share and included both new and existing investors. One of the Company's director's, Mr. Gerry Brunk, is a managing director of Lumira Ventures ("Lumira"), and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of 800,000 Common Shares for a total price of $8 million in the Company's 2024 PIPE Financing.

 

During the three and six months ended April 30, 2023 the Company had the following transactions with related parties:

On April 4, 2023, the Company entered into the April 2023 Notes for a principal amount of $8.0 million with the April 2023 investors, as described in Note 8. The April 2023 Notes had an interest free period of 45 days from the date of issuance, and commencing on the 46th day, is to accrue interest at a rate of 15% per annum. The April 2023 Notes had a maturity date which was the earlier of (i) July 31, 2023; or (ii) the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $20.0 million. Upon the completion of the 2023 Financing, which met the definition of a qualified financing as defined within the April 2023 Notes, the Company issued and aggregate amount of $8.0 million of convertible debentures and warrants of the Company to the April 2023 Note investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, for the extinguishment and settlement of the April 2023 Notes.

 

18.
Subsequent Events

 

The Company has evaluated subsequent events through the date these financial statements were issued. Except as noted below, the Company concluded that no additional subsequent events have occurred that require disclosure.

 

On May 15, 2024, the shareholders of the Company approved changes to the 2023 Plan. The original 2023 Plan contained an evergreen provision (the “Evergreen Provision”) pursuant to which, commencing with the first business day of each calendar year beginning in 2024, the aggregate number of the Company’s Common Shares that could be issued or transferred thereunder (the “Plan Share Reserve”) and the number of Common Shares available for options intended to qualify as incentive stock options (the “ISO Sublimit”) each increased by a number of Common Shares equal to the lesser of (x) 1,946,226 million Common Shares and (y) such lesser number of Common Shares as may be determined by the Compensation Committee. Pursuant to the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, on May 15, 2024, the Evergreen Provision was amended to provide for annual increases on the first business day of each calendar year of (i) the Plan Share Reserve by such number of Common Shares as equals 5% of the aggregate number of Common Shares outstanding on the final day of the immediately preceding calendar year (or such smaller number of shares as is determined by the compensation committee), and (ii) the ISO Sublimit by the lesser of 2,500,000 Common Shares and the increase in the Plan Share Reserve (or such smaller number of shares may be determined by the compensation committee of the Company’s board of directors).

28


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Throughout this section, unless otherwise noted, “we”, “our”, “us”, “enGene” and the “Company” refer to enGene Holdings Inc. and all of its subsidiaries immediately following the consummation of the Reverse Recapitalization. enGene Holdings Inc. is the new, publicly traded parent company of the combined business formed in connection with the Reverse Recapitalization, in which shareholders of enGene Inc. and Forbion European Acquisition Company exchanged their shares for shares in enGene Holdings Inc.

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. See the sections titled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” in our Annual Report on Form 10-K for the year ended October 31, 2023 and elsewhere in this Quarterly Report on Form 10-Q and in our other filings made with the SEC for a discussion of forward-looking statements and important factors that could cause actual results to differ materially from the results described in or implied by such forward-looking statements.

We operate as a single operating segment focused on research, discovery, and clinical development of human gene therapy products. Our fiscal year is the year ended October 31.

Overview

Business Overview

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

On June 13, 2024, enGene announced plans to explore additional applications of EG-70 within the bladder by expanding the Phase 2 LEGEND study to include a third cohort targeting high-risk BCG-unresponsive papillary-only NMIBC patients and plans to modify the second cohort to separately analyze responses between BCG-naïve patients and BCG-exposed patients. The planned third cohort of patients with BCG-unresponsive, papillary-only Ta/T1 disease is expected to enroll 70 to 100 patients and begin enrollment in the fourth quarter of 2024. The planned modification of the second cohort, for which enrollment has been temporarily paused, is designed to allow separate analysis of responses between BCG-naïve patients and BCG-exposed patients and enGene expects to resume enrollment in both groups in the fourth quarter of 2024. As a result of the prioritization of these potential new indications in bladder cancer, enGene deprioritized pre-clinical development of EG-i08 for cystic fibrosis.

We have never been profitable and have incurred net losses since inception. Our net loss was $15.0 million and $25.7 million for the three and six months ended April 30, 2024, respectively, and $5.3 million and $12.7 million for the three and six months ended April 30, 2023, respectively. We expect to continue to incur operating losses for at least the next several years as we advance the ongoing pivotal-stage LEGEND study of EG-70 in BCG-unresponsive NMIBC to completion; execute on our plan to file our Biologics License Application mid-2026; and pursue potential pipeline expansion via additional EG-70 development opportunities and other compounds.

If we obtain regulatory approval for a product candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, or other capital sources, which could include potential collaboration agreements, strategic alliances, or additional licensing arrangements. We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our product candidates.

As of April 30, 2024, we had $264.8 million in cash and cash equivalents. We believe that our existing cash and cash equivalents as of April 30, 2024 will be sufficient to fund our operating expenses, debt obligations, and capital expenditure requirements for at least the next 12 months from the issuance date of the condensed consolidated financial statements. While we have historically been successful in securing financing, raising additional funds is dependent on a number of factors outside of our control, and as such there is no assurance that we will be able to do so in the future. Refer to “Liquidity and Capital Resources” section below.

29


 

Reverse Recapitalization

On October 31, 2023, the Company, Forbion European Acquisition Corporation (“FEAC”), and enGene Inc., a corporation incorporated under the laws of Canada (now known as “enGene Inc” or “Old enGene”), consummated the merger (the “Reverse Recapitalization”) pursuant to a business combination agreement, dated as of May 16, 2023 (the “Merger Agreement”).

The transaction was accounted for as a “reverse recapitalization” in accordance with accounting principles generally accepted in the United States (“GAAP”). Under this method of accounting, FEAC was treated as the “acquired” company for financial reporting purposes. This determination is and was primarily based on the fact that subsequent to the Reverse Recapitalization, senior management of Old enGene continues as senior management of the combined company; Old enGene identifies a majority of the members of the board of directors of the combined company; the name of the combined company is enGene Holdings Inc. and it utilizes Old enGene’s current headquarters, and Old enGene’s operations comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Company is considered to be a continuation of Old enGene, with the net identifiable assets of FEAC deemed to have been acquired by Old enGene in exchange for Old enGene common shares accompanied by a recapitalization, with no goodwill or intangible assets recorded. The number of redeemable convertible preferred shares, number of common shares, net loss per common share, the number of warrants to purchase common shares, and the number of stock options and the related exercise prices of the stock options issued and outstanding prior to the Reverse Recapitalization, have been retrospectively restated to reflect an exchange ratio of approximately 0.18048 (the “Exchange Ratio”) established in the Merger Agreement. Operations prior to the Reverse Recapitalization are those of Old enGene.

As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its ordinary shares and warrants on the Nasdaq Global Market under the symbols “ENGN” and “ENGNW,” respectively, commencing trading on November 1, 2023, with Old enGene, a subsidiary of the Company continuing the existing business operations. Immediately after giving effect to the Reverse Recapitalization and the PIPE Financing, the Company had 23,197,976 Common Shares and 10,411,641 Warrants outstanding.

As part of the Reverse Recapitalization, the Company received net proceeds of $7.4 million from the FEAC trust account, net of the redemption payment to FEAC’s public shareholders and FEAC expenses. As a part of the Reverse Recapitalization, the Company raised an aggregate amount of $56.9 million through a series of convertible debt investments made to Old enGene which were exchanged for equity interests in the Company pursuant to the Reverse Recapitalization.

Components of Our Results of Operations

Revenue

We do not have any product candidates approved for sale, have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products or from other sources in the near future, if at all. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate, if ever. If our development efforts for our current lead product candidate, EG-70 or additional product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.

Operating Expenses

Research and Development

Research and development expenses account for a significant portion of our operating expenses and consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:

Direct Costs:

expenses incurred under agreements with Contract Research Organization (CROs) that are primarily engaged in the oversight and conduct of our clinical trials; Contract Development and Manufacturing Organization (CDMOs) that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct our clinical trials, nonclinical studies and other scientific development services;
the cost of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches;

30


 

costs of outside consultants, including their fees, share-based compensation and related travel expenses;
costs related to compliance with quality and regulatory requirements; and
payments made under third-party licensing agreements.

Indirect Costs:

personnel-related expenses including, salaries, benefits, share-based compensation and other related costs for individuals involved in research and development activities; and
facilities, patent costs, laboratory supplies and other expenses not directly tied to a program.

We expense research and development costs as incurred. We recognize direct development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting date. Payments for these development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid expenses or accrued expenses.

A significant portion of our research and development costs to date have been third-party costs, which we track on an individual product candidate basis after a clinical product candidate has been identified. Currently, our main clinical product candidate is EG-70. Our indirect research and development costs are primarily personnel-related costs, facilities and other costs. Employees and infrastructure are not directly tied to any one program and are deployed across our programs. As such, we do not track these costs on a specific program basis. We utilize third party contractors for our research and development activities and CDMOs for our manufacturing activities and we do not have our own laboratory or manufacturing facilities.

Research and development activities are central to our business model. Currently, the Company’s sole laboratory facility is located in Montreal, Quebec, Canada, and as such, a portion of the Company’s research and development and other operating expenses are incurred in Canada and denominated in the Canadian dollar. We expect that our research and development expenses will continue to increase for the foreseeable future as we progress our ongoing Phase 1/2 clinical trial for EG-70, continue to discover and develop additional product candidates, expand our headcount and maintain, expand and enforce our intellectual property portfolio. If EG-70 or any future product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. There are numerous factors associated with the successful development and commercialization of any product candidates we may develop in the future, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development program and plans.

The duration, costs, and timing of clinical studies and development of our product candidate will depend on a variety of factors, any of which could mean a significant change in the costs and timing associated with the development of our product candidate including:

the scope, rate of progress, and expense of our ongoing as well as any additional clinical studies and other research and development activities we undertake;
future clinical study results;
uncertainties in clinical study enrollment rates;
new manufacturing processes or protocols that we may choose to or be required to implement in the manufacture of our drug substance and drug product;
regulatory feedback on requirements for regulatory approval, as well as changing standards for regulatory approval; and
the timing and receipt of any regulatory approvals.

General and Administrative

General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits, and share-based compensation expenses for personnel in executive and other administrative functions. Other significant general and administrative expenses include professional services, including legal, accounting and audit services and other consulting fees as well as facility costs not otherwise included in research and development expenses, insurance, and other operating costs.

31


 

We expect that our general and administrative expenses will continue to increase in the foreseeable future as our business expands to support our continued research and development activities, including our clinical trials. These increases will likely include increased costs related to the hiring of additional personnel and fees for outside consultants, among other expenses. We also anticipate increased expenses associated with operating as a public company, including costs for accounting, audit, legal, regulatory, and tax-related services related to compliance with the rules and regulations of the SEC, listing standards applicable to companies listed on a national securities exchange, director and officer insurance premiums and investor relations costs. In addition, if we obtain regulatory approval for our current product candidate or any product candidates we may develop in the future and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities.

Other (Income) Expense, Net

Change in fair value of convertible debenture embedded derivative liabilities

Old enGene’s convertible debentures consisted of a debt instrument, a minimum interest obligation, and a share conversion feature. Old enGene identified embedded derivatives related to share conversion features within the convertible notes that required bifurcation as a single compound derivative instrument and were classified as liabilities on our consolidated balance sheets. The convertible debenture embedded derivative liabilities were initially recorded at fair value upon the date of issuance using a probability weighted expected return model and were subsequently remeasured to fair value at each reporting date. The estimated probability and timing of underlying events triggering the conversion features contained within the convertible debentures are inputs used to determine the estimated fair value of the embedded derivative. Changes in the fair value of the convertible debenture embedded derivative liabilities were recognized in change in fair value of convertible embedded derivative liabilities as a component of other expense in our consolidated statements of operations and comprehensive loss. Upon the close of the Reverse Recapitalization Old enGene’s convertible debentures were exchanged for Common Shares of the Company, or settled through repayment, resulting in an extinguishment of the convertible debentures and related embedded derivative liabilities.

Change in fair value of warrant liabilities

Old enGene issued warrants to purchase redeemable convertible preferred shares as part of the issuance of certain redeemable convertible preferred shares and convertible debentures. Old enGene accounted for the redeemable convertible preferred shares warrants issued based upon the characteristics and provisions of the instrument and determined that the warrants were liability classified. The redeemable convertible preferred share warrants were recognized at their fair value on the date of issuance and remeasured to fair value at each reporting period, with the changes in fair value recognized in the change in fair value of warrant liabilities as a component of other expense in our consolidated statements of operations and comprehensive loss. Upon the close of the Reverse Recapitalization, the preferred share warrants were surrendered for no consideration and the fair value was determined to be zero.

The warrants issued by Old enGene as part of the PIPE Financing (the “2023 Warrants”) were concluded to be freestanding, liability classified instruments upon issuance, which were subsequently reclassified to equity upon the consummation of the Reverse Recapitalization. The fair value of the 2023 Warrants was estimated based on the underlying quoted market price of the FEAC public warrants, prior to the close of the Reverse Recapitalization. The 2023 Warrants were classified as a Level 2 measurement given they were substantially similar to FEAC public warrants. The 2023 Warrants were initially measured at fair value and were subsequently remeasured at fair value with any changes in fair value recorded as a component of other expense in our consolidated statements of operations and comprehensive loss, so long as they remain liability classified. Upon the execution of the PIPE Financing and consummation of the Reverse Recapitalization, the 2023 Warrants were reclassified to equity as the number of warrants became fixed and it was determined that the warrants met the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s shares as prescribed by ASC 815.

Interest Expense

Interest expense is made of interest paid on our term loans, as well as non-cash interest expense for amortization of our debt discounts. In fiscal year 2023, interest expense also included interest on Old enGene's convertible debentures.

Interest Income

Interest income is associated with our interest-bearing cash and cash equivalents.

Other expense, net

Other expense, net primarily consists of foreign exchange gains and losses.

32


 

Income Taxes

Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each period or for deductible temporary differences, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be realized. As of April 30, 2024 and October 31, 2023, we have recorded a full valuation allowance against our deferred tax assets.

 

Critical Accounting Estimates

This management’s discussion and analysis is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make judgments and estimates that affect the reported amounts of assets, liabilities and expenses, as well as related disclosures during the reported periods. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates. Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended October 31, 2023, which was filed with the Securities and Exchange Commission on January 29, 2024. There were no material changes to our critical accounting policies through April 30, 2024 from those disclosed in our Annual Report on Form 10-K for the year ended October 31, 2023.

Results of Operations

Comparison of the three and six months ended April 30, 2024 and 2023

The following table summarizes our results of operations for each of the periods presented (in thousands):

 

 

Three months ended April 30,

 

 

 

 

 

Six months ended April 30,

 

 

 

 

 

2024

 

 

2023

 

 

Change

 

 

2024

 

 

2023

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

9,855

 

 

$

3,215

 

 

$

6,640

 

 

$

15,493

 

 

$

6,886

 

 

$

8,607

 

General and administrative

 

 

7,455

 

 

 

1,522

 

 

 

5,933

 

 

 

12,590

 

 

 

2,484

 

 

 

10,106

 

Total operating expenses

 

 

17,310

 

 

 

4,737

 

 

 

12,573

 

 

 

28,083

 

 

 

9,370

 

 

 

18,713

 

Loss from operations

 

 

17,310

 

 

 

4,737

 

 

 

12,573

 

 

 

28,083

 

 

 

9,370

 

 

 

18,713

 

Other (income) expense, net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of convertible debenture embedded derivative liabilities

 

 

 

 

 

(625

)

 

 

625

 

 

 

 

 

 

(318

)

 

 

318

 

Change in fair value of warrant liabilities

 

 

 

 

 

341

 

 

 

(341

)

 

 

 

 

 

1,526

 

 

 

(1,526

)

Interest income

 

 

(2,984

)

 

 

(149

)

 

 

(2,835

)

 

 

(4,009

)

 

 

(316

)

 

 

(3,693

)

Interest expense

 

 

728

 

 

 

1,177

 

 

 

(449

)

 

 

1,291

 

 

 

2,352

 

 

 

(1,061

)

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

 

366

 

 

 

 

 

 

366

 

Other expense, net

 

 

(91

)

 

 

(199

)

 

 

108

 

 

 

(27

)

 

 

86

 

 

 

(113

)

Total other (income) expense, net

 

 

(2,347

)

 

 

545

 

 

 

(2,892

)

 

 

(2,379

)

 

 

3,330

 

 

 

(5,709

)

Net loss before provision for income tax

 

 

14,963

 

 

 

5,282

 

 

 

9,681

 

 

 

25,704

 

 

 

12,700

 

 

 

13,004

 

Provision for (benefit from) income taxes

 

 

21

 

 

 

 

 

 

21

 

 

 

(9

)

 

 

 

 

 

(9

)

Net loss

 

$

14,984

 

 

$

5,282

 

 

$

9,702

 

 

$

25,695

 

 

$

12,700

 

 

$

12,995

 

 

33


 

Research and Development expenses

The following table summarizes our research and development expenses for each of the periods presented (in thousands):

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

Change

 

 

2024

 

 

2023

 

 

Change

 

Direct expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EG-70

 

$

6,547

 

 

$

1,715

 

 

$

4,832

 

 

$

9,167

 

 

$

3,557

 

 

$

5,610

 

Early research and platform expansion

 

 

194

 

 

 

(78

)

 

 

272

 

 

 

352

 

 

 

53

 

 

 

299

 

Total direct research and development expenses

 

$

6,741

 

 

$

1,637

 

 

$

5,104

 

 

$

9,519

 

 

$

3,610

 

 

$

5,909

 

Indirect expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Personnel related costs

 

 

2,737

 

 

 

1,172

 

 

 

1,565

 

 

 

5,180

 

 

 

2,520

 

 

 

2,660

 

Unallocated laboratory, facility and other costs

 

 

377

 

 

 

406

 

 

 

(29

)

 

 

794

 

 

 

756

 

 

 

38

 

Total indirect research and development expenses

 

$

3,114

 

 

$

1,578

 

 

$

1,536

 

 

$

5,974

 

 

$

3,276

 

 

$

2,698

 

Total research and development expenses

 

$

9,855

 

 

$

3,215

 

 

$

6,640

 

 

$

15,493

 

 

$

6,886

 

 

$

8,607

 

 

Research and development expenses increased by $6.6 million from $3.2 million for the three months ended April 30, 2023 to $9.9 million for the three months ended April 30, 2024. This increase was attributable to the following:

a $4.8 million increase in EG-70 direct expense is a result of our increasing clinical and manufacturing activities to advance our LEGEND study of EG-70 in BCG-unresponsive NMIBC, as well as in preparation for our Biologics License Application submission;
a $0.3 million increase in early research and platform expansion work is a result of the Company’s effort to perform exploratory work on the platform; and
a $1.6 million increase in personnel-related costs as the Company hired a number of key personnel to ramp up its clinical operation, quality, medical affair and manufacturing functions to support our pivotal-stage LEGEND study of EG-70 in BCG-unresponsive NMIBC.

 

Research and development expenses increased by $8.6 million from $6.9 million for the six months ended April 30, 2023 to $15.5 million for the six months ended April 30, 2024. This increase was attributable to the following:

a $5.6 million increase in EG-70 direct expense is a result of our increasing clinical and manufacturing activities to advance our LEGEND study of EG-70 in BCG-unresponsive NMIBC, as well as in preparation for our Biologics License Application submission;
a $0.3 million increase in early research and platform expansion work is a result of the Company’s effort to perform exploratory work on the platform; and
a $2.7 million increase in personnel-related costs as the Company hired a number of key personnel to ramp up its clinical operation, quality, medical affair and manufacturing functions to support our pivotal-stage LEGEND study of EG-70 in BCG-unresponsive NMIBC.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for each of the periods presented (in thousands):

 

 

Three months ended April 30,

 

 

 

 

 

Six months ended April 30,

 

 

 

 

 

2024

 

 

2023

 

 

Change

 

 

2024

 

 

2023

 

 

Change

 

Personnel-related expenses

 

$

3,256

 

 

$

606

 

 

$

2,650

 

 

$

4,252

 

 

$

1,190

 

 

$

3,062

 

Professional fees

 

 

2,100

 

 

 

710

 

 

 

1,390

 

 

 

4,077

 

 

 

999

 

 

 

3,078

 

Patent maintenance and legal fees

 

 

1,368

 

 

 

126

 

 

 

1,242

 

 

 

2,869

 

 

 

141

 

 

 

2,728

 

Other expenses

 

 

731

 

 

 

80

 

 

 

651

 

 

 

1,392

 

 

 

154

 

 

 

1,238

 

Total general and administrative expenses

 

$

7,455

 

 

$

1,522

 

 

$

5,933

 

 

$

12,590

 

 

$

2,484

 

 

$

10,106

 

 

34


 

 

General and administrative expenses increased by $5.9 million from $1.5 million for the three months ended April 30, 2023 to $7.5 million for the three months ended April 30, 2024. This increase was primarily attributable to the following:

a $2.7 million increase in personnel-related expenses driven by the hires of key general and administrative personnel necessary to support the operation of a public company as well as an increase in stock based compensation expense;
a $1.4 million increase in third-party accounting and finance consulting and audit related fees to support the associated financial reporting requirements and the 2024 PIPE Financing as well as the costs to implement the necessary general and administration systems and software applications to support the operation of a public company;
a $1.2 million increase in legal fees and patent maintenance driven by the need to maintain regulatory compliance of a public company in both Canada and US jurisdictions ; and
a $0.6 million increase in other expenses driven by directors and officers insurance expense as a result of operating as a public company.

 

General and administrative expenses increased by $10.1 million from $2.5 million for the six months ended April 30, 2023 to $12.6 million for the six months ended April 30, 2024 . This increase was primarily attributable to the following:

a $3.1 million increase in personnel-related expenses driven by the hires of key general and administrative personnel necessary to support the operation of a public company as well as an increase in stock-based compensation expense;
a $3.1 million increase in third-party accounting and finance consulting as well as audit related fees to support the SPAC transaction, the 2024 PIPE Financing and associated financial reporting requirements as well as the costs to implement the necessary general and administration systems and software applications to support the operation of a public company;
a $2.7 million increase in legal fees and patent maintenance driven by the need to support regulatory reporting and compliance of a public company in both Canada and US jurisdiction; and
a $1.2 million increase in other expenses driven by directors and officers insurance expense as a result of operating as a public company.

Other (Income) Expense, Net

Other (income) expenses, net varied by approximately $2.9 million from expense of $0.5 million for the three months ended April 30, 2023 to income of $2.3 million for the three months ended April 30, 2024, primarily due to a $2.8 million increase in interest income earned in the current period from larger cash balances arising from the 2024 PIPE Financing. In addition, $0.3 million change in fair value of warrant liabilities, $0.6 million change in fair value of convertible debenture liabilities and $0.4 million interest expense associated with the conversion and repayments of our convertible debentures were no longer applicable to the current period as the associated instruments were settled upon the close of the Reverse Recapitalization. Further, there is a $0.1 million decrease in other expense primarily due to foreign exchange gains.

Other (income) expenses, net varied by approximately $5.7 million from expense of $3.3 million for the six months ended April 30, 2023 to income of $2.4 million for the six months ended April 30, 2024, primarily due to a $3.7 million increase in interest income earned in the current period from larger cash balances arising from the 2024 PIPE Financing. In addition, $1.5 million change in fair value of warrant liabilities, $0.3 million change in fair value of convertible debenture liabilities and $1.1 million interest expense associated with the conversion and repayments of our convertible debentures were no longer applicable to the current period as the associated instruments were settled upon the close of the Reverse Recapitalization. Further, there is also a $0.4 million loss on extinguishment of debt.

Liquidity and Capital Resources

Sources of Liquidity

As of April 30, 2024, we had cash and cash equivalents of approximately $264.8 million. Based on our current operating plans, we expect our cash and cash equivalents will be sufficient to fund the Company’s operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of the condensed consolidated financial statements, without giving effect to any potential milestone debt tranches we may be eligible to drawdown further under our debt facility with Hercules Capital. Our current operating plan is based on various assumptions. If we use our capital resources sooner than expected, we will evaluate further reductions in expense or obtaining additional financing. This may include pursuing a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurance that such financing will be available in sufficient amounts or on acceptable terms, if at all, and some could be dilutive to existing stockholders. If we are

35


 

unable to obtain additional funding on a timely basis, we may be forced to significantly curtail, delay, or discontinue one or more of our planned research or development programs or be unable to expand our operations.

We have incurred losses and have experienced negative operating cash flows for all periods presented. During the three and six months ended April 30, 2024, we incurred a loss of $15.0 million and $25.7 million, respectively, and used $21.5 million of cash in operations. We will continue to incur research and development and selling, general and administrative expenses and we expect to continue to generate operating losses and negative operating cash flows for the next few years.

Cash Flows

Comparison of the six months ended April 30, 2024 and 2023

The following table provides information regarding our cash flows for each of the periods presented (in thousands):

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

Net cash used in operating activities

 

$

(21,532

)

 

$

(10,667

)

Net cash used in investing activities

 

 

(685

)

 

 

(23

)

Net cash provided by financing activities

 

 

205,505

 

 

 

7,753

 

Effect of exchange rate changes on cash

 

 

1

 

 

 

1

 

Net increase in cash and cash equivalents

 

$

183,289

 

 

$

(2,936

)

 

Net Cash Used in Operating Activities

Net cash used in operating activities for the six months ended April 30, 2024 was $21.5 million and was primarily due to our net loss of $25.7 million, partially offset by adjustments for non-cash charges totaling $3.2 million. The non-cash charges consisted of non-cash interest expense of $0.4 million, a loss on extinguishment of debt of $0.4 million, share based compensation expense of $2.2 million and depreciation of property and equipment of $0.2 million. Further there were changes in operating assets and liabilities of $0.9 million, which were driven by a $1.1 million increase in the investment tax credit receivable and $2.6 million increase in accrued expenses and other liabilities, and offset by a $2.1 million decrease in the prepaid expenses and other assets, and a $0.7 million decrease in accounts payable.

Net cash used in operating activities for the six months ended April 30, 2023 was $10.7 million and was primarily due to our net loss of $12.7 million, partially offset by adjustments for non-cash charges totaling $3.2 million which was primarily driven by non-cash interest expense of $1.7 million and changes in fair value of convertible debenture embedded derivative liabilities and warrant liabilities of $1.2 million, share-based compensation expense of $0.1 million, and depreciation of property and equipment of $0.1 million. Further there were changes in operating assets and liabilities of $1.1 million, which was primarily associated with a $2.3 million decrease in accrued expenses and other liabilities, a $2.0 million increase in accounts payable, $0.7 million increase in the investment tax credit receivable, and a $0.2 million increase in prepaid expenses and other assets.

Net Cash Used in Investing Activities

Net cash used in investing activities for each of the six months ended April 30, 2024 and 2023 was $0.7 million and $23 thousand, respectively, consisting of purchases of property and equipment.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the six months ended April 30, 2024 was $205.5 million, resulting from proceeds of $6.0 million from exercise of common share warrants, $200.0 million received from the 2024 PIPE financing, which was partially offset by $12.4 million of issuance costs associated with the 2024 PIPE financing, $22.5 million received from the Term Loan, which was offset by $9.4 million in principal repayments of the Prior Term Loan, $0.6 million in debt issuance costs paid as part of the Term Loan, and $0.6 million of SPAC transaction costs paid during the six months ended April 30, 2024.

Cash flows from financing activities for the six months ended April 30, 2023 was $7.8 million, resulting from proceeds of $8.0 million received from he issuance of the April 2023 Notes, partially offset by the payment of Reverse Recapitalization and PIPE financing transaction costs of $0.1 million and payment of issuance costs associated with the April 2023 Notes of $0.1 million.

36


 

Hercules Loan Agreement

On December 30, 2021, we entered into a Loan and Security Agreement (the “Prior Loan Agreement”) with Hercules Capital, Inc. (“Hercules” or “the Bank” or the “Lender”) for the issuance of a term loan facility of up to an aggregate principal amount of up to $20.0 million (the “Prior Term Loan”). The Prior Loan Agreement has remained in place after the consummation of the Reverse Recapitalization. The Prior Loan Agreement provided for (i) an initial term loan advance of $7.0 million, which closed on December 30, 2021, (ii) subject to the achievement of certain Clinical Milestones (the “Clinical Milestone”), a right of the Company to request that the Lender make additional term loan advances to us in an aggregate principal amount of up to $4.0 million from the achievement of the Clinical Milestone through June 15, 2022, which was drawn in June 2022, and (iii) subject to the achievement of certain financial milestones (the “Financial Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $9.0 million from achievement of the Financial Milestone through December 15, 2022, which was not achieved. We are required to pay an end of term fee (the “Prior End of Term Charge”) equal to 6.35% of the aggregate principal amount of the Term Loans advances upon repayment. The financing agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness.

The Prior Term Loan were scheduled to mature on July 1, 2025, with no option for extension (the “Prior Term Loan Maturity Date”).

Under the Prior Loan Agreement, Old enGene agreed to issue to Hercules warrants (the “Old Hercules Warrants”) to purchase a number of shares of Old enGene’s redeemable convertible preferred shares at the exercise price equal to 2.5% of the aggregate amount of the Prior Term Loans that are funded, as such amounts are funded. Old enGene issued a total of 136,692 warrants to purchase Class C redeemable convertible preferred shares. Upon the close of the Reverse Recapitalization, the Old Hercules Warrants, along with all other warrants to purchase shares of Old enGene's redeemable convertible preferred shares, were surrendered for no consideration.

Amended Loan and Security Agreement

On December 22, 2023, we entered into an amended and restated loan and security agreement (the "Amended Loan Agreement”), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the "Lenders”). The Amended Loan Agreement amends and restates in its entirety the Prior Loan Agreement with Hercules dated December 30, 2021.

The Amended Loan Agreement provides for a term loan facility of up to $50.0 million available in multiple tranches (the "Term Loan”), as follows: (i) an initial term loan advance (the "Tranche 1 Advance”) that was made on the Hercules Closing Date of $22.5 million, approximately $8.6 million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified interim milestone (the "Interim Milestone”) and satisfaction of certain other conditions precedent, our right to request that the Lenders make additional term loan advances to us in an aggregate principal amount of up to $7.5 million from the achievement of the Interim Milestone through the earlier of (x) 60 days following the Interim Milestone and (y) March 31, 2025, and (iii) an uncommitted tranche subject to the Lenders’ investment committee approval and satisfaction of certain other conditions precedent (including payment of a 0.75% facility charge on the amount borrowed), pursuant to which we may request from time to time up to and including the Amortization Date (defined below) that the Lenders make additional term loan advances to us in an aggregate principal amount of up to $20.0 million. We are required to pay upon the earlier of January 1, 2028 ( the “Maturity Date”) or payment in full of the Term Loans, an end of term fee equal to 5.50% of the aggregate principal amount of the Term Loans (the "End of Term Charge"). We are also required to pay on July 1, 2025 or, if earlier, the date we prepay the Term Loans, $0.7 million representing the Prior Term Loan End of Term Charge (the Prior Term Loan End of Term Charge and End of Term Charge, collectively the "End of Term Charges").

The Term Loans mature on January 1, 2028, with no option for extension.

The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the Wall Street Journal plus 0.75% (capped at 9.75%) and (b) 9.25%. The Term Loan also bears additional payment-in-kind interest at an annual rate of 1.15%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement are repayable in monthly interest-only payments through the "Amortization Date”, which is either: (x) July 1, 2025 or (y) if the Interim Milestone is achieved and there has been no default, January 1, 2026, or (z) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, July 1, 2026. After the Amortization Date, the outstanding Term Loans and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date.

37


 

At our option, we may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Hercules Closing Date; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Hercules Closing Date but on or prior to twenty-four months following the Hercules Closing Date; and (iii) 1.0% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.

In connection with the Amended Loan Agreement, we granted Hercules a security interest senior to any current and future debts and to any security interest in all of our right, title, and interest in, to and under all of our property and other assets, subject to limited exceptions including our intellectual property.

The Amended Loan Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement also contains certain events of default and representations, warranties and non-financial covenants of ours. We have been in compliance with the financial covenants and non-financial covenants since inception of the Term Loan.

We accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan. As a result of the extinguishment, we recorded a loss of $0.4 million as a component within other income and expense in our consolidated statement of operations during the three and six months ended April 30, 2024, which represented the reacquisition price of the debt, including fees and the initial fair value of the warrants to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.

As of April 30, 2024, we borrowed $22.5 million under the Amended Loan Agreement and incurred $2.1 million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan.

In connection with the Amended Loan Agreement, we also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of our Common Shares as shall be equal to 2% of the aggregate principal amount of such Term Loan advance divided by the Warrant per share exercise price of $7.21 (which exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary adjustments under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of seven years from issuance. On the Hercules Closing Date, we issued to the Lenders 62,413 Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans. Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is 138,696.

As of April 30, 2024 and October 31, 2023 the carrying value of the note payable consists of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Note payable, including End of Term Charge

 

$

24,530

 

 

$

10,144

 

Debt discount, net of accretion

 

 

(1,974

)

 

 

(474

)

Accrued interest

 

 

174

 

 

 

108

 

Note payable, net of discount

 

$

22,730

 

 

$

9,778

 

 

As of October 31, 2023, we classified $0.6 million of the note payable as current, which represents the principal payments due and amortization of the debt discount between October 31, 2023 and the date the Prior Term Loan was amended in December 2023, as the debt was refinanced on a long-term in the subsequent period.

 

During the three and six months ended April 30, 2024, we recognized $0.7 million and $1.3 million of interest expense, respectively, related to the term loans, of which $0.1 million and $0.3 million was related to the amortization of the debt discounts, respectively. During the three and six months ended April 30, 2023, we recognized $0.4 million and $0.9 million of interest expense, respectively, related to the term loans, of which $0.1 million and $0.2 million was related to the amortization of the debt discounts, respectively.

38


 

Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and paid in kind interest as of April 30, 2024 are as follows:

 

2024

 

$

 

2025

 

 

3,285

 

2026

 

 

8,254

 

2027

 

 

9,047

 

2028

 

 

4,617

 

Total principal payments, including End of Term Charge

 

$

25,203

 

 

The Hercules Term Loan is our only outstanding debt instrument as of April 30, 2024.

Funding Requirements

Our primary uses of capital are, and we expect will continue to be, research and development activities, compensation and related expenses and general overhead costs. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we expect to incur additional costs associated with operating as a public company. We anticipate that our expenses will increase significantly in connection with our ongoing activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy.

Based on our current operating plan, we believe that our existing cash and cash equivalents as of April 30, 2024 will be sufficient to fund our operating expenses, debt obligations, and capital expenditure requirements for at least the next 12 months from the issuance date of the condensed consolidated financial statements. We could use our available capital resources sooner than we currently expect. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.

Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of many factors, including:

the initiation, timing, costs, progress and results of our planned clinical trials of EG-70;
the scope, progress, results and costs of our earlier-stage research programs, including the progress of preclinical development and possible clinical trials;
the scope, progress, results and costs of our research programs and preclinical development of any future product candidates we may pursue;
the cost of regulatory submissions and timing of regulatory approvals;
the progress of the development efforts of parties with whom we may in the future enter into collaborations and/or research and development agreements;
the timing and amount of milestone and other payments we are obligated to make under our Nature Technology Corporation Agreement or any future license agreements;
the cash requirements of any future acquisitions or discovery of product candidates;
our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all;
the costs involved in prosecuting and enforcing patent and other intellectual property claims;
the costs of manufacturing our product candidates by third parties;
the cost of commercialization activities if our lead candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs;
our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates; and
the costs of operating as a public company.

39


 

A change in the outcome of any of these or other variables with respect to the development of our lead candidates or any product or development candidate we may develop in the future could significantly change the costs and timing associated with our development plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

The Company was eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (“CCPC”) on eligible scientific research and development expenditures (“SR&ED”) through September 2023, at which time the Company lost its status as a CCPC in connection with the Reverse Recapitalization. As such, the Company will no longer be eligible for cash refunds on federal tax credit earned with respect to federally eligible SR&ED expenditures. Following the loss of CCPC status, the Company’s federal SR&ED tax credits will be earned at a lower rate and may only be used to offset future federal taxes payable. Provincial tax credits earned in Québec in relation to SR&ED are anticipated to continue to result in a cash refund to the Company, albeit at a reduced rate.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, which could include collaborations, strategic alliances or licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of such shareholders. Debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research program or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide. Because of the numerous risks and uncertainties associated with product development, there is no assurance that we will ever be profitable or generate positive cash flow from operating activities.

Contractual Obligations and Other Commitments

License Agreement with Nature Technology Corporation

On April 10, 2020, we entered into the License Agreement with NTC pursuant to which NTC granted us a worldwide non-exclusive, royalty-bearing and sublicensable license to certain patents and know-how relating to the Nanoplasmid™ vector backbone that is used in detalamogene voraplasmid to research, develop, make, use, import, sell and offer and sell, any gene and cell therapy products incorporating the Nanoplasmid™ vector backbone (excluding any such products in the field of dermatology). Unless terminated earlier, the License Agreement will continue until no valid claim of any licensed patent exists in any country. We can voluntarily terminate the License Agreement with prior notice to NTC.

We paid NTC an initial, upfront fee of $50,000 which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, we are required to pay NTC a $50,000 annual maintenance fee until the first sale of a product for which a royalty is due. We are also required to make a payment to NTC of $50,000 upon assigning the License Agreement to a third-party. The License Agreement provides for a one-time payment of $50,000 for the first dose of a product covered by a valid claim of a licensed patent (a “Milestone Product”) in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well as a one-time payment of $450,000 upon regulatory approval of a Milestone Product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a Milestone Product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a Milestone Product, has not yet been achieved as of the year ended October 31, 2023. We are also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by us, our affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the License Agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. In the event that we or any of our affiliates or sublicensees manufactures any GMP lot of a licensed product, then we or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. Such manufacturing payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.

For a more detailed description of this agreement, see Note 7 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

40


 

Lease Obligations

Our leases are comprised of all operating leases for office and lab space. We previously held a month-to-month office and lab space lease located in Montreal, Quebec, Canada, which commenced in November 2021 and had an initial term of 12 months that expired on October 31, 2022. The lease included options to renew for consecutive twelve-month periods upon landlord consent, at new lease rates. In October 2022, we entered into a lease amendment to extend the lease for an additional term of six months through April 2023, with an option to extend the lease through September 2023. In April 2023, the Company extended the lease through September 2023. In September 2023, the Company extended the lease term through November 5, 2023, at which time the Company vacated the lease. The amendment resulted in $0.2 million of additional lease commitments to be paid during the extended term, inclusive of the extension through November 5, 2023.

On December 29, 2022, we signed a new lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for 10 years beginning on the commencement date and requires an annual initial base rent of $36.50 Canadian dollar (“CAD”) per square foot, which is subject to annual increases of 2%. The lease commenced in November 2023.

On January 1, 2024, we entered into a lease agreement, in which we are sub-leasing approximately 6,450 square feet of office space located at 200 Fifth Avenue, Waltham, MA. We will make an aggregate amount of base rental payments of $0.5 million, under the initial term of the lease, which is set to expire on December 30, 2026 and does not have an option to renew.

Purchase and Other Obligations

We enter into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.

The Company does not have material capital expenditure commitments as of April 30, 2024.

CEO Transition Agreement

On February 13, 2024, we entered into a Transition and Modified Employment Agreement (the "Transition Agreement") with the Company's Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement dated November 8, 2023 (the “Amended Employment Agreement”). As part of the Transition Agreement, Mr. Hanson was entitled to receive his full 2023 cash bonus on or before March 15, 2024. Under the terms of the Amended Employment Agreement, upon Mr. Hanson’s voluntary resignation or death or disability and subject to execution and non-revocation of a customary release, Mr. Hanson will be entitled to:

(i)
twelve months of continued health insurance benefits;
(ii)
payment of a prorated portion of his 2024 target annual bonus;
(iii)
acceleration and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination; and
(iv)
extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of Mr. Hanson’s vested equity awards extend beyond the respective applicable term thereof.

Pursuant to the Amended Employment Agreement, (a) upon the termination of Mr. Hanson’s employment by the Company without Cause (as defined in the Amended Employment Agreement) or by Mr. Hanson for Good Reason (as defined in the Amended Employment Agreement), in addition to the above severance benefits, Mr. Hanson will also be entitled to 12 months’ base salary continuation or, if such even occurs during a change of control period (as described in the Amended Employment Agreement), 18 months’ base salary continuation.

The Transition Agreement further provides that, in the event Mr. Hanson resigns upon the appointment by the Company of a new chief executive officer, Mr. Hanson will be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of his resignation (the “Consulting Period”) in exchange for a monthly fee of $25,000 for the initial six-month Consulting Period, and $500 per hour thereafter, provided that Mr. Hanson need not devote more than fifteen (15) hours per week to providing such transition services.

41


 

As a result of the Transition Agreement, the 1,216,266 stock option awards issued to the CEO were modified to allow for an extended exercise period described above. The modification resulted in an incremental share-based compensation expense of approximately $1.0 million which was recorded upon the effective date of the Transition Agreement.

Emerging Growth Company and Smaller Reporting Company Status

Under Section 107(b) of the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, an “emerging growth company” can delay the adoption of new or revised accounting standards until such time as those standards would apply to private companies. However, we do not elect this exemption in relation to accounting standards. We will continue to be an “emerging growth company” until the earliest of the following: (i) the last day of the fiscal year following the fifth anniversary of the date of FEAC's initial public offering; (ii) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.07 billion; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

As of the most recent calculation of our public float on April 30, 2024, we are also a “smaller reporting company,” meaning that the market value of our common shares held by non-affiliates was less than $700.0 million as of such date and our annual revenue was less than $100.0 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our common shares held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700.0 million, calculated as of the last business day of our most recently completed second fiscal quarter.

If we are a smaller reporting company at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations including regarding executive compensation.

Recent Accounting Pronouncements

We have reviewed all recently issued accounting pronouncements and have determined that, other than as disclosed in Note 2 to the interim financial statements of this Quarterly Report on Form 10-Q, such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Outstanding Share Data

As of June 12, 2024, we had 44,166,159 Common Shares issued and outstanding, outstanding warrants to purchase an additional 8,449,555 Common Shares and outstanding stock options to purchase an additional 3,973,861 Common Shares. The warrants amount listed in the foregoing sentence excludes the Hercules Common Share Warrants described above under “Liquidity and Capital Resources—Cash Flows—Amended Loan and Security Agreement”.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, resulting from the Federal Reserve’s increase of interest rates over the past several years. Our Term Loan has a variable interest rate that fluctuates with the U.S. prime rate, subject to an interest rate floor and cap.

Credit Risk

Our primary exposure to credit risk is through financial instruments and consist primarily of cash and cash equivalents. We regularly maintain deposits in accredited financial institutions in excess of federally insured limits. As of April 30, 2024, we held cash deposits in Canada at the National Bank of Canada, or NBC in excess of CDIC insured limits, and in the United States at Silicon Valley Bank, or SVB, in excess of FDIC insured limits. On March 10, 2023, SVB was closed by the California Department of Financial

42


 

Protection and Innovation, and the Federal Deposit Insurance Corporation, or FDIC, was appointed as receiver. No losses have been incurred by us on material deposits that were held at SVB to date.

We are dependent on third-party CDMO’s (“Contract Development and Manufacturing Organization”) and CRO’s (“Contract Research Organization”) with whom we do business. In particular, we rely and expect to continue to rely on a small number of manufacturers to supply us with the requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. We also rely on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.

Foreign Currency Exchange Risk

Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions that are conducted in a currency other than the Company’s functional currency are included in other expenses, net in the Consolidated Statements of Operations and Comprehensive Loss.

Our operating expenses are denominated in the currencies of the countries in which our operations are located, which are primarily in Canada and the United States. Our consolidated results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. To date, we have not entered into any hedging arrangements with respect to foreign currency risk or other derivative financial instruments, although we may choose to do so in the future.

Effects of Inflation

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We have experienced a general increase in costs as a result of global inflation however we believe that inflation has not had a material effect on our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Item 4. Controls and Procedures.

Our management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of April 30, 2024. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the Principal Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures.

In connection with our preparation and the audit of our consolidated financial statements as of and for the years ended October 31, 2023 and 2022, management and our independent registered public accounting firm identified material weaknesses, as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. The material weaknesses identified related to: lack of formal policies, procedures and controls related to the design of internal controls over financial reporting including risk assessment process and control activities for certain key financial reporting processes; lack of sufficient accounting and financial reporting personnel to perform appropriate accounting analysis and review procedures; lack of personnel with requisite knowledge and experience in the application of GAAP; general information technology controls that were not designed appropriately (access and system changes); and lack of appropriate segregation of duties in the preparation and review of account reconciliations and journal entries.

We intend to and have begun to implement in the near term measures designed to improve our internal control over financial reporting to remediate these material weaknesses, including formalizing our processes and internal control documentation and strengthening supervisory reviews by our financial management; hiring additional qualified accounting and finance personnel with requisite knowledge and experience in the application of complex areas of GAAP, engaging financial consultants to enable the implementation of internal control over financial reporting and improving segregation of duties among accounting and finance personnel in the preparation and review of account reconciliations and journal entries. We will also review and improve the design of our general information technology controls including managing user access and privileged access, managing changes in the information system and segregation of duties.

43


 

While we are implementing these measures, we cannot assure you that these efforts will remediate our material weaknesses in a timely manner, or at all, or prevent restatements of our financial statements in the future. If we are unable to successfully remediate our material weaknesses, or identify any future material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports, and the market price of our Common Shares may decline as a result.

Based on this evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that, as of April 30, 2024, the Company did not have effective disclosure controls and procedures designed and implemented as of that date due to the material weakness previously identified which has not yet been remediated.

Changes in Internal Control over Financial Reporting

Other than the changes described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended April 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

44


 

PART II—OTHER INFORMATION

From time to time, we may be involved in legal proceedings that arise in the regular course of our business. Our management believes that we are not currently involved in any legal proceedings that are likely to have a significant negative effect on our business. However, legal proceedings can negatively affect our business, financial condition, results, and future prospects, regardless of the outcome, due to costs associated with defense and settlement, as well as the diversion of management resources, among other factors.

Item 1A. Risk Factors.

An investment in our Common Shares and Warrants involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our financial statements and related notes hereto, before deciding to invest in our common securities. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. In these circumstances, the market price of our securities could decline, and you may lose all or part of your investment.

As of the quarter ended January 31, 2024, those risk factors denoted below with a “*” were newly added or have been materially updated from our 2023 Annual Report on Form 10-K.

*If we do not successfully manage the transition associated with the pending resignation of Jason D. Hanson, our Chief Executive Officer, and the appointment of a new Chief Executive Officer, it could have an adverse impact on our business.

On February 14, 2024, we announced that Jason D. Hanson, our Chief Executive Officer, had informed the Company of his intent to resign from his positions as Chief Executive Officer and as a member of our Board, as well as positions at our subsidiaries. Mr. Hanson’s decision to resign is due to personal family and health reasons and was not the result of any dispute or disagreement with the Company or our Board on any matter relating to our operations, policies or practices. Our Board has engaged an executive search firm to assist in a comprehensive search for a successor Chief Executive Officer of the Company. On February 13, 2024, we entered into a Transition Agreement with Mr. Hanson. Pursuant to the Transition Agreement, Mr. Hanson agreed to continue his roles as our Chief Executive Officer and as a member of our Board, together with any roles held at our subsidiaries, until the appointment of a successor Chief Executive Officer of the Company.

Leadership transitions can be inherently difficult to manage. An inadequate transition to a new Chief Executive Officer may result in the loss of institutional knowledge and changes to business strategy or objectives. In addition, these changes have the potential to negatively impact our operations and relationships with employees, customers and investors due to increased or unanticipated expenses, operational inefficiencies, uncertainty regarding changes in strategy, decreased employee morale and productivity and increased turnover. In addition, if we are unable to attract and retain a qualified candidate to become our new Chief Executive Officer in a timely manner, our ability to meet our financial and operational goals and strategic plans may be adversely impacted, as well as our financial performance. This may also make it more difficult for us to retain and hire key management and other team members.

*Certain existing securityholders acquired their securities in enGene at prices below the current trading price of such securities, and may experience a positive rate of return based on the current trading price. Future investors in our Company may not experience a similar rate of return.

Certain security holders in the Company, including the “Selling Holders” named in our resale registration statement on Form S-1 (File No. 333-275700), acquired their securities in enGene at prices below recent trading prices of such securities. As a result, those Selling Holders would experience a positive rate of return based on such recent trading prices if they were to sell their securities. Accordingly, the Selling Holders have an incentive to sell because they will profit on sales due to having purchased their securities at lower prices than the public investors, and in some cases such gains may be significant.

Given the relatively lower purchase prices that our Selling Holders paid to acquire securities compared to their current trading prices, these Selling Holders may earn a significant positive rate of return on their investment depending on the market price of our Common Shares and Warrants at the time that such Selling Holders choose to sell their securities. The Selling Holders acquired the securities offered for resale in exchange for non-cash consideration, or at effective purchase prices that are below current trading prices. Investors who purchase our Common Shares and Warrants on the Nasdaq following the Business Combination may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading price.

 

*There is no assurance that Warrants will be and/or remain in the money prior to their expiration or that the holders of Warrants will elect to exercise any or all of their Warrants for cash; the Warrants may expire worthless.

45


 

The exercise price for our Warrants is $11.50 per Common Share. The Warrants will expire on October 31, 2028, the date that is five years after the completion of the Business Combination.

The Warrants' cashless exercise period ended when the Company's registration statement on Form S-1 was declared effective on March 5, 2024. We will receive proceeds from Warrants only in the event that such Warrants are exercised for cash. We believe the likelihood that holders will exercise their Warrants will depend on the trading price of our Common Shares. If the market price for our Common Shares is less than the exercise price of Warrants, we believe the holders of Warrants will be unlikely to exercise them. If the market price for our Common Shares exceeds the exercise price of the Warrants, it is more likely that holders of the Warrants will exercise them.

There is no assurance that Warrants will be in the money and/or remain in the money prior to their expiration or that the holders of Warrants will elect to exercise any or all of their Warrants for cash. As such, the Warrants may expire worthless.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

2024 PIPE Financing

On February 13, 2024, we entered into subscription agreements in connection with the 2024 PIPE Financing (as defined herein) pursuant to which we issued 20,000,000 Common Shares to the 2024 PIPE Investors (as defined herein) for an aggregate gross purchase price equal to $200 million. The 2024 PIPE Financing transaction closed February 20, 2024.

Cashless Warrant Exercises

Through April 30, 2024, 1,379,391 of the Company’s public Warrants were exercised by investors on a cashless basis, with such cashless Warrant exercises resulting in the issuance of 383,355 Common Shares.

 

The sales of the securities described above were exempt from the registration requirements of the Securities Act in reliance on the exemptions afforded by Section 4(a)(2) of the Securities Act, with respect to the 2024 PIPE Financing, and Section 3(a)(9), with respect to the Cashless Warrant Exercises. No sales involved underwriters, underwriting discounts or commissions or public offerings of securities of the Registrant.

Item 3. Defaults Upon Senior Securities.

Omitted.

 

Item 4. Mine Safety Disclosures.

Omitted.

Item 5. Other Information.

Insider Adoption or Termination of Trading Arrangements.

On April 19, 2024, Anthony Cheung, our Chief Technology Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Dr. Cheung’s plan covers the sale of 250,000 of our common shares, including 197,060 shares to be acquired upon exercise of stock options. Transactions under Dr. Cheung’s plan are based upon pre-established stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Dr. Cheung’s plan will terminate on October 31, 2025 or the date all shares subject to the plan have been sold. Other than Dr. Cheung’s plan, during the fiscal quarter ended April 30, 2024, none of our directors or officers informed us of the adoption or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408(a) of Regulation S-K).

46


 

Item 6. Exhibits.

 

 

Exhibit

Number

Description

 

 

 

10.1

 

Transition and Modification Agreement, dated February 13, 2024 by and between enGene USA, Inc. and Jason D. Hanson (incorporated herein by reference to Exhibit 10.2 of enGene’s Current Report on Form 8-K filed with the SEC on February 14, 2024).

10.2*†

 

Employment Agreement, dated April 22, 2024, by and between enGene USA, Inc. and Lee Giguere.

10.3

 

Form of Subscription Agreement, dated February 13, 2024 (incorporated herein by reference to Exhibit 10.1 of enGene’s Current Report on Form 8-K filed with the SEC on February 14, 2024).

10.4

 

Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.1 of enGene’s Current Report on Form 8-K filed with the SEC on May 15, 2024).

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

† Indicates a management contract or compensatory plan or arrangement.

47


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

enGene Holdings Inc.

Date: June 14, 2024

By:

/s/ Jason D. Hanson

Name: Jason D. Hanson

Title: Chief Executive Officer

 

Date: June 14, 2024

By:

/s/ Ryan Daws

 

 

 

Name: Ryan Daws

 

 

 

Title: Chief Financial Officer

 

 

 

 

 

48


EX-10.2 2 engn-ex10_2.htm EX-10.2 EX-10.2

Exhibit 10.2

 

EMPLOYMENT AGREEMENT FOR LEE GIGUERE

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between EnGene USA, Inc., its successors and assigns (the “Company”) and Lee Giguere (the “Executive”) as of the date first written below.

WHEREAS, the Company desires to employ the Executive as its Chief Legal Officer and the Executive desires to serve in such capacity on behalf of the Company.

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Executive hereby agree as follows:

1.
Employment.
(a)
Term. This Agreement shall begin on January 29, 2024 (the “Effective Date”) and shall continue until the termination of the Executive’s employment. The period commencing on the Effective Date and ending on the date on which the term of this Agreement terminates is referred to herein as the “Term.” The Executive’s employment during the Term shall be as an “at-will” employee; the Executive may resign his employment at any time, and the Company may terminate the Executive’s employment at any time, for any reason or no reason, subject to the provisions of this Agreement.
(b)
Duties. During the Term, the Executive shall serve as the Chief Legal Officer, with such duties, responsibilities, and authority commensurate therewith, and shall report to the Chief Executive Officer of the Company (the “CEO”). The Executive shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned to the Executive by the CEO that are consistent with and within the scope of Executive’s position.
(c)
Best Efforts. During the Term, the Executive shall devote the Executive’s best efforts and full business time and attention to promote the business and affairs of the Company and its affiliated entities, and shall be engaged in other business activities only to the extent that such activities do not materially interfere or conflict with the Executive’s obligations to the Company hereunder, including, without limitation, obligations pursuant to Section 15 below. The foregoing shall not be construed as preventing the Executive from (i) serving on civic, educational, philanthropic or charitable boards or committees, or, with the prior written consent of the CEO, which shall not be unreasonably withheld, on corporate, advisory or scientific advisory boards, or service in an advisory capacity to a corporate entity and (ii) managing personal investments, so long as such activities are permitted under the Company’s Code of Conduct and employment policies and do not violate the provisions of Section 15 below.
(d)
Principal Place of Employment. The Executive understands and agrees that the Executive’s principal place of employment will be in the Company’s office located in or around Boston, Massachusetts (“Principal Place of Employment”), which office is located at 200 Fifth Avenue, Waltham, Massachusetts on the date of this Agreement. The Executive’s employment and all services hereunder shall be provided in the United States and the Executive shall not be required to work in Canada during the Term of this Agreement. Executive will be required to travel for business in the course of performing the Executive’s duties for the Company.
2.
Compensation.
(a)
Base Salary. During the Term, the Company shall pay the Executive a base salary (“Base Salary”), at the annual rate of $410,000, which shall be paid in installments in accordance with the Company’s normal payroll practices. The Executive’s Base Salary shall be reviewed annually by the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Parent Board”) of EnGene Holdings Inc. (“Parent”), and may be increased, but not decreased.
(b)
Sign-On Bonus. The Executive will be eligible to receive a one-time sign-on bonus in the amount of $137,150, less applicable deductions and withholdings, (the “Sign-On Bonus”), which will be paid to the Executive in the first regular payroll period of 2024. The Sign-On Bonus will not actually be deemed earned until the Executive has completed one full year of active employment with the Company in good standing, and shall be deemed an unearned advance until this condition has been satisfied. In the event that the Executive voluntarily resign from employment with the Company for any reason within the Executive’s first year of employment, or is terminated by the Company for Cause (as defined in Section 13 below), the Executive agrees to repay to the Company the entire value of the Sign-On Bonus, with such repayment occurring within thirty (30) days following the Executive’s last day of employment with the Company. The Executive further agrees that the Company may make any deduction necessary from the Executive’s last paycheck(s) to satisfy this repayment obligation, and the Executive hereby (i) consent to any such deduction and any other action that may be taken by the Company and as permitted by law, and (ii) agrees that, at the time of such separation, the Executive will sign any additional agreement or document that the Company deems necessary with respect to making this deduction or otherwise enforcing its right to receive the repayment amount.
(c)
Annual Bonus. The Executive shall be eligible to receive an annual bonus for each calendar year during the Term, commencing with the 2024 calendar year, based on the attainment of individual and corporate performance goals and targets established by the Compensation Committee (“Annual Bonus”). The target amount of the Executive’s Annual Bonus for any calendar year during the Term is 40% of the Executive’s annual Base Salary (the “Target Annual Bonus”). Any Annual Bonus shall be paid after the end of the calendar year to which it relates, at the same time and under the same terms and conditions as the bonuses are

paid to other executives of the Company; provided, that, in no event shall the Executive’s Annual Bonus be paid later than two and a half months after the last day of the calendar year to which the Annual Bonus relates.
(d)
Equity Compensation. The Executive shall be eligible to participate in the Engene Holdings Inc. 2023 Incentive Equity Plan (as amended and in effect from time to time, the “Equity Plan”) at a level commensurate with similarly situated C-Suite executives of the Company, as determined in the sole discretion of the Compensation Committee. Additionally, the Executive shall be eligible to receive a grant under the Equity Plan of an option to acquire 225,000 common shares of Parent (“Common Shares”) at an exercise price equal to the fair market value of such Common Shares on the date of the grant, vesting over four years, 25% on the first anniversary of the Effective Date and monthly thereafter for three years.
3.
Retirement and Welfare Benefits. During the Term, the Executive shall be eligible to participate in the Company’s health, life insurance, long-term disability, retirement and welfare

benefit plans and programs, pursuant to their respective terms and conditions. Nothing in this Agreement shall preclude the Company or any Affiliate (as defined in Section 15(a) below) of the Company from terminating or amending any employee benefit plan or program from time to time after the Effective Date.

4.
Vacation. During the Term, the Executive shall be eligible to vacation each year and holiday and sick leave at levels commensurate with those provided to similarly situated US executives of the Company, in accordance with the Company’s policy and/or practice which as of the Effective Date is an unlimited policy.
5.
Business Expenses. The Company shall reimburse the Executive for all necessary and reasonable travel (which does not include commuting to Executive’s Principal Place of Employment) and other business expenses incurred by the Executive in the performance of his duties hereunder in accordance with such policies and procedures as the Company may adopt generally from time to time for executives.
6.
Termination of Employment Without Cause; Resignation for Good Reason. If the Executive’s employment is terminated by the Company without Cause or by the Executive for Good Reason (as defined in Section 13 below), the provisions of this Section 6 shall apply.
(a)
The Company may terminate the Executive’s employment with the Company at any time without Cause upon not less than thirty (30) days’ prior written notice to the Executive and the Executive may resign for Good Reason.
(b)
Unless the Executive complies with the provisions of Section 6(c) below, upon termination of employment under Section 6(a) above, no other payments or benefits shall be due under this Agreement to the Executive other than the Accrued Obligations (as defined in Section 13 below).
(c)
Notwithstanding the provisions of Section 6(b) above, upon termination of employment under Section 6(a) above, if the Executive executes and does not revoke the Release (as defined in Section 13 below), and so long as the Executive continues to comply with the provisions of Section 15 below, in addition to the Accrued Obligations, the Executive shall be entitled to receive the following:
(i)
Continuation of the Executive’s Base Salary for a twelve (12) month period (the “Severance Term”), at the rate in effect for the year in which the Executive’s date of termination of employment occurs, which amount shall be paid in regular payroll installments over the Severance Term;
(ii)
If the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), then continued health (including hospitalization, medical, dental, vision etc.) insurance coverage substantially similar in all material respects as the coverage provided to other Company employees for the Severance Term; provided that the Executive shall pay the employee portion of such coverage, if any, the period of COBRA health care continuation coverage provided under section 4980B of the Code (as defined in Section 14(a) below) shall run concurrently with the Severance Term, and notwithstanding the foregoing, the amount of any benefits provided by this subsection (ii) shall be reduced or eliminated to the extent the Executive obtains duplicative benefits by virtue of the Executive’s subsequent or other employment. Notwithstanding the foregoing, if the Company’s making payments under this Section 6(c) would violate any nondiscrimination rules applicable to the Company’s group health plan under which such coverage is made available, or result in the imposition of penalties under the Code or the Patient Protection and Affordable Care Act (the “Affordable Care Act”), the Parties agree to reform this Section 6(c) in a manner as is necessary to comply with such requirements and avoid such penalties;
(iii)
An amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination, payable within forty-five (45) days of Executive’s termination of employment; provided, that such termination occurs six months or more into the applicable performance period for such Annual Bonus; and
(iv)
Any time-based equity awards shall accelerate and vest with respect to the number of shares underlying the equity awards that would vest over the Severance Term had the Executive remained employed for such Severance

Term and any equity awards that are subject to performance-based vesting shall vest and become exercisable, if at all, subject to the terms of such equity awards.
7.
Change in Control. Notwithstanding anything to the contrary herein, if there is a CIC Termination (as defined in Section 13 below), then the provisions of this Section 7 shall apply.
(a)
Unless the Executive complies with the provisions of Section 7(b) below, upon CIC Termination, no other payments or benefits shall be due under this Agreement to the Executive other than the Accrued Obligations.
(b)
Notwithstanding the provisions of Section 7(a) above, upon CIC Termination, if the Executive executes and does not revoke the Release, and so long as the Executive continues to comply with the provisions of Section 15 below, then, in addition to the Accrued Obligations, the Executive shall be entitled to receive the following:
(i)
Continuation of the Executive’s Base Salary for a twelve (12) month period (the “CIC Severance Term”), at the rate in effect for the year in which the Executive’s date of termination of employment occurs, which amount shall be paid in regular payroll installments over the CIC Severance Term;
(ii)
An amount equal to the Annual Target Bonus, payable within forty-five (45) days of Executive’s termination of employment;
(iii)
COBRA continuation benefits as set forth in Section 6(c)(ii), except that the Severance Term shall be the CIC Severance Term; and
(iv)
All time-based equity awards shall accelerate and become fully vested and any equity awards that are subject to performance-based vesting shall vest and become exercisable, if at all, subject to the terms of such equity awards.
8.
Cause. The Company may terminate the Executive’s employment at any time for Cause upon written notice to the Executive, in which event all payments under this Agreement shall cease, except for any Accrued Obligations.
9.
Voluntary Resignation Without Good Reason. The Executive may voluntarily terminate employment without Good Reason upon 30 days’ prior written notice to the Company. In such event, after the effective date of such termination, no payments shall be due under this Agreement, except that the Executive shall be entitled to any Accrued Obligations.
10.
Disability. If the Executive incurs a Disability (as defined below) during the Term, the Company may terminate the Executive’s employment on or after the date of Disability. If the Executive’s employment terminates on account of Disability, the Executive shall be entitled to receive any Accrued Obligations and, if the Executive executes and does not revoke the Release, an amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination for Disability; provided, that such termination occurs six months or more into the applicable performance period. For purposes of this Agreement, the term “Disability” shall mean the Executive is eligible to receive long-term disability benefits under the Company’s long-term disability plan or, if the Company does not have a long-term disability plan, shall mean the Executive’s inability, due to physical or mental incapacity, to perform the essential functions of Executive’s position, with or without reasonable accommodation, for 120 days out of any 365 day period.
11.
Death. If the Executive dies during the Term, the Executive’s employment shall terminate on the date of death and the Company shall pay to the Executive’s executor, legal representative, administrator or designated beneficiary, as applicable, any Accrued Obligations. The Company shall have no further liability or obligation under this Agreement to the Executive’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through the Executive.
12.
Resignation of Positions. Effective as of the date of any termination of employment, the Executive will resign from all Company-related positions, including as an officer and director of the Company and its parent(s), subsidiaries, and Affiliates.
13.
Definitions. For purposes of this Agreement, the following terms shall have the following meanings:
(a)
Accrued Obligations” shall mean (i) any Base Salary earned through the Executive’s termination of employment that remains unpaid; (ii) any Annual Bonus payable with respect to any calendar year which ended prior to the effective date of the Executive’s termination of employment, which remains unpaid; (iii) in the event of a termination of employment as a result of death, an amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination; provided, that such termination occurs six months or more into the applicable performance period for such Annual Bonus; (iv) any accrued, unused personal time off days, if required to be paid out under the Company’s policies; or (v) the amount of any documented expenses properly incurred by the Executive on behalf of the Company prior to such termination and not yet reimbursed. The Accrued Obligations shall be paid following the Executive’s termination of employment at such times and in accordance with such policies as would normally apply to such amounts and regardless of whether the Executive executes or revokes the Release.
(b)
Cause” shall mean any of the following grounds for the Executive’s termination of employment listed: (i)

the Executive’s knowing and material dishonesty or fraud committed in connection with the Executive’s employment; (ii) theft, misappropriation, or embezzlement by the Executive of the Company’s funds; (iii) the Executive repeatedly negligently performing or failing to perform, or willfully refusing to perform, the Executive’s duties to the Company (other than a failure resulting from Executive’s incapacity due to physical or mental illness); (iv) the Executive’s conviction of or a plea of guilty or nolo contendere to any felony, a crime involving fraud or misrepresentation, or any other crime (whether or not connected with his employment) the effect of which is likely to adversely affect the Company or its Affiliates; (v) a material breach by the Executive of any of the provisions or covenants set forth in this Agreement; (vi) a material breach by the Executive of the Company’s Code of Conduct and Business Ethics; or (vii) any other act or omission by the Executive that has a material adverse effect on the Company’s ability to operate. Prior to any termination of employment for Cause pursuant to each such event listed in (i), (iii), (v), (vi), or (vii) above, to the extent such event(s) is capable of being cured by the Executive, the Company shall give the Executive written notice thereof describing in reasonable detail the circumstances constituting Cause and the Executive shall have the opportunity to remedy same within thirty (30) days after receiving written notice. If the circumstances alleged to constitute Cause are remedied within the thirty (30) day cure period, no Cause shall exist to terminate Executive.
(c)
Change in Control” shall have the meaning set forth in the Equity Plan.
(d)
Change in Control Period” shall mean the period commencing 90 days prior to a Change in Control and ending on the first anniversary of such Change in Control.
(e)
CIC Termination” shall mean termination of the Executive’s employment by the Company without Cause or by the Executive for Good Reason during the Change in Control Period, provided that, in either case, a Change in Control actually occurs.
(f)
Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent, other than on account of the Executive’s Disability:
(i)
A material diminution by the Company of the Executive’s title, authority, reporting structure, duties or responsibilities;
(ii)
A material change in the geographic location at which the Executive must perform services under this Agreement (which, for purposes of this Agreement, means relocation of the Executive’s Principal Place of Employment to a location that increases the Executive’s commute to work by more than 35 miles);
(iii)
A reduction in the Executive’s Base Salary (other than an across the board reduction of base salary for similarly situated senior level executives); or
(iv)
Any action or inaction that constitutes a material breach by the Company of this Agreement.

The Executive must provide written notice of termination for Good Reason to the Company within 60 days after the event constituting Good Reason. The Company shall have a period of 30 days in which it may correct the act or failure to act that constitutes the grounds for Good Reason as set forth in the Executive’s notice of termination. If the Company does not correct the act or failure to act, the Executive’s employment will terminate for Good Reason on the first business day following the Company’s 30-day cure period.

(g)
Release” shall mean a separation agreement and general release of any and all claims against the Company and its Affiliates with respect to all matters arising out of the Executive’s employment by the Company, and the termination thereof (other than claims for any entitlements under the terms of this Agreement or under any plans or programs of the Company under which the Executive has accrued and is due a benefit). The Release will be in form and substance specified by and acceptable to the Company and Executive, and will include provisions in which the Executive shall reaffirm and agree to remain bound by the restrictive covenants set forth in Section 15 below. Such general release shall be executed and delivered (and no longer subject to the 7 business day revocation period) by the Executive within sixty (60) days following delivery of the general release to the Executive.
14.
Section 409A.
(a)
This Agreement is intended to comply with section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and its corresponding regulations, or an exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by section 409A of the Code, to the extent applicable. Severance benefits under this Agreement are intended to be exempt from section 409A of the Code under the “short-term deferral” exception, to the maximum extent applicable, and then under the “separation pay” exception, to the maximum extent applicable. Notwithstanding anything in this Agreement to the contrary, if required by section 409A of the Code, if the Executive is considered a “specified employee” for purposes of section 409A of the Code and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to section 409A of the Code, payment of such amounts shall be delayed as required by section 409A of the Code, and the accumulated amounts shall be paid in a lump-sum payment within 10 days after the end of the six-month period. If the Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of section

409A of the Code shall be paid to the personal representative of the Executive’s estate within 60 days after the date of the Executive’s death.
(b)
All payments to be made upon a termination of employment under this Agreement may only be made upon a “separation from service” under section 409A of the Code. For purposes of section 409A of the Code, each payment hereunder shall be treated as a separate payment, and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. In no event may the Executive, directly or indirectly, designate the fiscal year of a payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive’s execution of the Release, directly or indirectly, result in the Executive’s designating the fiscal year of payment of any amounts of deferred compensation subject to section 409A of the Code, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year.
(c)
All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement be for expenses incurred during the period specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in- kind benefits provided, during a fiscal year not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other fiscal year, (iii) the reimbursement of an eligible expense be made no later than the last day of the fiscal year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits not be subject to liquidation or exchange for another benefit.
15.
Restrictive Covenants.
(a)
Noncompetition. The Executive agrees that during the Executive’s employment with the Company and its Affiliates and (i) the number of months in the CIC Severance Term after a CIC Termination and (ii) for any other termination of employment, including a termination of employment where severance is not payable to the Executive, twelve months (the “Restriction Period”), the Executive will not, without the Parent Board’s express written consent, engage (directly or indirectly) in any Competitive Business in the United States or Canada; provided, however, that per Rule 5.6 of the Massachusetts Rules of Professional Conduct, nothing in this Section 15(a) or in any other section of this Agreement shall be applied or interpreted to restrict the Executive’s right to practice law following termination of Executive’s employment with the Company and its Affiliates. The term “Competitive Business” means any person, concern or entity which is engaged in or conducts a business substantially the same as the Business of the Company and its Affiliates. The term “Business” means the discovery, research, development and commercialization by the Company or its Affiliates of gene therapy treatments currently under active discovery, development or commercialization (generally referred to internally as “Programs” and “Pipeline”), including material external sponsored research agreements. The Executive understands and agrees that, given the nature of the business of the Company and its Affiliates and the Executive’s position with the Company, the foregoing scope is reasonable and appropriate, and necessary to protect the Company’s legitimate business interests. For purposes of this Agreement, the term “Affiliate” means any subsidiary of the Company or Parent or any other entity under common control with the Company. The Executive and the Company agree that the terms set forth in this Agreement, including without limitation, the increase in Base Salary, the Annual Bonus opportunity and severance rights that the Company is awarding the Executive as consideration for the covenants in this Section 15(a) is mutually-agreed upon consideration for the Executive’s compliance with this Section 15(a).
(b)
Nonsolicitation of Company Personnel. The Executive agrees that during the Restriction Period, the Executive will not, either directly or through others, hire or attempt to hire any employee of the Company or its Affiliates, or solicit or attempt to solicit any such person to change or terminate his or her relationship with the Company or an Affiliate or otherwise to become an employee, consultant or independent contractor to, for or of any other person or business entity; provided that the foregoing does not prohibit general solicitation or recruitment activities not directed at employees of the Company or soliciting, recruiting or hiring any person who responds thereto.
(c)
Nonsolicitation of Customers. The Executive agrees that during the Restriction Period, the Executive will not, either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate, any customer of the Company or an Affiliate for the purpose of providing such customer with services or products competitive with those offered by the Company or an Affiliate during the Executive’s employment with the Company or an Affiliate.
(d)
Proprietary Information. At all times, the Executive will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such disclosure, use or publication may be required in connection with the Executive’s work for the Company or as described in Section 15(e) below, or unless the Company expressly authorizes such disclosure in writing. “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company and its Affiliates and shareholders, including but not limited to information relating to financial matters, investments, budgets, business plans, marketing plans, personnel matters, business contacts, products, processes, know-how, designs, methods, improvements, discoveries, inventions, ideas, data, programs, and other works of authorship. For purposes of this Agreement, the term “Proprietary Information” shall not include information which is or becomes publicly available without breach of: (i) this Agreement; (ii) any other agreement or instrument to which the Company or an Affiliate is a party or a beneficiary; or (iii) any duty owed to the Company or an Affiliate by the Executive or by any third party. It shall also not include any information that was reasonably demonstrated to be known to Executive prior to Executive’s employment with the

Company; provided, however, that if the Executive shall desire or seek to disclose, use, lecture upon, or publish any Proprietary Information, the Executive shall first obtain approval from the Company.
(e)
Reports to Government Entities. Nothing in this Agreement shall prohibit or restrict the Executive from initiating communications directly with, responding to any inquiry from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, Congress, any agency Inspector General or any other federal, state or local regulatory authority (collectively, the “Regulators”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. The Executive does not need the prior authorization of the Company to engage in conduct protected by this subsection, and the Executive does not need to notify the Company that the Executive has engaged in such conduct. Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose trade secrets to their attorneys, courts, or government officials in certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.
(f)
Inventions Assignment. The Executive agrees that all inventions, innovations, improvements, developments, methods, designs, analyses, reports, and all related information which relates to the Company’s or its Affiliates’ actual business, research and development of existing or future products or services and which are actually being developed or made by the Executive while employed by the Company, on Company time and using Company resources (“Work Product”) belong to the Company. The Executive will perform all actions reasonably requested by the Company or the Parent Board (whether during or after the Term) to establish and confirm such ownership (including, without limitation, assignments, consents, limited powers of attorney and other instruments). If requested by the Company, the Executive agrees to execute any inventions assignment and confidentiality agreement that is required to be signed by Company employees generally.
(g)
Return of Company Property. Within a reasonable time after termination of the Executive’s employment with the Company for any reason, and at any earlier time the Company requests, the Executive will deliver to the person designated by the Company all originals and copies of all documents and property of the Company or an Affiliate that is in the Executive’s possession or under the Executive’s control or to which the Executive may have access. The Executive will not reproduce or appropriate for the Executive’s own use, or for the use of others, any property, proprietary information, or Work Product.
(h)
Restrictive Covenant Acknowledgement. The Executive acknowledges and agrees that the foregoing restrictions contained in this Section 15 are reasonable, proper and necessitated by the legitimate business interests of the Company and will not prevent the Executive from earning a living or pursuing a career. In the event that a court of competent jurisdiction determines that any of the provisions of this Agreement (including, without limitation, the provisions of this Section 15) would be unenforceable as written because they cover too extensive a geographic area, too broad a range of activities, too long a period of time, insufficient consideration, or otherwise, then such provisions automatically shall be modified to cover the maximum geographic area, range of activities, and period of time as may be enforceable, and the minimum amount of required consideration as may be enforceable, and in addition, such court is hereby expressly authorized so to modify this Agreement and to enforce it as so modified.
16.
Legal and Equitable Remedies. Because the Executive’s services are personal and unique and the Executive has had and will continue to have access to and has become and will continue to become acquainted with the proprietary information of the Company and its Affiliates, and because any breach by the Executive of any of the restrictive covenants contained in Section 15 would result in irreparable injury and damage for which money damages would not provide an adequate remedy, the Company shall have the right to seek to enforce Section 15 and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set forth in Section 15.
17.
Survival. The respective rights and obligations of the parties under this Agreement (including, but not limited to, under Sections 15 and 16) shall survive any termination of the Executive’s employment or termination or expiration of this Agreement to the extent necessary to the intended preservation of such rights and obligations.
18.
No Mitigation or Set-Off. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not be reduced regardless of whether the Executive obtains other employment. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right which the Company may have against the Executive or others.
19.
Section 280G. In the event of a change in ownership or control under section 280G of the Code, if it shall be determined that any payment or distribution in the nature of compensation (within the meaning of section 280G(b)(2) of the Code) to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a “Payment”), would constitute an “excess parachute payment” within the meaning of section 280G of the Code, the aggregate present value of the Payments under this Agreement shall be reduced (but not below zero) to the Reduced Amount (defined below) if and only if the Accounting Firm (described below) determines that the reduction will provide the Executive with a greater net after-tax

benefit than would no reduction. No reduction shall be made unless the reduction would provide Executive with a greater net after-tax benefit. The determinations under this Section shall be made as follows:
(a)
The “Reduced Amount” shall be an amount expressed in present value which maximizes the aggregate present value of Payments under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax (defined below), determined in accordance with section 280G(d)(4) of the Code. The term “Excise Tax” means the excise tax imposed under section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.
(b)
Payments under this Agreement shall be reduced on a nondiscretionary basis in such a way as to minimize the reduction in the economic value deliverable to the Executive. Where more than one payment has the same value for this purpose and they are payable at different times, they will be reduced on a pro rata basis. Only amounts payable under this Agreement shall be reduced pursuant to this Section.
(c)
All determinations to be made under this Section shall be made by an independent certified public accounting firm selected by the Company and agreed to by the Executive immediately prior to the change-in-ownership or -control transaction (the “Accounting Firm”). The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and the Executive within 10 days of the transaction. Any such determination by the Accounting Firm shall be binding upon the Company and the Executive. All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be borne solely by the Company.
20.
Tax Equalization. The Company will reimburse the Executive for all reasonable and necessary costs incurred in connection with any cross-border tax filings that may be required, as well as the cost of joining the NEXUS program and any other visa or related issues with respect to the Executive’s employment with the Company. To the extent the Executive is subject to additional taxes in respect of services performed in Canada (whenever such services were performed on the Company’s behalf), the Company will reimburse the Executive for such additional taxes with an appropriate gross up calculation such that the Executive pays no more income taxes in respect of compensation from the Company then the Executive would have paid had the services solely been performed in the United States. Without limiting any of the foregoing provisions of this Section 20, the Company hereby agrees to fully indemnify the Executive against: (i) any and all tax liability that the Executive incurs in Canada arising with respect to any services that Executive performs in Canada for and on behalf of the Company, Parent or any of their respective subsidiaries, (ii) any and all tax liability that Executive incurs in the United States by virtue of Parent or any of its subsidiaries being a Passive Foreign Investment Company and that Executive would not have incurred if each of Parent and its subsidiaries were a corporation incorporated and existing under the laws of a State in the United States, and (iii) any other tax liability or penalties that Executive incurs in the United States or Canada by virtue of the Parent or any of its subsidiaries being a Canadian corporation and that Executive would not have incurred if each of Parent and its subsidiaries were a corporation incorporated and existing under the laws of a State in the United States.
21.
Notices. All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when emailed, hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received):

If to the Company, to:

200 Fifth Avenue

Waltham, MA 02451

Attn: Chief Executive Officer

If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or the Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this Section.

22.
Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. The Executive shall bear all expense of, and be solely responsible for, all federal, state and local taxes due with respect to any payment received under this Agreement.
23.
Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity. No delay or omission by a party in exercising any right, remedy or power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.
24.
Binding Arbitration and Waiver of Right to Participate in Class Actions. Except for disputes relating to, or arising out of, the Executive’s obligations set forth in Section 15, including the Company’s right to independently seek and obtain injunctive relief in state or federal courts, the parties agree to arbitrate any and all claims, disputes or controversies relating to, or arising out of, or concerning, this Agreement and/or the Executive’s employment with the Company, including termination of the Executive’s employment. The parties’ agreement to arbitrate employment-related claims is intended to include, but is not limited to, claims concerning compensation, benefits or other terms and conditions of employment, or any other claims whether arising by statute or

otherwise including, but not limited to, employment claims of wrongful discharge, discrimination, harassment or retaliation under federal, state or local laws including, without limitation, Commonwealth of Massachusetts; Title VII of the Civil Rights Act as amended, the Equal Pay Act, the Americans With Disabilities Act (as amended), the Age Discrimination in Employment Act, the Older Workers Benefits Protection Act; the Affordable Care Act, and claims arising under the Fair Labor Standards Acts, or any other national, federal, state or local employment or discrimination laws, rules or regulations. The Executive’s agreement to arbitrate also includes claims for breach of contract, violation of internal procedure or policy, wrongful termination in violation of public policy, wrongful discharge or termination, tort claims including negligence, defamation, loss of reputation, interference with contractual relations or prospective economic advantage, retaliation, and negligent or intentional infliction of emotional distress. The Executive agrees that all such claims will be fully and finally resolved by mandatory, binding arbitration conducted by the American Arbitration Association (“AAA”) located within thirty miles of the Executive’s Principal Place of Employment, pursuant to the AAA then-current Employment Arbitration Rules and Mediation Procedures. A copy of those rules is available online at www.adr.org/aaa. The Company as the employer will bear the administrative costs and arbitrator fees, and the arbitrator in such action may award whatever remedies would be available to the parties in a court of law. The purpose of this provision is to require binding arbitration of such disputes, claims or controversies that are or may be arbitrable, and the inclusion of any claim in this provision as to which a jury trial or civil action may not be waived will not taint or invalidate the remainder of this provision. To be clear, this agreement to arbitrate does not apply to any lawsuit to enforce this arbitration clause, or, as referenced above, to seek relief as set forth in Section 15 of this Agreement. Those lawsuits will be commenced in the state or federal courts sitting in the Commonwealth of Massachusetts and the Executive consents to the jurisdiction of the federal or state courts of Massachusetts.
25.
Assignment. All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that the duties and responsibilities of the Executive under this Agreement are of a personal nature and shall not be assignable or delegable in whole or in part by the Executive. The Company may assign its rights, together with its obligations hereunder, in connection with any sale, transfer or other disposition of all or substantially all of its business and assets, and such rights and obligations shall inure to, and be binding upon, any successor to the business or any successor to substantially all of the assets of the Company, whether by merger, purchase of stock or assets or otherwise, which successor shall expressly assume such obligations, and the Executive acknowledges that in such event the obligations of the Executive hereunder, including but not limited to those under Section 15, will continue to apply in favor of the successor.
26.
Company Policies. This Agreement and the compensation payable hereunder shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may be implemented by the Parent Board or the Company from time to time with respect to officers of the Company.
27.
Indemnification. In the event the Executive is made, or threatened to be made, a party to any legal action or proceeding, whether civil or criminal, including any governmental or regulatory proceedings or investigations, by reason of the fact that the Executive is or was a director or officer of the Company or any of its Affiliates, the Executive shall be fully indemnified by the Company, and the Company shall pay the Executive’s related expenses (including reasonable attorneys’ fees, judgments, fines, settlements and other amounts incurred in connection with any proceeding arising out of) when and as incurred, to the fullest extent permitted by applicable law and the Company’s articles of incorporation and bylaws. During the Executive’s employment with the Company or any of its Affiliates and after termination of employment for any reason, the Company shall cover the Executive under the Company’s directors’ and officers’ insurance policy applicable to other officers and directors according to the terms of such policy. Such obligations shall be binding upon the Company’s successors and assigns and shall inure to the benefit of the Executive’s heirs and personal representatives.
28.
Entire Agreement. This Agreement sets forth the entire agreement of the parties related to the items set forth herein and supersedes any and all prior agreements and understandings related thereto. Without limiting the generality of the immediately preceding sentence, this Agreement replaces and supersedes in its entirety that certain letter agreement, dated January 4, 2024, between the Company and Executive. This Agreement may be changed only by a written document signed by the Executive and the Company.
29.
Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement, which can be given effect without the invalid or unenforceable provision or application, and shall not invalidate or render unenforceable such provision or application in any other jurisdiction. If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances.
30.
Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive and procedural laws of the Commonwealth of Massachusetts without regard to rules governing conflicts of law.
31.
Counterparts. This Agreement may be executed in any number of counterparts (including facsimile counterparts), each of which shall be an original, but all of which together shall constitute one instrument.
32.
Acknowledgments. The Executive acknowledges that (a) the Executive has the right to consult with counsel prior to signing this Agreement and has had a full and adequate opportunity to read, understand and discuss with the Executive’s advisors, including counsel, the terms and conditions contained in this Agreement prior to signing hereunder, (b) this Agreement is supported by fair and

reasonable consideration independent from the continuation of employment, and (c) the Executive received notice of this Agreement at least ten business days before it is to be effective.

(Signature Page Follows)

 


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of April 22, 2024.

ENGENE USA, INC.

 

/s/ Jason Hanson

 

Name: Jason Hanson

Title: Chief Executive Officer

 

 

 

 

EXECUTIVE

/s/ Lee Giguere

 

Name: Lee Giguere


EX-31.1 3 engn-ex31_1.htm EX-31.1 EX-31.1

 

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jason D. Hanson, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of enGene Holdings Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Omitted;

c.
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 14, 2024

By:

/s/ Jason D. Hanson

Jason D. Hanson

Chief Executive Officer

(Principal Executive Officer)

 


EX-31.2 4 engn-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ryan Daws, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of enGene Holdings Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Omitted;

c.
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 14, 2024

By:

/s/ Ryan Daws

Ryan Daws

Chief Financial Officer

(Principal Financial Officer and Accounting Officer)

 


EX-32.1 5 engn-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of enGene Holdings Inc. (the “Company”) for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: June 14, 2024

By:

/s/ Jason D. Hanson

Jason D. Hanson

Chief Executive Officer

(Principal Executive Officer)

 


EX-32.2 6 engn-ex32_2.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of enGene Holdings Inc. (the “Company”) for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: June 14, 2024

By:

/s/ Ryan Daws

Ryan Daws

Chief Financial Officer

(Principal Financial Officer and Accounting Officer)

 


EX-101.SCH 7 engn-20240430.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Reverse Recapitalization link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - License Agreement and Clinical Research Organization link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Convertible Debentures link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Redeemable Convertible Preferred Shares link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Common Shares link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Reverse Recapitalization (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Convertible Debentures (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Common Shares (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Description of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Reverse Recapitalization -Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Reverse Recapitalization - Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Fair Value Measurements - Summary Of Change In Estimated Fair Value Of Convertible Debentures Embedded Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Fair Value Measurements - Summary of Change in Estimated Fair Value of Warrant Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - License Agreement and Clinical Research Organization - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Notes Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Notes Payable - Schedule of Carrying Value of Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Convertible Debentures - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Redeemable Convertible Preferred Shares - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Common Shares - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Common Shares - Schedule of Shares Reserved For Future Issuance Under The Plan (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Description of Business [Table] Description of business. Business combination reverse recapitalization description Business Acquisition, Description of Acquired Entity Total Convertible debentures Convertible Debt, Total Convertible debt Convertible Debt Old enGene's Equity and Convertible Note Holders Old enGene's Equity and Convertible Note Holders [Member] Old enGene’s equity and convertible note holders. Auditor Firm ID Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Transition Report Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Weighted- Average Remaining Contractual Term (in years), Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Transaction costs as part of reverse recapitalization and pipe financing Transaction Costs Of Reverse Recapitalization And PIPE Financing Transaction costs of reverse recapitalization and pipe financing. Additional awards approved for issuance Additional Awards Approved For Issuance Additional awards approved for issuance. Interest expense, including the amortization of debt discounts Interest Expense Including Amortization Of Debt Discounts Interest expense including amortization of debt discounts. Foreign exchange (gain)/loss Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Foreign Exchange (Gain) Loss Fair value measurement with unobservable inputs reconciliation recurring basis liability foreign exchange (gain) loss. One-time payment for milestone product Milestone Product Payment Milestone product payment Initial annual base rent Initial Annual Base Rent Per Square Foot Initial annual base rent per square foot. Company Shareholders Company Shareholders [Member] Company shareholders member. Options vesting period Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Repayment Debt Instrument, Repaid, Principal Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Other Assets [Member] Entity Public Float Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Fair Value Measurements Fair Value Disclosures [Text Block] Temporary equity shares authorized Temporary Equity, Shares Authorized Income Taxes Income Tax, Policy [Policy Text Block] Estimated Useful Life Property, Plant and Equipment, Useful Life Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares) Issuance Of Common Stock In Connection With Pipe Financing Shares Issuance of common stock in connection with PIPE financing shares. May 2023 Notes May Two Thousand Twenty Three Notes [Member] May two thousand twenty three notes. Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount ICFR Auditor Attestation Flag Applied to Refinance of Amount Outstanding Applied to Refinance of Amount Outstanding [Member] Applied to refinance of amount outstanding. Embedded derivative liability measured at fair value Embedded Derivative, Fair Value of Embedded Derivative Liability Title of Individual [Domain] Reverse recapitalization embedded derivative fair value of embedded derivative Reverse Recapitalization Embedded Derivative Fair Value Of Embedded Derivative Reverse recapitalization embedded derivative fair value of embedded derivative. Subsequent Events Subsequent Events [Text Block] Temporary equity shares issued Temporary Equity, Shares Issued Area of office space Rentable square feet Area Of Space Area of space. Class B-1 Redeemable Convertible Preferred Shares Class B-1 Redeemable Convertible Preferred Shares [Member] Class b-1 redeemable convertible preferred shares. Government Assistance Programs for Research and Development Expenditures Government Assistance Programs For Research And Development Expenditures [Policy Text Block] Government assistance programs for research and development expenditures. Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Percentage of prepayment premium of principal amount outstanding of the closing date Percentage of Prepayment Premium of Principal Amount Outstanding of the Closing Date Percentage of prepayment premium of principal amount outstanding of the closing date. Cash dividend paid Common Stock, Dividends, Per Share, Cash Paid Schedule of Stock by Class [Table] Debt discount, net of accretion Debt Instrument, Unamortized Discount, Total Debt Instrument, Unamortized Discount Term loan reduced annual interest rate Debt Instrument, Interest Rate, Increase (Decrease) Class of Stock [Line Items] Related Party Transactions [Abstract] Balance Sheet Location [Axis] Total current assets Assets, Current Total current assets Vesting [Domain] Old enGene Shareholders (Excluding Convertible Notes) Old EnGene Shareholders [Member] Old EnGene shareholders. Total liabilities, redeemable convertible preferred shares and shareholder's equity Liabilities and Equity Entity Address, State or Province Stock Issued During Period, Value, New Issues Issuance of common shares, value Share exchange ratio Stockholders' Equity Note, Stock Split, Conversion Ratio April 2023 Notes April Two Zero Two Three Notes [Member] April two zero two three notes. Number of shares outstanding, Beginning balance Number of shares outstanding, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Reverse Recapitalization and PIPE Financing transaction costs included within accrued expenses and accounts payable Reverse Recapitalization And Pipe Financing Transaction Costs Included Within Accrued Expenses And Accounts Payable Reverse recapitalization and pipe financing transaction costs included within accrued expenses and accounts payable. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value per share of share options granted Convertible Debenture Embedded Derivative Liabilities Derivatives, Embedded Derivatives [Policy Text Block] Trading Symbol Payment of Financing and Stock Issuance Costs, Total Payment of Financing and Stock Issuance Costs Offering expenses Common stock shares issued Common Stock, Shares, Issued 2025 Long-Term Debt, Maturity, Year Two Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Issuance of common shares upon exercise of warrants Stock Issued During Period Value Warrants Exercised Stock issued during period value warrants exercised. Investment tax credit receivable Investment tax credit receivable Increase (Decrease) In Investment Tax Credit Receivable Increase (decrease) in investment tax credit receivable. Prepaid and other current assets Prepaid Expense and Other Assets, Current Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing Common Stock Outstanding After Reverse Recapitalization and PIPE Financing Common stock outstanding after reverse recapitalization and pipe financing. FEAC Shareholders, including sponsor's and shareholder with non-redemption agreement FEAC Shareholders [Member] FEAC shareholders. Lease expiration date Lease Expiration Date Schedule of Long-Term Debt Instruments [Table] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Class A Redeemable Convertible Preferred Shares Class A Redeemable Convertible Preferred Shares [Member] Class a redeemable convertible preferred shares. Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Common stock shares reserved for future issuance Aggregate number of common shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Warrant To Purchase Common Stock [Member] Warrant To Purchase Common Stock. Warrants to purchase common shares Class B Redeemable Convertible Preferred Shares Class B Redeemable Convertible Preferred Shares [Member] Class b redeemable convertible preferred shares. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Functional Currency Change Foreign Currency Transactions and Translations Policy [Policy Text Block] License Agreement [Table] License Agreement Table Number of common stock warrants exercised by investors on cashless basis. Number Of Common Stock Warrants Exercised By Investors On Cashless Basis Number of common stock warrants exercised by investors on cashless basis PIPE Financing PIPE Financing [Member] PIPE financing. Entity Address, City or Town Related Party Transaction [Line Items] Aggregate sale of convertible promissory notes, warrants, preferred shares, common shares, or combined thereof Aggregate Sale Of Convertible Promissory Notes Warrants Preferred Shares Common Shares Or Combined Thereof Aggregate sale of convertible promissory notes warrants preferred shares common shares or combined thereof. Warrants outstanding Class of Warrant or Right, Outstanding Operating lease renewal term Lessee, Operating Lease, Renewal Term Notes Payable Debt Disclosure [Text Block] Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Issuance of common shares upon cashless exercise of warrants (in shares) Stock Issued During Period Shares Cashless Exercise Of Warrants Stock issued during period shares cashless exercise of warrants. Description of Business [Line Items] Description of business. Subsequent Event Subsequent Event [Member] Subsequent Event Type [Axis] Fair Value Option Fair Value Option [Policy Text Block] Fair value option. Weighted-Average Exercise Price, Forfeited or expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Chief Executive Officer [Member] CEO Additional Paid in Capital Additional Paid-in Capital [Member] Summary Of Components Of The Provision For Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Notes purchase principal amount Debt Instrument, Issued, Principal Current liabilities: Liabilities, Current [Abstract] 2022 Notes and BDC Notes Convertible Debentures Embedded Derivative Liabilities for 2022 Notes and BDC Notes [Member] Convertible debentures embedded derivative liabilities for 2022 notes and BDC notes Current assets: Assets, Current [Abstract] Counterparty Name [Axis] June 2023 Financing June Twenty Twenty Three Financing [Member] June Twenty Twenty Three Financing Member. Statement of Stockholders' Equity [Abstract] Change in Accounting Principle, Accounting Standards Update, Immaterial Effect Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Weighted-Average Exercise Price, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Current Operating lease liabilities, current Lender Name [Axis] Assumptions Used to Determine Fair Value of Liabilities Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Term loan maturity date Maturity date Debt Instrument, Maturity Date Long-Term Debt Note payable, net of discount Derivative Contract [Domain] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Exercise price equal to percentage of aggregate amount of term loans Percentage of Aggregate Term Loan Funded Percentage of aggregate term loan funded. Class of Stock [Domain] Interest income Interest income Investment Income, Interest Prior Loan Agreement Prior Loan Agreement [Member] Prior loan agreement. Tranche Two Tranche Two [Member] Tranche two. Aggregate Intrinsic Value, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Remaining shares reserved for future issuance under the 2023 Plan Shares Reserved For Future Issuance Under The 2023 Plan [Member] Shares Reserved For Future Issuance Under The 2023 Plan. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] CIK Entity Central Index Key Share warrants issued Number of securities into which the class of warrant or right may be converted Warrant issued to purchase preferred shares Plan Name [Domain] Change in Accounting Principle, Accounting Standards Update, Adopted Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Assets, Fair Value Disclosure, Total Financial assets, fair value Assets, Fair Value Disclosure Preferred stock shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Cashless warrant exercises. Cashless Warrant Exercises [Member] Cashless Warrant Exercises Cash Warrant Exercises Cash Warrant Exercises [Member] Cash warrant exercises. Issuance of common shares upon cashless exercise of warrants Stock Issued During Period Value Cashless Exercise Of Warrants Stock issued during period value cashless exercise of warrants. Total current liabilities Total current liabilities Liabilities, Current Entity Tax Identification Number Net loss before provision for income taxes Net loss before provision for income taxes Net loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Payments of debt issuance costs associated with the term loan Payments of Debt Issuance Costs Financial Instruments [Domain] Aggregate Intrinsic Value, Options unvested Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Aggregate Intrinsic Value Share based compensation arrangement by share based payment award options unvested aggregate intrinsic value. Payment of issuance costs associated with April 2023 Notes Payment Of Issuance Costs Associated With Convertible Debt Payment of issuance costs associated with convertible debt. Leases Lessee, Operating Leases [Text Block] Maximum hours of CEO devote per week to providing transition services. Maximum Hours Of CEO Devote Per Week To Providing Transition Services Maximum hours of ceo devote per week to providing transition services Plan Name [Axis] Derivative Instrument [Axis] Operating lease initial term Lessee, Operating Lease, Term of Contract Fair value of common shares and exercise price of options Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options. Total assets Assets Reverse Recapitalization Reverse Recapitalization TextBlock Reverse Recapitalization TextBlock Operating lease right of use assets Operating Lease, Right-of-Use Asset Foreign exchange (gain)/loss Foreign exchange (gain)/loss Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Foreign Exchange (Gain) Loss Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation foreign exchange (gain) loss Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Class C Warrants Class C Warrants [Member] Class C Warrants. Registrant Name Entity Registrant Name Transfers or reclassifications out of level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Debt Issuance Costs, Net, Total Debt issuance costs Debt Issuance Costs, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total Increase in number of share reserved for future issuance in the beginning of the year Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease) Cash - PIPE Financing Proceeds from Issuance or Sale of Equity, Total Proceeds from PIPE financing Proceeds from Issuance or Sale of Equity Operating lease, option to extend Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, Lease, Description [Line Items] Related Party, Type [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Weighted-Average Exercise Price, Options unvested Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price Share based compensation arrangement by share based payment award options unvested weighted average exercise price. Amended Loan Agreement Amended Loan Agreement [Member] Amended loan agreement. Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Reverse Recapitalization [Line Items] Reverse recapitalization. May 2023 Notes May Twenty Twenty Three Notes [Member] May Twenty Twenty Three Notes. Accumulated Deficit Retained Earnings [Member] Class of Stock [Axis] Minimum Minimum [Member] Cash - FEAC's Trust Account and Cash (net of redemptions and cash paid for FEAC expenses prior to close) Proceeds from trust account Proceeds From Trust Account Proceeds from trust account. Proceeds from exercise of stock options Proceeds from Stock Options Exercised Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Operating Lease, Liability, Total Operating lease liabilities Operating Lease, Liability Total Lease liability Preferred share warrants fair value Preferred Share Warrants Fair Value Preferred share warrants fair value. Vesting Immediately Upon Grant Date Tranche One Share-Based Payment Arrangement, Tranche One [Member] Expected volatility, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Accrued income tax payable Accrued Income Taxes, Current Equity Component [Domain] Notes Payable, Noncurrent, Total Note payable, net of current portion Notes Payable, Noncurrent Options to purchase common shares Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in Accounting Principle, Accounting Standards Update, Adoption Date 2023 Warrants Two Thousand Twenty Three Warrants [Member] Two thousand twenty three warrants. Securities Financing Transaction [Axis] End of term charge End of Term Charge End of term charge. Initial consulting period. Initial Consulting Period Initial consulting Period Warrants exercisable period Class Of Warrant Or Right Year From Which Warrants Or Rights Exercisable Class of warrant or right year from which warrants or rights exercisable. Wall Street Journal Wall Street Journal [Member] Wall street journal. Computer Software Software Development [Member] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total Debt discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Measurement Frequency [Axis] Tranche One Tranche One [Member] Tranche One. Debt Disclosure [Abstract] Net loss attributable to common stockholders, diluted Net loss attributable to common shareholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted, Total Net loss attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Incremental compensation cost Share-Based Payment Arrangement, Plan Modification, Incremental Cost Percentage of aggregate principal amount of term loan advance to purchase number of common shares Percentage Of Aggregate Principal Amount Of Term Loan Advance To Purchase Number Of Common Shares Percentage of aggregate principal amount of term loan advance to purchase number of common shares. Debt instrument, basis spread on variable rate Term loan annual interest rate Debt Instrument, Basis Spread on Variable Rate Entity Current Reporting Status Research and Development Expense, Total Research and development Research and Development Expense Convertible Notes - Common Shares issued Convertible Notes Convertible Notes [Member] Convertible notes. Unrealized foreign currency losses Unrealized foreign currency transaction losses Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Unrealized foreign currency losses (gains) Convertible Debentures Debt, Policy [Policy Text Block] Common Share and Preferred Share Warrants Common Share And Preferred Share Warrants [Policy Text Block] Common share and preferred share warrants. Operating lease commencement period Operating Lease Commencement Period Operating lease commencement period. Assets Assets [Abstract] Proceeds from Issuance of Common Stock Aggregate gross proceeds of common stock Number of options remain available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Measurement Input, Expected Term Expected Time to Respective Scenarios Measurement Input, Expected Term [Member] Preferred Stock, as converted Convertible Preferred Stock [Member] Common shares, no par value; unlimited shares authorized, 44,158,587 and 23,197,976 shares issued and outstanding as of April 30, 2024 and October 31, 2023, respectively. Common Stock, Value, Issued Realized foreign currency transaction losses Realized Gain (Loss), Foreign Currency Transaction, before Tax Office Furniture Furniture and Fixtures [Member] Current Fiscal Year End Date Total share-based compensation expense Share-Based Payment Arrangement, Noncash Expense, Total Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Percentage of tax benefit to be realized for recognition in the income statement Percentage Of Tax Benefit To Be Realized For Recognition In The Income Statement Percentage of tax benefit to be realized for recognition in the income statement. Auditor Name Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Thereafter Loss from operations Operating Income (Loss) Operating Income (Loss), Total Interest rate Related Party Transaction, Rate ASU-2019-12 Accounting Standards Update 2019-12 [Member] Entity Ex Transition Period Total income tax expense (benefit) Income Tax Expense (Benefit) Income tax provision or benefit Provision for (benefit from) income taxes Total commitment amount Commitment Amount Commitment amount. Issuance of common shares upon cashless exercise of options Stock Issued During Period Value Upon Cashless Exercise of Options Stock issued during period value upon cashless exercise of options. Price per unit paid for common shares and warrants Price Per Unit Paid for Common Shares and Warrants Price per unit paid for common shares and warrants. Research and Development Research and Development Expense [Member] Long-Term Debt, Maturity, Year Four 2027 Cash Leases Lessee, Leases [Policy Text Block] Accrued Expenses and Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Total share-based compensation expense Stock-based compensation expense Share-Based Payment Arrangement, Expense Expected volatility, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Percentage of vesting rights Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Measurement Input Type [Domain] Percentage of increase in annual base rent Percentage of Increase in Annual Base Rent Percentage of increase in annual base rent. Lab Equipment Equipment [Member] Increase (Decrease) in Operating Lease Liability Lease liabilities Accrued interest Debt Instrument, Accrued Interest Debt instrument, accrued interest. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of exchange rate changes on cash and cash equivalents Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Principal amount Term loans aggregate principal amount Borrowed amount Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Class A Initial Closing Class A Initial Closing [Member] Class A initial closing. Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Other expense, net Total other (income) expense, net Other expense, net Other Nonoperating Income (Expense) Redeemable convertible preferred shares at a price per share Sale of Stock, Price Per Share Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing [Table Text Block] Summary of net proceeds from reverse recapitalization and pipe financing. Employee entitled base salary continuation after termination for a period Employee Entitled Base Salary Continuation After Termination For Period Employee entitled base salary continuation after termination for period. Operating expenses: Operating Expenses [Abstract] Property, Plant and Equipment [Abstract] Long-Term Debt, Type [Domain] Entity Voluntary Filers Subsequent Events [Abstract] Options unvested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Commitments and Contingencies Disclosure [Abstract] Other assets Other Assets, Noncurrent Series 1 Class C Redeemable Convertible Preferred Series 1 Class C Redeemable Convertible Preferred [Member] Series 1 class c redeemable convertible preferred. Shares Granted Granted Number of stock option award issued during the period Other Other Accrued Liabilities, Current Common Shares Equity [Text Block] Depreciation, Total Depreciation of property and equipment Depreciation Term Loan Term Loan [Member] Term loan. Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Securities Financing Transaction [Domain] Employee entitled base salary continuation in case of change in control after termination for a period Employee Entitled Base Salary Continuation In Case Of Change in Control After Termination For Period Employee entitled base salary continuation in case of change in control after termination for period. Annual maintenance fee Cost, Maintenance Change in fair value of convertible debenture embedded derivative liabilities Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Equity, Attributable to Parent [Abstract] Shareholder's equity: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Components of Operating Lease Cost Lease, Cost [Table Text Block] 2023 Plan Two Zero Two Three Plan [Member] Two zero two three plan. All Entities Entity [Domain] Debenture Debenture [Member] Debenture member. Line of credit, maximum amount available Term loan facility aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Entity Listings [Line Items] Earnings Per Share [Abstract] Weighted- Average Remaining Contractual Term (in years), Options unvested Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term1 Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1. Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Maturities of Operating Lease Liabilities Office Space Office Space [Member] Office space. Accounting Policies [Abstract] Lessee Disclosure [Abstract] Lessee, Lease, Description [Table] Reclassification of Warrants to equity upon consummation of the Reverse Recapitalization Reclassification of Warrants to equity upon consummation of the Reverse Recapitalization Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Warrants To Equity Upon Consummation Of Reverse Recapitalization Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification of warrants to equity upon consummation of reverse recapitalization. Fair Value of Common Share Fair Value of Common Share at Conversion of Listing Event Measurement Input, Conversion Price [Member] License Agreement and Clinical Research Organization [Line Items] License agreement and clinical research organization line items. Risk of Concentrations of Credit and Off-Balance Sheet Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Value of stock and warrant issued during the period Value of Stock and Warrant Issued During the Period Value of stock and warrant issued during the period. Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Summary of Change in Estimated Fair Value of Liabilities Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block] Effective interest rate of outstanding debt Debt Instrument, Interest Rate, Effective Percentage Interest rate Less transaction costs withheld from cash proceeds on Closing Date Transaction Cost Withheld From Proceeds Received Transaction cost withheld from rroceeds received. Tranche 3 Advance Tranche Three Advance [Member] Tranche three advance. Earnings Per Share, Basic, Total Net loss per share of common shares, basic Earnings Per Share, Basic Cash Equivalents, at Carrying Value, Total Cash equivalents Cash Equivalents, at Carrying Value 2023 Financing Two Zero Two Three Financing Member Two Zero Two Three Financing. Income Statement [Abstract] Weighted-Average Exercise Price, Options vested and not exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Exercise Price Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Common shares and warrants on relative fair value, basis price per unit paid Reverse Recapitalization Price Per Unit Paid Common Shares And Warrants On Relative Fair Value Basis Reverse recapitalization price per unit paid common shares and warrants on relative fair value basis. Warrant liabilities Warrant Liabilities Non-current Warrant liabilities non-current. Related Party, Type [Axis] Issuance of warrants in connection with Amended Term Loan Adjustments to Additional Paid in Capital, Warrant Issued Operating lease cost Operating Lease, Cost Short-term operating lease cost Short-Term Lease, Cost Rule10 B51 Trading Plan Rule10 B51 Trading Plan [Member] Rule10 b51 trading plan. Measurement Input Type [Axis] Remaining options vesting Shares Vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Statistical Measurement [Domain] Number of new warrant issued during the period Number of New Warrant Issued During the Period Number of new warrant issued during the period. Cash flows from operating activities Net cash used in operating activities Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities ASU 2021-10 Accounting Standards Update 2021-10 [Member] Proceeds from issuance of term loan Proceeds from Issuance of Debt Forbion Growth Sponsor FEAC I B.V Forbion Growth Sponsor FEAC I B.V [Member] Forbion Growth Sponsor FEAC I B.V Member. Period End Date Document Period End Date Statistical Measurement [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Stockholders' Equity Note [Abstract] Issuance of common shares upon exercise of warrants (in shares) Stock Issued During Period Shares Warrants Exercised Stock issued during period shares warrants exercised. Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Deferred Transaction Costs Deferred Policy Acquisition Costs, Policy [Policy Text Block] Common stock issued redemption price Common Stock Issued Redemption Price Common stock issued redemption price. Earnings Per Share, Diluted, Total Net loss per share of common shares, diluted Earnings Per Share, Diluted Lease Cost: Lease, Cost [Abstract] Additional reserves of common stock for issuance Additional reserves of common stock for issuance Additional reserves of common stock for issuance. Stock options vesting service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Class C Second Tranche Class C Second Tranche [Member] Class c second tranche. Class C Redeemable Convertible Preferred Shares Class C Redeemable Convertible Preferred Shares [Member] Class C redeemable convertible preferred shares. Debt Instrument, Name [Domain] Preferred stock shares authorized unlimited Preferred Stock, Shares Authorized, Unlimited [Fixed List] Series 4 Class C Redeemable Convertible Preferred Series 4 Class C Redeemable Convertible Preferred [Member] Series 4 class c redeemable convertible preferred. Conversion and exchange of Old enGene convertible debentures and common share warrants into enGene Holdings common shares and common share warrants in connection with the Reverse Recapitalization (in shares) Conversion and Exchange of Old Convertible Debentures and Common Share Warrants Into New Common Shares and Common Share Warrants in Connection With Reverse Recapitalization Shares Conversion and exchange of old convertible debentures and common share warrants into new common shares and common share warrants in connection with reverse recapitalization shares. Old enGenes Warrant Old enGenes Warrant Holders Member Old enGenes Warrant Holders Member Unaudited interim financial information policy. Unaudited Interim Financial Information [Policy Text Block] Unaudited Interim Financial Information Fair Value Measurement Recurring Fair Value, Recurring [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Schedule of Estimated Future Principal Payments Due Under the Loan Agreement Schedule of Maturities of Long-Term Debt [Table Text Block] Preferred stock no par value Preferred Stock, No Par Value Total aggregate proceeds Proceeds from Issuance of Redeemable Convertible Preferred Stock Cash proceeds received from the Reverse Recapitalization and PIPE Financing on Closing Date Gross Cash Proceeds Received from Reverse Recapitalization and Pipe Financing Gross cash proceeds received from reverse recapitalization and pipe financing. Exercised Exercised Exercise of stock options (in shares) Stock options exercised Liabilities, redeemable convertible preferred shares and Shareholder's equity (deficit) Liabilities and Equity [Abstract] Lease expiration month and year Lease Expiration Month and Year Lease expiration month and year. Common stock, value issued Stock Issued During Period, Value, Acquisitions Entity Address, Postal Zip Code Entity Interactive Data Current Private Placement [Member] Private Placement Series 3 Class C Redeemable Convertible Preferred Series 3 Class C Redeemable Convertible Preferred [Member] Series 3 class c redeemable convertible preferred. Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Anthony Cheung Anthony Cheung [Member] Anthony cheung. Credit Facility [Domain] Equity [Abstract] Common stock shares authorized unlimited Common Stock, Shares Authorized, Unlimited [Fixed List] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Interest If Interim Milestone Achieved and No Default If Interim Milestone Achieved and No Default [Member] If interim milestone achieved and no default. Schedule of Short-Term Debt [Table] Weighted- Average Remaining Contractual Term (in years), Options vested and not exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Remaining Contractual Term. Entity Well-known Seasoned Issuer Amount of convertible debentures and warrants Convertible Debentures And Warrants Convertible debentures and warrants. Weighted-Average Exercise Price, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Entity Incorporation, State or Country Code Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Equity Components [Axis] Investissement Quebec Investissement Quebec [Member] Investissement Quebec Member. Lab equipment Lab Equipment [Member] Lab equipment. Merger agreement date Business Acquisition, Date of Acquisition Agreement Financial liabilities, fair value Financial Liabilities Fair Value Disclosure, Total Financial liabilities Financial Liabilities Fair Value Disclosure Common shares and common share warrants issued upon Reverse Recapitalization and PIPE Financing, net of issuance costs of $11.1 million Common Shares and Common Share Warrants Issued Upon Reverse Recapitalization and Pipe Financing Value Common shares and common share warrants issued upon reverse recapitalization and pipe financing value. End of term fee percentage End of Term Fee Percentage End of term fee percentage. Accrued interest percentage Debt Instrument Accrued Interest Rate Debt instrument accrued interest rate. Conversion and exchange of Old enGene convertible debentures and common share warrants into enGene Holdings common shares and common share warrants in connection with the Reverse Recapitalization Conversion and Exchange of Old Convertible Debentures and Common Share Warrants Into New Common Shares and Common Share Warrants in Connection With Reverse Recapitalization Value Conversion and exchange of old convertible debentures and common share warrants into new common shares and common share warrants in connection with reverse recapitalization value. Local Phone Number Property, Plant and Equipment [Line Items] Sale of Stock [Axis] Date of closed private placement. Date of Closed Private Placement Date of closed private placement Warrant liabilities recognized upon issuance Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Warrant Liability Recognized Upon Issuance Fair value measurement with unobservable inputs reconciliation recurring basis liability warrant liability recognized upon issuance. Shares issued in exchange of debt instrument Debt Conversion, Converted Instrument, Shares Issued Warrants exercisable period Class Of Warrant Or Rights Number Of Days From Which Warrants Or Rights Exercisable Class of warrant or rights number of days from which warrants or rights exercisable. Goodwill, Total Goodwill, Beginning Balance Goodwill, Ending Balance Goodwill Note payable current Notes Payable, Current, Total Current portion of notes payable Notes Payable, Current Options vested and not exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Number. Statement of Cash Flows [Abstract] Convertible Debentures Embedded Derivative Liabilities Embedded Derivative Financial Instruments [Member] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Transaction costs related to issuance of notes Transaction Costs Related To Issuance Of Notes Transaction costs related to issuance of notes. April 2023 Notes April Twenty Twenty Three Notes [Member] April Twenty Twenty Three Notes Member. May 2023 Notes May Two Thousand Two Three Notes Member May Two Thousand Two Three Notes. Reverse recapitalization price per unit paid common shares and warrants Reverse Recapitalization Price Per Unit Paid Common Shares And Warrants Reverse recapitalization price per unit paid common shares and warrants. Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Common Stock, Par or Stated Value Per Share Common Stock Par Or Stated Value Per Share Common shares price per share Class C Inital Closing Class C Initial Closing [Member] Class C initial closing. 2024 PIPE investors. Two Thousand Twenty Four PIPE Investors [Member] 2024 PIPE Investors Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Interest rate Debt Instrument, Interest Rate, Stated Percentage Accrue interest rate percentage Unrecognized compensation expense weighted-average period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Long-Lived Tangible Asset [Axis] Class B Intial Closing Class B Initial Closing [Member] Class B initial closing. Weighted- Average Remaining Contractual Term (in years), Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized increased Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Maximum Maximum [Member] Convertible debentures Convertible Debt, Noncurrent Research and development investment tax credits Research And Development Investment Tax Credits Research and development investment tax credits. Amended Employment Agreement Amended Employment Agreement [Member] Amended Employment Agreement. License Agreement and Clinical Research Organization [Abstract] License Agreement and Clinical Research Organization Proceeds from the 2024 PIPE Financing Proceeds from Issuance of Private Placement Aggregate gross proceeds from the Private Placement BDC Notes BDC Notes [Member] BDC Notes Member. Temporary equity shares outstanding Beginning balance (in shares) Ending balance (in shares) Temporary Equity, Shares Outstanding Percentage of principal Percentage Of Principal Amount Percentage Of Principal Amount. Income Tax Contingency [Line Items] Old enGenes Equity and Convertible Note Old enGenes Equity and Convertible Note Holder Member Old enGenes Equity and Convertible Note Holder. Repayments of term loan principal Repayments of term loan principal Repayments of term loan principal. Fair Value, Recurring and Nonrecurring [Table] Change in fair value of warrant liabilities Change in fair value of warrant liabilities Fair Value Adjustment of Warrants Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Transfers or reclassifications into level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Payables and Accruals [Abstract] General and Administrative General and Administrative Expense [Member] Intangible Assets, Gross (Excluding Goodwill), Total Intangible assets Intangible Assets, Gross (Excluding Goodwill) Supplemental disclosure of non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Percentage of prepayment premium of principal amount outstanding prior to twenty-four months Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Twenty Four Months Percentage of prepayment premium of principal amount outstanding prior to twenty four months. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Change in fair value of warrant liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Document Financial Statement Error Correction [Flag] Class A Second Tranche Class A Second Tranche [Member] Class a second tranche. Schedule of Shares Reserved for Future Issuance Under the Plan Schedule of Shares Reserved For Future Issuance Under The Plan Table Text Block Schedule of shares reserved for future issuance under the plan. Summary of Shares Excluded from Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] City Area Code Cash Flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net cash proceeds from the Reverse Recapitalization and PIPE Financing Net Cash Proceeds Received from Reverse Recapitalization and Pipe Financing. Net cash proceeds received from reverse recapitalization and pipe financing. Non-Voting Common Shares Nonvoting Common Stock [Member] Common stock voting rights Common Stock, Voting Rights If Interim Milestone and Certain Clinical Milestones Achieved and No Default If Interim Milestone and Certain Clinical Milestones Achieved and No Default [Member] If interim milestone and certain clinical milestones achieved and no default. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment General and Administrative Expense, Total General and administrative General and Administrative Expense Weighted-average number of common shares used in net loss per share, basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Shares Acquired Eexercise of Stock Options Rule10 B51 Trading Plan One [Member] Rule10 b51 trading plan one Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Probability of Qualified Financing Measurement Input Probability Of Qualified Financing [Member] Measurement input probability of qualified financing. Reverse Recapitalization [Table] Reverse recapitalization. Loss on extinguishment of convertible debentures Gain (Loss) on Extinguishment of Debt, Total Loss on extinguishment of convertible debentures Gain (Loss) on Extinguishment of Debt Gain on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Statement [Table] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Document Fiscal Period Focus Preferred Share Warrant Liabilities Preferred Share Warrant Liabillities [Member] Preferred share warrant liabilities. Additional lease commitments to be paid Lessee, Operating Lease, Liability, to be Paid Total Common shares and common share warrants issued upon Reverse Recapitalization and PIPE Financing, net of issuance costs of $11.1 million (in shares) Common Shares and Common Share Warrants Issued Upon Reverse Recapitalization and Pipe Financing Shares Common shares and common share warrants issued upon reverse recapitalization and pipe financing shares. Payment-in-kind interest rate Paid-in-kind Interest Percentage Paid-in-kind interest percentage. Related Party Transactions Related Party Transactions Disclosure [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Professional fees Accrued Professional Fees, Current Phase II Clinical Trial [Member] Phase II Clinical Trial Statement [Line Items] Summary of Outstanding Principal, Accrued Interest and Unamortized Deferred Financing Costs of Convertible Debentures Recorded on Balance Sheet Debt Instrument, Fair Value Disclosure, Total Fair value of debt instrument Debt Instrument, Fair Value Disclosure Estimated Useful Life Property Plant And Equipment Estimated Useful Live Property plant and equipment estimated useful live. Shares excluded from computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Aggregate Intrinsic Value, Options vested and not exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Aggregate Intrinsic Value. Investment tax credits receivable Investment Tax Credits Receivable Investment tax credits receivable. Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Total operating lease cost Lease, Cost Aggregate number of common shares outstanding percentage Common Shares Percentage Common shares percentage. Subsequent Event [Line Items] Warrants to purchase common shares Warrant Liabilities Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share Date of incorporation Entity Incorporation, Date of Incorporation Summary Of Net Deferred Income Tax Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Operating lease extended term Lessee, Operating Lease, Extended Term Lessee, operating lease, extended term. Common Shares Common Stock [Member] Debt Instrument [Line Items] Warrants, maturity date Warrants and Rights Outstanding, Maturity Date Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Summary of Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Maximum automatically increase in authorized shares issued under share-based plan each year. Maximum Automatically Increase in Authorized Shares Issued Under Share-Based Plan Each Year Maximum automatically increase in authorized shares issued under share-based plan each year Summary of Estimated Useful Life of Each Asset Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block] Schedule of estimated useful lives of property, plant and equipment. Entity Common Stock, Shares Outstanding Office and Lab Space Office and Lab Space [Member] Office and lab space. Fair Value Measurements of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Antidilutive Securities, Name [Domain] Entity Bankruptcy Proceedings, Reporting Current Conversion and exchange of redeemable convertible preferred stock into common shares in connection with the Reverse Recapitalization Stock Issued During Period, Value, Conversion of Convertible Securities Old hercules warrants. Old Hercules Warrants [Member] Old Hercules Warrants Schedule of Carrying Value of Term Loan Schedule of Debt [Table Text Block] Cover Cover [Abstract] Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Summary of Number of Common Shares Outstanding Vesting [Axis] Document Fiscal Year Focus Sale of Stock [Domain] Common stock capital shares reserved for remaining future issuance Common Stock Capital Shares Reserved for Remaining Future Issuance Common stock capital shares reserved for remaining future issuance. Income Tax Contingency [Table] Deemed dividend attributable to redeemable convertibleb preferred shareholders Redeemable Preferred Stock Dividends Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Repayments of convertible notes and warrants Repayments Of Convertible Notes and Warrants Repayments of convertible notes and warrants. Percentage of facility charge on amount borrowed Percentage of Facility Charge on Amount Borrowed Percentage of facility charge on amount borrowed. Security Exchange Name Stock option term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Accrued research and development expenses Accrued Research And Development Expense Current Accrued research and development expenses current. Balance Balance Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Percentage of prepayment premium of principal amount outstanding prior to maturity date Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Maturity Date Percentage of prepayment premium of principal amount outstanding prior to maturity date. Preferred stock shares issued Preferred Stock, Shares Issued License Agreement and Clinical Research Organization License agreement and clinical research organization Property, Plant and Equipment, Gross, Total Property and equipment Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Issued options were fully vested Remaining shares reserved for future issuance under the equity plans Shares Reserved For Future Issuance Under the Equity Plans [Member] Shares reserved for future issuance under the equity plans. Merger Agreement [Member] Merger agreement. Transition services for consulting fee per hour. Transition Services For Consulting Fee Per Hour Transition services for consulting fee per hour Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right of Use Assets obtained in exchange for lease liabilities 2022 Notes Twenty Twenty Two Notes [Member] Twenty Twenty Two Notes Member. Payments of issuance costs associated with the 2024 PIPE Financing Payments of issuance costs associated with the 2024 PIPE Financing Payments Of Issuance Costs Associated With The Pipe Financing Payments of issuance costs associated with the pipe financing. Entity Listings [Table] Class B Third Tranche Class B Third Tranche [Member] Class b third tranche. Business Acquisition, Acquiree [Domain] Legal Entity: Legal Entity [Axis] Financial Instrument [Axis] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average expected life (in years) Warrants, contractual term Warrants exercisable period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Entity Emerging Growth Company Proceeds from issuance of April 2023 Notes Proceeds from convertible debt Proceeds from Convertible Debt Aggregate amount of shares exchanged Convertible Preferred Stock, Shares Issued upon Conversion Amendment Amendment Flag Summary of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Tranche Three Tranche Three [Member] Tranche three. Percentage of price per share Percentage Of Price Per Share Percentage of price per share. Accounting Standards Update [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Initial maturity term Debt Instrument Initial Maturity Term Debt instrument initial maturity term. Proceeds from Lines of Credit, Total Proceeds from line of credit Proceeds from Lines of Credit Leases [Abstract] Debt Issuance Costs Debt Issuance Costs [Policy Text Block] Debt issuance costs. Variable Rate [Domain] Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Line of credit, maturity date Line of Credit Facility, Expiration Date Class B Second Tranche Class B Second Tranche [Member] Class b second tranche. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 (remaining) Debt issuance costs expensed upon issuance of debt recorded at the fair value option Debt Issuance Costs Expensed upon Issuance of Debt Recorded at the Fair Value Option Debt issuance costs expensed upon issuance of debt recorded at the fair value option. Equity, Class of Treasury Stock [Line Items] Expiring term of warrants Class of Warrant or Right, Date from which Warrants or Rights Exercisable Short-Term Debt [Line Items] Fair value debt inputs measurement input Debt Instrument, Measurement Input Share-Based Payment Arrangement [Abstract] Initial maturity date Debt Instrument Initial Maturity Date Debt instrument initial maturity date. Temporary equity no par value Temporary Equity No Par Value Temporary equity no par value. Quoted market price of public warrants Quoted Market Price of Public Warrants Quoted market price of public warrants. Tranche 2 Advance Subject to Achievement of Specified Interim Milestone Tranche Two Advance Subject to Achievement of Specified Interim Milestone [Member] Tranche two advance subject to achievement of specified interim milestone. Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Debt Instrument [Axis] Long-Term Debt, Maturity, Year Five 2028 Temporary equity aggregate amount of redemption requirement Temporary Equity, Aggregate Amount of Redemption Requirement Total operating expenses Operating Expenses Severance benefits entitled to base salary Severance Benefits Entitled to Base Salary Severance benefits entitled to base salary. 2024 Subscription agreements. 2024 Subscription Agreements [Member] 2024 Subscription Agreements Restricted Investments Restricted Investments [Policy Text Block] Restricted Investments [Policy Text Block] 2024 Long-Term Debt, Maturity, Year One Auditor Location Exchange ratio Reverse Recapitalization Exchange Ratio Reverse recapitalization exchange ratio. Total accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Preferred shares, no par value; unlimited shares authorized, no shares issued and outstanding as of April 30, 2024 and October 31, 2023. Preferred Stock, Value, Issued Entity Small Business Entity Shell Company Title of Individual [Axis] Initial aggregate amount that company agreed to sell Sale of Stock, Number of Shares Issued in Transaction Payment of Reverse Recapitalization and PIPE Financing costs Payment Of Reverse Recapitalization And Pipe Financing Costs Payment of reverse recapitalization and pipe financing costs. Warrants, exercise price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Transaction costs Business Acquisition, Transaction Costs Phase I Clinical Trial [Member] Phase I Clinical Trial Class of Warrant or Right [Domain] Common stock no par value Common Stock, No Par Value Issuance of common shares in connection with PIPE Financing, net of issuance costs Issuance of Common Stock in Connection With Pipe Financing Value Issuance of common stock in connection with PIPE financing value Computer Equipment Computer Equipment [Member] Net Loss Per Share Earnings Per Share [Text Block] Forfeited or expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Forfeited or expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Entity Address, Address Line One Period within loan disbursements to be made Period Within Loan Disbursements to be Made Period within loan disbursements to be made. Antidilutive Securities [Axis] Warrants, maturity period Warrants And Rights Outstanding Maturity Period Warrants and rights outstanding maturity period. Debt instrument, interest rate Interest rate Debt Instrument, Interest Rate During Period Weighted-Average Exercise Price, Options unvested Exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Subsequent Event Type [Domain] Preferred Share Warrants Preferred Share Warrants [Member] Preferred share warrants. Aggregate amount of base rental payments Aggregate Amount Of Base Rental Payments Aggregate amount of base rental payments. Risk-free interest rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Income Statement Location [Axis] Variable operating lease cost Variable Lease, Cost Long-Term Debt, Maturity, Year Three 2026 Value of stock and warrant issued price per units. Value of stock and warrant issued price per units Value of stock and warrant price per unit Risk-free interest rate, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Amortization of debt discount Amortization of Debt Discount (Premium) Payment to NTC upon assigning the License Agreement Payment On Assigning License to Third Party Payment on assigning license to third party Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Long-Term Debt, Type [Axis] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Old enGenes Share Option Old enGenes Share Option Holders Member Old enGenes Share Option Holders. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Warrants to Purchase Redeemable Convertible Preferred Shares Warrants to purchase redeemable convertible preferred shares Warrants to Purchase Redeemable Convertible Preferred Shares [Member] Warrants to purchase redeemable convertible preferred shares. Line of Credit Facility, Lender [Domain] Class C Preferred Shares Series C Preferred Stock [Member] Fair value of shares Share Price Share price Two thousand twenty four subscription agreements. Two Thousand Twenty Four Subscription Agreements [Member] 2024 Subscription Agreements Share-based compensation expense APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Note payable, including End of Term Charge Long-Term Debt, Gross Acquirer [Axis] Acquirer. Depreciation, Depletion and Amortization, Total Depreciation and amortization expense Depreciation, Depletion and Amortization Title of 12(b) Security Redeemable convertible preferred shares value Beginning balance Ending balance Temporary Equity, Carrying Amount, Attributable to Parent Non-cash lease expense Non Cash Lease Expenses Non cash lease expenses. FEAC FEAC [Member] FEAC. FEAC Prime Rate Prime Rate [Member] Evergreen Provision Evergreen Provision [Member] Evergreen provision. Convertible debenture embedded derivative liabilities Convertible Debenture Embedded Derivative Liabilities Convertible Debenture Embedded Derivative Liabilities Accounting Standards Update [Axis] Convertible Debentures Convertible Debentures DisclosureTextBlock Convertible Debentures. Other (income) expense, net: Other Nonoperating Income (Expense) [Abstract] Common Shares Issued to Pipe Investors Common Shares Issued to Pipe Investors [Member] Common shares issued to pipe investors. Deferred Costs, Total Deferred transaction costs Deferred Costs Entity Address, Country Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Tranche 1 Advance Tranche One Advance [Member] Tranche one advance. May 2023 Financing May Twenty Twenty Three Financing [Member] May Twenty Twenty Three Financing Member. Segment Information Segment Reporting, Policy [Policy Text Block] CEO Transition Agreement. CEO Transition Agreement [Member] CEO Transition Agreement Long-Lived Tangible Asset [Domain] Subsequent Event [Table] Cash dividends declared Common Stock, Dividends, Per Share, Declared Conversion and exchange of redeemable convertible preferred shares into common shares in connection with the Reverse Recapitalization Conversion and Exchange of Temporary Equity Into Common Shares in Connection With Reverse Recapitalization Value Conversion and exchange of temporary equity into common shares in connection with reverse recapitalization value. Percentage of issuance of common stock options Percentage of issuance of common stock options Percentage of issuance of common stock options Schedule of Fair Value, off-Balance-Sheet Risks [Table] Convertible Notes Payable, Total Convertible notes net Convertible Notes Payable Options to purchase common shares Share Based Compensation Arrangement By Share Based Payment Award Option to Purchase Common Shares Share based compensation arrangement by share based payment award option to purchase common shares. Interest Expense, Debt, Total Interest expense Interest Expense, Debt The Old Plans The Old Plans [Member] The old plans. Common stock shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Share-Based Payment Arrangement [Text Block] Change in fair value of convertible debenture embedded derivative liabilities Change in fair value of convertible debenture embedded derivative liabilities Change In Fair Value Of Convertible Debenture Embedded Derivative Liabilities Change in fair value of convertible debenture embedded derivative liabilities. Fair value of common shares and exercise price of options, Maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Maximum Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options maximum. Amount of monthly fee for consulting period. Amount Of Monthly Fee For Consulting Period Amount of monthly fee for consulting period Issuance costs Stock Issuance Costs Stock issuance costs. Hercules Warrants Hercules Warrants [Member] Hercules warrants. Class of Treasury Stock [Table] Proceeds from exercise of common share warrants Proceeds from exercises of warrants Proceeds from Warrant Exercises Change in fair value of convertible debentures embedded derivative liabilities Change in fair value of convertible debentures embedded derivative liabilities Change In Fair Value Of Convertible Debentures Embedded Derivative Liabilities Change in fair value of convertible debentures embedded derivative liabilities. Expenses related to the annual maintenance fee Annual Maintenance Fee Under License Agreement Annual maintenance fee under license agreement Warrants issued during period, value Warrants Issued During Period, Value Warrants issued during period, value. Income Statement Location [Domain] Exercise price of options granted Weighted-Average Exercise Price, Granted Exercise price Document Type Document Type Conversion and exchange of redeemable convertible preferred stock into common shares in connection with the Reverse Recapitalization (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities ASU 2020-06 Accounting Standards Update 2020-06 [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Document Quarterly Report Counterparty Name [Domain] Warrant value issued as part of amended term loan. Warrant Value Issued as Part of Amended Term Loan Warrant value issued as part of Amended Term Loan Warrants to purchase shares of common stock Warrants To Purchase Shares Of Common Stock Warrants to purchase shares of common stock. Conversion ratio Preferred Stock, Convertible, Conversion Ratio Net loss attributable to common shareholders, basic Net loss attributable to common shareholders, basic Net loss attributable to common stockholders, basic Net loss attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Summary of Significant Accounting Policies [Table] Summary of significant accounting policies. Loan amortization date Loan Amortization Date Loan amortization date. Entity Filer Category Balance Sheet Location [Domain] Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Summary of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Summary of Loss Before Provision for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Hercules Capital Hercules Capital [Member] Hercules capital. Variable Rate [Axis] Acquirer [Domain] Acquirer. Fair value of common shares and exercise price of options, Minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Minimum Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options minimum. Conversion and exchange of redeemable convertible preferred shares into common shares in connection with the Reverse Recapitalization (in shares) Conversion and Exchange of Temporary Equity Into Common Shares in Connection With Reverse Recapitalization Shares Conversion and exchange of temporary equity into common shares in connection with reverse recapitalization shares. Total other (income) expense, net Total other (income) expense, net Nonoperating Income (Expense) Loan and Security Agreement Loan and Security Agreements [Member] Loan and security agreements. Temporary equity shares authorized unlimited Temporary Equity Shares Authorized Unlimited Temporary equity shares authorized unlimited. Liabilities, Total Total liabilities Liabilities Property, Plant and Equipment [Table] Advance on loan allocated to warrants. Advance on Loan Allocated to Warrants. Advance on loan allocated to warrants Less transaction costs previously deferred and netted against proceeds Transactions costs deferred and netted against proceeds Transactions Costs Deferred and Netted Against Proceeds Transactions costs deferred and netted against proceeds. Less transaction costs previously deferred and netted against proceeds Beginning balance Ending balance Equity, Attributable to Parent Total shareholder's equity Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Net loss Net loss Net loss and comprehensive loss Percentage of total commitment amount Percentage Of Commitment Amount Percentage of commitment amount. 2021 Loan and Security Agreement 2021 Loan and Security Agreement [Member] 2021 loan and security agreement. Interest Expense, Total Interest Expense Description of Business Business Description and Basis of Presentation [Text Block] Non-cash interest expense Non-cash Interest Expense Non-cash interest expense. Settlement upon the consummation of the Reverse Recapitalization Repayment of convertible debentures Repayment of aggregate amount Repayment of convertible debentures Repayments of Convertible Debt Restricted investments Restricted Investments Warrant term Warrant Term Warrant term. Redeemable Convertible Preferred Shares Preferred Stock [Text Block] Statement of Financial Position [Abstract] Weighted-average number of common shares used in net loss per share, diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted-average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Summary Of Reconciliation Of Company's Statutory Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Credit Facility [Axis] New Laboratory and Office Space New Laboratory and Office Space [Member] New laboratory and office space. Shares issued, price per share Shares Issued, Price Per Share Schedule of Fair Value Hierarchy for Financial Liabilities Measured at Fair Value Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Deemed dividend attributable to redeemable convertible preferred shareholders Dilutive Securities, Effect on Basic Earnings Per Share, ESOP Convertible Preferred Stock Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Interest free period Debt Instrument Interest Free Period Debt instrument interest free period. Percentage of common stock value on date of grant Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Initial maturity period Debt Instrument Initial Maturity Period Debt instrument initial maturity period. Use of Estimates Use of Estimates, Policy [Policy Text Block] Series 2 Class C Redeemable Convertible Preferred Series 2 Class C Redeemable Convertible Preferred [Member] Series 2 class c redeemable convertible preferred. Income Taxes Income Tax Disclosure [Text Block] Term loan facility, drawn term Line of Credit Facility, Drawn Term Line of credit facility, drawn term. Upfront fee Upfront Fees Upfront Fees Patent Costs Patent Costs Policy [Policy Text Block] Patent costs. Issuance of common shares upon cashless exercise of options (in shares) Stock Issued During Period Shares Upon Cashless Exercise of Options Stock issued during period shares upon cashless exercise of options. Exercise price Weighted-Average Exercise Price Outstanding, Beginning balance Weighted-Average Exercise Price Outstanding, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Less transaction costs withheld from cash proceeds on Closing Date Transaction costs withheld from proceeds received Transaction Costs Withheld From Proceeds Received Transaction costs withheld from proceeds received. Summary of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Percentage of aggregate principle amount of term loan advances amount fee Percentage of Aggregate Pricipal Amount of Term Loan Advances Amount Fee Percentage of aggregate principle amount of term loan advances amount fee. Leasehold Improvements Leasehold Improvements [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common share options issued Common Share Options Issued Common Share Options Issued Fair Value Disclosures [Abstract] Measurement Frequency [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Redeemable convertible preferred shares Redeemable Convertible Preferred Stock [Member] Number of new stock issued during the period Stock Issued During Period, Shares, New Issues Issuance of common shares Employee compensation and related benefits Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Business Acquisition [Axis] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Class of Warrant or Right [Axis] Income Tax Disclosure [Abstract] XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information - shares
6 Months Ended
Apr. 30, 2024
Jun. 11, 2024
Entity Listings [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Apr. 30, 2024  
Document Fiscal Year Focus 2024  
Entity File Number 001-41854  
Entity Registrant Name enGene Holdings Inc.  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Current Fiscal Year End Date --04-30  
Document Fiscal Period Focus Q2  
Entity Incorporation, State or Country Code A1  
Entity Central Index Key 0001980845  
Entity Tax Identification Number 00-0000000  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Address, Address Line One 4868 Rue Levy, Suite 220  
Entity Address, City or Town Saint-Laurent  
Entity Address, State or Province QC  
Entity Address, Country CA  
Entity Address, Postal Zip Code H4R 2P1  
City Area Code 514  
Local Phone Number 332-4888  
Entity Ex Transition Period true  
Entity Common Stock, Shares Outstanding   44,166,159
Common Shares    
Entity Listings [Line Items]    
Trading Symbol ENGN  
Title of 12(b) Security Common Shares  
Security Exchange Name NASDAQ  
Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share    
Entity Listings [Line Items]    
Trading Symbol ENGNW  
Title of 12(b) Security Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per share  
Security Exchange Name NASDAQ  
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Apr. 30, 2024
Oct. 31, 2023
Current assets:    
Cash and cash equivalents $ 264,810 $ 81,521
Restricted investments 75 76
Investment tax credits receivable 1,213 2,343
Prepaid and other current assets 3,511 1,500
Total current assets 269,609 85,440
Property, Plant and Equipment, Net 1,107 589
Operating lease right of use assets 1,837  
Other assets 975 930
Total assets 273,528 86,959
Current liabilities:    
Accounts payable 211 1,156
Accrued expenses and other current liabilities 5,667 3,539
Operating lease liabilities, current 421  
Current portion of notes payable   562
Total current liabilities 6,299 5,257
Note payable, net of current portion 22,730 9,216
Operating lease liabilities, net of current portion 1,533  
Liabilities, Total 30,562 14,473
Shareholder's equity:    
Preferred shares, no par value; unlimited shares authorized, no shares issued and outstanding as of April 30, 2024 and October 31, 2023.
Common shares, no par value; unlimited shares authorized, 44,158,587 and 23,197,976 shares issued and outstanding as of April 30, 2024 and October 31, 2023, respectively. 453,405 259,373
Additional paid-in capital 15,860 13,717
Accumulated other comprehensive loss (1,016) (1,016)
Accumulated deficit (225,283) (199,588)
Total shareholder's equity 242,966 72,486
Total liabilities, redeemable convertible preferred shares and shareholder's equity $ 273,528 $ 86,959
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) - $ / shares
6 Months Ended 12 Months Ended
Apr. 30, 2024
Oct. 31, 2023
Preferred stock no par value $ 0 $ 0
Preferred stock shares authorized unlimited Unlimited Unlimited
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
Common stock no par value $ 0 $ 0
Common stock shares authorized unlimited Unlimited Unlimited
Common stock shares issued 44,158,587 23,197,976
Common stock shares outstanding 44,158,587 23,197,976
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Operating expenses:        
Research and development $ 9,855 $ 3,215 $ 15,493 $ 6,886
General and administrative 7,455 1,522 12,590 2,484
Total operating expenses 17,310 4,737 28,083 9,370
Loss from operations 17,310 4,737 28,083 9,370
Other (income) expense, net:        
Change in fair value of convertible debentures embedded derivative liabilities   (625)   (318)
Change in fair value of warrant liabilities   341   1,526
Interest income (2,984) (149) (4,009) (316)
Interest Expense 728 1,177 1,291 2,352
Loss on extinguishment of debt     366  
Other expense, net (91) (199) (27) 86
Total other (income) expense, net (2,347) 545 (2,379) 3,330
Net loss before provision for income taxes 14,963 5,282 25,704 12,700
Provision for (benefit from) income taxes 21 0 (9) 0
Net loss and comprehensive loss 14,984 5,282 25,695 12,700
Deemed dividend attributable to redeemable convertibleb preferred shareholders   1,175   2,389
Net loss attributable to common shareholders, basic 14,984 6,457 25,695 15,089
Net loss attributable to common shareholders, diluted $ 14,984 $ 6,457 $ 25,695 $ 15,089
Net loss per share of common shares, basic $ 0.38 $ 9.3 $ 0.82 $ 22.19
Net loss per share of common shares, diluted $ 0.38 $ 9.3 $ 0.82 $ 22.19
Weighted-average common shares outstanding, basic 39,443,768 694,497 31,186,238 680,003
Weighted-average common shares outstanding, diluted 39,443,768 694,497 31,186,238 680,003
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Class A Redeemable Convertible Preferred Shares
Class B Redeemable Convertible Preferred Shares
Class C Redeemable Convertible Preferred Shares
Beginning balance (in shares) at Oct. 31, 2022           266,696 156,036 5,560,607
Beginning balance at Oct. 31, 2022           $ 1,899 $ 1,554 $ 49,665
Beginning balance (in shares) at Oct. 31, 2022   665,767            
Beginning balance at Oct. 31, 2022 $ (76,614) $ 16,390 $ 7,683 $ (1,016) $ (99,671)      
Exercise of stock options (in shares)   1,804            
Exercise of stock options   $ 6 (6)          
Share-based compensation expense 20   20          
Net Income (Loss) (7,418)       (7,418)      
Ending balance (in shares) at Jan. 31, 2023           266,696 156,036 5,560,607
Ending balance at Jan. 31, 2023           $ 1,899 $ 1,554 $ 49,665
Ending balance (in shares) at Jan. 31, 2023   667,571            
Ending balance at Jan. 31, 2023 (84,012) $ 16,396 7,697 (1,016) (107,089)      
Beginning balance (in shares) at Oct. 31, 2022           266,696 156,036 5,560,607
Beginning balance at Oct. 31, 2022           $ 1,899 $ 1,554 $ 49,665
Beginning balance (in shares) at Oct. 31, 2022   665,767            
Beginning balance at Oct. 31, 2022 (76,614) $ 16,390 7,683 (1,016) (99,671)      
Net Income (Loss) (12,700)              
Ending balance (in shares) at Apr. 30, 2023           266,696 156,036 5,560,607
Ending balance at Apr. 30, 2023           $ 1,899 $ 1,554 $ 49,665
Ending balance (in shares) at Apr. 30, 2023   701,323            
Ending balance at Apr. 30, 2023 (89,238) $ 16,434 7,715 (1,016) (112,371)      
Beginning balance (in shares) at Oct. 31, 2022           266,696 156,036 5,560,607
Beginning balance at Oct. 31, 2022           $ 1,899 $ 1,554 $ 49,665
Beginning balance (in shares) at Oct. 31, 2022   665,767            
Beginning balance at Oct. 31, 2022 (76,614) $ 16,390 7,683 (1,016) (99,671)      
Ending balance (in shares) at Oct. 31, 2023   23,197,976            
Ending balance at Oct. 31, 2023 72,486 $ 259,373 13,717 (1,016) (199,588)      
Beginning balance (in shares) at Jan. 31, 2023           266,696 156,036 5,560,607
Beginning balance at Jan. 31, 2023           $ 1,899 $ 1,554 $ 49,665
Beginning balance (in shares) at Jan. 31, 2023   667,571            
Beginning balance at Jan. 31, 2023 (84,012) $ 16,396 7,697 (1,016) (107,089)      
Exercise of stock options (in shares)   18,258            
Exercise of stock options 17 $ 27 (10)          
Issuance of common shares upon cashless exercise of options (in shares)   15,494            
Issuance of common shares upon cashless exercise of options   $ 11 (11)          
Share-based compensation expense 39   39          
Net Income (Loss) (5,282)       (5,282)      
Ending balance (in shares) at Apr. 30, 2023           266,696 156,036 5,560,607
Ending balance at Apr. 30, 2023           $ 1,899 $ 1,554 $ 49,665
Ending balance (in shares) at Apr. 30, 2023   701,323            
Ending balance at Apr. 30, 2023 (89,238) $ 16,434 7,715 (1,016) (112,371)      
Beginning balance (in shares) at Oct. 31, 2023   23,197,976            
Beginning balance at Oct. 31, 2023 72,486 $ 259,373 13,717 (1,016) (199,588)      
Share-based compensation expense 291   291          
Issuance of warrants in connection with Amended Term Loan 319   319          
Net Income (Loss) (10,711)       (10,711)      
Ending balance (in shares) at Jan. 31, 2024   23,197,976            
Ending balance at Jan. 31, 2024 62,385 $ 259,373 14,327 (1,016) (210,299)      
Beginning balance (in shares) at Oct. 31, 2023   23,197,976            
Beginning balance at Oct. 31, 2023 $ 72,486 $ 259,373 13,717 (1,016) (199,588)      
Exercise of stock options (in shares) 56,974              
Net Income (Loss) $ (25,695)              
Ending balance (in shares) at Apr. 30, 2024   44,158,587            
Ending balance at Apr. 30, 2024 242,966 $ 453,405 15,860 (1,016) (225,283)      
Beginning balance (in shares) at Jan. 31, 2024   23,197,976            
Beginning balance at Jan. 31, 2024 62,385 $ 259,373 14,327 (1,016) (210,299)      
Exercise of stock options (in shares)   56,974            
Exercise of stock options 51 $ 207 (156)          
Share-based compensation expense 1,917   1,917          
Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares)   20,000,000            
Issuance of common shares in connection with PIPE Financing, net of issuance costs 187,614 $ 187,614            
Issuance of common shares upon exercise of warrants (in shares)   520,282            
Issuance of common shares upon exercise of warrants 5,983 $ 6,114 (131)          
Issuance of common shares upon cashless exercise of warrants (in shares)   383,355            
Issuance of common shares upon cashless exercise of warrants   $ 97 (97)          
Net Income (Loss) (14,984)       (14,984)      
Ending balance (in shares) at Apr. 30, 2024   44,158,587            
Ending balance at Apr. 30, 2024 $ 242,966 $ 453,405 $ 15,860 $ (1,016) $ (225,283)      
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Oct. 31, 2023
Cash Flows from operating activities:        
Net loss   $ (25,695) $ (12,700)  
Adjustments to reconcile net loss to net cash used in operating activities        
Non-cash interest expense   372 1,663  
Loss on extinguishment of debt   366    
Change in fair value of warrant liabilities $ 341   1,526  
Change in fair value of convertible debenture embedded derivative liabilities     (318)  
Debt issuance costs expensed upon issuance of debt recorded at the fair value option     132  
Non-cash lease expense   67    
Unrealized foreign currency losses   8 22  
Share-based compensation expense   2,208 59  
Depreciation of property and equipment   158 83  
Changes in operating assets and liabilities:        
Investment tax credit receivable   1,130 (722)  
Prepaid expenses and other assets   (2,057) (190)  
Accounts payable   (689) 2,049  
Accrued expenses and other liabilities   2,565 (2,271)  
Lease liabilities   35    
Net cash used in operating activities   (21,532) (10,667)  
Investing activities        
Purchases of property and equipment   (685) (23)  
Net cash used in investing activities   (685) (23)  
Financing activities        
Proceeds from the 2024 PIPE Financing   200,000    
Payments of issuance costs associated with the 2024 PIPE Financing   (12,386)    
Proceeds from exercise of common share warrants   5,983    
Proceeds from exercise of stock options   51 17  
Proceeds from issuance of term loan   22,500    
Repayments of term loan principal   (9,445)    
Payments of debt issuance costs associated with the term loan   (585)    
Proceeds from issuance of April 2023 Notes     8,000  
Payment of issuance costs associated with April 2023 Notes     (132)  
Payment of Reverse Recapitalization and PIPE Financing costs   (613) (132)  
Net cash provided by financing activities   205,505 7,753  
Effect of exchange rate changes on cash and cash equivalents   1 1  
Net increase in cash and cash equivalents   183,289 (2,936)  
Cash and cash equivalents at beginning of period   81,521 20,434 $ 20,434
Cash and cash equivalents at end of period $ 17,498 264,810 17,498 $ 81,521
Supplemental cash flow information:        
Cash paid for interest   867 676  
Supplemental disclosure of non-cash investing and financing activities        
Warrant value issued as part of Amended Term Loan   319    
Right of Use Assets obtained in exchange for lease liabilities   $ 1,904    
Reverse Recapitalization and PIPE Financing transaction costs included within accrued expenses and accounts payable     $ 1,167  
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Jan. 31, 2024
Apr. 30, 2023
Jan. 31, 2023
Apr. 30, 2024
Apr. 30, 2023
Pay vs Performance Disclosure            
Net Income (Loss) $ (14,984) $ (10,711) $ (5,282) $ (7,418) $ (25,695) $ (12,700)
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Insider Trading Arrangements - shares
3 Months Ended
Apr. 19, 2024
Apr. 30, 2024
Trading Arrangements, by Individual    
Rule 10b5-1 Arrangement Adopted   false
Non-Rule 10b5-1 Arrangement Adopted   false
Rule 10b5-1 Arrangement Terminated   false
Non-Rule 10b5-1 Arrangement Terminated   false
Anthony Cheung    
Trading Arrangements, by Individual    
Name Anthony Cheung  
Title Chief Technology Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date April 19, 2024  
Rule 10b5-1 Arrangement Terminated true  
Termination Date October 31, 2025  
Rule10 B51 Trading Plan | Anthony Cheung    
Trading Arrangements, by Individual    
Aggregate Available 250,000  
Shares Acquired Eexercise of Stock Options | Anthony Cheung    
Trading Arrangements, by Individual    
Aggregate Available 197,060  
XML 17 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Description of Business
6 Months Ended
Apr. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business
1.
Description of Business

enGene Holdings Inc. (together with its consolidated subsidiaries “enGene” or the “Company”) formed in connection with the Merger Agreement (as defined below) was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. enGene Inc., its wholly owned subsidiary since October 31, 2023 (now known as “enGene Inc.” or “Old enGene”), is a biopharmaceutical company located in Montreal, Quebec, Canada, and incorporated pursuant to the Canada Business Corporations Act on November 9, 1999.

The Company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients, and its head office is located in Montreal, Quebec, Canada. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or “DDX”, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Merger with Forbion European Acquisition Corp.

Forbion European Acquisition Corporation (“FEAC”) was a special purpose acquisition company (“SPAC”), incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the “Closing Date”), the Company, FEAC, and enGene Inc., consummated the merger (the “Reverse Recapitalization”) pursuant to a business combination agreement, dated as of May 16, 2023 (the “Merger Agreement”).

The transaction was accounted for as a “reverse recapitalization” in accordance with accounting principles generally accepted in the United States (“GAAP”). Under this method of accounting, FEAC was treated as the “acquired” company for financial reporting purposes. This determination is primarily based on the fact that subsequent to the Reverse Recapitalization, senior management of Old enGene continued as senior management of the combined company; Old enGene identified a majority of the members of the board of directors of the combined company; the name of the combined company is enGene Holdings Inc. and it utilized Old enGene’s current headquarters, and Old enGene’s operations comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Company is considered to be a continuation of Old enGene, with the net identifiable assets of FEAC deemed to have been acquired by Old enGene in exchange for Old enGene common shares accompanied by a recapitalization, with no goodwill or intangible assets recorded. The number of redeemable convertible preferred shares, number of common shares, net loss per common share, the number of warrants to purchase common shares, and the number of stock options and the related exercise prices of the stock options issued and outstanding prior to the Reverse Recapitalization, have been retrospectively restated to reflect an exchange ratio of approximately 0.18048 (the “Exchange Ratio”) established in the Merger Agreement. Operations prior to the Reverse Recapitalization are those of Old enGene.

As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its ordinary shares and warrants on the Nasdaq Global Market under the symbols “ENGN” and “ENGNW,” respectively, commencing trading on November 1, 2023, with Old enGene, a subsidiary of the Company, continuing the existing business operations.

Liquidity and Going Concern

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.

The Company’s interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.

As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for developing non-viral gene therapies and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. The Company has not yet commercialized any product candidates and does not expect to generate revenue from sales of any product candidates or from other sources for several

years, if at all. The Company will need substantial additional funding to support its continuing operations and pursue its development strategy.

The Company has incurred a net loss of $15.0 million and $25.7 million for the three and six months ended April 30, 2024, respectively, and negative cash flows from operating activities of $21.5 million for the six months ended April 30, 2024, and, as of that date, has an accumulated deficit of $225.3 million. To date, the Company has not generated any revenues and has financed its liquidity needs primarily through the 2024 PIPE financing, the Reverse Recapitalization and the PIPE financing conducted by the Company as part of the Reverse Recapitalization (the "PIPE Financing"), debt and convertible debentures, and issuance of redeemable convertible preferred shares and warrants.

The Company’s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of outstanding loans. As of the issuance date of these condensed consolidated financial statements, the Company expects that its existing cash and cash equivalents as of April 30, 2024 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements. Effective from the first quarter interim condensed consolidated financial statements, the Company has ceased its disclosure of the existence of a material uncertainty that raised substantial doubt about the Company’s ability to continue as a going concern due to the proceeds received from the 2024 PIPE Financing.

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies
6 Months Ended
Apr. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2.
Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated annual financial statements for the years ended October 31, 2023 and 2022 and notes thereto, as found in our Annual Report on Form 10-K for the year ended October 31, 2023. These interim condensed consolidated financial statements should be read in conjunction with the consolidated annual financial statements. Since the date of those annual financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated balance sheet at October 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These interim financial statements include the accounts of the Company and its wholly owned subsidiaries, enGene, Inc. and enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements as of October, 31 2023 and 2022 and for the years ended October 31, 2023, and 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of April 30, 2024, the condensed consolidated statements of operations for the three and six months ended April 30, 2024 and 2023, the condensed consolidated statement of redeemable convertible preferred shares and shareholders' equity (deficit) for the three and six months ended April 30, 2024 and 2023, and condensed consolidated statements of cash flows for the six months ended April 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended April 30, 2024 and 2023 are unaudited. The results for the three and six months ended April 30, 2024 and 2023, are not necessarily indicative of results to be expected for the year ending October 31, 2024, any other interim periods, or any future year or period.

Recently Adopted Accounting Pronouncements

There have been no changes from the financial statements for the year ended October 31, 2023.

XML 19 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization
6 Months Ended
Apr. 30, 2024
Stockholders' Equity Note [Abstract]  
Reverse Recapitalization
3.
Reverse Recapitalization

On October 31, 2023 (the "Closing Date”), FEAC, Old enGene, and the Company consummated the merger pursuant to the Merger Agreement, dated as of May 16, 2023. As a result of the Reverse Recapitalization, the Company became a publicly traded company, with Old enGene, a subsidiary of the Company, continuing the existing business operations.

 

At the effective time of the Reverse Recapitalization:

each outstanding common share of Old enGene was exchanged for common shares of the Company at the Exchange Ratio;
each of Old enGene’s redeemable convertible preferred shares outstanding immediately prior to the close of the Reverse Recapitalization was exchanged for shares of the Company’s common shares based on the same Exchange Ratio, with no dividends or distributions being declared or paid on Old enGene’s redeemable convertible preferred shares;
the 2022 Notes and May 2023 Notes (each as defined in Note 9) of Old enGene’s existing convertible notes outstanding immediately prior to the close of the Reverse Recapitalization were converted to Old enGene common shares at the conversion ratio in place at the time of conversion and were exchanged for shares of the Company at the Exchange Ratio;
each outstanding option to purchase old enGene common shares became fully vested and converted into an option to purchase a number of common shares of the Company equal to the number of common shares of old enGene subject to such option multiplied by the Exchange Ratio, rounded down to the nearest whole share, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio, rounded up to the nearest whole cent;
all of Old enGene’s outstanding warrants exercisable for common shares of Old enGene were exchanged for warrants exercisable for the Company’s common shares using the Exchange Ratio, with the warrants maintaining the same terms and conditions;
all of Old enGene’s existing outstanding Class C warrants outstanding at the time of the Reverse Recapitalization were terminated; and
all outstanding shares of FEAC being 3,670,927 shares, held by Forbion Growth Sponsor FEAC I B.V. ("FEAC Sponsor") and shareholders were converted into the same number of the Company’s common shares, and outstanding FEAC warrants of 5,029,444 held by FEAC warrant holders were converted into the same number of warrants to purchase one of the Company’s common shares.

 

Upon the close of the Reverse Recapitalization, 13,091,608 common shares of the Company were issued to Old enGene’s equity and convertible note holders, 2,679,432 common share warrants of the Company were issued to Old enGene’s warrant holders, and 2,706,941 common share options of the Company were issued to Old enGene’s share option holders.

 

In connection with the Merger Agreement, FEAC, the Company, and investors under the PIPE Financing (the "PIPE Investors") entered into Subscription Agreements pursuant to which, the PIPE Investors agreed to purchase the Company’s shares and warrants for an aggregate commitment amount of $56.9 million. As part of the PIPE Financing, the Company issued 6,435,441 of the Company’s common shares and 2,702,791 warrants to purchase the Company’s common shares for an aggregate purchase price equal to $56.9 million on October 31, 2023. The common shares and warrants issued as part of the PIPE Financing were determined to be equity classified. The proceeds were allocated between the common shares and warrants on a relative fair value basis, taking into consideration the quoted market price of the FEAC common shares and warrants on the close of the market on October 31, 2023, resulting in $56.1 million being allocated to the common shares and $0.8 million being allocated to the warrants. In connection with the Merger Agreement, FEAC, the FEAC Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A. and the other holders of Class B shares in the capital of FEAC ("FEAC Class B Shares"), Old enGene, the Company and the other parties named therein entered into the side letter agreements, pursuant to which the FEAC Sponsor agreed to surrender and in effect issue to PIPE Investors FEAC Class B Shares and FEAC private placement warrants, immediately prior to the closing of the Reverse Recapitalization. Immediately following the Reverse Recapitalization and the PIPE Financing, the Company had 23,197,976 common shares and 10,411,641 warrants outstanding.

 

On October 31, 2023, as part of the close of the Reverse Recapitalization, the Company received proceeds of $7.4 million from the FEAC trust account, net of the redemption payment to FEAC’s public shareholders and cash paid from the trust for FEAC expenses. Additionally, the Company received proceeds of approximately $56.9 million from the PIPE Financing. Upon the closing of the Reverse Recapitalization and PIPE Financing, the Company incurred $6.0 million in transaction costs, which was withheld from the proceeds received. The Company incurred a total of $11.1 million of transaction costs associated with the Reverse Recapitalization and PIPE Financing, of which $5.1 million was previously deferred by the Company and netted against the proceeds upon close. The transaction costs were allocated to the common shares and warrants on a relative fair value basis and netted against the proceeds upon close.

 

The following table summarizes the elements of the net proceeds from the Reverse Recapitalization and PIPE Financing transaction as of October 31, 2023:

 

 

Recapitalization

 

Cash – FEAC’s Trust Account and Cash (net of redemptions
   and cash paid for FEAC expenses prior to close)

 

$

7,363

 

Cash – PIPE Financing

 

 

56,892

 

Less transaction costs withheld from cash proceeds on Closing
   Date

 

 

(6,024

)

Cash proceeds received from the Reverse Recapitalization and
   PIPE Financing on Closing Date

 

$

58,231

 

Less transaction costs previously deferred and netted against
   proceeds

 

 

(5,086

)

Net cash proceeds from the Reverse Recapitalization and PIPE
   Financing

 

 

53,145

 

 

The total transaction costs of $11.1 million were related to third-party legal, accounting services and other professional services used to consummate the Reverse Recapitalization and the PIPE Financing incurred by Old enGene. These transaction costs are allocated between common shares and additional paid-in capital, based on the relative fair value of the common shares and warrants issued upon the close of the Reverse Recapitalization, on the Company’s consolidated balance sheet as the Company’s common shares have no par value.

The following table summarizes the number of common shares outstanding immediately following the consummation of the Reverse Recapitalization and PIPE Financing transaction:

 

 

Number
of Shares

 

Old enGene Shareholders (Excluding Convertible Notes)

 

 

6,711,786

 

FEAC Shareholders, including sponsor's and shareholder with
   non-redemption agreement

 

 

3,670,927

 

Convertible Notes - Common Shares issued

 

 

6,379,822

 

Common Shares issued to PIPE Investors

 

 

6,435,441

 

Total Common Shares outstanding immediately after the
   Reverse Recapitalization and PIPE Financing

 

 

23,197,976

 

XML 20 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements
6 Months Ended
Apr. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements
4.
Fair Value Measurements

The Company did not have any financial assets or liabilities that required fair value measurement on a recurring basis as of April 30, 2024 or October 31, 2023.

During the three and six months ended April 30, 2024 and during the year ended October 31, 2023, there were no transfers or reclassifications between fair value measure levels of liabilities. The carrying values of all financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.

During the three and six months ended April 30, 2023, and as of April 30, 2023, the Company had the following instruments which were measured at fair value.

April 2023 Notes

The Company elected the fair value option of accounting for the April 2023 Notes (see Note 8). The Company recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be the total cash proceeds received of $8.0 million. No change in fair value was recorded on the April 2023 Notes during the three and six months ended April 30, 2023, given the close proximity between the issuance date of the notes and the period end.

Convertible Debentures Embedded Derivative Liabilities

Prior to the Reverse Recapitalization, the Company’s convertible debentures contained equity conversion options, and certain repayment features, that have been identified as a single compound embedded derivative requiring bifurcation from the host contract for the convertible debentures for which the fair value has not been elected. The Company estimated the fair value of the convertible debenture embedded derivative liabilities on issuance using a probability weighted scenario expected return model. The estimated probability and timing of underlying events triggering the conversion and liquidity repayment features and probability of exercise of the extension features within the convertible debentures as well as discount rates, volatility and share prices are inputs used to determine the estimated fair value of the embedded derivative.

Upon the close of the Reverse Recapitalization the 2022 Notes were converted and exchanged for common shares of the Company, resulting in an extinguishment of the 2022 Notes and related embedded derivative liability. Further the BDC Note (as defined below) was repaid in full. Refer to Note 3 and Note 9.

The following table provides a summary of the change in the estimated fair value of the Company’s convertible debentures embedded derivative liabilities for three and six months ended April 30, 2023.

 

 

Total

 

Balance as of October 31, 2022

 

$

3,791

 

Change in fair value of convertible debenture embedded
   derivative liabilities

 

 

307

 

Foreign exchange (gain)/loss

 

 

5

 

Balance as of January 31, 2023

 

 

4,103

 

Change in fair value of convertible debenture embedded
   derivative liabilities

 

 

(625

)

Foreign exchange (gain)/loss

 

 

(4

)

Balance as of April 30, 2023

 

$

3,474

 

 

Warrant Liabilities

Prior to the consummation of the Reverse Recapitalization, Old enGene issued warrants to purchase redeemable convertible preferred shares as part of the issuance of certain redeemable convertible preferred shares, convertible debentures, and the term loan (the “Preferred Share Warrants”). Upon the close of the Reverse Recapitalization, the Preferred Share Warrants were surrendered for no consideration and the fair value was determined to be zero. The Company estimated the fair value of its Preferred Share Warrant liabilities using a Modified Black-Scholes option-pricing model, which included assumptions that are based on the individual characteristics of the Preferred Share Warrants on the valuation date, and assumptions related to the fair value of the underlying redeemable convertible preferred shares, expected volatility, expected life, dividends, risk-free interest rate and discount for lack of marketability (“DLOM”). Due to the nature of these inputs, the Preferred Share Warrants are considered a Level 3 liability.

The weighted average expected life of the Preferred Share Warrants was estimated based on the weighting of scenarios considering the probability of different terms up to the contractual term of 10 years in light of the expected timing of a future exit event, which includes a SPAC transaction. The Company determines the expected volatility based on an analysis of reported data for a group of guideline companies that have issued instruments with substantially similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The risk-free interest rate is determined by reference to the Canadian treasury yield curve in effect at the time of measurement of the warrant liabilities for time periods approximately equal to the weighted average expected life of the warrants. The Company has not paid, and did not anticipate paying, cash dividends on its redeemable convertible preferred shares; therefore, the expected dividend yield is assumed to be zero.

Because there was no public market for the underlying redeemable convertible preferred shares, the Company determined their fair value based on third-party valuations. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company’s various securities of its capital structure using an option pricing method, or “OPM”, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of redeemable convertible preferred shares include volatility, DLOM, and the expected timing of a future liquidity event such as an IPO, SPAC transaction or sale of the Company, in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios.

In addition to considering the results of these valuations, the Company considered various objective and subjective factors to determine the fair value of the Company's preferred shares as of each valuation date, including the prices at which the Company sold redeemable convertible preferred in the most recent transactions, external market conditions, the progress of the Company's research and development programs, the Company's financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company's redeemable convertible preferred shares, among other factors.

The following table provides a summary of the change in the estimated fair value of the Company’s warrant liabilities for the three and six months ended April 30, 2023:

 

 

Total

 

Balance as of October 31, 2022

 

$

11,456

 

Change in fair value of warrant liabilities

 

 

1,185

 

Foreign exchange (gain)/loss

 

 

217

 

Balance as of January 31, 2023

 

 

12,858

 

Change in fair value of warrant liabilities

 

 

341

 

Foreign exchange (gain)/loss

 

 

(196

)

Balance as of April 30, 2023

 

$

13,003

 

XML 21 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property and Equipment, Net
6 Months Ended
Apr. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net
5.
Property and Equipment, Net

As of April 30, 2024, and October 31, 2023, property and equipment consisted of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Lab equipment

 

$

2,167

 

 

$

1,779

 

Computer equipment

 

 

287

 

 

 

269

 

Computer software

 

 

146

 

 

 

70

 

Office furniture

 

 

177

 

 

 

69

 

Leasehold improvements

 

 

215

 

 

 

129

 

Property and equipment

 

 

2,992

 

 

 

2,316

 

Less: Accumulated depreciation and amortization

 

 

1,885

 

 

 

1,727

 

Property and equipment, net

 

$

1,107

 

 

$

589

 

 

Depreciation and amortization expense related to property and equipment was $78 and $37 for the three months ended April 30, 2024 and 2023, respectively. Depreciation and amortization expense related to property and equipment was $158 and $83 for the six months ended April 30, 2024 and 2023, respectively.

XML 22 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses and Other Current Liabilities
6 Months Ended
Apr. 30, 2024
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities
6.
Accrued Expenses and Other Current Liabilities

As of April 30, 2024, and October 31, 2023, accrued expenses and other current liabilities consisted of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Accrued research and development expenses

 

$

2,427

 

 

$

759

 

Professional fees

 

 

1,427

 

 

 

1,708

 

Employee compensation and related benefits

 

 

1,511

 

 

 

814

 

Accrued income tax payable

 

 

30

 

 

 

39

 

Other

 

 

272

 

 

 

219

 

Total accrued expenses and other current liabilities

 

$

5,667

 

 

$

3,539

 

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
License Agreement and Clinical Research Organization
6 Months Ended
Apr. 30, 2024
License Agreement and Clinical Research Organization [Abstract]  
License Agreement and Clinical Research Organization
7.
License Agreement and Clinical Research Organization

License Agreement – Nature Technology Corporation

On April 10, 2020, the Company entered into a Non-Exclusive License Agreement (the “License Agreement”) with Nature Technology Corporation (“NTC”) whereby the Company licenses certain rights to the technology of radiopharmaceutical products from NTC for commercialization. Under the terms of the License Agreement, NTC granted to the Company and its affiliates a non-exclusive, royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can voluntarily terminate the license agreement with prior notice to NTC.

The Company paid NTC an initial, upfront fee of $50 which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $50 annual maintenance fee. The Company is also required to make a payment to NTC of $50 upon assigning the License Agreement to a third party.

The License Agreement provides for a one-time payment of $50 for the first dose of a milestone product, as defined in the License Agreement, in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well as a one-time payment of $450 upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a milestone product, has not yet been achieved as of the period ended April 30, 2024. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by the Company, its affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country.

In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (“GMP”) lot of a product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.

During each of the three and six months ended April 30, 2024 and 2023, the Company incurred $13 and $25, respectively of expenses related to the annual maintenance fee under the License Agreement, which is recorded within research and development expenses.

XML 24 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Notes Payable
6 Months Ended
Apr. 30, 2024
Debt Disclosure [Abstract]  
Notes Payable
8.
Notes Payable

2021 Loan and Security Agreement

On December 30, 2021, the Company entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. (“Hercules” or the “Lender”) for the issuance of a term loan facility with an aggregate principal amount of up to $20.0 million (the “Prior Term Loan”). The Prior Loan Agreement provided for (i) an initial term loan advance of $7.0 million, which closed on December 30, 2021, (ii) subject to the achievement of certain clinical milestones (“Clinical Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $4.0 million from the achievement of the Clinical Milestone through June 15, 2022, which was drawn in June 2022, and (iii) subject to the achievement of certain financial milestones (“Financial Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $9.0 million from achievement of the Financial Milestone through December 15, 2022, which was not achieved. The Company is required to pay an end of term fee (“Prior Term Loan End of Term Charge”) equal to 6.35% of the aggregate principal amount of the Prior Term Loan advances upon repayment.

The Prior Term Loans were scheduled to mature on July 1, 2025, with no option for extension (the “Prior Term Loan Maturity Date”).

The Prior Term Loan accrued interest at an annual rate equal to the greater of (i) 8.25% plus the prime rate of interest as reported in the Wall Street Journal minus 3.25% and (ii) 8.25% provided, that, from and after the date the Company achieves the financial milestone, as defined within the agreement, the reference to 8.25% in clauses (i) and (ii) is reduced to 8.15%. Borrowings under the

Prior Term Loan are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the Prior Term Loan are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. At the Company’s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the closing date of the last draw down; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the closing date of the last draw down, but on or prior to twenty-four months following the closing date of the last draw down; and 1.0% of the principal amount outstanding at any time thereafter but prior to the Maturity Date.

In connection with the Prior Term Loan, the Company granted Hercules a security interest senior to any current and future debts and to any security interest, in all of the Company’s right, title, and interest in, to and under all of the Company’s property and other assets, and certain equity interests and accounts of Old enGene, subject to limited exceptions including the Borrower’s intellectual property. The Prior Loan Agreement also contains certain events of default, representations, warranties and non-financial covenants of the Company.

The debt discount and issuance costs under the Prior Term Loan were accreted to the principal amount of debt and being amortized from the date of issuance through the Maturity Date to interest expense using the effective-interest rate method. The effective interest rate of the outstanding debt under the Prior Loan Agreement was approximately 18.3% as of October 31, 2023.

The Company borrowed $11.0 million under the Prior Loan Agreement and incurred $1.1 million of debt discount and issuance costs inclusive of facilities fees, legal fees, Prior Term Loan End of Term Charge and initial fair value of the warrants under the Prior Term Loan.

Old Hercules Warrants

Under the Prior Loan Agreement, the Company agreed to issue to Hercules warrants (the “Old Hercules Warrants”) to purchase a number of shares of Old enGene’s redeemable convertible preferred shares at the exercise price equal to 2.5% of the aggregate amount of the Prior Term Loans that are funded, as such amounts are funded. On the first tranche closing, Old enGene issued a warrant to purchase 84,714 Class C Preferred Shares which were determined to have a fair value of $34 upon issuance. On the second tranche closing, in June 2022, Old enGene issued an additional warrant to purchase 48,978 Class C Preferred Shares which were determined to have a fair value of $23 upon issuance. The fair value of the Old Hercules Warrant values were initially recorded as a discount to the Prior Term Loan principal balance and are being amortized to interest expense using the effective interest method over the life of the Prior Term Loan.

The Old Hercules Warrants were initially exercisable for a period of ten years from the date of the issuance of each warrant at a per-share exercise price equal to $2.632 Canadian dollars, subject to certain adjustments as specified in the warrants. In addition, the Company has granted to the holders of the Old Hercules Warrants certain registration rights on a pari passu basis with the holders of outstanding preferred shares and warrants to purchase preferred shares.

The Company accounted for the warrants as a liability prior to the consummation of the Reverse Recapitalization since they were indexed to Old enGene’s redeemable convertible preferred shares that were classified as temporary equity. The Company remeasured the fair value of the warrants at each reporting date with changes being recorded as a change in the fair value of the warrant liabilities.

Upon the close of the Reverse Recapitalization, the Old Hercules Warrants, along with all other warrants to purchase shares of Old enGene's redeemable convertible preferred shares, were surrendered for no consideration.

 

Amended Loan and Security Agreement

On December 22, 2023 (the "Hercules Closing Date"), the Company entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement”), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the "Lenders”). The Amended Loan Agreement amends and restates in its entirety the Prior Loan Agreement with Hercules dated December 30, 2021.

The Amended Loan Agreement provides for a term loan facility of up to $50.0 million available in multiple tranches (the "Term Loan”), as follows: (i) an initial term loan advance (the "Tranche 1 Advance”) that was made on the Tranche 1 Advance closing of $22.5 million, approximately $8.6 million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the "Interim Milestone”), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical

evaluation of EG-70 in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances to us in an aggregate principal amount of up to $7.5 million from the date of achievement of the Interim Milestone through the earlier of (x) 60 days following the achievement of the Interim Milestone and (y) March 31, 2025, and (iii) an uncommitted tranche subject to the Lenders’ investment committee approval and satisfaction of certain other conditions precedent (including payment of a 0.75% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (defined below) that the Lenders make additional term loan advances to the Company in an aggregate principal amount of up to $20.0 million. The Company is required to pay upon the earlier of January 1, 2028 ( the “Maturity Date”) or payment in full of the Term Loans, an end of term fee equal to 5.50% of the aggregate principal amount of the Term Loans (the "End of Term Charge"). The Company is also required to pay on July 1, 2025 or, if earlier, the date the Company prepays the Term Loans, $0.7 million representing the Prior Term Loan End of Term Charge (the Prior Term Loan End of Term Charge and End of Term Charge, collectively the "End of Term Charges").

The Term Loans mature on January 1, 2028, with no option for extension.

The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the Wall Street Journal plus 0.75% (capped at 9.75%) and (b) 9.25%. The Term Loan also bears additional payment-in-kind interest at an annual rate of 1.15%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement are repayable in monthly interest-only payments through the "Amortization Date”, which is either: (x) July 1, 2025 or (y) if the Interim Milestone is achieved and there has been no default, January 1, 2026, or (z) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, July 1, 2026. After the Amortization Date, the outstanding Term Loans and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. The effective interest rate of the Term Loan was 12.38% as of April 30, 2024.

At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) 1.0% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.

In connection with the Amended Loan Agreement, the Borrowers granted Hercules a security interest senior to any current and future debts and to any security interest in all of the Borrowers’ right, title, and interest in, to and under all of the Company’s property and other assets, subject to limited exceptions including the Borrowers’ intellectual property.

The Amended Loan Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict the Borrowers’ ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement also contains certain events of default and representations, warranties and non-financial covenants of the Borrowers. The Borrowers have been in compliance with the financial covenants since inception of the Term Loan.

The Company accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan. As a result of the extinguishment, the Company recorded a loss of $0.4 million as a component within other income and expense in the Company's consolidated statement of operations during the three and six months ended April 30, 2024, which represented the difference between the reacquisition price of the debt, including fees and the initial fair value of the warrants paid directly to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.

As of April 30, 2024, the Company had borrowed $22.5 million under the Amended Loan Agreement and incurred $2.1 million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan.

Hercules Common Share Warrants

In connection with the Amended Loan Agreement, the Company also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of the Company’s common shares, as shall be equal to 2% of the aggregate principal amount of such Term Loan advance divided by the Warrants per share exercise price of $7.21 (which exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary

adjustments under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of seven years from issuance.

Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is 138,696. On the Hercules Closing Date, the Company issued to the Lenders 62,413 Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans (the "Closing Date Warrants”). The Closing Date Warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815. Upon entering into the Amended Loan Agreement, $0.3 million of the total $22.5 million Tranche 1 Advance was allocated to the warrants, on a relative fair value basis, and recorded within additional paid in capital.

Subsequently issued Hercules Common Share Warrants shall be substantially in the form of the Closing Date Warrants. Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and resultant underlying common shares of the Company that could be issued is 138,696 (i.e. 2% of the $50.0 million total commitment amount divided by the exercise price of $7.21 price specified in the Closing Date Warrant), assuming no adjustments are made under the terms of the Hercules Common Share Warrants and further assuming the full amount of Term Loans are drawn.

As of April 30, 2024 and October 31, 2023, the carrying value of the term loans consisted of the following:

 

 

April 30, 2024

 

 

October 31, 2023

 

Note payable, including End of Term Charge

 

$

24,530

 

 

$

10,144

 

Debt discount, net of accretion

 

 

(1,974

)

 

 

(474

)

Accrued interest

 

 

174

 

 

 

108

 

Note payable, net of discount

 

$

22,730

 

 

$

9,778

 

 

As of October 31, 2023, the Company classified $0.6 million of the note payable as current, which represents the principal payments due and amortization of the debt discount between October 31, 2023 and the date the Prior Term Loan was amended in December 2023, as the debt was refinanced on a long-term basis in the subsequent period.

 

During the three months ended April 30, 2024 and 2023, the Company recognized $0.7 million and $0.4 million of interest expense, respectively, related to the term loans, of which $0.1 million and $0.1 million was related to the amortization of the debt discounts, respectively. During the six months ended April 30, 2024 and 2023, the Company recognized $1.3 million and $0.9 million of interest expense, respectively, related to the term loans, of which $0.3 million and $0.2 million was related to the amortization of the debt discounts, respectively.

Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and paid in kind interest are as follows as of April 30, 2024:

 

 

Note Principal
Payments

 

2024

 

$

 

2025

 

 

3,285

 

2026

 

 

8,254

 

2027

 

 

9,047

 

2028

 

 

4,617

 

Total principal payments, including End of Term Charge

 

 

25,203

 

 

As of April 30, 2024, based on borrowing rates available to the Company for loans with similar terms and consideration of the Company’s credit risk, the carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value.

 

April 2023 Notes

On April 4, 2023, Old enGene entered into a note purchase agreement (the “April 2023 Notes”) for a principal amount of $8.0 million with Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Quebec), L.P., Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Fond de solidarité des travailleurs du Québec (F.T.Q.), and Forbion Capital Fund III Cooperatief U.A. (collectively the “April 2023 Investors”). The April 2023 Notes had an interest free period of 45 days from the date of issuance, and commencing on the 46th day, began to accrue interest at a rate of 15% per annum. The April 2023 Notes were classified as current as they matured on the earlier of (i) July 31, 2023; or (ii) the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $20.0 million. Upon the completion of the 2023 Financing (as defined below) in May 2023, Old enGene issued convertible debentures and warrants of Old enGene to the April 2023 Note investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, as repayment of the April 2023 Notes.

The Company elected the fair value option of accounting for the April 2023 Notes. The Company recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be $8.0 million. Given the short period of time that the April 2023 Notes were outstanding, no change in fair value was recorded during the three months ended April 30, 2023. The April 2023 Notes were extinguished in May 2023 as part of the issuance of the May 2023 Notes (see Note 9).

XML 25 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Convertible Debentures
6 Months Ended
Apr. 30, 2024
Debt Disclosure [Abstract]  
Convertible Debentures
9.
Convertible Debentures

Old enGene had issued convertible debentures to various investors. There was no outstanding principal, accrued interest, and unamortized deferred financing costs of the convertible debentures recorded on the balance sheet as of April 30, 2024 and October 31, 2023, as the convertible debentures were converted and exchanged for common shares of the Company or repaid upon the closing of the Reverse Recapitalization. Refer to Note 3.

BDC Notes

In September 2020, Old enGene issued a convertible debenture to the Business Development Bank of Canada (“BDC”) in the amount of $2.2 million (the “BDC Notes”). The debt bears interest at rate of 8% per annum and had an initial maturity date of September 28, 2023. In December 2021 Old enGene amended the agreement which resulted in the maturity date extending to September 29, 2025. The BDC Notes were convertible at the option of the holder into Old enGene's Class B redeemable convertible preferred shares at a price of 80% of the price paid per share in qualified financing, as defined within the BDC convertible debenture agreement. The issuance of the Prior Term Loan in 2021 met the definition of a qualified financing per the BDC convertible debenture agreement. As the conversion option was not exercised upon the issuance of the Prior Term Loan, the conversion rights upon a qualified financing were waived. There were optional conversion options that existed if Old enGene is in default, or in the event of certain liquidation events, as defined within the BDC Notes, which allow for conversion of the BDC Note into the most senior share outstanding at the time of the event. If a liquidation event, as defined within the BDC Note agreement, and which included a SPAC transaction, is consummated after a qualified financing, and optional conversion is not elected, the Company is required to pay the investor in cash, the outstanding principal and the accrued but unpaid interest and in addition an amount equal to 20% of the principal.

Upon issuance of the BDC Notes, Old enGene identified embedded derivatives related to the equity conversion features and liquidity event repayment features which required bifurcation as a single compound derivative instrument. Old enGene estimated the fair value of the embedded derivative liabilities upon issuance at $0.2 million. Old enGene remeasured the fair value of the embedded derivatives in effect at each reporting period, with the subsequent changes in the fair value of the derivative being recognized in changes in fair value of derivatives within the Company’s consolidated statements of operations and comprehensive loss. During the three and six months ended April 30, 2023, Old enGene recorded a change in fair value on the convertible debentures embedded derivative liability associated with the BDC Note of $0.2 million and $0.1 million, respectively. Total interest expense for the BDC Notes, including the amortization of debt discounts, was $60 and $0.1 million for the three and six months ended April 30, 2023. As part of the issuance of the BDC Notes, Old enGene incurred an aggregate of $36 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the BDC Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. Upon the close of the Reverse Recapitalization the Company repaid the BDC Note, resulting in full settlement of the note.

2022 Notes

During the year ended October 31, 2022, Old enGene issued convertible debentures for an aggregate amount of $18.4 million on October 20, 2022 (the “2022 Notes”). The 2022 Notes had an initial maturity that is the later of (i) three years from the date of issuance; or (ii) the maturity date of the Prior Term Loan (see Note 8). The 2022 Notes bear interest at 10% per annum commencing on the date of issuance. The 2022 Notes are automatically convertible into common shares or redeemable convertible preferred shares of Old enGene upon certain events. Upon the close of the Reverse Recapitalization, the 2022 Notes were converted into 2,081,359 common shares of the Company.

Upon issuance of the 2022 Notes, Old enGene identified embedded derivatives related to the equity conversion features which required bifurcation as a single compound derivative instrument. Old enGene estimated the fair value of the embedded derivative liabilities upon issuance at $3.5 million. During the three and six months ended April 30, 2023, the Company recorded a loss on the change in fair value associated of 2022 Notes embedded derivative liability of $0.8 million and $0.4 million, respectively. Total interest expense for the 2022 Notes, including the amortization of debt discounts, of $0.6 million and $1.3 million was recorded for the three and six months ended April 30, 2023. As part of the issuance of the 2022 Notes, the Company incurred an aggregate of $44 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the 2022 Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred.

On October 31, 2023 upon the close of the Reverse Recapitalization, the 2022 Notes were converted into 2,081,359 common shares of the Company. The Company accounted for the conversion as an extinguishment and recorded a loss on extinguishment of $3.1 million, relating to the difference between the fair value of the common shares issued and the carrying value of the 2022 Notes and fair value of the embedded derivative liability at the time of conversion.

 

May 2023 Notes

On May 16, 2023, concurrently with the execution and delivery of the Merger Agreement, Old enGene entered into agreements pursuant to which it agreed to issue new convertible notes and warrants (i) for cash in an aggregate principal amount of $30.0 million and (ii) in repayment of the April 2023 Notes in an aggregate amount of $8.0 million (collectively, the "May 2023 Notes” and, together with the warrants purchased concurrently, the "2023 Financing”; the 2023 Financing together with the Amended 2022 Financing, the "Convertible Bridge Financing”).

The 2023 Financing occurred in two separate issuances with $28.0 million issued in May 2023 for $20.0 million in cash and $8.0 million in repayment of the April 2023 Notes, and an additional $10.0 million issued in June 2023 for $10.0 million in cash, of which Forbion Growth Sponsor FEAC I B.V. funded an aggregate amount of $20.0 million of the total $38.0 million. The May 2023 Notes issued as part of the 2023 Financing, if not converted, have an initial maturity date of October 20, 2025 and are to accrue interest at 10% per annum, which is payable upon maturity.

The warrants issued as part of the 2023 Financing were for the purchase of common shares of Old enGene. The 2023 Warrants were only to become exercisable upon the completion of the merger. Upon the close of the Reverse Recapitalization, the 2023 Warrants were exchanged for 2,679,432 warrants of the Company and have the same terms as the public warrants issued upon the FEAC initial public offering, with an exercise price of $11.50, and which will expire five years after the completion of the merger.

The warrants issued as part of the 2023 Financing were concluded to be liability classified upon issuance, as they failed the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s own stock as prescribed by ASC 815. The terms of the warrants initially required the Company to issue a variable number of shares until the PIPE Financing was executed, at which time the number of warrants became fixed. The 2023 Warrants were initially and subsequently measured at fair value with any changes in fair value recorded as a component of other income and expense within the change in fair value of warrant liabilities. Refer to Note 3. Upon the execution of the PIPE Financing and consummation of the Reverse Recapitalization, the warrants were reclassified to equity as the number of warrants became fixed and it was determined that the warrants met the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s own stock as prescribed by ASC 815.

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Redeemable Convertible Preferred Shares
6 Months Ended
Apr. 30, 2024
Equity [Abstract]  
Redeemable Convertible Preferred Shares
10.
Redeemable Convertible Preferred Shares

As of October 31, 2022, Old enGene’s Articles of Amendment had an unlimited number of authorized shares of each class of redeemable convertible preferred shares.

Class A Redeemable Convertible Preferred Shares

On July 26, 2013, Old enGene entered into a subscription agreement (the “Class A Agreement”) with multiple investors, whereby Old enGene agreed to sell to the investors an initial aggregate amount of 610,333 Class A redeemable convertible preferred shares at a price of $1.5929 ($1.63845 CAD) per share for total aggregate proceeds of $1.0 million (the “Class A Initial Closing”). Included within the Class A Agreement were three additional future tranche obligations (the “Class A Second Tranche,” “Class A Third Tranche” and “Class A Fourth Tranche”) for Old enGene to issue and sell shares of Class A redeemable convertible preferred shares upon the achievement of certain milestone events. Only the Class A Second Tranche closed under the Class A Agreement. The Class A Second Tranche obligated Old enGene to sell and the Class A Investors to purchase 1,830,999 shares of Class A redeemable convertible preferred shares at a price of $1.56967 ($1.63845 CAD) per share for total proceeds of $2.9 million, upon the establishment of the Company’s headquarters in Montreal Quebec and completion of experiments required to bolster a patent application for dually-derivatized chitosan (the “Second Closing Milestone Event”), which occurred in 2013. Additionally, upon completing the Class A redeemable convertible preferred share financing, convertible notes of Old enGene held by multiple investors converted into Class A redeemable convertible preferred shares.

Class B Redeemable Convertible Preferred Shares

On January 6, 2015, Old enGene entered into a subscription agreement (the “Class B Agreement”) with multiple investors, where Old enGene agreed to sell to the investors an initial aggregate amount of 2,758,221 Class B redeemable convertible preferred shares at a price of $1.85032 ($2.17532 CAD) per share for total proceeds of $5.1 million (the “Class B Initial Closing”). Included within the Class B Agreement were two additional closings (the “Class B Second Tranche,” and the “Class B Third Tranche,” respectively) which obligated Old enGene to sell and Class B investors to purchase additional Class B redeemable convertible preferred shares upon certain events. The Class B Second Tranche obligated Old enGene to sell and the Class B Investors to purchase 1,838,815 Class B Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $3.0 million and the Class B Third Tranche obligated Old enGene to sell and the Class B Investors to purchase 1,608,963 Class B Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $2.6 million. The Class B Second Tranche and Class B Third Tranche closed on March 1, 2017.

Class B-1 Redeemable Convertible Preferred Shares

On September 10, 2015, Old enGene entered into a Subscription Agreement (the Class “B-1 Agreement”), in which Old enGene was to issue 1,523,809 Class B-1 redeemable convertible preferred shares for a purchase price of $1.64367 ($2.17532 CAD) per share, resulting in aggregate proceeds of $2.5 million. During the year ended October 31, 2020, the Class B-1 redeemable convertible preferred shares converted to common shares on a 1:1 basis. Therefore, as of each of the years ended October 31, 2020, October 31, 2021, and October 31, 2022, no shares of the Class B-1 redeemable convertible preferred shares remained outstanding. The Company has presented these shares within temporary equity as of October 31, 2019 within the consolidated statements of redeemable convertible preferred shares and shareholder deficit, as they contained the same redemption features as the Class B redeemable convertible preferred shares (further described above). Upon conversion to common shares, the carrying value of the Class B-1 redeemable convertible preferred shares was reclassified to additional paid in capital within shareholders’ deficit.

Class C Redeemable Convertible Preferred Shares

The Class C redeemable convertible preferred shares are issuable in series, of which an unlimited number are designated as Series 1 Class C redeemable convertible preferred shares with an issue price per share of $1.5929 ($1.63845 CAD); an unlimited number are designated as Series 2 Class C redeemable convertible preferred shares with an issue price per share of $1.85032 ($2.175315 CAD); an unlimited number are designated as Series 3 Class C redeemable convertible preferred shares with an issue price per share of $2.12376 ($2.6320 CAD); and an unlimited number are designated as Series 4 Class C redeemable convertible preferred shares that is reserved for the potential conversion of the BDC Notes, and will each have an issue price per share of $1.69901 ($2.10559 CAD).

On June 30, 2021, Old enGene entered into a subscription agreement (the “Class C Agreement”) with multiple investors, where Old enGene agreed to sell to the Investors an initial aggregate amount of 3,662,813 Series 3 Class C redeemable convertible preferred shares (the “Series 3 Class C Shares”) at a price of $2.12376 ($2.6320 CAD) per share for total proceeds of $7.8 million (the “Class C Initial Closing”). Included within the Class C Agreement was one additional closing (the “Class C Second Tranche”) which obligated Old enGene to sell and Class C investors to purchase additional Class C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class C Second Tranche obligated Old enGene to sell and the Class C investors to purchase 3,662,810 Series 3 Class C Shares at a price of $2.13192 ($2.6320 CAD) per share for total proceeds of $7.8 million. The Class C Second Tranche closed on October 29, 2021.

As part of each of the Class C Initial Closing and Class C Second Tranche, each Class C investor received 3,662,813 and 3,662,810 warrants, respectively, to purchase Class C redeemable convertible preferred shares (the “Class C Warrants”), resulting in an aggregate issued amount of 7,325,623 Class C Warrants. The Class C Warrants have an exercise price of $2.12376 ($2.6320 CAD) per share and a term of 10 years. The Class C Warrants were determined to be liabilities. The Company estimated the fair value of the warrant liabilities upon issuance and remeasured the fair value of the warrant liabilities at each reporting period, with the subsequent changes in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabilities within the Company’s consolidated statements of operations and comprehensive loss. Upon the completion of the Reverse Recapitalization, all existing Class C Warrants of Old enGene were extinguished.

Under the terms of the Class C Agreement, certain convertible notes held by various Class C investors and other investors were exchanged for an aggregate amount of 16,464,646 Class B redeemable convertible preferred shares. Additionally, upon entering into the Class C Agreement, Old enGene also entered into a share exchange agreement (the “Share Exchange Agreement”) with the Class A investors and the Class B investors. As part of the Share Exchange Agreement, certain of the Class A redeemable convertible preferred shares issued to Class A investors were exchanged for Series 1 Class C redeemable convertible preferred shares and certain of the Class B redeemable convertible preferred shares issued to the Class B investors were exchanged for Series 2 Class C redeemable convertible preferred shares. This exchange resulted in the derecognition of Class A and B redeemable convertible preferred shares and the recognition of Class C redeemable convertible preferred shares at the fair value of the Class C redeemable convertible preferred shares. The difference between the carrying value of the Class A and Class B redeemable convertible preferred shares and the fair value of the Class C redeemable convertible preferred shares for which they converted into was recorded within additional paid in capital and no gain or loss on extinguishment was recorded within the consolidated statements of operations and comprehensive loss. Further, the February 2020 Warrants, June 2020 Warrants, and 2021 Warrants, which consisted of warrants to purchase Old enGene's Class B redeemable convertible preferred shares and were issued as part of the convertible debentures were cancelled and replaced by the terms of the Class C Warrants. The aggregate amount of outstanding warrants of 10,242,130 from the February 2020 Warrants, the June 2020 Warrants, and the 2021 Warrants converted into 10,242,130 Class C Warrants, which have an exercise price of $2.12376 ($2.6320 CAD) per share and a term expiring on February 14, 2030. Immediately prior to conversion, the warrants were marked to fair value, with the change in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabilities within the Company’s consolidated statements of operations and comprehensive loss.

Upon issuance of each series of Class A, Class B, and Class C Preferred Shares, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features.

Conversion of Redeemable Convertible Preferred Shares

Pursuant to the terms of the Merger Agreement, upon the consummation of the Reverse Recapitalization, each share of Old enGene’s redeemable convertible preferred shares issued and outstanding immediately prior to the close was exchanged for common shares of the Company using the Exchange Ratio of approximately 0.18048. A retrospective adjustment has been applied to all periods presented to reflect the Reverse Recapitalization. Refer to Note 3 for additional discussion.

Undesignated Preferred Shares

The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue an unlimited number of preferred shares with no par value. The preferred shares are currently undesignated.

XML 27 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Shares
6 Months Ended
Apr. 30, 2024
Equity [Abstract]  
Common Shares
11.
Common Shares

The Company has an unlimited number of Common Shares authorized shares for issuance, with no par value. As of April 30, 2024 and October 31, 2023, there were 44,158,587 and 23,197,976 Common Shares outstanding, respectively.

The holders of the Common Shares are entitled to one vote per Common Share held on all matters submitted to a vote of shareholders. Common shareholders are entitled to receive dividends, as may be declared by the board of directors, or the "Board", if any, subject to the preferential dividend rights of preferred shares. Through April 30, 2024, no cash dividends had been declared or paid.

On February 13, 2024, the Company entered into subscription agreements (collectively, the "2024 Subscription Agreements”) with the investors named therein, for the private placement (the "2024 PIPE Financing") of 20,000,000 common shares of the Company,

at a price of $10.00 per share. The aggregate gross proceeds from the 2024 PIPE Financing was $200 million, before deducting offering expenses of $12.4 million. The 2024 PIPE Financing closed on February 20, 2024.

Warrants to purchase Common Shares

As of April 30, 2024 and October 31, 2023, the Company had 8,511,968 and 10,411,641 warrants to purchase Common Shares outstanding, respectively.

Of the warrants to purchase Common Shares outstanding as of April 30, 2024, 8,449,555 have the same terms as the FEAC public warrants issued in connection with FEAC’s IPO, and have an exercise price of $11.50, and are exercisable beginning 30 days after the completion of the Reverse Recapitalization and which will expire on October 31, 2028, or five years after the completion of the Reverse Recapitalization. Through April 30, 2024, 383,355 common shares have been issued as a result of the exercise of 1,379,391 warrants on a cashless basis and 520,282 common shares have been issued through cash exercises of warrants for proceeds totaling $6.0 million.

The number of Common Shares to be issued upon the cashless exercise is equal to the quotient obtained by dividing (x) the product of the number of shares underlying the warrants, multiplied by the excess of the “Fair Market Value” over the warrant exercise price of $11.50 by (y) the Fair Market Value. The Fair Market Value is the volume weighted average price of the shares for the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Company’s Warrant Agent from the holder or its broker or intermediary. The warrants had a cashless exercise period until such time as the registration statement under the Securities Act with respect to the enGene Common Shares underlying the enGene Warrants was declared effective, which occurred on March 5, 2024. The Company may elect to call in the warrants for a redemption if the share price of the Company reaches redemption trigger price of $18.00.

The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815.

The additional 62,413 of the warrants to purchase Common Shares outstanding as of April 30, 2024, were issued as part of the Amended Term Loan on December 22, 2023, have an exercise price of $7.21, and are exercisable at any time beginning on December 22, 2023 expiring on December 22, 2030, or seven years from the issuance date. The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815.

As of April 30, 2024, and October 31, 2023, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the Company's 2023 Plan ( as defined below):

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Warrants to purchase Common Shares

 

 

8,511,968

 

 

 

10,411,641

 

Options to purchase Common Shares

 

 

3,981,433

 

 

 

2,706,941

 

Remaining shares reserved for future issuance under
   the 2023 Plan

 

 

3,222,703

 

 

 

2,607,943

 

Total

 

 

15,716,104

 

 

 

15,726,525

 

XML 28 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-Based Compensation
6 Months Ended
Apr. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
12.
Share-Based Compensation

Pursuant to the terms of the Reverse Recapitalization, upon the Closing Date, each outstanding option to purchase Old enGene’s common shares issued under the Old Plan’s was exchanged for an option to purchase common shares of the Company, and the number of shares and exercise price of each granted option was adjusted using the exchange ratio of approximately 0.18048. Further, the currency of all exercise prices of the options issued under the Old Plans were converted from CAD to USD using the exchange rate in effect on the day immediately prior to the Closing Date. A retrospective adjustment has been applied to the number of options and exercise price of stock options for all periods presented to reflect the Reverse Recapitalization as discussed further in Note 3.

The Old Plans

Old enGene had an employee share option plan (the “ESOP”) and an equity incentive plan (the “EIP”) (collectively, the “ Old Plans”) which was adopted by the Board of Directors, and approved by the shareholders, effective July 5, 2018.

Under the Old Plans, options to purchase non-voting common shares of Old enGene’s shares may be granted to directors, officers, employees, consultants and members of the scientific advisory board. The Old Plans provide for the issuance of stock options up to a maximum of 15% of the aggregate issued and outstanding common shares and non-voting common shares of Old enGene calculated on an as converted and fully diluted basis. The Old Plans were administered by Old enGene’s Board of Directors. Old enGene’s Board of Directors determined the number of options to be granted, the vesting period and the exercise price of new options. It was Old enGene’s policy to establish the exercise price at an amount that approximates the fair value of the underlying shares on the date of grant as determined by Old enGene’s Board of Directors. The options vest in accordance with the vesting terms determined for each grant by Old enGene’s Board of Directors. The vesting terms of Old enGene’s granted stock options with service only conditions are typically 100% vesting immediately upon grant date, or over a three- or four-year service period. Upon the consummation of the Reverse Recapitalization, the Company recognized stock based compensation expense of $0.4 million associated with the acceleration of the vesting for the outstanding awards with service only vesting conditions under the Old Plan. As of April 30, 2024, no unrecognized compensation cost remains for the outstanding awards granted under the Old Plan with service only vesting conditions.

 

On July 7, 2023, the Board of Directors approved the reservation of an additional 1,046,764 non-voting common shares for issuance under the Company’s employee equity incentive plan, revising the number of shares reserved from 1,775,729 to 2,822,493. Also on July 7, 2023, the Company granted 1,046,764 options to employees at an exercise price of $5.87 CAD ($4.24 USD). These options are not exercisable unless and until the completion of the Reverse Recapitalization and there is an effective registration statement for the shares underlying such granted options and will terminate automatically in the event of the termination of the Merger Agreement. The Company has valued these awards at the grant date using Black-Scholes pricing model in which the fair value of the stock on the grant date was equal to the exercise price of the award. The expected term has been determined using management’s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers. Upon the grant date, 794,643 of the issued options were fully vested, and the remaining 252,121 options will vest over varying terms up to four years on a pro rata basis. The Company recognizes compensation expense when achievement of the performance condition is deemed probable using an accelerated attribution method, as if each vesting tranche was treated as an individual award. During the year ended October 31, 2023, $2.6 million of stock based compensation expense was recorded associated with the 1,046,764 stock options granted in July 2023 because the Reverse Recapitalization was completed and the Company determined that the filing of the registration statement was probable to occur.

Upon the consummation of the Reverse Recapitalization on October 31, 2023, all options outstanding under the Old Plans were exchanged for 2,706,941 shares options to purchase common shares of the Company based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement. Further, all exercise prices were adjusted by the Exchange Ratio and the currency of the exercise prices was changed from CAD to USD based on the exchange rate in effect on October 30, 2023, the day immediately before the consummation of the Reverse Recapitalization. No incremental compensation cost was recorded as a result of the change in underlying common shares from Old enGene to the Company, or as a result of the change of the exercise prices to reflect the adjustment for the Exchange Ratio and the change in currency from CAD to USD, as it was concluded that the fair value of the awards immediately before and immediately after the modifications did not change. No options remain available for grant under the Old Plans as of October 31, 2023.

The 2023 Plan

On October 31, 2023, upon the completion of the Reverse Recapitalization, the shareholders approved and the Company adopted the enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which superseded the Old Plans. The 2023 Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Stock Units, Stock Appreciation Rights, or SARs, and other share-based awards including performance awards and share bonus awards.

The number of shares initially reserved for issuance under the 2023 Plan is 2,607,943 Common Shares, plus 2,706,941 common shares subject to the outstanding grants under the Old Plans, and shall automatically increase on January 1 of each calendar year beginning in 2024 by a number of shares equal to the lesser of 1,946,226 million Common Shares and such lesser number as may be determined by the Board. The Common Shares authorized under the 2023 Plan increased by 1,946,225 on January 1, 2024. As of April 30, 2024, the total number of Common Shares reserved for issuance under the 2023 Plan is 7,261,110, and there are 5,929,643 shares remaining for issuance.

The 2023 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board. The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the Common Shares on the date of grant and the term of stock option may not be greater than ten years. Common Shares that are expired terminated, surrendered or cancelled under the 2023 Plan without having been fully exercised will be available for future awards.

On May 15, 2024, the shareholders of the Company approved changes to the 2023 Plan. See Note 18 for additional information.

Stock Options

The assumptions that the Company used to determine the grant-date fair value of stock options during the three and six months ended April 30, 2024 and 2023 are summarized below:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Expected term (in years)

 

5.75 - 6.08

 

 

6.08

 

 

5.75 - 6.08

 

 

6.08

 

Expected volatility

 

78.30 - 78.92%

 

 

 

81.39

%

 

78.24 - 78.92%

 

 

 

81.39

%

Risk-free interest rate

 

4.27 - 4.66%

 

 

 

3.56

%

 

4.27 - 4.66%

 

 

 

3.56

%

Expected dividend yield

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of common shares and exercise price of options (USD)

 

$ 14.80 - 17.80

 

 

 

1.55

 

 

$ 7.66 - 17.80

 

 

 

1.55

 

Fair value of common shares and exercise price of options (CAD)

 

N/A

 

 

$

2.11

 

 

N/A

 

 

$

2.11

 

 

The following table summarizes the Company’s stock option activity:

 

 

Number of
Shares

 

 

Weighted-
Average
Exercise
Price (USD)

 

 

Weighted-
Average
Remaining
Contractual
Term (in years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding as of October 31, 2023

 

 

2,706,941

 

 

$

2.40

 

 

 

8.1

 

 

$

52,192

 

Granted

 

 

1,331,700

 

 

 

12.49

 

 

 

 

 

 

 

Exercised

 

 

(56,974

)

 

 

0.89

 

 

 

 

 

 

 

Forfeited or expired

 

 

(234

)

 

 

0.89

 

 

 

 

 

 

 

Outstanding as of April 30, 2024

 

 

3,981,433

 

 

$

5.69

 

 

8.4

 

 

$

41,181

 

Vested and exercisable as of April 30, 2024

 

 

2,434,737

 

 

$

2.10

 

 

7.6

 

 

$

33,597

 

Options unvested as of April 30, 2024

 

 

1,546,696

 

 

$

11.35

 

 

9.7

 

 

$

7,584

 

 

The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company’s common share as of each reporting period.

The weighted-average grant-date fair value per share of share options granted during the three and six months ended April 30, 2024 was $11.60 and $8.87, respectively. The weighted-average grant date fair value per share of share options granted during the three and six months ended April 30, 2023 was $1.50.

CEO Modification

 

On February 13, 2024, the Company entered into a Transition and Modified Employment Agreement (the "Transition Agreement") with the Company's Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement dated November 8, 2023 (the “Amended Employment Agreement”). Under the terms of the Amended Employment Agreement the CEO will be entitled to:

(i)
twelve months of continued health insurance benefits;
(ii)
payment of a prorated portion of his 2024 target annual bonus;
(iii)
acceleration and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination; and
(iv)
extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of the CEO’s vested equity awards extend beyond the respective applicable term thereof.

 

The Transition Agreement further provides that, in the event the CEO resigns upon the appointment by the Company of a new chief executive officer, the CEO will be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of resignation (the “Consulting Period”) in exchange for a monthly fee of $25,000 for the initial six-month Consulting Period, and $500 per hour thereafter, provided that the CEO need not devote more than fifteen (15) hours per week to providing such transition services.

 

As a result of the Transition Agreement, the 1,216,266 stock option awards issued to the CEO were modified to allow for an extended exercise period described above. The modification resulted in an incremental share-based compensation expense of $1.0 million which was recorded upon the effective date of the Transition Agreement.

 

Pursuant to the Amended Employment Agreement, (a) upon the termination of Mr. Hanson’s employment by the Company without Cause (as defined in the Amended Employment Agreement) or by Mr. Hanson for Good Reason (as defined in the Amended Employment Agreement), in addition to the above severance benefits, Mr. Hanson will also be entitled to 12 months’ base salary continuation or, if such even occurs during a change of control period (as described in the Amended Employment Agreement), 18 months’ base salary continuation.

Share-based Compensation Expense

Share-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss was as follows:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Research and development

 

$

337

 

 

$

7

 

 

$

530

 

 

$

12

 

General and administrative

 

 

1,580

 

 

32

 

 

 

1,678

 

 

47

 

Total share-based compensation expense

 

$

1,917

 

 

$

39

 

 

$

2,208

 

 

$

59

 

 

As of April 30, 2024, there was $11.3 million of unrecognized compensation, which is expected to be recognized over a weighted-average period of 3.60 years.

XML 29 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share
6 Months Ended
Apr. 30, 2024
Earnings Per Share [Abstract]  
Net Loss Per Share
13.
Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the Reverse Recapitalization:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

14,984

 

 

$

5,282

 

 

$

25,695

 

 

$

12,700

 

Deemed dividend attributable to redeemable convertible
   preferred shareholders

 

 

 

 

 

1,175

 

 

 

 

 

 

2,389

 

Net loss attributable to common shareholders, basic and
   diluted

 

$

14,984

 

 

$

6,457

 

 

$

25,695

 

 

$

15,089

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares used in net
   loss per share, basic and diluted

 

 

39,443,768

 

 

 

694,497

 

 

 

31,186,238

 

 

 

680,003

 

Net loss per common share, basic and diluted

 

$

0.38

 

 

$

9.30

 

 

$

0.82

 

 

$

22.19

 

 

The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders for the three and six months ended April 30, 2024 and 2023 because including them would have had an anti-dilutive effect:

 

 

Three and Six Months Ended April 30,

 

 

2024

 

 

2023

 

Redeemable convertible preferred shares

 

 

 

 

 

5,983,339

 

Warrants to purchase redeemable convertible preferred shares

 

 

 

 

 

3,194,756

 

Warrants to purchase common shares

 

 

8,511,968

 

 

 

 

Options to purchase common shares

 

 

3,981,433

 

 

 

1,620,599

 

Total

 

 

12,493,401

 

 

 

10,798,694

 

XML 30 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes
6 Months Ended
Apr. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
14.
Income Taxes

During the three months ended April 30, 2024 and 2023, the Company recorded $21 thousand and zero, respectively, in income tax provision. During the six months ended April 30, 2024 and 2023, the Company recorded $9 thousand and zero, respectively, in income tax benefit.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of April 30, 2024, the Company has maintained a full valuation allowance against its remaining net deferred tax assets.

XML 31 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases
6 Months Ended
Apr. 30, 2024
Leases [Abstract]  
Leases
15.
Leases

The Company’s leases are comprised of operating leases for office and lab space.

In November 2021, the Company entered into an office and lab space lease approximating 9,360 of rentable square feet for designated office and lab spaces located at 7171 Frederick-Banting, City of Montreal, judicial district of Montreal, Province of Quebec. The leased commenced in November 2021 and had an initial term of 12 months that would have expired on October 31, 2022, and includes options to renew for consecutive twelve-month periods upon landlord consent at new lease rates. As the Company has elected

to not recognize leases with a lease term of 12 months or less on the balance sheet, this was considered a short-term lease, and no operating lease right of use assets and liabilities were recognized. In October 2022, the Company entered into a lease amendment to extend the lease for an additional term of six months through April 2023, with an option to extend the lease through September 2023. In April 2023, the Company extended the lease through September 2023. The lease was further extended through November 5, 2023, at which time the Company vacated the lease.

On December 29, 2022, the Company signed a lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for 10 years, beginning on the commencement date, and requires an annual initial base rent of $36.50 CAD per square foot, which is subject to annual increases of 2%. The lease commenced in November 2023. Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $1.4 million.

On January 1, 2024, the Company entered into a lease agreement, in which the Company is sub-leasing approximately 6,450 square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $0.5 million under the initial term of the lease, which is set to expire on December 30, 2026 and does not have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $0.4 million.

During the three and six months ended April 30, 2024 and 2023, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Lease Cost:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease cost

 

 

119

 

 

 

 

 

 

209

 

 

 

 

Variable operating lease cost

 

 

 

 

 

16

 

 

 

24

 

 

 

32

 

Short-term operating lease cost

 

 

 

 

 

106

 

 

 

 

 

 

212

 

Total operating lease cost

 

 

119

 

 

 

122

 

 

 

233

 

 

 

244

 

 

Maturities of the Company's operating lease liabilities as of April 30, 2024 are as follows:

 

2024 (remaining)

 

 

223

 

2025

 

 

456

 

2026

 

 

468

 

2027

 

 

327

 

2028

 

 

303

 

Thereafter

 

 

1,722

 

Total

 

 

3,499

 

Less: Interest

 

 

(1,545

)

Total Lease liability

 

 

1,954

 

XML 32 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies
6 Months Ended
Apr. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
16.
Commitments and Contingencies

Legal Proceedings

From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of April 30, 2024, and October 31, 2023, there were no matters which would have a material impact on the Company’s financial results.

Purchase and Other Obligations

The Company enters into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.

XML 33 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Party Transactions
6 Months Ended
Apr. 30, 2024
Related Party Transactions [Abstract]  
Related Party Transactions
17.
Related Party Transactions

During the three and six months ended April 30, 2024 the Company had the following transactions with related parties:

 

On February 20, 2024, the Company completed the 2024 PIPE Financing, which provided for the private placement of 20,000,000 Common Shares, at a price of $10.00 per share and included both new and existing investors. One of the Company's director's, Mr. Gerry Brunk, is a managing director of Lumira Ventures ("Lumira"), and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of 800,000 Common Shares for a total price of $8 million in the Company's 2024 PIPE Financing.

 

During the three and six months ended April 30, 2023 the Company had the following transactions with related parties:

On April 4, 2023, the Company entered into the April 2023 Notes for a principal amount of $8.0 million with the April 2023 investors, as described in Note 8. The April 2023 Notes had an interest free period of 45 days from the date of issuance, and commencing on the 46th day, is to accrue interest at a rate of 15% per annum. The April 2023 Notes had a maturity date which was the earlier of (i) July 31, 2023; or (ii) the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $20.0 million. Upon the completion of the 2023 Financing, which met the definition of a qualified financing as defined within the April 2023 Notes, the Company issued and aggregate amount of $8.0 million of convertible debentures and warrants of the Company to the April 2023 Note investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, for the extinguishment and settlement of the April 2023 Notes.

XML 34 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events
6 Months Ended
Apr. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events
18.
Subsequent Events

 

The Company has evaluated subsequent events through the date these financial statements were issued. Except as noted below, the Company concluded that no additional subsequent events have occurred that require disclosure.

 

On May 15, 2024, the shareholders of the Company approved changes to the 2023 Plan. The original 2023 Plan contained an evergreen provision (the “Evergreen Provision”) pursuant to which, commencing with the first business day of each calendar year beginning in 2024, the aggregate number of the Company’s Common Shares that could be issued or transferred thereunder (the “Plan Share Reserve”) and the number of Common Shares available for options intended to qualify as incentive stock options (the “ISO Sublimit”) each increased by a number of Common Shares equal to the lesser of (x) 1,946,226 million Common Shares and (y) such lesser number of Common Shares as may be determined by the Compensation Committee. Pursuant to the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, on May 15, 2024, the Evergreen Provision was amended to provide for annual increases on the first business day of each calendar year of (i) the Plan Share Reserve by such number of Common Shares as equals 5% of the aggregate number of Common Shares outstanding on the final day of the immediately preceding calendar year (or such smaller number of shares as is determined by the compensation committee), and (ii) the ISO Sublimit by the lesser of 2,500,000 Common Shares and the increase in the Plan Share Reserve (or such smaller number of shares may be determined by the compensation committee of the Company’s board of directors).

XML 35 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Apr. 30, 2024
Accounting Policies [Abstract]  
Unaudited Interim Financial Information

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated balance sheet at October 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These interim financial statements include the accounts of the Company and its wholly owned subsidiaries, enGene, Inc. and enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements as of October, 31 2023 and 2022 and for the years ended October 31, 2023, and 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of April 30, 2024, the condensed consolidated statements of operations for the three and six months ended April 30, 2024 and 2023, the condensed consolidated statement of redeemable convertible preferred shares and shareholders' equity (deficit) for the three and six months ended April 30, 2024 and 2023, and condensed consolidated statements of cash flows for the six months ended April 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended April 30, 2024 and 2023 are unaudited. The results for the three and six months ended April 30, 2024 and 2023, are not necessarily indicative of results to be expected for the year ending October 31, 2024, any other interim periods, or any future year or period.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

There have been no changes from the financial statements for the year ended October 31, 2023.

XML 36 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization (Tables)
6 Months Ended
Apr. 30, 2024
Stockholders' Equity Note [Abstract]  
Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing

The following table summarizes the elements of the net proceeds from the Reverse Recapitalization and PIPE Financing transaction as of October 31, 2023:

 

Recapitalization

 

Cash – FEAC’s Trust Account and Cash (net of redemptions
   and cash paid for FEAC expenses prior to close)

 

$

7,363

 

Cash – PIPE Financing

 

 

56,892

 

Less transaction costs withheld from cash proceeds on Closing
   Date

 

 

(6,024

)

Cash proceeds received from the Reverse Recapitalization and
   PIPE Financing on Closing Date

 

$

58,231

 

Less transaction costs previously deferred and netted against
   proceeds

 

 

(5,086

)

Net cash proceeds from the Reverse Recapitalization and PIPE
   Financing

 

 

53,145

 

Summary of Number of Common Shares Outstanding

The following table summarizes the number of common shares outstanding immediately following the consummation of the Reverse Recapitalization and PIPE Financing transaction:

 

 

Number
of Shares

 

Old enGene Shareholders (Excluding Convertible Notes)

 

 

6,711,786

 

FEAC Shareholders, including sponsor's and shareholder with
   non-redemption agreement

 

 

3,670,927

 

Convertible Notes - Common Shares issued

 

 

6,379,822

 

Common Shares issued to PIPE Investors

 

 

6,435,441

 

Total Common Shares outstanding immediately after the
   Reverse Recapitalization and PIPE Financing

 

 

23,197,976

 

XML 37 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements (Tables)
6 Months Ended
Apr. 30, 2024
Convertible Debentures Embedded Derivative Liabilities  
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]  
Summary of Change in Estimated Fair Value of Liabilities

The following table provides a summary of the change in the estimated fair value of the Company’s convertible debentures embedded derivative liabilities for three and six months ended April 30, 2023.

 

 

Total

 

Balance as of October 31, 2022

 

$

3,791

 

Change in fair value of convertible debenture embedded
   derivative liabilities

 

 

307

 

Foreign exchange (gain)/loss

 

 

5

 

Balance as of January 31, 2023

 

 

4,103

 

Change in fair value of convertible debenture embedded
   derivative liabilities

 

 

(625

)

Foreign exchange (gain)/loss

 

 

(4

)

Balance as of April 30, 2023

 

$

3,474

 

Preferred Share Warrant Liabilities  
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]  
Summary of Change in Estimated Fair Value of Liabilities

The following table provides a summary of the change in the estimated fair value of the Company’s warrant liabilities for the three and six months ended April 30, 2023:

 

 

Total

 

Balance as of October 31, 2022

 

$

11,456

 

Change in fair value of warrant liabilities

 

 

1,185

 

Foreign exchange (gain)/loss

 

 

217

 

Balance as of January 31, 2023

 

 

12,858

 

Change in fair value of warrant liabilities

 

 

341

 

Foreign exchange (gain)/loss

 

 

(196

)

Balance as of April 30, 2023

 

$

13,003

 

XML 38 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property and Equipment, Net (Tables)
6 Months Ended
Apr. 30, 2024
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment

As of April 30, 2024, and October 31, 2023, property and equipment consisted of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Lab equipment

 

$

2,167

 

 

$

1,779

 

Computer equipment

 

 

287

 

 

 

269

 

Computer software

 

 

146

 

 

 

70

 

Office furniture

 

 

177

 

 

 

69

 

Leasehold improvements

 

 

215

 

 

 

129

 

Property and equipment

 

 

2,992

 

 

 

2,316

 

Less: Accumulated depreciation and amortization

 

 

1,885

 

 

 

1,727

 

Property and equipment, net

 

$

1,107

 

 

$

589

 

XML 39 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses and Other Current Liabilities (Tables)
6 Months Ended
Apr. 30, 2024
Payables and Accruals [Abstract]  
Summary of Accrued Expenses and Other Current Liabilities

As of April 30, 2024, and October 31, 2023, accrued expenses and other current liabilities consisted of the following:

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Accrued research and development expenses

 

$

2,427

 

 

$

759

 

Professional fees

 

 

1,427

 

 

 

1,708

 

Employee compensation and related benefits

 

 

1,511

 

 

 

814

 

Accrued income tax payable

 

 

30

 

 

 

39

 

Other

 

 

272

 

 

 

219

 

Total accrued expenses and other current liabilities

 

$

5,667

 

 

$

3,539

 

XML 40 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Notes Payable (Tables)
6 Months Ended
Apr. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Carrying Value of Term Loan

As of April 30, 2024 and October 31, 2023, the carrying value of the term loans consisted of the following:

 

 

April 30, 2024

 

 

October 31, 2023

 

Note payable, including End of Term Charge

 

$

24,530

 

 

$

10,144

 

Debt discount, net of accretion

 

 

(1,974

)

 

 

(474

)

Accrued interest

 

 

174

 

 

 

108

 

Note payable, net of discount

 

$

22,730

 

 

$

9,778

 

Schedule of Estimated Future Principal Payments Due Under the Loan Agreement

Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and paid in kind interest are as follows as of April 30, 2024:

 

 

Note Principal
Payments

 

2024

 

$

 

2025

 

 

3,285

 

2026

 

 

8,254

 

2027

 

 

9,047

 

2028

 

 

4,617

 

Total principal payments, including End of Term Charge

 

 

25,203

 

XML 41 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Shares (Tables)
6 Months Ended
Apr. 30, 2024
Equity [Abstract]  
Schedule of Shares Reserved for Future Issuance Under the Plan

As of April 30, 2024, and October 31, 2023, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the Company's 2023 Plan ( as defined below):

 

 

April 30,

 

 

October 31,

 

 

2024

 

 

2023

 

Warrants to purchase Common Shares

 

 

8,511,968

 

 

 

10,411,641

 

Options to purchase Common Shares

 

 

3,981,433

 

 

 

2,706,941

 

Remaining shares reserved for future issuance under
   the 2023 Plan

 

 

3,222,703

 

 

 

2,607,943

 

Total

 

 

15,716,104

 

 

 

15,726,525

 

XML 42 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-Based Compensation (Tables)
6 Months Ended
Apr. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options

The assumptions that the Company used to determine the grant-date fair value of stock options during the three and six months ended April 30, 2024 and 2023 are summarized below:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Expected term (in years)

 

5.75 - 6.08

 

 

6.08

 

 

5.75 - 6.08

 

 

6.08

 

Expected volatility

 

78.30 - 78.92%

 

 

 

81.39

%

 

78.24 - 78.92%

 

 

 

81.39

%

Risk-free interest rate

 

4.27 - 4.66%

 

 

 

3.56

%

 

4.27 - 4.66%

 

 

 

3.56

%

Expected dividend yield

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of common shares and exercise price of options (USD)

 

$ 14.80 - 17.80

 

 

 

1.55

 

 

$ 7.66 - 17.80

 

 

 

1.55

 

Fair value of common shares and exercise price of options (CAD)

 

N/A

 

 

$

2.11

 

 

N/A

 

 

$

2.11

 

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity:

 

 

Number of
Shares

 

 

Weighted-
Average
Exercise
Price (USD)

 

 

Weighted-
Average
Remaining
Contractual
Term (in years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding as of October 31, 2023

 

 

2,706,941

 

 

$

2.40

 

 

 

8.1

 

 

$

52,192

 

Granted

 

 

1,331,700

 

 

 

12.49

 

 

 

 

 

 

 

Exercised

 

 

(56,974

)

 

 

0.89

 

 

 

 

 

 

 

Forfeited or expired

 

 

(234

)

 

 

0.89

 

 

 

 

 

 

 

Outstanding as of April 30, 2024

 

 

3,981,433

 

 

$

5.69

 

 

8.4

 

 

$

41,181

 

Vested and exercisable as of April 30, 2024

 

 

2,434,737

 

 

$

2.10

 

 

7.6

 

 

$

33,597

 

Options unvested as of April 30, 2024

 

 

1,546,696

 

 

$

11.35

 

 

9.7

 

 

$

7,584

 

Summary of Share-based Compensation Expense

Share-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss was as follows:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Research and development

 

$

337

 

 

$

7

 

 

$

530

 

 

$

12

 

General and administrative

 

 

1,580

 

 

32

 

 

 

1,678

 

 

47

 

Total share-based compensation expense

 

$

1,917

 

 

$

39

 

 

$

2,208

 

 

$

59

 

XML 43 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share (Tables)
6 Months Ended
Apr. 30, 2024
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the Reverse Recapitalization:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

14,984

 

 

$

5,282

 

 

$

25,695

 

 

$

12,700

 

Deemed dividend attributable to redeemable convertible
   preferred shareholders

 

 

 

 

 

1,175

 

 

 

 

 

 

2,389

 

Net loss attributable to common shareholders, basic and
   diluted

 

$

14,984

 

 

$

6,457

 

 

$

25,695

 

 

$

15,089

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares used in net
   loss per share, basic and diluted

 

 

39,443,768

 

 

 

694,497

 

 

 

31,186,238

 

 

 

680,003

 

Net loss per common share, basic and diluted

 

$

0.38

 

 

$

9.30

 

 

$

0.82

 

 

$

22.19

 

Summary of Shares Excluded from Computation of Diluted Net Loss Per Share

The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders for the three and six months ended April 30, 2024 and 2023 because including them would have had an anti-dilutive effect:

 

 

Three and Six Months Ended April 30,

 

 

2024

 

 

2023

 

Redeemable convertible preferred shares

 

 

 

 

 

5,983,339

 

Warrants to purchase redeemable convertible preferred shares

 

 

 

 

 

3,194,756

 

Warrants to purchase common shares

 

 

8,511,968

 

 

 

 

Options to purchase common shares

 

 

3,981,433

 

 

 

1,620,599

 

Total

 

 

12,493,401

 

 

 

10,798,694

 

XML 44 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases (Tables)
6 Months Ended
Apr. 30, 2024
Lessee Disclosure [Abstract]  
Schedule of Components of Operating Lease Cost

During the three and six months ended April 30, 2024 and 2023, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:

 

 

Three months ended April 30,

 

 

Six months ended April 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Lease Cost:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease cost

 

 

119

 

 

 

 

 

 

209

 

 

 

 

Variable operating lease cost

 

 

 

 

 

16

 

 

 

24

 

 

 

32

 

Short-term operating lease cost

 

 

 

 

 

106

 

 

 

 

 

 

212

 

Total operating lease cost

 

 

119

 

 

 

122

 

 

 

233

 

 

 

244

 

Schedule of Maturities of Operating Lease Liabilities

Maturities of the Company's operating lease liabilities as of April 30, 2024 are as follows:

 

2024 (remaining)

 

 

223

 

2025

 

 

456

 

2026

 

 

468

 

2027

 

 

327

 

2028

 

 

303

 

Thereafter

 

 

1,722

 

Total

 

 

3,499

 

Less: Interest

 

 

(1,545

)

Total Lease liability

 

 

1,954

 

XML 45 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Description of Business - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
May 16, 2023
Apr. 30, 2024
Jan. 31, 2024
Apr. 30, 2023
Jan. 31, 2023
Apr. 30, 2024
Apr. 30, 2023
Oct. 31, 2023
Description of Business [Line Items]                
Exchange ratio           0.18048%    
Net Income (Loss)   $ (14,984,000) $ (10,711,000) $ (5,282,000) $ (7,418,000) $ (25,695,000) $ (12,700,000)  
Cash flows from operating activities           21,532,000 $ 10,667,000  
Accumulated deficit   $ 225,283,000       $ 225,283,000   $ 199,588,000
FEAC                
Description of Business [Line Items]                
Goodwill $ 0              
Intangible assets $ 0              
Exchange ratio 0.18048%              
XML 46 R38.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Summary of Significant Accounting Policies [Line Items]    
Unrealized foreign currency transaction losses $ (8) $ (22)
XML 47 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization -Additional Information (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Oct. 31, 2023
Apr. 30, 2024
Oct. 31, 2023
Jun. 30, 2021
Equity, Class of Treasury Stock [Line Items]        
Common stock shares outstanding 23,197,976 44,158,587 23,197,976  
Warrants outstanding 10,411,641 8,511,968 10,411,641 10,242,130
Common stock shares issued 23,197,976 44,158,587 23,197,976  
Proceeds from trust account     $ 7,363  
Proceeds from PIPE financing     56,892  
Transactions costs deferred and netted against proceeds     $ 5,086  
FEAC        
Equity, Class of Treasury Stock [Line Items]        
Common stock shares outstanding 3,670,927   3,670,927  
Warrants outstanding 5,029,444 8,449,555 5,029,444  
Proceeds from trust account     $ 7,400  
Merger Agreement [Member]        
Equity, Class of Treasury Stock [Line Items]        
Business combination reverse recapitalization description   On October 31, 2023 (the "Closing Date”), FEAC, Old enGene, and the Company consummated the merger pursuant to the Merger Agreement, dated as of May 16, 2023. As a result of the Reverse Recapitalization, the Company became a publicly traded company, with Old enGene, a subsidiary of the Company, continuing the existing business operations.    
Merger agreement date May 16, 2023      
PIPE Financing        
Equity, Class of Treasury Stock [Line Items]        
Common stock shares outstanding 23,197,976   23,197,976  
Warrants outstanding 10,411,641   10,411,641  
Value of stock and warrant issued during the period     $ 56,900  
Transaction costs $ 11,100   11,100  
Transactions costs deferred and netted against proceeds     5,100  
PIPE Financing | FEAC        
Equity, Class of Treasury Stock [Line Items]        
Value of stock and warrant issued during the period     $ 56,900  
Number of new stock issued during the period     6,435,441  
Number of new warrant issued during the period     2,702,791  
Common stock, value issued     $ 56,100  
Warrants issued during period, value     800  
Proceeds from PIPE financing     56,900  
Transaction costs withheld from proceeds received     $ 6,000  
Old enGenes Equity and Convertible Note        
Equity, Class of Treasury Stock [Line Items]        
Common stock shares issued 13,091,608   13,091,608  
Old enGenes Warrant        
Equity, Class of Treasury Stock [Line Items]        
Share warrants issued 2,679,432   2,679,432  
Old enGenes Share Option        
Equity, Class of Treasury Stock [Line Items]        
Common stock shares issued   2,706,941    
Common share options issued 2,706,941   2,706,941  
XML 48 R40.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization - Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing (Details)
$ in Thousands
12 Months Ended
Oct. 31, 2023
USD ($)
Stockholders' Equity Note [Abstract]  
Cash - FEAC's Trust Account and Cash (net of redemptions and cash paid for FEAC expenses prior to close) $ 7,363
Cash - PIPE Financing 56,892
Less transaction costs withheld from cash proceeds on Closing Date (6,024)
Cash proceeds received from the Reverse Recapitalization and PIPE Financing on Closing Date 58,231
Less transaction costs previously deferred and netted against proceeds (5,086)
Net cash proceeds from the Reverse Recapitalization and PIPE Financing $ 53,145
XML 49 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Details)
Apr. 30, 2024
shares
Reverse Recapitalization [Line Items]  
Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing 23,197,976
Old enGene Shareholders (Excluding Convertible Notes)  
Reverse Recapitalization [Line Items]  
Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing 6,711,786
FEAC Shareholders, including sponsor's and shareholder with non-redemption agreement  
Reverse Recapitalization [Line Items]  
Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing 3,670,927
Convertible Notes - Common Shares issued  
Reverse Recapitalization [Line Items]  
Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing 6,379,822
Common Shares Issued to Pipe Investors  
Reverse Recapitalization [Line Items]  
Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing 6,435,441
XML 50 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2024
Apr. 30, 2024
Apr. 30, 2023
Oct. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Transfers or reclassifications into level 3 $ 0 $ 0   $ 0
Transfers or reclassifications out of level 3 $ 0 $ 0   0
Proceeds from convertible debt     $ 8,000,000  
Fair value of shares $ 18 $ 18    
Preferred Share Warrants        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Warrants, contractual term 10 years 10 years    
April 2023 Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Proceeds from convertible debt   $ 8,000,000    
Fair Value Measurement Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Financial assets, fair value $ 0 0   0
Financial liabilities, fair value $ 0 $ 0   $ 0
XML 51 R43.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements - Summary Of Change In Estimated Fair Value Of Convertible Debentures Embedded Derivative Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2023
Jan. 31, 2023
Apr. 30, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Change In Fair Value Of Convertible Debentures Embedded Derivative Liabilities Change In Fair Value Of Convertible Debentures Embedded Derivative Liabilities  
2022 Notes and BDC Notes      
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Balance $ 4,103 $ 3,791 $ 3,791
Change in fair value of convertible debenture embedded derivative liabilities (625) 307  
Foreign exchange (gain)/loss (4) 5  
Balance $ 3,474 $ 4,103 $ 3,474
XML 52 R44.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements - Summary of Change in Estimated Fair Value of Warrant Liabilities (Details) - USD ($)
3 Months Ended
Apr. 30, 2023
Jan. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance $ 12,858 $ 11,456
Change in fair value of warrant liabilities 341 1,185
Foreign exchange (gain)/loss (196) 217
Ending Balance $ 13,003 $ 12,858
XML 53 R45.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Apr. 30, 2024
Oct. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment $ 2,992 $ 2,316
Less: Accumulated depreciation and amortization 1,885 1,727
Property and equipment, net 1,107 589
Lab Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 2,167 1,779
Computer Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 287 269
Computer Software    
Property, Plant and Equipment [Line Items]    
Property and equipment 146 70
Office Furniture    
Property, Plant and Equipment [Line Items]    
Property and equipment 177 69
Leasehold Improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment $ 215 $ 129
XML 54 R46.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Property, Plant and Equipment [Abstract]        
Depreciation and amortization expense $ 78 $ 37 $ 158 $ 83
XML 55 R47.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Apr. 30, 2024
Oct. 31, 2023
Payables and Accruals [Abstract]    
Accrued research and development expenses $ 2,427 $ 759
Professional fees 1,427 1,708
Employee compensation and related benefits 1,511 814
Accrued income tax payable 30 39
Other 272 219
Total accrued expenses and other current liabilities $ 5,667 $ 3,539
XML 56 R48.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
License Agreement and Clinical Research Organization - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 10, 2020
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
License Agreement and Clinical Research Organization [Line Items]          
Annual maintenance fee $ 50        
Payment to NTC upon assigning the License Agreement 50        
Phase I Clinical Trial [Member]          
License Agreement and Clinical Research Organization [Line Items]          
One-time payment for milestone product 50        
Phase II Clinical Trial [Member]          
License Agreement and Clinical Research Organization [Line Items]          
One-time payment for milestone product 450        
Research and Development          
License Agreement and Clinical Research Organization [Line Items]          
Upfront fee $ 50        
Expenses related to the annual maintenance fee   $ 13 $ 13 $ 25 $ 25
XML 57 R49.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Notes Payable - Additional Information (Details)
3 Months Ended 6 Months Ended
Dec. 22, 2023
USD ($)
$ / shares
shares
Apr. 04, 2023
USD ($)
Jun. 15, 2022
USD ($)
Dec. 30, 2021
USD ($)
Apr. 30, 2024
USD ($)
$ / shares
shares
Apr. 30, 2023
USD ($)
Apr. 30, 2024
USD ($)
$ / shares
shares
Apr. 30, 2023
USD ($)
Apr. 30, 2024
$ / shares
Oct. 31, 2023
USD ($)
Dec. 15, 2022
USD ($)
Jun. 30, 2022
USD ($)
shares
Debt Instrument [Line Items]                        
Loss on extinguishment of debt             $ (366,000)          
Note payable current                   $ 562,000    
Warrants, exercise price per share | $ / shares         $ 11.5   $ 11.5          
Old Hercules Warrants                        
Debt Instrument [Line Items]                        
Warrants exercisable period         10 years   10 years          
Warrants, exercise price per share | $ / shares                 $ 2.632      
Loan and Security Agreement | Old Hercules Warrants                        
Debt Instrument [Line Items]                        
Exercise price equal to percentage of aggregate amount of term loans             2.50%          
Loan and Security Agreement | Old Hercules Warrants | Class C Preferred Shares                        
Debt Instrument [Line Items]                        
Warrant issued to purchase preferred shares | shares         84,714   84,714         48,978
Preferred share warrants fair value         $ 34   $ 34         $ 23
Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Warrant issued to purchase preferred shares | shares 138,696                      
Warrants, exercise price per share | $ / shares $ 7.21                      
Percentage of aggregate principal amount of term loan advance to purchase number of common shares 2.00%                      
Warrants exercisable period 7 years                      
Term Loan | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Percentage of prepayment premium of principal amount outstanding of the closing date 3.00%                      
Percentage of prepayment premium of principal amount outstanding prior to twenty-four months 2.00%                      
Percentage of prepayment premium of principal amount outstanding prior to maturity date 1.00%                      
Loss on extinguishment of debt         $ 400,000   $ 400,000          
Effective interest rate of outstanding debt         12.38%   12.38%          
Line of credit, maturity date Jan. 01, 2028                      
End of term fee percentage 5.50%                      
End of term charge $ 0.7                      
Debt instrument, interest rate 9.25%                      
Payment-in-kind interest rate 1.15%                      
Loan amortization date Jul. 01, 2025                      
Percentage of total commitment amount 2.00%                      
Total commitment amount $ 50,000,000                      
Term Loan | Wall Street Journal | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Term loan annual interest rate 0.75%                      
Term Loan | Maximum | Wall Street Journal | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Debt instrument, interest rate 9.75%                      
2021 Loan and Security Agreement | Hercules Capital                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount       $ 20,000,000                
Percentage of aggregate principle amount of term loan advances amount fee       6.35%                
Term loan maturity date       Jul. 01, 2025                
Term loan annual interest rate       8.25%                
Term loan reduced annual interest rate       8.15%                
Percentage of prepayment premium of principal amount outstanding of the closing date       3.00%                
Percentage of prepayment premium of principal amount outstanding prior to twenty-four months       2.00%                
Percentage of prepayment premium of principal amount outstanding prior to maturity date       1.00%                
Effective interest rate of outstanding debt                   18.30%    
Note payable current                   $ 600,000    
Interest expense         $ 700,000 $ 400,000 $ 1,300,000 $ 900,000        
Amortization of debt discount         100,000 100,000 300,000 $ 200,000        
Borrowed amount         22,500,000   22,500,000     11,000,000    
Debt discount and issuance costs         2,100,000   2,100,000     $ 1,100,000    
2021 Loan and Security Agreement | Hercules Capital | Prime Rate                        
Debt Instrument [Line Items]                        
Term loan annual interest rate       3.25%                
2021 Loan and Security Agreement | Tranche One | Hercules Capital                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount       $ 7,000,000                
2021 Loan and Security Agreement | Tranche Two | Hercules Capital                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount     $ 4,000,000                  
Term loan facility, drawn term     2022-06                  
2021 Loan and Security Agreement | Tranche Three | Hercules Capital                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount                     $ 9,000,000  
April 2023 Notes                        
Debt Instrument [Line Items]                        
Term loan maturity date   Jul. 31, 2023                    
Loss on extinguishment of debt           $ 0            
Borrowed amount   $ 8,000,000                    
Interest free period   45 days                    
Fair value of debt instrument   $ 8,000,000                    
Accrue interest rate percentage   15.00%                    
April 2023 Notes | Minimum                        
Debt Instrument [Line Items]                        
Aggregate sale of convertible promissory notes, warrants, preferred shares, common shares, or combined thereof   $ 20,000,000                    
Tranche 1 Advance | Term Loan | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount $ 50,000,000                      
Warrant issued to purchase preferred shares | shares 62,413                      
Proceeds from line of credit $ 22,500,000                      
Tranche 1 Advance | Term Loan | Amended Loan Agreement | Hercules Warrants                        
Debt Instrument [Line Items]                        
Borrowed amount         $ 22,500,000   22,500,000          
Advance on loan allocated to warrants             $ 300,000          
Tranche 3 Advance | Term Loan | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount $ 20,000,000                      
Percentage of facility charge on amount borrowed 0.75%                      
Applied to Refinance of Amount Outstanding | Term Loan | Prior Loan Agreement                        
Debt Instrument [Line Items]                        
Proceeds from line of credit $ 8,600,000                      
Tranche 2 Advance Subject to Achievement of Specified Interim Milestone | Term Loan | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Term loan facility aggregate principal amount $ 7,500,000                      
Period Within Loan Disbursements to be Made 60 days                      
Line of credit, maturity date Mar. 31, 2025                      
If Interim Milestone and Certain Clinical Milestones Achieved and No Default | Term Loan | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Loan amortization date Jul. 01, 2026                      
If Interim Milestone Achieved and No Default | Term Loan | Amended Loan Agreement                        
Debt Instrument [Line Items]                        
Loan amortization date Jan. 01, 2026                      
XML 58 R50.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Notes Payable - Schedule of Carrying Value of Term Loan (Details) - Term Loan - USD ($)
$ in Thousands
Apr. 30, 2024
Oct. 31, 2023
Debt Instrument [Line Items]    
Note payable, including End of Term Charge $ 24,530 $ 10,144
Debt discount, net of accretion (1,974) (474)
Accrued interest 174 108
Note payable, net of discount $ 22,730 $ 9,778
XML 59 R51.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details) - 2021 Loan and Security Agreement
$ in Thousands
Apr. 30, 2024
USD ($)
Debt Instrument [Line Items]  
2024 $ 0
2025 3,285
2026 8,254
2027 9,047
2028 4,617
Note payable, net of discount $ 25,203
XML 60 R52.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Convertible Debentures - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 16, 2023
Apr. 04, 2023
Jun. 30, 2023
May 31, 2023
Apr. 30, 2023
Sep. 30, 2020
Apr. 30, 2023
Jan. 31, 2023
Apr. 30, 2024
Apr. 30, 2023
Oct. 31, 2023
Oct. 31, 2022
Short-Term Debt [Line Items]                        
Initial maturity date           Sep. 28, 2023            
Change in fair value of convertible debentures embedded derivative liabilities             $ (625,000)     $ (318,000)    
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]             Change in fair value of convertible debentures embedded derivative liabilities Change in fair value of convertible debentures embedded derivative liabilities        
Loss on extinguishment of convertible debentures                 $ (366,000)      
Convertible debentures                 $ 0   $ 0  
Proceeds from Convertible Debt                   8,000,000    
Warrants, exercise price per share                 $ 11.5      
Forbion Growth Sponsor FEAC I B.V                        
Short-Term Debt [Line Items]                        
Notes purchase principal amount     $ 20,000,000                  
BDC Notes                        
Short-Term Debt [Line Items]                        
Convertible debt           $ 2,200,000            
Interest rate           8.00%            
Maturity date           Sep. 29, 2025            
Percentage of price per share           80.00%            
Percentage of principal           20.00%            
Embedded derivative liability measured at fair value           $ 200,000            
Change in fair value of convertible debenture embedded derivative liabilities             $ 200,000     100,000    
Interest expense, including the amortization of debt discounts             60,000,000     100,000    
Debt issuance costs           $ 36,000            
2022 Notes                        
Short-Term Debt [Line Items]                        
Convertible notes net                       $ 18,400,000
Interest rate                       10.00%
Initial maturity term                       3 years
Embedded derivative liability measured at fair value                       $ 3,500,000
Change in fair value of convertible debentures embedded derivative liabilities             800,000     400,000    
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]               Change in fair value of convertible debentures embedded derivative liabilities        
Interest expense, including the amortization of debt discounts             600,000     $ 1,300,000    
Debt issuance costs                       $ 44,000
Loss on extinguishment of convertible debentures                     $ 3,100,000  
Conversion and exchange of redeemable convertible preferred stock into common shares in connection with the Reverse Recapitalization (in shares)                     2,081,359 2,081,359
May 2023 Notes                        
Short-Term Debt [Line Items]                        
Initial maturity date Oct. 20, 2025                      
Proceeds from Convertible Debt $ 30,000,000                      
Accrued interest percentage       10.00%                
2023 Financing                        
Short-Term Debt [Line Items]                        
Borrowed amount     10,000,000 $ 28,000,000                
Cash     10,000,000 $ 20,000,000                
Warrants to purchase shares of common stock 2,679,432                      
Warrants, exercise price per share $ 11.5                      
2023 Financing | Forbion Growth Sponsor FEAC I B.V                        
Short-Term Debt [Line Items]                        
Borrowed amount     $ 38,000,000                  
April 2023 Notes                        
Short-Term Debt [Line Items]                        
Repayment of aggregate amount $ 8,000,000                      
Repayment         $ 8,000,000              
April 2023 Notes                        
Short-Term Debt [Line Items]                        
Interest rate   15.00%                    
Maturity date   Jul. 31, 2023                    
Loss on extinguishment of convertible debentures             $ 0          
Borrowed amount   $ 8,000,000                    
XML 61 R53.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Redeemable Convertible Preferred Shares - Additional Information (Details)
$ / shares in Units, $ in Millions
Jun. 30, 2021
USD ($)
shares
Sep. 10, 2015
USD ($)
shares
Jan. 06, 2015
USD ($)
shares
Jul. 26, 2013
USD ($)
shares
Apr. 30, 2024
$ / shares
shares
Apr. 30, 2024
$ / shares
shares
Oct. 31, 2023
shares
Jun. 30, 2021
$ / shares
shares
Jun. 30, 2021
$ / shares
shares
Sep. 10, 2015
$ / shares
Sep. 10, 2015
$ / shares
Jan. 06, 2015
$ / shares
Jan. 06, 2015
$ / shares
Jul. 26, 2013
$ / shares
Jul. 26, 2013
$ / shares
Class of Stock [Line Items]                              
Warrants, exercise price per share | $ / shares           $ 11.5                  
Warrants outstanding         8,511,968 8,511,968 10,411,641 10,242,130 10,242,130            
Share exchange ratio 0.18048                            
Class C Second Tranche                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell 3,662,810                            
Redeemable convertible preferred shares at a price per share | (per share)               $ 2.632 $ 2.13192            
Total aggregate proceeds | $ $ 7.8                            
Share warrants issued               3,662,810 3,662,810            
Class A Redeemable Convertible Preferred Shares | Class A Initial Closing                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell       610,333                      
Redeemable convertible preferred shares at a price per share | (per share)                           $ 1.63845 $ 1.5929
Total aggregate proceeds | $       $ 1.0                      
Class A Redeemable Convertible Preferred Shares | Class A Second Tranche                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell       1,830,999                      
Redeemable convertible preferred shares at a price per share | (per share)                           $ 1.63845 $ 1.56967
Total aggregate proceeds | $       $ 2.9                      
Class B Redeemable Convertible Preferred Shares | Class B Intial Closing                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell     2,758,221                        
Redeemable convertible preferred shares at a price per share | (per share)                       $ 2.17532 $ 1.85032    
Total aggregate proceeds | $     $ 5.1                        
Class B Redeemable Convertible Preferred Shares | Class B Second Tranche                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell     1,838,815                        
Redeemable convertible preferred shares at a price per share | (per share)                       2.17532 1.63419    
Total aggregate proceeds | $     $ 3.0                        
Class B Redeemable Convertible Preferred Shares | Class B Third Tranche                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell     1,608,963                        
Redeemable convertible preferred shares at a price per share | (per share)                       $ 2.17532 $ 1.63419    
Total aggregate proceeds | $     $ 2.6                        
Class B-1 Redeemable Convertible Preferred Shares                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell   1,523,809                          
Redeemable convertible preferred shares at a price per share | (per share)                   $ 2.17532 $ 1.64367        
Total aggregate proceeds | $   $ 2.5                          
Conversion ratio                   1 1        
Series 1 Class C Redeemable Convertible Preferred                              
Class of Stock [Line Items]                              
Shares issued, price per share | (per share)         $ 1.63845 $ 1.5929                  
Series 2 Class C Redeemable Convertible Preferred                              
Class of Stock [Line Items]                              
Shares issued, price per share | (per share)         2.175315 1.85032                  
Series 3 Class C Redeemable Convertible Preferred                              
Class of Stock [Line Items]                              
Shares issued, price per share | (per share)         2.632 2.12376                  
Share warrants issued               3,662,813 3,662,813            
Series 3 Class C Redeemable Convertible Preferred | Class C Inital Closing                              
Class of Stock [Line Items]                              
Initial aggregate amount that company agreed to sell 3,662,813                            
Redeemable convertible preferred shares at a price per share | (per share)               $ 2.632 $ 2.12376            
Total aggregate proceeds | $ $ 7.8                            
Series 4 Class C Redeemable Convertible Preferred                              
Class of Stock [Line Items]                              
Shares issued, price per share | (per share)         $ 2.10559 $ 1.69901                  
Class C Warrants                              
Class of Stock [Line Items]                              
Share warrants issued               7,325,623 7,325,623            
Warrants, exercise price per share | (per share)               $ 2.632 $ 2.12376            
Warrants outstanding               10,242,130 10,242,130            
Warrant term 10 years                            
Expiring term of warrants Feb. 14, 2030                            
Aggregate amount of shares exchanged               16,464,646 16,464,646            
XML 62 R54.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Shares - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Feb. 13, 2024
Apr. 30, 2024
Oct. 31, 2023
Dec. 22, 2023
Apr. 30, 2023
Jan. 31, 2023
Jun. 30, 2021
Class of Stock [Line Items]              
Common stock shares authorized unlimited   Unlimited Unlimited        
Common stock no par value   $ 0 $ 0   $ 0    
Common stock shares outstanding   44,158,587 23,197,976        
Common stock voting rights   Common Shares are entitled to one vote          
Share price   $ 18          
Cash dividend paid   $ 0          
Warrants outstanding   8,511,968 10,411,641       10,242,130
Warrants, exercise price per share   $ 11.5          
Warrants exercisable period   30 days          
Warrants, maturity date   Oct. 31, 2028          
Warrants, maturity period   5 years          
Proceeds from exercises of warrants   $ 5,983          
Amended Loan Agreement              
Class of Stock [Line Items]              
Warrants, exercise price per share       $ 7.21      
2024 PIPE Investors              
Class of Stock [Line Items]              
Issuance of common shares 800,000            
Cashless Warrant Exercises              
Class of Stock [Line Items]              
Issuance of common shares   383,355          
Number of common stock warrants exercised by investors on cashless basis   1,379,391          
Cash Warrant Exercises              
Class of Stock [Line Items]              
Issuance of common shares   520,282          
Proceeds from exercises of warrants   $ 6,000          
2024 Subscription Agreements              
Class of Stock [Line Items]              
Aggregate gross proceeds of common stock $ 200,000            
Date of closed private placement   Feb. 20, 2024          
Offering expenses $ 12,400            
2024 Subscription Agreements | Private Placement              
Class of Stock [Line Items]              
Common shares price per share $ 10            
Issuance of common shares 20,000,000            
FEAC              
Class of Stock [Line Items]              
Common stock shares outstanding     3,670,927        
Warrants outstanding   8,449,555 5,029,444        
Warrants, exercise price per share   $ 11.5       $ 7.21  
Warrants, maturity date   Dec. 22, 2030          
Warrants, maturity period   7 years          
FEAC | Amended Loan Agreement              
Class of Stock [Line Items]              
Warrants outstanding   62,413          
XML 63 R55.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Common Shares - Schedule of Shares Reserved For Future Issuance Under The Plan (Details) - shares
Apr. 30, 2024
Oct. 31, 2023
Class of Stock [Line Items]    
Common stock shares reserved for future issuance 15,716,104 15,726,525
Remaining shares reserved for future issuance under the equity plans    
Class of Stock [Line Items]    
Common stock shares reserved for future issuance 3,222,703 2,607,943
Options to purchase common shares    
Class of Stock [Line Items]    
Common stock shares reserved for future issuance 3,981,433 2,706,941
Warrants to purchase common shares    
Class of Stock [Line Items]    
Common stock shares reserved for future issuance 8,511,968 10,411,641
XML 64 R56.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-Based Compensation - Additional Information (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Feb. 13, 2024
USD ($)
shares
Jul. 07, 2023
$ / shares
shares
Jul. 05, 2018
Apr. 30, 2024
USD ($)
$ / shares
shares
Apr. 30, 2023
USD ($)
$ / shares
Apr. 30, 2024
USD ($)
$ / shares
shares
Apr. 30, 2023
USD ($)
$ / shares
Oct. 31, 2023
USD ($)
$ / shares
shares
Jan. 01, 2024
shares
Jul. 07, 2023
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Exchange ratio           0.18048%        
Stock-based compensation expense | $       $ 1,917,000 $ 39,000 $ 2,208,000 $ 59,000      
Unrecognized compensation expense | $       $ 11,300,000   $ 11,300,000        
Common stock shares reserved for future issuance       15,716,104   15,716,104   15,726,525    
Shares Granted           1,331,700        
Exercise price | $ / shares       $ 5.69   $ 5.69   $ 2.4    
Issued options were fully vested   794,643                
Remaining options vesting   252,121               252,121
Award vesting period   4 years                
Unrecognized compensation expense weighted-average period of recognition           3 years 7 months 6 days        
Weighted-average grant-date fair value per share of share options granted | $ / shares       $ 11.6 $ 1.5 $ 8.87 $ 1.5      
CEO Transition Agreement                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Incremental compensation cost | $ $ 1,000,000                  
CEO | CEO Transition Agreement                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Shares Granted 1,216,266                  
Award vesting period 12 months                  
Amount of monthly fee for consulting period | $ $ 25,000                  
Initial consulting Period 6 months                  
Maximum hours of ceo devote per week to providing transition services 15 hours                  
Transition services for consulting fee per hour | $ $ 500                  
Employee entitled base salary continuation after termination for a period 12 months                  
Employee entitled base salary continuation in case of change in control after termination for a period 18 months                  
Employee Stock Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation expense | $               $ 2,600,000    
Common stock shares reserved for future issuance       3,981,433   3,981,433   2,706,941    
Shares Granted   1,046,764                
Exercise price | (per share)   $ 5.87               $ 4.24
The Old Plans                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation expense | $           $ 400,000        
Unrecognized compensation expense | $       $ 0   $ 0        
Common stock shares reserved for future issuance               2,706,941    
Options to purchase common shares               2,706,941    
Incremental compensation cost | $               $ 0    
Number of options remain available for grant               0    
The Old Plans | Maximum                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Percentage of issuance of common stock options     15.00%              
The Old Plans | Maximum | Employee Stock Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock options vesting service period     4 years              
The Old Plans | Minimum | Employee Stock Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock options vesting service period     3 years              
2023 Plan                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Common stock shares reserved for future issuance       7,261,110   7,261,110   2,607,943    
Common stock capital shares reserved for remaining future issuance       5,929,643            
Increase in number of share reserved for future issuance in the beginning of the year               1,946,226,000,000    
Number of shares authorized increased                 1,946,225  
2023 Plan | Employee Stock Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Percentage of common stock value on date of grant           100.00%        
2023 Plan | Maximum | Employee Stock Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock option term           10 years        
Non-Voting Common Shares                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Additional awards approved for issuance   1,046,764               1,046,764
Common stock shares reserved for future issuance   1,775,729   2,822,493   2,822,493       1,775,729
Vesting Immediately Upon Grant Date | Employee Stock Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Percentage of vesting rights     100.00%              
XML 65 R57.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details) - Employee Stock Option [Member]
3 Months Ended 6 Months Ended
Apr. 30, 2024
$ / shares
Apr. 30, 2023
$ / shares
Apr. 30, 2023
$ / shares
Apr. 30, 2024
$ / shares
Apr. 30, 2023
$ / shares
Apr. 30, 2023
$ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Expected term (in years)   6 years 29 days 6 years 29 days   6 years 29 days 6 years 29 days
Expected volatility, Minimum 78.30%     78.24%    
Expected volatility, Maximum 78.92%     78.92%    
Expected volatility   81.39% 81.39%   81.39% 81.39%
Risk-free interest rate, Minimum 4.27%     4.27%    
Risk-free interest rate, Maximum 4.66%     4.66%    
Risk-free interest rate   3.56% 3.56%   3.56% 3.56%
Fair value of common shares and exercise price of options, Minimum $ 14.8     $ 7.66    
Fair value of common shares and exercise price of options, Maximum $ 17.8     $ 17.8    
Fair value of common shares and exercise price of options | (per share)   $ 1.55 $ 2.11   $ 1.55 $ 2.11
Minimum            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Expected term (in years) 5 years 9 months     5 years 9 months    
Maximum            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Expected term (in years) 6 years 29 days     6 years 29 days    
XML 66 R58.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-Based Compensation - Summary of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Apr. 30, 2024
USD ($)
$ / shares
shares
Oct. 31, 2023
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]    
Number of shares outstanding, Beginning balance | shares 2,706,941  
Granted | shares 1,331,700  
Exercised | shares (56,974)  
Forfeited or expired | shares (234)  
Number of shares outstanding, Ending balance | shares 3,981,433 2,706,941
Options vested and exercisable | shares 2,434,737  
Options unvested | shares 1,546,696  
Weighted-Average Exercise Price Outstanding, Beginning balance | $ / shares $ 2.4  
Weighted-Average Exercise Price, Granted | $ / shares 12.49  
Weighted-Average Exercise Price, Exercised | $ / shares 0.89  
Weighted-Average Exercise Price, Forfeited or expired | $ / shares 0.89  
Weighted-Average Exercise Price Outstanding, Ending balance | $ / shares 5.69 $ 2.4
Weighted-Average Exercise Price, Options vested and exercisable | $ / shares 2.1  
Weighted-Average Exercise Price, Options unvested | $ / shares $ 11.35  
Weighted- Average Remaining Contractual Term (in years), Outstanding 8 years 4 months 24 days 8 years 1 month 6 days
Weighted- Average Remaining Contractual Term (in years), Options vested and exercisable 7 years 7 months 6 days  
Weighted- Average Remaining Contractual Term (in years), Options unvested 9 years 8 months 12 days  
Aggregate Intrinsic Value, Outstanding | $ $ 41,181 $ 52,192
Aggregate Intrinsic Value, Options vested and exercisable | $ 33,597  
Aggregate Intrinsic Value, Options unvested | $ $ 7,584  
XML 67 R59.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total share-based compensation expense $ 1,917 $ 39 $ 2,208 $ 59
Research and Development        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total share-based compensation expense 337 7 530 12
General and Administrative        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total share-based compensation expense $ 1,580 $ 32 $ 1,678 $ 47
XML 68 R60.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Jan. 31, 2024
Apr. 30, 2023
Jan. 31, 2023
Apr. 30, 2024
Apr. 30, 2023
Numerator:            
Net loss $ 14,984 $ 10,711 $ 5,282 $ 7,418 $ 25,695 $ 12,700
Deemed dividend attributable to redeemable convertible preferred shareholders     1,175     2,389
Net loss attributable to common shareholders, basic 14,984   6,457   25,695 15,089
Net loss attributable to common shareholders, diluted $ 14,984   $ 6,457   $ 25,695 $ 15,089
Denominator:            
Weighted-average number of common shares used in net loss per share, basic 39,443,768   694,497   31,186,238 680,003
Weighted-average number of common shares used in net loss per share, diluted 39,443,768   694,497   31,186,238 680,003
Net loss per share of common shares, basic $ 0.38   $ 9.3   $ 0.82 $ 22.19
Net loss per share of common shares, diluted $ 0.38   $ 9.3   $ 0.82 $ 22.19
XML 69 R61.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details) - shares
3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Shares excluded from computation of diluted net loss per share 12,493,401 10,798,694 12,493,401 10,798,694
Redeemable convertible preferred shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Shares excluded from computation of diluted net loss per share 0 5,983,339 0 5,983,339
Warrants to purchase redeemable convertible preferred shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Shares excluded from computation of diluted net loss per share 0 3,194,756 0 3,194,756
Warrants to purchase common shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Shares excluded from computation of diluted net loss per share 8,511,968 0 8,511,968 0
Options to purchase common shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Shares excluded from computation of diluted net loss per share 3,981,433 1,620,599 3,981,433 1,620,599
XML 70 R62.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Income Tax Contingency [Line Items]        
Income tax provision or benefit $ 21 $ 0 $ (9) $ 0
XML 71 R63.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Additional Information (Details)
1 Months Ended 3 Months Ended
Jan. 01, 2024
USD ($)
ft²
Dec. 29, 2022
USD ($)
ft²
$ / ft²
Apr. 30, 2023
Oct. 31, 2022
Nov. 30, 2021
USD ($)
ft²
Jan. 31, 2024
Apr. 30, 2024
USD ($)
Lessee, Lease, Description [Line Items]              
Operating lease right of use assets             $ 1,837,000
Operating lease liabilities             1,954,000
Additional lease commitments to be paid             $ 3,499,000
Office Space              
Lessee, Lease, Description [Line Items]              
Rentable square feet | ft² 6,450            
Lease expiration date Dec. 30, 2026            
Operating lease right of use assets $ 400,000            
Operating lease liabilities $ 400,000            
Operating lease, option to extend false            
Aggregate amount of base rental payments $ 500,000            
Office and Lab Space              
Lessee, Lease, Description [Line Items]              
Rentable square feet | ft²         9,360    
Operating lease commencement period         2021-11    
Lease expiration date         Oct. 31, 2022    
Operating lease initial term         12 months    
Operating lease renewal term       6 months 12 months    
Operating lease right of use assets         $ 0    
Operating lease liabilities         $ 0    
Lease expiration month and year     2023-09 2023-04      
Operating lease, option to extend       true   true  
Operating lease extended term       2023-09      
New Laboratory and Office Space              
Lessee, Lease, Description [Line Items]              
Rentable square feet | ft²   10,620          
Operating lease commencement period   2023-11          
Operating lease initial term   10 years          
Operating lease right of use assets   $ 1,400,000          
Operating lease liabilities   $ 1,400,000          
Initial annual base rent | $ / ft²   36.5          
Percentage of increase in annual base rent   2.00%          
XML 72 R64.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Schedule of Components of Operating Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Lease Cost:        
Operating lease cost $ 119   $ 209,000  
Variable operating lease cost   $ 16 24,000 $ 32,000
Short-term operating lease cost   106   212,000
Total operating lease cost $ 119 $ 122 $ 233,000 $ 244,000
XML 73 R65.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Schedule of Maturities of Operating Lease Liabilities (Details)
$ in Thousands
Apr. 30, 2024
USD ($)
Leases [Abstract]  
2024 (remaining) $ 223
2025 456
2026 468
2027 327
2028 303
Thereafter 1,722
Total 3,499
Less: Interest (1,545)
Total Lease liability $ 1,954
XML 74 R66.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Party Transactions - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
Feb. 13, 2024
Apr. 04, 2023
April 2023 Notes    
Related Party Transaction [Line Items]    
Principal amount   $ 8.0
Interest free period   45 days
Interest rate   15.00%
Amount of convertible debentures and warrants   $ 8.0
Maturity date   Jul. 31, 2023
Minimum | April 2023 Notes    
Related Party Transaction [Line Items]    
Aggregate sale of convertible promissory notes, warrants, preferred shares, common shares, or combined thereof   $ 20.0
2024 Subscription Agreements | Private Placement    
Related Party Transaction [Line Items]    
Issuance of common shares 20,000,000  
Common shares price per share $ 10  
2024 PIPE Investors    
Related Party Transaction [Line Items]    
Issuance of common shares 800,000  
Issuance of common shares, value $ 8.0  
XML 75 R67.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events - Additional Information (Details) - 2023 Plan - shares
12 Months Ended
May 15, 2024
Oct. 31, 2023
Subsequent Event [Line Items]    
Increase in number of share reserved for future issuance in the beginning of the year   1,946,226,000,000
Subsequent Event | Evergreen Provision    
Subsequent Event [Line Items]    
Issuance of common shares 2,500,000  
Aggregate number of common shares outstanding percentage 5.00%  
Increase in number of share reserved for future issuance in the beginning of the year 1,946,226,000,000  
EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 279 388 1 false 105 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 100030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) Sheet http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) Statements 3 false false R4.htm 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 100080 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Sheet http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - Description of Business Sheet http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusiness1 Description of Business Notes 9 false false R10.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995475 - Disclosure - Reverse Recapitalization Sheet http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalization Reverse Recapitalization Notes 11 false false R12.htm 995485 - Disclosure - Fair Value Measurements Sheet http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurements1 Fair Value Measurements Notes 12 false false R13.htm 995495 - Disclosure - Property and Equipment, Net Sheet http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNet1 Property and Equipment, Net Notes 13 false false R14.htm 995505 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 14 false false R15.htm 995515 - Disclosure - License Agreement and Clinical Research Organization Sheet http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization License Agreement and Clinical Research Organization Notes 15 false false R16.htm 995525 - Disclosure - Notes Payable Notes http://engene.com/20240430/taxonomy/role/DisclosureNotesPayable1 Notes Payable Notes 16 false false R17.htm 995535 - Disclosure - Convertible Debentures Sheet http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebentures1 Convertible Debentures Notes 17 false false R18.htm 995545 - Disclosure - Redeemable Convertible Preferred Shares Sheet http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredShares Redeemable Convertible Preferred Shares Notes 18 false false R19.htm 995555 - Disclosure - Common Shares Sheet http://engene.com/20240430/taxonomy/role/DisclosureCommonShares1 Common Shares Notes 19 false false R20.htm 995565 - Disclosure - Share-Based Compensation Sheet http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensation Share-Based Compensation Notes 20 false false R21.htm 995575 - Disclosure - Net Loss Per Share Sheet http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 21 false false R22.htm 995585 - Disclosure - Income Taxes Sheet http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 22 false false R23.htm 995595 - Disclosure - Leases Sheet http://engene.com/20240430/taxonomy/role/DisclosureLeases1 Leases Notes 23 false false R24.htm 995605 - Disclosure - Commitments and Contingencies Sheet http://engene.com/20240430/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 24 false false R25.htm 995615 - Disclosure - Related Party Transactions Sheet http://engene.com/20240430/taxonomy/role/RelatedPartyTransactions Related Party Transactions Notes 25 false false R26.htm 995625 - Disclosure - Subsequent Events Sheet http://engene.com/20240430/taxonomy/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 995635 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 995655 - Disclosure - Reverse Recapitalization (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationTables Reverse Recapitalization (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalization 28 false false R29.htm 995665 - Disclosure - Fair Value Measurements (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurements1 29 false false R30.htm 995675 - Disclosure - Property and Equipment, Net (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNet1 30 false false R31.htm 995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 31 false false R32.htm 995695 - Disclosure - Notes Payable (Tables) Notes http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableTables Notes Payable (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureNotesPayable1 32 false false R33.htm 995715 - Disclosure - Common Shares (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesTables Common Shares (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureCommonShares1 33 false false R34.htm 995725 - Disclosure - Share-Based Compensation (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationTables Share-Based Compensation (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensation 34 false false R35.htm 995735 - Disclosure - Net Loss Per Share (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShare 35 false false R36.htm 995755 - Disclosure - Leases (Tables) Sheet http://engene.com/20240430/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://engene.com/20240430/taxonomy/role/DisclosureLeases1 36 false false R37.htm 995765 - Disclosure - Description of Business - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails Description of Business - Additional Information (Details) Details 37 false false R38.htm 995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 38 false false R39.htm 995795 - Disclosure - Reverse Recapitalization -Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails Reverse Recapitalization -Additional Information (Details) Details 39 false false R40.htm 995805 - Disclosure - Reverse Recapitalization - Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails Reverse Recapitalization - Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing (Details) Details 40 false false R41.htm 995815 - Disclosure - Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Details) Details 41 false false R42.htm 995835 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 42 false false R43.htm 995845 - Disclosure - Fair Value Measurements - Summary Of Change In Estimated Fair Value Of Convertible Debentures Embedded Derivative Liabilities (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails Fair Value Measurements - Summary Of Change In Estimated Fair Value Of Convertible Debentures Embedded Derivative Liabilities (Details) Details 43 false false R44.htm 995855 - Disclosure - Fair Value Measurements - Summary of Change in Estimated Fair Value of Warrant Liabilities (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails Fair Value Measurements - Summary of Change in Estimated Fair Value of Warrant Liabilities (Details) Details 44 false false R45.htm 995865 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails Property and Equipment, Net - Summary of Property and Equipment (Details) Details 45 false false R46.htm 995875 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 46 false false R47.htm 995885 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Details 47 false false R48.htm 995895 - Disclosure - License Agreement and Clinical Research Organization - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails License Agreement and Clinical Research Organization - Additional Information (Details) Details 48 false false R49.htm 995905 - Disclosure - Notes Payable - Additional Information (Details) Notes http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails Notes Payable - Additional Information (Details) Details 49 false false R50.htm 995915 - Disclosure - Notes Payable - Schedule of Carrying Value of Term Loan (Details) Notes http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails Notes Payable - Schedule of Carrying Value of Term Loan (Details) Details 50 false false R51.htm 995925 - Disclosure - Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details) Notes http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details) Details 51 false false R52.htm 995935 - Disclosure - Convertible Debentures - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails Convertible Debentures - Additional Information (Details) Details 52 false false R53.htm 995945 - Disclosure - Redeemable Convertible Preferred Shares - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails Redeemable Convertible Preferred Shares - Additional Information (Details) Details 53 false false R54.htm 995955 - Disclosure - Common Shares - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails Common Shares - Additional Information (Details) Details 54 false false R55.htm 995965 - Disclosure - Common Shares - Schedule of Shares Reserved For Future Issuance Under The Plan (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails Common Shares - Schedule of Shares Reserved For Future Issuance Under The Plan (Details) Details 55 false false R56.htm 995975 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 56 false false R57.htm 995985 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details) Details 57 false false R58.htm 995995 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails Share-Based Compensation - Summary of Stock Option Activity (Details) Details 58 false false R59.htm 996005 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails Share-Based Compensation - Summary of Share-based Compensation Expense (Details) Details 59 false false R60.htm 996015 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) Details 60 false false R61.htm 996025 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details) Details 61 false false R62.htm 996035 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 62 false false R63.htm 996045 - Disclosure - Leases - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 63 false false R64.htm 996055 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails Leases - Schedule of Components of Operating Lease Cost (Details) Details 64 false false R65.htm 996075 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails Leases - Schedule of Maturities of Operating Lease Liabilities (Details) Details 65 false false R66.htm 996085 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 66 false false R67.htm 996095 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 67 false false All Reports Book All Reports [dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-Q, CurrentFiscalYearEndDate value, --04-30, should match the Entity Registrant Fiscal Year End Date "10/31" on record within EDGAR. engn-20240430.htm 28 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 - engn-20240430.htm 8 engn-20240430.htm engn-20240430.xsd http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 false false JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "engn-20240430.htm": { "nsprefix": "engn", "nsuri": "http://engene.com/20240430", "dts": { "inline": { "local": [ "engn-20240430.htm" ] }, "schema": { "local": [ "engn-20240430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] } }, "keyStandard": 284, "keyCustom": 104, "axisStandard": 26, "axisCustom": 1, "memberStandard": 25, "memberCustom": 74, "hidden": { "total": 16, "http://fasb.org/us-gaap/2023": 12, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 279, "entityCount": 1, "segmentCount": 105, "elementCount": 824, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 713, "http://xbrl.sec.gov/dei/2023": 34, "http://xbrl.sec.gov/ecd/2023": 12 }, "report": { "R1": { "role": "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R2": { "role": "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R3": { "role": "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "longName": "100030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:PreferredStockNoParValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:PreferredStockNoParValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R4": { "role": "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R5": { "role": "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited", "longName": "100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_e51ec91d-474a-47a4-a7d0-7040f17f586a", "name": "us-gaap:TemporaryEquitySharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_690ca98a-112a-4a72-badf-6a24a185c31f", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R6": { "role": "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "longName": "100080 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R9": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusiness1", "longName": "995455 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R10": { "role": "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R11": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalization", "longName": "995475 - Disclosure - Reverse Recapitalization", "shortName": "Reverse Recapitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ReverseRecapitalizationTextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ReverseRecapitalizationTextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R12": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurements1", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R13": { "role": "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNet1", "longName": "995495 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R14": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995505 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R15": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization", "longName": "995515 - Disclosure - License Agreement and Clinical Research Organization", "shortName": "License Agreement and Clinical Research Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R16": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayable1", "longName": "995525 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R17": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebentures1", "longName": "995535 - Disclosure - Convertible Debentures", "shortName": "Convertible Debentures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ConvertibleDebenturesDisclosuretextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ConvertibleDebenturesDisclosuretextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R18": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredShares", "longName": "995545 - Disclosure - Redeemable Convertible Preferred Shares", "shortName": "Redeemable Convertible Preferred Shares", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R19": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureCommonShares1", "longName": "995555 - Disclosure - Common Shares", "shortName": "Common Shares", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R20": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensation", "longName": "995565 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R21": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShare", "longName": "995575 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R22": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxes", "longName": "995585 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R23": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLeases1", "longName": "995595 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R24": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureCommitmentsAndContingencies", "longName": "995605 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R25": { "role": "http://engene.com/20240430/taxonomy/role/RelatedPartyTransactions", "longName": "995615 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R26": { "role": "http://engene.com/20240430/taxonomy/role/SubsequentEvents", "longName": "995625 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R27": { "role": "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:UnauditedInterimFinancialInformationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:UnauditedInterimFinancialInformationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R28": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationTables", "longName": "995655 - Disclosure - Reverse Recapitalization (Tables)", "shortName": "Reverse Recapitalization (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:SummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:SummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R29": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables", "longName": "995665 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_d12ddd75-e345-406b-83c3-d31fbb25b0c3", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d12ddd75-e345-406b-83c3-d31fbb25b0c3", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R30": { "role": "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "longName": "995675 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R31": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R32": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableTables", "longName": "995695 - Disclosure - Notes Payable (Tables)", "shortName": "Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R33": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesTables", "longName": "995715 - Disclosure - Common Shares (Tables)", "shortName": "Common Shares (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R34": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationTables", "longName": "995725 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R35": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995735 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R36": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLeasesTables", "longName": "995755 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R37": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "longName": "995765 - Disclosure - Description of Business - Additional Information (Details)", "shortName": "Description of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ReverseRecapitalizationExchangeRatio", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "7", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7708f838-8c69-459c-a531-e4afa3468a83", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R38": { "role": "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "longName": "995795 - Disclosure - Reverse Recapitalization -Additional Information (Details)", "shortName": "Reverse Recapitalization -Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_a942b16a-a12f-4f19-a9b5-a7c9aaa5929a", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dfc0684d-4ea4-4d5e-85da-a3d508bc4c24", "name": "engn:ProceedsFromTrustAccount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R40": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails", "longName": "995805 - Disclosure - Reverse Recapitalization - Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing (Details)", "shortName": "Reverse Recapitalization - Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_7c07c5fd-6f47-42fc-851d-3b45dc5421e9", "name": "engn:ProceedsFromTrustAccount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7c07c5fd-6f47-42fc-851d-3b45dc5421e9", "name": "engn:TransactionCostWithheldFromProceedsReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R41": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails", "longName": "995815 - Disclosure - Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Details)", "shortName": "Reverse Recapitalization - Summary of Number of Common Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "engn:CommonStockOutstandingAfterReverseRecapitalizationAndPipeFinancing", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "div", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "engn:CommonStockOutstandingAfterReverseRecapitalizationAndPipeFinancing", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "div", "engn:ReverseRecapitalizationTextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R42": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "995835 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R43": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails", "longName": "995845 - Disclosure - Fair Value Measurements - Summary Of Change In Estimated Fair Value Of Convertible Debentures Embedded Derivative Liabilities (Details)", "shortName": "Fair Value Measurements - Summary Of Change In Estimated Fair Value Of Convertible Debentures Embedded Derivative Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_7063eaf8-02da-4fb6-8495-5468224bcc0a", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e3a8c7a3-1f55-4c9e-97a5-3171c47df168", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R44": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "longName": "995855 - Disclosure - Fair Value Measurements - Summary of Change in Estimated Fair Value of Warrant Liabilities (Details)", "shortName": "Fair Value Measurements - Summary of Change in Estimated Fair Value of Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_c71329b7-f78f-43e4-be17-4b2c40dc39a9", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8dbad426-5375-452b-a0d7-a974233ddac3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R45": { "role": "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "longName": "995865 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)", "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R46": { "role": "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "longName": "995875 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "shortName": "Property and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R47": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "995885 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "engn:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "engn:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R48": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails", "longName": "995895 - Disclosure - License Agreement and Clinical Research Organization - Additional Information (Details)", "shortName": "License Agreement and Clinical Research Organization - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_e796eced-e4da-4f88-b425-adb188c18ddd", "name": "us-gaap:CostMaintenance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e796eced-e4da-4f88-b425-adb188c18ddd", "name": "us-gaap:CostMaintenance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R49": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "longName": "995905 - Disclosure - Notes Payable - Additional Information (Details)", "shortName": "Notes Payable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_49f25209-961e-4156-a910-015e27451848", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_CanadaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R50": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails", "longName": "995915 - Disclosure - Notes Payable - Schedule of Carrying Value of Term Loan (Details)", "shortName": "Notes Payable - Schedule of Carrying Value of Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_b33d45f1-38e4-410f-90c0-9a2a7ff177e3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b33d45f1-38e4-410f-90c0-9a2a7ff177e3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R51": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails", "longName": "995925 - Disclosure - Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)", "shortName": "Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_14ff044d-1f1a-4eb8-9901-2d9595de772f", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_14ff044d-1f1a-4eb8-9901-2d9595de772f", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R52": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "longName": "995935 - Disclosure - Convertible Debentures - Additional Information (Details)", "shortName": "Convertible Debentures - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_c3fe2041-cf99-4e6e-b5e2-5fe0779301b7", "name": "engn:DebtInstrumentInitialMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "engn:ConvertibleDebenturesDisclosuretextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c3fe2041-cf99-4e6e-b5e2-5fe0779301b7", "name": "engn:DebtInstrumentInitialMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "engn:ConvertibleDebenturesDisclosuretextblock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R53": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "longName": "995945 - Disclosure - Redeemable Convertible Preferred Shares - Additional Information (Details)", "shortName": "Redeemable Convertible Preferred Shares - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_db37e2e8-3610-48f8-81cd-f45876e38b1d", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R54": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "longName": "995955 - Disclosure - Common Shares - Additional Information (Details)", "shortName": "Common Shares - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:CommonStockNoParValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_76874e60-e152-4be3-8600-5935045c6246", "name": "us-gaap:CommonStockNoParValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R55": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "longName": "995965 - Disclosure - Common Shares - Schedule of Shares Reserved For Future Issuance Under The Plan (Details)", "shortName": "Common Shares - Schedule of Shares Reserved For Future Issuance Under The Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e9c4f03-efdf-4b91-a3f3-94e2722497a9", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R56": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "longName": "995975 - Disclosure - Share-Based Compensation - Additional Information (Details)", "shortName": "Share-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "engn:ReverseRecapitalizationExchangeRatio", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "7", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_81fac89f-0bec-488e-a7f8-3e935d19d211", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R57": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails", "longName": "995985 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)", "shortName": "Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_b44da044-3907-46f7-a888-55f93976dc64", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_385d0a3f-06eb-4540-84aa-fff7f967c919", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R58": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails", "longName": "995995 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_a942b16a-a12f-4f19-a9b5-a7c9aaa5929a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7b00ba37-3bdb-494c-a032-27274ae13ce7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R59": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails", "longName": "996005 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Summary of Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_37ae8de9-caa4-41c6-9f4d-296b9e474647", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R60": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "longName": "996015 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9a02639f-5b91-49e1-90b0-426c4507858d", "name": "us-gaap:AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R61": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "longName": "996025 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)", "shortName": "Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R62": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996035 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996045 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6ab66677-343f-4fe7-8eff-26073e25701d", "name": "engn:AreaOfSpace", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R64": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails", "longName": "996055 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Details)", "shortName": "Leases - Schedule of Components of Operating Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_768e5192-aa40-443e-b298-078a1d896286", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R65": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "longName": "996075 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)", "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8a7c1f0d-c989-44cf-94bd-cc5756595907", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true, "unique": true } }, "R66": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "996085 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_f2922d06-f00f-4528-9954-0914a67ca2aa", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_81fae290-d964-4181-bcc4-f4f9eb0f422d", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } }, "R67": { "role": "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996095 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_b57303d7-7c6d-43e1-8126-6196116e4f05", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e17ee35c-a604-4a45-b731-7744e38c8693", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "engn-20240430.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201912Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201912Member", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "ASU-2019-12", "label": "Accounting Standards Update 2019-12 [Member]", "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." } } }, "auth_ref": [ "r464", "r465", "r466", "r467" ] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate202006Member", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2020-06", "label": "Accounting Standards Update 2020-06 [Member]", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "us-gaap_AccountingStandardsUpdate202110Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate202110Member", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2021-10", "label": "Accounting Standards Update 2021-10 [Member]", "documentation": "Accounting Standards Update 2021-10 Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance." } } }, "auth_ref": [ "r541", "r542" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued Expenses and Other Current Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28", "r795" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income tax payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r105", "r153" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total accrued expenses and other current liabilities", "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34" ] }, "engn_AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expenses", "label": "Accrued Research And Development Expense Current", "documentation": "Accrued research and development expenses current." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "terseLabel": "Less: Accumulated depreciation and amortization", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r59", "r188", "r638" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r42", "r43", "r114", "r195", "r634", "r654", "r658" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r16", "r43", "r492", "r495", "r567", "r649", "r650", "r906", "r907", "r908", "r917", "r918", "r919" ] }, "engn_AcquirerAxis": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "AcquirerAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Acquirer [Axis]", "documentation": "Acquirer." } } }, "auth_ref": [] }, "engn_AcquirerDomain": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AcquirerDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Acquirer [Domain]", "documentation": "Acquirer." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r850" ] }, "engn_AdditionalAwardsApprovedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "AdditionalAwardsApprovedForIssuance", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional awards approved for issuance", "label": "Additional Awards Approved For Issuance", "documentation": "Additional awards approved for issuance." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r109" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r443", "r444", "r445", "r671", "r917", "r918", "r919", "r964", "r990" ] }, "engn_AdditionalReservesOfCommonStockForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "AdditionalReservesOfCommonStockForIssuance", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional reserves of common stock for issuance", "label": "Additional reserves of common stock for issuance", "documentation": "Additional reserves of common stock for issuance." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r856" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r856" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r856" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r856" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r178", "r179", "r180", "r181", "r182", "r224", "r225", "r226", "r227", "r237", "r277", "r278", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r332", "r443", "r444", "r445", "r464", "r465", "r466", "r467", "r475", "r476", "r477", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r523", "r524", "r528", "r529", "r530", "r531", "r541", "r542", "r545", "r546", "r547", "r548", "r563", "r564", "r565", "r566", "r567", "r610", "r611", "r612", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of warrants in connection with Amended Term Loan", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r17", "r61", "r138" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "engn_AdvanceOnLoanAllocatedToWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "AdvanceOnLoanAllocatedToWarrants", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Advance on loan allocated to warrants.", "label": "Advance on Loan Allocated to Warrants.", "terseLabel": "Advance on loan allocated to warrants" } } }, "auth_ref": [] }, "engn_AggregateAmountOfBaseRentalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "AggregateAmountOfBaseRentalPayments", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount of base rental payments", "label": "Aggregate Amount Of Base Rental Payments", "documentation": "Aggregate amount of base rental payments." } } }, "auth_ref": [] }, "engn_AggregateSaleOfConvertiblePromissoryNotesWarrantsPreferredSharesCommonSharesOrCombinedThereof": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "AggregateSaleOfConvertiblePromissoryNotesWarrantsPreferredSharesCommonSharesOrCombinedThereof", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate sale of convertible promissory notes, warrants, preferred shares, common shares, or combined thereof", "label": "Aggregate Sale Of Convertible Promissory Notes Warrants Preferred Shares Common Shares Or Combined Thereof", "documentation": "Aggregate sale of convertible promissory notes warrants preferred shares common shares or combined thereof." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r820", "r832", "r842", "r868" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r823", "r835", "r845", "r871" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r856" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r863" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r827", "r836", "r846", "r863", "r872", "r876", "r884" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r882" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total share-based compensation expense", "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r437", "r451" ] }, "engn_AmendedEmploymentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AmendedEmploymentAgreementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Employment Agreement", "label": "Amended Employment Agreement [Member]", "documentation": "Amended Employment Agreement." } } }, "auth_ref": [] }, "engn_AmendedLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AmendedLoanAgreementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Loan Agreement", "label": "Amended Loan Agreement [Member]", "documentation": "Amended loan agreement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r11", "r94", "r121", "r371" ] }, "us-gaap_AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividend attributable to redeemable convertible preferred shareholders", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, ESOP Convertible Preferred Stock", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of convertible preferred stock of an employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r921" ] }, "engn_AmountOfMonthlyFeeForConsultingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "AmountOfMonthlyFeeForConsultingPeriod", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of monthly fee for consulting period.", "label": "Amount Of Monthly Fee For Consulting Period", "terseLabel": "Amount of monthly fee for consulting period" } } }, "auth_ref": [] }, "engn_AnnualMaintenanceFeeUnderLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "AnnualMaintenanceFeeUnderLicenseAgreement", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses related to the annual maintenance fee", "label": "Annual Maintenance Fee Under License Agreement", "documentation": "Annual maintenance fee under license agreement" } } }, "auth_ref": [] }, "engn_AnthonyCheungMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AnthonyCheungMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Anthony Cheung", "label": "Anthony Cheung [Member]", "documentation": "Anthony cheung." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares excluded from computation of diluted net loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r253" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r53" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r53" ] }, "engn_AppliedToRefinanceOfAmountOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AppliedToRefinanceOfAmountOutstandingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applied to Refinance of Amount Outstanding", "label": "Applied to Refinance of Amount Outstanding [Member]", "documentation": "Applied to refinance of amount outstanding." } } }, "auth_ref": [] }, "engn_AprilTwentyTwentyThreeNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AprilTwentyTwentyThreeNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Notes", "label": "April Twenty Twenty Three Notes [Member]", "documentation": "April Twenty Twenty Three Notes Member." } } }, "auth_ref": [] }, "engn_AprilTwoZeroTwoThreeNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "AprilTwoZeroTwoThreeNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Notes", "label": "April Two Zero Two Three Notes [Member]", "documentation": "April two zero two three notes." } } }, "auth_ref": [] }, "engn_AreaOfSpace": { "xbrltype": "areaItemType", "nsuri": "http://engene.com/20240430", "localname": "AreaOfSpace", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Area of office space", "terseLabel": "Rentable square feet", "label": "Area Of Space", "documentation": "Area of space." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r478" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r151", "r191", "r215", "r260", "r272", "r274", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r480", "r484", "r526", "r629", "r707", "r795", "r807", "r932", "r933", "r975" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total current assets", "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r184", "r196", "r215", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r480", "r484", "r526", "r795", "r932", "r933", "r975" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure, Total", "terseLabel": "Financial assets, fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r91" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r813", "r815", "r828" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r813", "r815", "r828" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r813", "r815", "r828" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r879" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r880" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r875" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r875" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r875" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r875" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r875" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r875" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r878" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r877" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r876" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r83", "r87" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "engn_BdcNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "BdcNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BDC Notes", "label": "BDC Notes [Member]", "documentation": "BDC Notes Member." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r474", "r786", "r787" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r80", "r82", "r474", "r786", "r787" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merger agreement date", "label": "Business Acquisition, Date of Acquisition Agreement", "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination reverse recapitalization description", "label": "Business Acquisition, Description of Acquired Entity", "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information." } } }, "auth_ref": [ "r81" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusiness1" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r103", "r127", "r128" ] }, "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Transaction Costs", "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs." } } }, "auth_ref": [ "r159", "r160" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r162", "r630", "r682", "r702", "r795", "r807", "r902" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r48", "r186", "r769" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r48", "r124", "r211" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r124" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r902", "r985" ] }, "engn_CashWarrantExercisesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "CashWarrantExercisesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Warrant Exercises", "label": "Cash Warrant Exercises [Member]", "documentation": "Cash warrant exercises." } } }, "auth_ref": [] }, "engn_CashlessWarrantExercisesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "CashlessWarrantExercisesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cashless warrant exercises.", "label": "Cashless Warrant Exercises [Member]", "terseLabel": "Cashless Warrant Exercises" } } }, "auth_ref": [] }, "engn_CeoTransitionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "CeoTransitionAgreementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "CEO Transition Agreement.", "label": "CEO Transition Agreement [Member]", "terseLabel": "CEO Transition Agreement" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r172", "r173", "r174", "r178", "r179", "r223", "r277", "r278", "r310", "r311", "r312", "r318", "r319", "r332", "r464", "r475", "r476", "r486", "r487", "r488", "r500", "r501", "r511", "r523", "r524", "r527", "r528", "r529", "r541", "r545", "r546", "r547", "r563", "r610", "r611", "r647", "r648" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r172", "r173", "r174", "r178", "r179", "r277", "r278", "r310", "r311", "r312", "r318", "r319", "r320", "r332", "r464", "r475", "r476", "r477", "r486", "r487", "r488", "r489", "r500", "r501", "r502", "r505", "r511", "r523", "r524", "r527", "r528", "r529", "r541", "r545", "r546", "r547", "r563", "r610", "r611", "r647", "r648", "r893" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": [ "r171", "r224", "r236", "r315", "r468" ] }, "engn_ChangeInFairValueOfConvertibleDebentureEmbeddedDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ChangeInFairValueOfConvertibleDebentureEmbeddedDerivativeLiabilities", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of convertible debenture embedded derivative liabilities", "terseLabel": "Change in fair value of convertible debenture embedded derivative liabilities", "label": "Change In Fair Value Of Convertible Debenture Embedded Derivative Liabilities", "documentation": "Change in fair value of convertible debenture embedded derivative liabilities." } } }, "auth_ref": [] }, "engn_ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilities", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of convertible debentures embedded derivative liabilities", "terseLabel": "Change in fair value of convertible debentures embedded derivative liabilities", "label": "Change In Fair Value Of Convertible Debentures Embedded Derivative Liabilities", "documentation": "Change in fair value of convertible debentures embedded derivative liabilities." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r854" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "CEO" } } }, "auth_ref": [ "r922" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "engn_ClassAInitialClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassAInitialClosingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Initial Closing", "label": "Class A Initial Closing [Member]", "documentation": "Class A initial closing." } } }, "auth_ref": [] }, "engn_ClassARedeemableConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassARedeemableConvertiblePreferredSharesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Redeemable Convertible Preferred Shares", "label": "Class A Redeemable Convertible Preferred Shares [Member]", "documentation": "Class a redeemable convertible preferred shares." } } }, "auth_ref": [] }, "engn_ClassASecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassASecondTrancheMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Second Tranche", "label": "Class A Second Tranche [Member]", "documentation": "Class a second tranche." } } }, "auth_ref": [] }, "engn_ClassB1RedeemableConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassB1RedeemableConvertiblePreferredSharesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B-1 Redeemable Convertible Preferred Shares", "label": "Class B-1 Redeemable Convertible Preferred Shares [Member]", "documentation": "Class b-1 redeemable convertible preferred shares." } } }, "auth_ref": [] }, "engn_ClassBInitialClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassBInitialClosingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Intial Closing", "label": "Class B Initial Closing [Member]", "documentation": "Class B initial closing." } } }, "auth_ref": [] }, "engn_ClassBRedeemableConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassBRedeemableConvertiblePreferredSharesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Redeemable Convertible Preferred Shares", "label": "Class B Redeemable Convertible Preferred Shares [Member]", "documentation": "Class b redeemable convertible preferred shares." } } }, "auth_ref": [] }, "engn_ClassBSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassBSecondTrancheMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Second Tranche", "label": "Class B Second Tranche [Member]", "documentation": "Class b second tranche." } } }, "auth_ref": [] }, "engn_ClassBThirdTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassBThirdTrancheMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Third Tranche", "label": "Class B Third Tranche [Member]", "documentation": "Class b third tranche." } } }, "auth_ref": [] }, "engn_ClassCInitialClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassCInitialClosingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Inital Closing", "label": "Class C Initial Closing [Member]", "documentation": "Class C initial closing." } } }, "auth_ref": [] }, "engn_ClassCRedeemableConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassCRedeemableConvertiblePreferredSharesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Redeemable Convertible Preferred Shares", "label": "Class C Redeemable Convertible Preferred Shares [Member]", "documentation": "Class C redeemable convertible preferred shares." } } }, "auth_ref": [] }, "engn_ClassCSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassCSecondTrancheMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Second Tranche", "label": "Class C Second Tranche [Member]", "documentation": "Class c second tranche." } } }, "auth_ref": [] }, "engn_ClassCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassCWarrantsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Warrants", "label": "Class C Warrants [Member]", "documentation": "Class C Warrants." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r177", "r192", "r193", "r194", "r215", "r242", "r243", "r250", "r252", "r258", "r259", "r309", "r340", "r342", "r343", "r344", "r347", "r348", "r382", "r383", "r387", "r390", "r398", "r526", "r661", "r662", "r663", "r664", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r694", "r718", "r741", "r758", "r759", "r760", "r761", "r762", "r892", "r913", "r920" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r192", "r193", "r194", "r258", "r382", "r383", "r385", "r387", "r390", "r396", "r398", "r661", "r662", "r663", "r664", "r785", "r892", "r913" ] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r71", "r72", "r73", "r74" ] }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiring term of warrants", "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable", "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, exercise price per share", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share warrants issued", "terseLabel": "Number of securities into which the class of warrant or right may be converted", "label": "Warrant issued to purchase preferred shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercisable period", "label": "Class Of Warrant Or Right Year From Which Warrants Or Rights Exercisable", "documentation": "Class of warrant or right year from which warrants or rights exercisable." } } }, "auth_ref": [] }, "engn_ClassOfWarrantOrRightsNumberOfDaysFromWhichWarrantsOrRightsExercisable": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "ClassOfWarrantOrRightsNumberOfDaysFromWhichWarrantsOrRightsExercisable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercisable period", "label": "Class Of Warrant Or Rights Number Of Days From Which Warrants Or Rights Exercisable", "documentation": "Class of warrant or rights number of days from which warrants or rights exercisable." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r855" ] }, "engn_CommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "CommitmentAmount", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total commitment amount", "label": "Commitment Amount", "documentation": "Commitment amount." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r132", "r334", "r335", "r766", "r931" ] }, "engn_CommonShareAndPreferredShareWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonShareAndPreferredShareWarrantsPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Common Share and Preferred Share Warrants", "label": "Common Share And Preferred Share Warrants [Policy Text Block]", "documentation": "Common share and preferred share warrants." } } }, "auth_ref": [] }, "engn_CommonShareOptionsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonShareOptionsIssued", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common share options issued", "label": "Common Share Options Issued", "documentation": "Common Share Options Issued" } } }, "auth_ref": [] }, "engn_CommonSharesAndCommonShareWarrantsIssuedUponReverseRecapitalizationAndPipeFinancingShares": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonSharesAndCommonShareWarrantsIssuedUponReverseRecapitalizationAndPipeFinancingShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares and common share warrants issued upon Reverse Recapitalization and PIPE Financing, net of issuance costs of $11.1 million (in shares)", "label": "Common Shares and Common Share Warrants Issued Upon Reverse Recapitalization and Pipe Financing Shares", "documentation": "Common shares and common share warrants issued upon reverse recapitalization and pipe financing shares." } } }, "auth_ref": [] }, "engn_CommonSharesAndCommonShareWarrantsIssuedUponReverseRecapitalizationAndPipeFinancingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonSharesAndCommonShareWarrantsIssuedUponReverseRecapitalizationAndPipeFinancingValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares and common share warrants issued upon Reverse Recapitalization and PIPE Financing, net of issuance costs of $11.1 million", "label": "Common Shares and Common Share Warrants Issued Upon Reverse Recapitalization and Pipe Financing Value", "documentation": "Common shares and common share warrants issued upon reverse recapitalization and pipe financing value." } } }, "auth_ref": [] }, "engn_CommonSharesIssuedToPipeInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonSharesIssuedToPipeInvestorsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares Issued to Pipe Investors", "label": "Common Shares Issued to Pipe Investors [Member]", "documentation": "Common shares issued to pipe investors." } } }, "auth_ref": [] }, "engn_CommonSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonSharesPercentage", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate number of common shares outstanding percentage", "label": "Common Shares Percentage", "documentation": "Common shares percentage." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock shares reserved for future issuance", "terseLabel": "Aggregate number of common shares reserved for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r39" ] }, "engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonStockCapitalSharesReservedForRemainingFutureIssuance", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock capital shares reserved for remaining future issuance", "label": "Common Stock Capital Shares Reserved for Remaining Future Issuance", "documentation": "Common stock capital shares reserved for remaining future issuance." } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend paid", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r138" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r138" ] }, "engn_CommonStockIssuedRedemptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonStockIssuedRedemptionPrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued redemption price", "label": "Common Stock Issued Redemption Price", "documentation": "Common stock issued redemption price." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r797", "r798", "r799", "r801", "r802", "r803", "r804", "r917", "r918", "r964", "r986", "r990" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNoParValue", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock no par value", "label": "Common Stock, No Par Value", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r108" ] }, "engn_CommonStockOutstandingAfterReverseRecapitalizationAndPipeFinancing": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "CommonStockOutstandingAfterReverseRecapitalizationAndPipeFinancing", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing", "label": "Common Stock Outstanding After Reverse Recapitalization and PIPE Financing", "documentation": "Common stock outstanding after reverse recapitalization and pipe financing." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock Par Or Stated Value Per Share", "verboseLabel": "Common shares price per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorizedUnlimited", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares authorized unlimited", "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]", "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r108", "r694", "r713", "r990", "r991" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, no par value; unlimited shares authorized, 44,158,587 and 23,197,976 shares issued and outstanding as of April 30, 2024 and October 31, 2023, respectively.", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r108", "r632", "r795" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockVotingRights", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock voting rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r67" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r860" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r859" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r861" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r858" ] }, "engn_CompanyShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "CompanyShareholdersMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company Shareholders", "label": "Company Shareholders [Member]", "documentation": "Company shareholders member." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Risk of Concentrations of Credit and Off-Balance Sheet Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r101", "r165" ] }, "engn_ConversionAndExchangeOfOldConvertibleDebenturesAndCommonShareWarrantsIntoNewCommonSharesAndCommonShareWarrantsInConnectionWithReverseRecapitalizationShares": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "ConversionAndExchangeOfOldConvertibleDebenturesAndCommonShareWarrantsIntoNewCommonSharesAndCommonShareWarrantsInConnectionWithReverseRecapitalizationShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion and exchange of Old enGene convertible debentures and common share warrants into enGene Holdings common shares and common share warrants in connection with the Reverse Recapitalization (in shares)", "label": "Conversion and Exchange of Old Convertible Debentures and Common Share Warrants Into New Common Shares and Common Share Warrants in Connection With Reverse Recapitalization Shares", "documentation": "Conversion and exchange of old convertible debentures and common share warrants into new common shares and common share warrants in connection with reverse recapitalization shares." } } }, "auth_ref": [] }, "engn_ConversionAndExchangeOfOldConvertibleDebenturesAndCommonShareWarrantsIntoNewCommonSharesAndCommonShareWarrantsInConnectionWithReverseRecapitalizationValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ConversionAndExchangeOfOldConvertibleDebenturesAndCommonShareWarrantsIntoNewCommonSharesAndCommonShareWarrantsInConnectionWithReverseRecapitalizationValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion and exchange of Old enGene convertible debentures and common share warrants into enGene Holdings common shares and common share warrants in connection with the Reverse Recapitalization", "label": "Conversion and Exchange of Old Convertible Debentures and Common Share Warrants Into New Common Shares and Common Share Warrants in Connection With Reverse Recapitalization Value", "documentation": "Conversion and exchange of old convertible debentures and common share warrants into new common shares and common share warrants in connection with reverse recapitalization value." } } }, "auth_ref": [] }, "engn_ConversionAndExchangeOfTemporaryEquityIntoCommonSharesInConnectionWithReverseRecapitalizationShares": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "ConversionAndExchangeOfTemporaryEquityIntoCommonSharesInConnectionWithReverseRecapitalizationShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion and exchange of redeemable convertible preferred shares into common shares in connection with the Reverse Recapitalization (in shares)", "label": "Conversion and Exchange of Temporary Equity Into Common Shares in Connection With Reverse Recapitalization Shares", "documentation": "Conversion and exchange of temporary equity into common shares in connection with reverse recapitalization shares." } } }, "auth_ref": [] }, "engn_ConversionAndExchangeOfTemporaryEquityIntoCommonSharesInConnectionWithReverseRecapitalizationValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ConversionAndExchangeOfTemporaryEquityIntoCommonSharesInConnectionWithReverseRecapitalizationValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion and exchange of redeemable convertible preferred shares into common shares in connection with the Reverse Recapitalization", "label": "Conversion and Exchange of Temporary Equity Into Common Shares in Connection With Reverse Recapitalization Value", "documentation": "Conversion and exchange of temporary equity into common shares in connection with reverse recapitalization value." } } }, "auth_ref": [] }, "engn_ConvertibleDebentureEmbeddedDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ConvertibleDebentureEmbeddedDerivativeLiabilities", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debenture embedded derivative liabilities", "label": "Convertible Debenture Embedded Derivative Liabilities", "documentation": "Convertible Debenture Embedded Derivative Liabilities" } } }, "auth_ref": [] }, "engn_ConvertibleDebenturesAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ConvertibleDebenturesAndWarrants", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of convertible debentures and warrants", "label": "Convertible Debentures And Warrants", "documentation": "Convertible debentures and warrants." } } }, "auth_ref": [] }, "engn_ConvertibleDebenturesDisclosuretextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "ConvertibleDebenturesDisclosuretextblock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebentures1" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debentures", "label": "Convertible Debentures DisclosureTextBlock", "documentation": "Convertible Debentures." } } }, "auth_ref": [] }, "engn_ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Notes and BDC Notes", "label": "Convertible Debentures Embedded Derivative Liabilities for 2022 Notes and BDC Notes [Member]", "documentation": "Convertible debentures embedded derivative liabilities for 2022 notes and BDC notes" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total Convertible debentures", "totalLabel": "Convertible Debt, Total", "terseLabel": "Convertible debt", "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r25", "r154", "r984" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Outstanding Principal, Accrued Interest and Unamortized Deferred Financing Costs of Convertible Debentures Recorded on Balance Sheet", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "engn_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ConvertibleNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes - Common Shares issued", "verboseLabel": "Convertible Notes", "label": "Convertible Notes [Member]", "documentation": "Convertible notes." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Convertible Notes Payable, Total", "terseLabel": "Convertible notes net", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r25", "r154", "r984" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, as converted", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r382", "r383", "r387", "r801", "r802", "r803", "r804" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount of shares exchanged", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r26", "r67", "r107", "r136", "r393" ] }, "us-gaap_CostMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostMaintenance", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual maintenance fee", "label": "Cost, Maintenance", "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered." } } }, "auth_ref": [ "r909" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r217", "r218", "r353", "r385", "r573", "r770", "r772" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "engn_DateOfClosedPrivatePlacement": { "xbrltype": "dateItemType", "nsuri": "http://engene.com/20240430", "localname": "DateOfClosedPrivatePlacement", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Date of closed private placement.", "label": "Date of Closed Private Placement", "terseLabel": "Date of closed private placement" } } }, "auth_ref": [] }, "engn_DebentureMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "DebentureMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture", "label": "Debenture [Member]", "documentation": "Debenture member." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in exchange of debt instrument", "label": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayable1" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r133", "r213", "r349", "r355", "r356", "r357", "r358", "r359", "r360", "r365", "r372", "r373", "r375" ] }, "engn_DebtInstrumentAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtInstrumentAccruedInterest", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Debt Instrument, Accrued Interest", "documentation": "Debt instrument, accrued interest." } } }, "auth_ref": [] }, "engn_DebtInstrumentAccruedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtInstrumentAccruedInterestRate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest percentage", "label": "Debt Instrument Accrued Interest Rate", "documentation": "Debt instrument accrued interest rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r25", "r104", "r105", "r152", "r154", "r219", "r350", "r351", "r352", "r353", "r354", "r356", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r544", "r780", "r781", "r782", "r783", "r784", "r914" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt instrument, basis spread on variable rate", "terseLabel": "Term loan annual interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable, including End of Term Charge", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r25", "r154", "r376" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal amount", "terseLabel": "Term loans aggregate principal amount", "label": "Borrowed amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r95", "r97", "r350", "r544", "r781", "r782" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Instrument, Fair Value Disclosure, Total", "terseLabel": "Fair value of debt instrument", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r363", "r525", "r781", "r782" ] }, "engn_DebtInstrumentInitialMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtInstrumentInitialMaturityDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial maturity date", "label": "Debt Instrument Initial Maturity Date", "documentation": "Debt instrument initial maturity date." } } }, "auth_ref": [] }, "engn_DebtInstrumentInitialMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtInstrumentInitialMaturityPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial maturity period", "label": "Debt Instrument Initial Maturity Period", "documentation": "Debt instrument initial maturity period." } } }, "auth_ref": [] }, "engn_DebtInstrumentInitialMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtInstrumentInitialMaturityTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial maturity term", "label": "Debt Instrument Initial Maturity Term", "documentation": "Debt instrument initial maturity term." } } }, "auth_ref": [] }, "engn_DebtInstrumentInterestFreePeriod": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtInstrumentInterestFreePeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest free period", "label": "Debt Instrument Interest Free Period", "documentation": "Debt instrument interest free period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt instrument, interest rate", "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r36", "r95", "r368" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate of outstanding debt", "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r36", "r95", "r379", "r544" ] }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateIncreaseDecrease", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan reduced annual interest rate", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Accrue interest rate percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r36", "r351" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes purchase principal amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r661" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r219", "r350", "r351", "r352", "r353", "r354", "r356", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r374", "r544", "r780", "r781", "r782", "r783", "r784", "r914" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Term loan maturity date", "terseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r176", "r780", "r966" ] }, "us-gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMeasurementInput", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value debt inputs measurement input", "label": "Debt Instrument, Measurement Input", "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt." } } }, "auth_ref": [ "r517" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r37", "r219", "r350", "r351", "r352", "r353", "r354", "r356", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r544", "r780", "r781", "r782", "r783", "r784", "r914" ] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r664" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r37", "r67", "r70", "r94", "r95", "r97", "r100", "r135", "r137", "r219", "r350", "r351", "r352", "r353", "r354", "r356", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r374", "r544", "r780", "r781", "r782", "r783", "r784", "r914" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt discount, net of accretion", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r94", "r97", "r935" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total", "terseLabel": "Debt discount and issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r96", "r361", "r377", "r781", "r782" ] }, "engn_DebtIssuanceCostsExpensedUponIssuanceOfDebtRecordedAtTheFairValueOption": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtIssuanceCostsExpensedUponIssuanceOfDebtRecordedAtTheFairValueOption", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs expensed upon issuance of debt recorded at the fair value option", "label": "Debt Issuance Costs Expensed upon Issuance of Debt Recorded at the Fair Value Option", "documentation": "Debt issuance costs expensed upon issuance of debt recorded at the fair value option." } } }, "auth_ref": [] }, "engn_DebtIssuanceCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "DebtIssuanceCostsPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Issuance Costs", "label": "Debt Issuance Costs [Policy Text Block]", "documentation": "Debt issuance costs." } } }, "auth_ref": [] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debentures", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Costs, Total", "terseLabel": "Deferred transaction costs", "label": "Deferred Costs", "documentation": "The carrying amount of deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Issuance Costs, Net, Total", "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r96", "r935" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation of property and equipment", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r58" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Total", "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r263" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r684", "r686", "r699", "r700", "r701", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r729", "r730", "r731", "r732", "r735", "r736", "r737", "r738", "r753", "r754", "r755", "r756", "r797", "r799" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r84", "r86", "r88", "r89", "r684", "r686", "r699", "r700", "r701", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r729", "r730", "r731", "r732", "r735", "r736", "r737", "r738", "r753", "r754", "r755", "r756", "r772", "r797", "r799" ] }, "us-gaap_DerivativesEmbeddedDerivatives": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesEmbeddedDerivatives", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debenture Embedded Derivative Liabilities", "label": "Derivatives, Embedded Derivatives [Policy Text Block]", "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts." } } }, "auth_ref": [ "r0", "r3", "r4", "r5" ] }, "engn_DescriptionOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "DescriptionOfBusinessLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Description of Business [Line Items]", "documentation": "Description of business." } } }, "auth_ref": [] }, "engn_DescriptionOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "DescriptionOfBusinessTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Description of Business [Table]", "documentation": "Description of business." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r404", "r407", "r438", "r439", "r442", "r789" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r813", "r815", "r828", "r864" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r814" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r849" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r810" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Net loss per share of common shares, basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r204", "r228", "r229", "r230", "r231", "r232", "r239", "r242", "r250", "r251", "r252", "r256", "r509", "r510", "r626", "r644", "r773" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "terseLabel": "Net loss per share of common shares, diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r204", "r228", "r229", "r230", "r231", "r232", "r242", "r250", "r251", "r252", "r256", "r509", "r510", "r626", "r644", "r773" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r53", "r54" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r238", "r253", "r254", "r255" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r533" ] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Embedded derivative liability measured at fair value", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r85" ] }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debentures Embedded Derivative Liabilities", "label": "Embedded Derivative Financial Instruments [Member]", "documentation": "Derivative instrument embedded in host contract." } } }, "auth_ref": [] }, "engn_EmployeeEntitledBaseSalaryContinuationAfterTerminationForPeriod": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "EmployeeEntitledBaseSalaryContinuationAfterTerminationForPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee entitled base salary continuation after termination for a period", "label": "Employee Entitled Base Salary Continuation After Termination For Period", "documentation": "Employee entitled base salary continuation after termination for period." } } }, "auth_ref": [] }, "engn_EmployeeEntitledBaseSalaryContinuationInCaseOfChangeInControlAfterTerminationForPeriod": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "EmployeeEntitledBaseSalaryContinuationInCaseOfChangeInControlAfterTerminationForPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee entitled base salary continuation in case of change in control after termination for a period", "label": "Employee Entitled Base Salary Continuation In Case Of Change in Control After Termination For Period", "documentation": "Employee entitled base salary continuation in case of change in control after termination for period." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee compensation and related benefits", "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r441" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense weighted-average period of recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r441" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Options to purchase common shares", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "engn_EndOfTermCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "EndOfTermCharge", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of term charge", "label": "End of Term Charge", "documentation": "End of term charge." } } }, "auth_ref": [] }, "engn_EndOfTermFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "EndOfTermFeePercentage", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of term fee percentage", "label": "End of Term Fee Percentage", "documentation": "End of term fee percentage." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r812" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "CIK", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r809" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Entities", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r809" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r891" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r809" ] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of incorporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r889" ] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r809" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r809" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r809" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r809" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r890" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingParentheticalDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r180", "r200", "r201", "r202", "r220", "r221", "r222", "r225", "r233", "r235", "r257", "r314", "r321", "r400", "r443", "r444", "r445", "r466", "r467", "r490", "r492", "r493", "r494", "r495", "r497", "r508", "r534", "r535", "r536", "r537", "r538", "r539", "r567", "r649", "r650", "r651", "r671", "r741" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r857" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r820", "r832", "r842", "r868" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r817", "r829", "r839", "r865" ] }, "engn_EvergreenProvisionMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "EvergreenProvisionMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Evergreen Provision", "label": "Evergreen Provision [Member]", "documentation": "Evergreen provision." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r863" ] }, "engn_FEACMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "FEACMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "FEAC", "label": "FEAC [Member]", "documentation": "FEAC.", "terseLabel": "FEAC" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r2", "r11" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r513", "r514", "r520" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r513", "r514", "r520" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions Used to Determine Fair Value of Liabilities", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r18" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Change in Estimated Fair Value of Liabilities", "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]", "documentation": "Tabular disclosure of the amount of gains or losses for the period included in earnings or resulted in a change to net assets, have arisen from the use of significant unobservable inputs (level 3) to measure the fair value of assets, liabilities, and financial instruments classified in shareholders' equity." } } }, "auth_ref": [ "r147", "r148" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r513", "r514", "r516", "r517", "r522" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurements1" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r512" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Hierarchy for Financial Liabilities Measured at Fair Value", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r91", "r146" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r19", "r92" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers or reclassifications into level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3", "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r519" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers or reclassifications out of level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r519" ] }, "engn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeGainLoss", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange (gain)/loss", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Foreign Exchange (Gain) Loss", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability foreign exchange (gain) loss." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total", "terseLabel": "Change in fair value of warrant liabilities", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19" ] }, "engn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToEquityUponConsummationOfReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToEquityUponConsummationOfReverseRecapitalization", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reclassification of Warrants to equity upon consummation of the Reverse Recapitalization", "terseLabel": "Reclassification of Warrants to equity upon consummation of the Reverse Recapitalization", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Warrants To Equity Upon Consummation Of Reverse Recapitalization", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification of warrants to equity upon consummation of reverse recapitalization." } } }, "auth_ref": [] }, "engn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantLiabilityRecognizedUponIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantLiabilityRecognizedUponIssuance", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liabilities recognized upon issuance", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Warrant Liability Recognized Upon Issuance", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability warrant liability recognized upon issuance." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r512", "r522" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19", "r23" ] }, "engn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationForeignExchangeGainLoss", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange (gain)/loss", "negatedLabel": "Foreign exchange (gain)/loss", "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Foreign Exchange (Gain) Loss", "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation foreign exchange (gain) loss" } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of convertible debenture embedded derivative liabilities", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r518", "r521" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r23", "r91" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r14", "r24" ] }, "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "engn_FairValueOptionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "FairValueOptionPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Option", "label": "Fair Value Option [Policy Text Block]", "documentation": "Fair value option." } } }, "auth_ref": [] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r518" ] }, "engn_FeacShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "FeacShareholdersMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FEAC Shareholders, including sponsor's and shareholder with non-redemption agreement", "label": "FEAC Shareholders [Member]", "documentation": "FEAC shareholders." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r374", "r396", "r498", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r643", "r778", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r923", "r924", "r925", "r926" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial liabilities, fair value", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total", "terseLabel": "Financial liabilities", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [] }, "engn_ForbionGrowthSponsorFeacIBVMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "ForbionGrowthSponsorFeacIBVMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forbion Growth Sponsor FEAC I B.V", "label": "Forbion Growth Sponsor FEAC I B.V [Member]", "documentation": "Forbion Growth Sponsor FEAC I B.V Member." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Realized foreign currency transaction losses", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r715", "r805", "r968", "r969", "r988" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized foreign currency losses", "terseLabel": "Unrealized foreign currency transaction losses", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "verboseLabel": "Unrealized foreign currency losses (gains)", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r126", "r716", "r805", "r968", "r969", "r989" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Functional Currency Change", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r532" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r824", "r836", "r846", "r872" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r824", "r836", "r846", "r872" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r824", "r836", "r846", "r872" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r824", "r836", "r846", "r872" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r824", "r836", "r846", "r872" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office Furniture", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on extinguishment of convertible debentures", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "terseLabel": "Loss on extinguishment of convertible debentures", "label": "Gain (Loss) on Extinguishment of Debt", "verboseLabel": "Gain on extinguishment of debt", "netLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r11", "r62", "r63" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r118", "r720" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r117" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Goodwill, Total", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r189", "r330", "r625", "r779", "r795", "r928", "r929" ] }, "engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Government Assistance Programs for Research and Development Expenditures", "label": "Government Assistance Programs For Research And Development Expenditures [Policy Text Block]", "documentation": "Government assistance programs for research and development expenditures." } } }, "auth_ref": [] }, "engn_GrossCashProceedsReceivedFromReverseRecapitalizationAndPipeFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "GrossCashProceedsReceivedFromReverseRecapitalizationAndPipeFinancing", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash proceeds received from the Reverse Recapitalization and PIPE Financing on Closing Date", "label": "Gross Cash Proceeds Received from Reverse Recapitalization and Pipe Financing", "documentation": "Gross cash proceeds received from reverse recapitalization and pipe financing." } } }, "auth_ref": [] }, "engn_HerculesCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "HerculesCapitalMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hercules Capital", "label": "Hercules Capital [Member]", "documentation": "Hercules capital." } } }, "auth_ref": [] }, "engn_HerculesWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "HerculesWarrantsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hercules Warrants", "label": "Hercules Warrants [Member]", "documentation": "Hercules warrants." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r813", "r815", "r828" ] }, "engn_IfInterimMilestoneAchievedAndNoDefaultMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "IfInterimMilestoneAchievedAndNoDefaultMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "If Interim Milestone Achieved and No Default", "label": "If Interim Milestone Achieved and No Default [Member]", "documentation": "If interim milestone achieved and no default." } } }, "auth_ref": [] }, "engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "If Interim Milestone and Certain Clinical Milestones Achieved and No Default", "label": "If Interim Milestone and Certain Clinical Milestones Achieved and No Default [Member]", "documentation": "If interim milestone and certain clinical milestones achieved and no default." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net loss before provision for income taxes", "totalLabel": "Net loss before provision for income taxes", "terseLabel": "Net loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r115", "r156", "r260", "r271", "r273", "r275", "r627", "r640", "r775" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r331", "r333", "r725" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r333", "r725" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r15", "r79", "r144", "r145" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r216", "r454", "r458", "r459", "r462", "r469", "r471", "r472", "r473", "r666" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Income tax provision or benefit", "terseLabel": "Provision for (benefit from) income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r161", "r175", "r234", "r235", "r264", "r457", "r470", "r645" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r199", "r455", "r456", "r459", "r460", "r461", "r463", "r660" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r912" ] }, "engn_IncreaseDecreaseInInvestmentTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "IncreaseDecreaseInInvestmentTaxCreditReceivable", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment tax credit receivable", "terseLabel": "Investment tax credit receivable", "label": "Increase (Decrease) In Investment Tax Credit Receivable", "documentation": "Increase (decrease) in investment tax credit receivable." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r894", "r912" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r10" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r827", "r836", "r846", "r863", "r872", "r876", "r884" ] }, "engn_InitialAnnualBaseRentPerSquareFoot": { "xbrltype": "perUnitItemType", "nsuri": "http://engene.com/20240430", "localname": "InitialAnnualBaseRentPerSquareFoot", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial annual base rent", "label": "Initial Annual Base Rent Per Square Foot", "documentation": "Initial annual base rent per square foot." } } }, "auth_ref": [] }, "engn_InitialConsultingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "InitialConsultingPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial consulting period.", "label": "Initial Consulting Period", "terseLabel": "Initial consulting Period" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r882" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r816", "r888" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r816", "r888" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r816", "r888" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, Gross (Excluding Goodwill), Total", "terseLabel": "Intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r189" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Total", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r96", "r158", "r203", "r262", "r543", "r726", "r805", "r987" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Debt, Total", "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r121", "r369", "r380", "r783", "r784" ] }, "engn_InterestExpenseIncludingAmortizationOfDebtDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "InterestExpenseIncludingAmortizationOfDebtDiscounts", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, including the amortization of debt discounts", "label": "Interest Expense Including Amortization Of Debt Discounts", "documentation": "Interest expense including amortization of debt discounts." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r206", "r209", "r210" ] }, "engn_InvestissementQuebecMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "InvestissementQuebecMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investissement Quebec", "label": "Investissement Quebec [Member]", "documentation": "Investissement Quebec Member." } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r119", "r261" ] }, "engn_InvestmentTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "InvestmentTaxCreditsReceivable", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment tax credits receivable", "label": "Investment Tax Credits Receivable", "documentation": "Investment tax credits receivable." } } }, "auth_ref": [] }, "engn_IssuanceOfCommonStockInConnectionWithPipeFinancingShares": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "IssuanceOfCommonStockInConnectionWithPipeFinancingShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares)", "label": "Issuance Of Common Stock In Connection With Pipe Financing Shares", "documentation": "Issuance of common stock in connection with PIPE financing shares." } } }, "auth_ref": [] }, "engn_IssuanceOfCommonStockInConnectionWithPipeFinancingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "IssuanceOfCommonStockInConnectionWithPipeFinancingValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with PIPE Financing, net of issuance costs", "label": "Issuance of Common Stock in Connection With Pipe Financing Value", "documentation": "Issuance of common stock in connection with PIPE financing value" } } }, "auth_ref": [] }, "engn_JuneTwentyTwentyThreeFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "JuneTwentyTwentyThreeFinancingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2023 Financing", "label": "June Twenty Twenty Three Financing [Member]", "documentation": "June Twenty Twenty Three Financing Member." } } }, "auth_ref": [] }, "engn_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "LabEquipmentMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab equipment", "label": "Lab Equipment [Member]", "documentation": "Lab equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r556", "r794" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Cost:", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Operating Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r971" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease expiration date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "engn_LeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://engene.com/20240430", "localname": "LeaseExpirationMonthAndYear", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease expiration month and year", "label": "Lease Expiration Month and Year", "documentation": "Lease expiration month and year." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r131" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity:", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r554" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r554" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r553" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, option to extend", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r555" ] }, "engn_LesseeOperatingLeaseExtendedTerm": { "xbrltype": "gYearMonthItemType", "nsuri": "http://engene.com/20240430", "localname": "LesseeOperatingLeaseExtendedTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease extended term", "label": "Lessee, Operating Lease, Extended Term", "documentation": "Lessee, operating lease, extended term." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r972" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional lease commitments to be paid", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r562" ] }, "engn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024 (remaining)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r972" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r970" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease initial term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r970" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeases1" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r549" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Liabilities, Total", "terseLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r33", "r215", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r481", "r484", "r485", "r526", "r693", "r774", "r807", "r932", "r975", "r976" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, redeemable convertible preferred shares and shareholder's equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r113", "r155", "r636", "r795", "r915", "r927", "r967" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, redeemable convertible preferred shares and Shareholder's equity (deficit)", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "terseLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r35", "r185", "r215", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r481", "r484", "r485", "r526", "r795", "r932", "r975", "r976" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "engn_LicenseAgreementAndClinicalResearchOrganizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "LicenseAgreementAndClinicalResearchOrganizationAbstract", "lang": { "en-us": { "role": { "label": "License Agreement and Clinical Research Organization [Abstract]", "documentation": "License Agreement and Clinical Research Organization" } } }, "auth_ref": [] }, "engn_LicenseAgreementAndClinicalResearchOrganizationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "LicenseAgreementAndClinicalResearchOrganizationLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "License Agreement and Clinical Research Organization [Line Items]", "documentation": "License agreement and clinical research organization line items." } } }, "auth_ref": [] }, "engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "LicenseAgreementAndClinicalResearchOrganizationTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization" ], "lang": { "en-us": { "role": { "label": "License Agreement and Clinical Research Organization", "documentation": "License agreement and clinical research organization" } } }, "auth_ref": [] }, "engn_LicenseAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "LicenseAgreementTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "License Agreement [Table]", "documentation": "License Agreement Table" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r30", "r914" ] }, "engn_LineOfCreditFacilityDrawnTerm": { "xbrltype": "gYearMonthItemType", "nsuri": "http://engene.com/20240430", "localname": "LineOfCreditFacilityDrawnTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan facility, drawn term", "label": "Line of Credit Facility, Drawn Term", "documentation": "Line of credit facility, drawn term." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, maturity date", "label": "Line of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r30", "r914" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Line of credit, maximum amount available", "terseLabel": "Term loan facility aggregate principal amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r30" ] }, "engn_LoanAmortizationDate": { "xbrltype": "dateItemType", "nsuri": "http://engene.com/20240430", "localname": "LoanAmortizationDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan amortization date", "label": "Loan Amortization Date", "documentation": "Loan amortization date." } } }, "auth_ref": [] }, "engn_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "LoanAndSecurityAgreementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Loan and Security Agreement", "label": "2021 Loan and Security Agreement [Member]", "documentation": "2021 loan and security agreement." } } }, "auth_ref": [] }, "engn_LoanAndSecurityAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "LoanAndSecurityAgreementsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan and Security Agreement", "label": "Loan and Security Agreements [Member]", "documentation": "Loan and security agreements." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Note payable, net of discount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r25", "r154", "r362", "r378", "r781", "r782", "r984" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r219", "r367" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r219", "r367" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r219", "r367" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r219", "r367" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r219", "r367" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Notes Payable, Noncurrent, Total", "terseLabel": "Note payable, net of current portion", "label": "Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r37" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r37" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r37", "r60" ] }, "engn_MaximumAutomaticallyIncreaseInAuthorizedSharesIssuedUnderShareBasedPlanEachYear": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "MaximumAutomaticallyIncreaseInAuthorizedSharesIssuedUnderShareBasedPlanEachYear", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum automatically increase in authorized shares issued under share-based plan each year.", "label": "Maximum Automatically Increase in Authorized Shares Issued Under Share-Based Plan Each Year", "terseLabel": "Maximum automatically increase in authorized shares issued under share-based plan each year" } } }, "auth_ref": [] }, "engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum hours of CEO devote per week to providing transition services.", "label": "Maximum Hours Of CEO Devote Per Week To Providing Transition Services", "terseLabel": "Maximum hours of ceo devote per week to providing transition services" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r403", "r608", "r646", "r685", "r686", "r749", "r750", "r751", "r752", "r757", "r767", "r768", "r777", "r785", "r788", "r796", "r934", "r977", "r978", "r979", "r980", "r981", "r982" ] }, "engn_MayTwentyTwentyThreeFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "MayTwentyTwentyThreeFinancingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2023 Financing", "label": "May Twenty Twenty Three Financing [Member]", "documentation": "May Twenty Twenty Three Financing Member." } } }, "auth_ref": [] }, "engn_MayTwentyTwentyThreeNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "MayTwentyTwentyThreeNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2023 Notes", "label": "May Twenty Twenty Three Notes [Member]", "documentation": "May Twenty Twenty Three Notes." } } }, "auth_ref": [] }, "engn_MayTwoThousandTwentyThreeNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "MayTwoThousandTwentyThreeNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "May 2023 Notes", "label": "May Two Thousand Twenty Three Notes [Member]", "documentation": "May two thousand twenty three notes." } } }, "auth_ref": [] }, "engn_MayTwoThousandTwoThreeNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "MayTwoThousandTwoThreeNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2023 Notes", "label": "May Two Thousand Two Three Notes Member", "documentation": "May Two Thousand Two Three Notes." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r855" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r855" ] }, "us-gaap_MeasurementInputConversionPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputConversionPriceMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value of Common Share", "terseLabel": "Fair Value of Common Share at Conversion of Listing Event", "label": "Measurement Input, Conversion Price [Member]", "documentation": "Measurement input using price per share at which convertible share can be converted into common stock." } } }, "auth_ref": [ "r965" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Measurement Input, Expected Term", "terseLabel": "Expected Time to Respective Scenarios", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r965" ] }, "engn_MeasurementInputProbabilityOfQualifiedFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "MeasurementInputProbabilityOfQualifiedFinancingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of Qualified Financing", "label": "Measurement Input Probability Of Qualified Financing [Member]", "documentation": "Measurement input probability of qualified financing." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r515" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "engn_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "MergerAgreementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Merger Agreement [Member]", "documentation": "Merger agreement." } } }, "auth_ref": [] }, "engn_MilestoneProductPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "MilestoneProductPayment", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One-time payment for milestone product", "label": "Milestone Product Payment", "documentation": "Milestone product payment" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r403", "r608", "r646", "r685", "r686", "r749", "r750", "r751", "r752", "r757", "r767", "r768", "r777", "r785", "r788", "r796", "r934", "r977", "r978", "r979", "r980", "r981", "r982" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r875" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r883" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r856" ] }, "engn_NetCashProceedsReceivedFromReverseRecapitalizationAndPipeFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "NetCashProceedsReceivedFromReverseRecapitalizationAndPipeFinancing", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash proceeds from the Reverse Recapitalization and PIPE Financing", "label": "Net Cash Proceeds Received from Reverse Recapitalization and Pipe Financing.", "documentation": "Net cash proceeds received from reverse recapitalization and pipe financing." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r208" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r208" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash flows from operating activities", "totalLabel": "Net cash used in operating activities", "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r124", "r125", "r126" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "totalLabel": "Net loss", "negatedTotalLabel": "Net loss and comprehensive loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r116", "r126", "r157", "r183", "r197", "r198", "r202", "r215", "r224", "r228", "r229", "r230", "r231", "r234", "r235", "r248", "r260", "r271", "r273", "r275", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r510", "r526", "r642", "r717", "r739", "r740", "r775", "r805", "r932" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to common shareholders, basic", "negatedTotalLabel": "Net loss attributable to common shareholders, basic", "totalLabel": "Net loss attributable to common stockholders, basic", "terseLabel": "Net loss attributable to common stockholders, basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r205", "r228", "r229", "r230", "r231", "r239", "r240", "r249", "r252", "r260", "r271", "r273", "r275", "r775" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net loss attributable to common stockholders, diluted", "negatedLabel": "Net loss attributable to common shareholders, diluted", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total", "terseLabel": "Net loss attributable to common stockholders, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r205", "r241", "r244", "r245", "r246", "r247", "r249", "r252" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "engn_NewLaboratoryAndOfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "NewLaboratoryAndOfficeSpaceMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Laboratory and Office Space", "label": "New Laboratory and Office Space [Member]", "documentation": "New laboratory and office space." } } }, "auth_ref": [] }, "engn_NonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "NonCashInterestExpense", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Non-cash Interest Expense", "documentation": "Non-cash interest expense." } } }, "auth_ref": [] }, "engn_NonCashLeaseExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "NonCashLeaseExpenses", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash lease expense", "label": "Non Cash Lease Expenses", "documentation": "Non cash lease expenses." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r855" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r824", "r836", "r846", "r863", "r872" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r853" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r852" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r863" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r883" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r883" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other (income) expense, net", "totalLabel": "Total other (income) expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r120" ] }, "us-gaap_NonvotingCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvotingCommonStockMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Voting Common Shares", "label": "Nonvoting Common Stock [Member]", "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors." } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Note payable current", "totalLabel": "Notes Payable, Current, Total", "terseLabel": "Current portion of notes payable", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r32" ] }, "engn_NumberOfCommonStockWarrantsExercisedByInvestorsOnCashlessBasis": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "NumberOfCommonStockWarrantsExercisedByInvestorsOnCashlessBasis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of common stock warrants exercised by investors on cashless basis.", "label": "Number Of Common Stock Warrants Exercised By Investors On Cashless Basis", "terseLabel": "Number of common stock warrants exercised by investors on cashless basis" } } }, "auth_ref": [] }, "engn_NumberOfNewWarrantIssuedDuringThePeriod": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "NumberOfNewWarrantIssuedDuringThePeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of new warrant issued during the period", "label": "Number of New Warrant Issued During the Period", "documentation": "Number of new warrant issued during the period." } } }, "auth_ref": [] }, "engn_OfficeAndLabSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OfficeAndLabSpaceMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office and Lab Space", "label": "Office and Lab Space [Member]", "documentation": "Office and lab space." } } }, "auth_ref": [] }, "engn_OfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OfficeSpaceMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office Space", "label": "Office Space [Member]", "documentation": "Office space." } } }, "auth_ref": [] }, "engn_OldEngeneShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OldEngeneShareholdersMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old enGene Shareholders (Excluding Convertible Notes)", "label": "Old EnGene Shareholders [Member]", "documentation": "Old EnGene shareholders." } } }, "auth_ref": [] }, "engn_OldEngenesEquityAndConvertibleNoteHolderMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OldEngenesEquityAndConvertibleNoteHolderMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old enGenes Equity and Convertible Note", "label": "Old enGenes Equity and Convertible Note Holder Member", "documentation": "Old enGenes Equity and Convertible Note Holder." } } }, "auth_ref": [] }, "engn_OldEngenesEquityAndConvertibleNoteHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OldEngenesEquityAndConvertibleNoteHoldersMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old enGene's Equity and Convertible Note Holders", "label": "Old enGene's Equity and Convertible Note Holders [Member]", "documentation": "Old enGene\u2019s equity and convertible note holders." } } }, "auth_ref": [] }, "engn_OldEngenesShareOptionHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OldEngenesShareOptionHoldersMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old enGenes Share Option", "label": "Old enGenes Share Option Holders Member", "documentation": "Old enGenes Share Option Holders." } } }, "auth_ref": [] }, "engn_OldEngenesWarrantHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OldEngenesWarrantHoldersMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old enGenes Warrant", "label": "Old enGenes Warrant Holders Member", "documentation": "Old enGenes Warrant Holders Member" } } }, "auth_ref": [] }, "engn_OldHerculesWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "OldHerculesWarrantsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Old hercules warrants.", "label": "Old Hercules Warrants [Member]", "terseLabel": "Old Hercules Warrants" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Loss from operations", "label": "Operating Income (Loss)", "totalLabel": "Operating Income (Loss), Total", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r260", "r271", "r273", "r275", "r775" ] }, "engn_OperatingLeaseCommencementPeriod": { "xbrltype": "gYearMonthItemType", "nsuri": "http://engene.com/20240430", "localname": "OperatingLeaseCommencementPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease commencement period", "label": "Operating Lease Commencement Period", "documentation": "Operating lease commencement period." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r557", "r794" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Total", "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "verboseLabel": "Total Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r551" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r551" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r551" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r552", "r560" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right of use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r550" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r34" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r83", "r90" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r190" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r8" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense, net", "totalLabel": "Total other (income) expense, net", "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r122" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net:", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r822", "r834", "r844", "r870" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "engn_PIPEFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "PIPEFinancingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PIPE Financing", "label": "PIPE Financing [Member]", "documentation": "PIPE financing." } } }, "auth_ref": [] }, "engn_PaidInKindInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PaidInKindInterestPercentage", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment-in-kind interest rate", "label": "Paid-in-kind Interest Percentage", "documentation": "Paid-in-kind interest percentage." } } }, "auth_ref": [] }, "engn_PatentCostsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "PatentCostsPolicyPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Patent Costs", "label": "Patent Costs Policy [Policy Text Block]", "documentation": "Patent costs." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r851" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Payment of Financing and Stock Issuance Costs, Total", "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Offering expenses", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r45" ] }, "engn_PaymentOfIssuanceCostsAssociatedWithConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "PaymentOfIssuanceCostsAssociatedWithConvertibleDebt", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of issuance costs associated with April 2023 Notes", "label": "Payment Of Issuance Costs Associated With Convertible Debt", "documentation": "Payment of issuance costs associated with convertible debt." } } }, "auth_ref": [] }, "engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "PaymentOfReverseRecapitalizationAndPipeFinancingCosts", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of Reverse Recapitalization and PIPE Financing costs", "label": "Payment Of Reverse Recapitalization And Pipe Financing Costs", "documentation": "Payment of reverse recapitalization and pipe financing costs." } } }, "auth_ref": [] }, "engn_PaymentOnAssigningLicenseToThirdParty": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "PaymentOnAssigningLicenseToThirdParty", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment to NTC upon assigning the License Agreement", "label": "Payment On Assigning License to Third Party", "documentation": "Payment on assigning license to third party" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of debt issuance costs associated with the term loan", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r47" ] }, "engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of issuance costs associated with the 2024 PIPE Financing", "terseLabel": "Payments of issuance costs associated with the 2024 PIPE Financing", "label": "Payments Of Issuance Costs Associated With The Pipe Financing", "documentation": "Payments of issuance costs associated with the pipe financing." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r123" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r854" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r854" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r853" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r863" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r856" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r852" ] }, "engn_PercentageOfAggregatePricipalAmountOfTermLoanAdvancesAmountFee": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfAggregatePricipalAmountOfTermLoanAdvancesAmountFee", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate principle amount of term loan advances amount fee", "label": "Percentage of Aggregate Pricipal Amount of Term Loan Advances Amount Fee", "documentation": "Percentage of aggregate principle amount of term loan advances amount fee." } } }, "auth_ref": [] }, "engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate principal amount of term loan advance to purchase number of common shares", "label": "Percentage Of Aggregate Principal Amount Of Term Loan Advance To Purchase Number Of Common Shares", "documentation": "Percentage of aggregate principal amount of term loan advance to purchase number of common shares." } } }, "auth_ref": [] }, "engn_PercentageOfAggregateTermLoanFunded": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfAggregateTermLoanFunded", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price equal to percentage of aggregate amount of term loans", "label": "Percentage of Aggregate Term Loan Funded", "documentation": "Percentage of aggregate term loan funded." } } }, "auth_ref": [] }, "engn_PercentageOfCommitmentAmount": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfCommitmentAmount", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total commitment amount", "label": "Percentage Of Commitment Amount", "documentation": "Percentage of commitment amount." } } }, "auth_ref": [] }, "engn_PercentageOfFacilityChargeOnAmountBorrowed": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfFacilityChargeOnAmountBorrowed", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of facility charge on amount borrowed", "label": "Percentage of Facility Charge on Amount Borrowed", "documentation": "Percentage of facility charge on amount borrowed." } } }, "auth_ref": [] }, "engn_PercentageOfIncreaseInAnnualBaseRent": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfIncreaseInAnnualBaseRent", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of increase in annual base rent", "label": "Percentage of Increase in Annual Base Rent", "documentation": "Percentage of increase in annual base rent." } } }, "auth_ref": [] }, "engn_PercentageOfIssuanceOfCommonStockOptions": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfIssuanceOfCommonStockOptions", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of issuance of common stock options", "label": "Percentage of issuance of common stock options", "documentation": "Percentage of issuance of common stock options" } } }, "auth_ref": [] }, "engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of prepayment premium of principal amount outstanding of the closing date", "label": "Percentage of Prepayment Premium of Principal Amount Outstanding of the Closing Date", "documentation": "Percentage of prepayment premium of principal amount outstanding of the closing date." } } }, "auth_ref": [] }, "engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of prepayment premium of principal amount outstanding prior to maturity date", "label": "Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Maturity Date", "documentation": "Percentage of prepayment premium of principal amount outstanding prior to maturity date." } } }, "auth_ref": [] }, "engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of prepayment premium of principal amount outstanding prior to twenty-four months", "label": "Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Twenty Four Months", "documentation": "Percentage of prepayment premium of principal amount outstanding prior to twenty four months." } } }, "auth_ref": [] }, "engn_PercentageOfPricePerShare": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfPricePerShare", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of price per share", "label": "Percentage Of Price Per Share", "documentation": "Percentage of price per share." } } }, "auth_ref": [] }, "engn_PercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfPrincipalAmount", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of principal", "label": "Percentage Of Principal Amount", "documentation": "Percentage Of Principal Amount." } } }, "auth_ref": [] }, "engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of tax benefit to be realized for recognition in the income statement", "label": "Percentage Of Tax Benefit To Be Realized For Recognition In The Income Statement", "documentation": "Percentage of tax benefit to be realized for recognition in the income statement." } } }, "auth_ref": [] }, "engn_PeriodWithinLoanDisbursementsToBeMade": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "PeriodWithinLoanDisbursementsToBeMade", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period within loan disbursements to be made", "label": "Period Within Loan Disbursements to be Made", "documentation": "Period within loan disbursements to be made." } } }, "auth_ref": [] }, "engn_PhaseIClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "PhaseIClinicalTrialMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Phase I Clinical Trial [Member]", "documentation": "Phase I Clinical Trial" } } }, "auth_ref": [] }, "engn_PhaseIiClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "PhaseIiClinicalTrialMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Phase II Clinical Trial [Member]", "documentation": "Phase II Clinical Trial" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963" ] }, "engn_PreferredShareWarrantLiabillitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "PreferredShareWarrantLiabillitiesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Share Warrant Liabilities", "label": "Preferred Share Warrant Liabillities [Member]", "documentation": "Preferred share warrant liabilities." } } }, "auth_ref": [] }, "engn_PreferredShareWarrantsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "PreferredShareWarrantsFairValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred share warrants fair value", "label": "Preferred Share Warrants Fair Value", "documentation": "Preferred share warrants fair value." } } }, "auth_ref": [] }, "engn_PreferredShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "PreferredShareWarrantsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Share Warrants", "label": "Preferred Share Warrants [Member]", "documentation": "Preferred share warrants." } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r384" ] }, "us-gaap_PreferredStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNoParValue", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock no par value", "label": "Preferred Stock, No Par Value", "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r107", "r936" ] }, "us-gaap_PreferredStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorizedUnlimited", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock shares authorized unlimited", "label": "Preferred Stock, Shares Authorized, Unlimited [Fixed List]", "documentation": "Indicates that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r107", "r382" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r107", "r694", "r713", "r990", "r991" ] }, "us-gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredShares" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Shares", "label": "Preferred Stock [Text Block]", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } }, "auth_ref": [ "r134" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, no par value; unlimited shares authorized, no shares issued and outstanding as of April 30, 2024 and October 31, 2023.", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r107", "r631", "r795" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r905" ] }, "engn_PricePerUnitPaidForCommonSharesAndWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "PricePerUnitPaidForCommonSharesAndWarrants", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per unit paid for common shares and warrants", "label": "Price Per Unit Paid for Common Shares and Warrants", "documentation": "Price per unit paid for common shares and warrants." } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "engn_PriorLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "PriorLoanAgreementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Loan Agreement", "label": "Prior Loan Agreement [Member]", "documentation": "Prior loan agreement." } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from issuance of April 2023 Notes", "terseLabel": "Proceeds from convertible debt", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Aggregate gross proceeds of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of term loan", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r911" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the 2024 PIPE Financing", "label": "Proceeds from Issuance of Private Placement", "verboseLabel": "Aggregate gross proceeds from the Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total aggregate proceeds", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash - PIPE Financing", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "terseLabel": "Proceeds from PIPE financing", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r9", "r661" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Lines of Credit, Total", "terseLabel": "Proceeds from line of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r44", "r914" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r9", "r22" ] }, "engn_ProceedsFromTrustAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ProceedsFromTrustAccount", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash - FEAC's Trust Account and Cash (net of redemptions and cash paid for FEAC expenses prior to close)", "terseLabel": "Proceeds from trust account", "label": "Proceeds From Trust Account", "documentation": "Proceeds from trust account." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercise of common share warrants", "terseLabel": "Proceeds from exercises of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r910" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r183", "r197", "r198", "r207", "r215", "r224", "r234", "r235", "r260", "r271", "r273", "r275", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r479", "r482", "r483", "r510", "r526", "r627", "r641", "r670", "r717", "r739", "r740", "r775", "r792", "r793", "r806", "r908", "r932" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNet1" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r130", "r166", "r169", "r170" ] }, "engn_PropertyPlantAndEquipmentEstimatedUsefulLive": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "PropertyPlantAndEquipmentEstimatedUsefulLive", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life", "label": "Property Plant And Equipment Estimated Useful Live", "documentation": "Property plant and equipment estimated useful live." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property, Plant and Equipment, Gross, Total", "terseLabel": "Property and equipment", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r131", "r187", "r639" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r628", "r639", "r795" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r166", "r169", "r637" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r131" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r851" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r851" ] }, "engn_QuotedMarketPriceOfPublicWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "QuotedMarketPriceOfPublicWarrants", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted market price of public warrants", "label": "Quoted Market Price of Public Warrants", "documentation": "Quoted market price of public warrants." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r401", "r403", "r433", "r434", "r435", "r584", "r608", "r646", "r685", "r686", "r749", "r750", "r751", "r752", "r757", "r767", "r768", "r777", "r785", "r788", "r796", "r799", "r930", "r934", "r978", "r979", "r980", "r981", "r982" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r401", "r403", "r433", "r434", "r435", "r584", "r608", "r646", "r685", "r686", "r749", "r750", "r751", "r752", "r757", "r767", "r768", "r777", "r785", "r788", "r796", "r799", "r930", "r934", "r978", "r979", "r980", "r981", "r982" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r817", "r829", "r839", "r865" ] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableConvertiblePreferredStockMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred shares", "label": "Redeemable Convertible Preferred Stock [Member]", "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_RedeemablePreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemablePreferredStockDividends", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividend attributable to redeemable convertibleb preferred shareholders", "label": "Redeemable Preferred Stock Dividends", "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r17", "r52", "r138" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r402", "r571", "r572", "r688", "r689", "r690", "r691", "r692", "r712", "r714", "r748" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r721", "r722", "r725" ] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r402", "r571", "r572", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r688", "r689", "r690", "r691", "r692", "r712", "r714", "r748", "r974" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r568", "r569", "r570", "r572", "r574", "r667", "r668", "r669", "r723", "r724", "r725", "r745", "r747" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement upon the consummation of the Reverse Recapitalization", "negatedLabel": "Repayment of convertible debentures", "verboseLabel": "Repayment of aggregate amount", "terseLabel": "Repayment of convertible debentures", "label": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r46" ] }, "engn_RepaymentsOfConvertibleNotesAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "RepaymentsOfConvertibleNotesAndWarrants", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of convertible notes and warrants", "label": "Repayments Of Convertible Notes and Warrants", "documentation": "Repayments of convertible notes and warrants." } } }, "auth_ref": [] }, "engn_RepaymentsOfTermLoanPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "RepaymentsOfTermLoanPrincipal", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of term loan principal", "label": "Repayments of term loan principal", "documentation": "Repayments of term loan principal." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r217", "r218", "r353", "r385", "r573", "r771", "r772" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r102", "r453", "r983" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r452" ] }, "engn_ResearchAndDevelopmentInvestmentTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ResearchAndDevelopmentInvestmentTaxCredits", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development investment tax credits", "label": "Research And Development Investment Tax Credits", "documentation": "Research and development investment tax credits." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r818", "r830", "r840", "r866" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r819", "r831", "r841", "r867" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r826", "r838", "r848", "r874" ] }, "us-gaap_RestrictedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestments", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted investments", "label": "Restricted Investments", "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet." } } }, "auth_ref": [ "r764", "r765" ] }, "engn_RestrictedInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "RestrictedInvestmentsPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Investments", "label": "Restricted Investments [Policy Text Block]", "documentation": "Restricted Investments [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r110", "r138", "r635", "r653", "r658", "r665", "r695", "r795" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r220", "r221", "r222", "r225", "r233", "r235", "r314", "r321", "r443", "r444", "r445", "r466", "r467", "r490", "r493", "r494", "r497", "r508", "r649", "r651", "r671", "r990" ] }, "engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization and PIPE Financing transaction costs included within accrued expenses and accounts payable", "label": "Reverse Recapitalization And Pipe Financing Transaction Costs Included Within Accrued Expenses And Accounts Payable", "documentation": "Reverse recapitalization and pipe financing transaction costs included within accrued expenses and accounts payable." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationEmbeddedDerivativeFairValueOfEmbeddedDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationEmbeddedDerivativeFairValueOfEmbeddedDerivative", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse recapitalization embedded derivative fair value of embedded derivative", "label": "Reverse Recapitalization Embedded Derivative Fair Value Of Embedded Derivative", "documentation": "Reverse recapitalization embedded derivative fair value of embedded derivative." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationExchangeRatio": { "xbrltype": "percentItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationExchangeRatio", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange ratio", "label": "Reverse Recapitalization Exchange Ratio", "documentation": "Reverse recapitalization exchange ratio." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Reverse Recapitalization [Line Items]", "documentation": "Reverse recapitalization." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationPricePerUnitPaidCommonSharesAndWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationPricePerUnitPaidCommonSharesAndWarrants", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse recapitalization price per unit paid common shares and warrants", "label": "Reverse Recapitalization Price Per Unit Paid Common Shares And Warrants", "documentation": "Reverse recapitalization price per unit paid common shares and warrants." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationPricePerUnitPaidCommonSharesAndWarrantsOnRelativeFairValueBasis": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationPricePerUnitPaidCommonSharesAndWarrantsOnRelativeFairValueBasis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares and warrants on relative fair value, basis price per unit paid", "label": "Reverse Recapitalization Price Per Unit Paid Common Shares And Warrants On Relative Fair Value Basis", "documentation": "Reverse recapitalization price per unit paid common shares and warrants on relative fair value basis." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationTable": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Reverse Recapitalization [Table]", "documentation": "Reverse recapitalization." } } }, "auth_ref": [] }, "engn_ReverseRecapitalizationTextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "ReverseRecapitalizationTextblock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalization" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization", "label": "Reverse Recapitalization TextBlock", "documentation": "Reverse Recapitalization TextBlock" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right of Use Assets obtained in exchange for lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r561", "r794" ] }, "engn_Rule10B51TradingPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "Rule10B51TradingPlanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule10 B51 Trading Plan", "label": "Rule10 B51 Trading Plan [Member]", "documentation": "Rule10 b51 trading plan." } } }, "auth_ref": [] }, "engn_Rule10B51TradingPlanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "Rule10B51TradingPlanOneMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Acquired Eexercise of Stock Options", "label": "Rule10 B51 Trading Plan One [Member]", "documentation": "Rule10 b51 trading plan one" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r883" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r883" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial aggregate amount that company agreed to sell", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred shares at a price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Shares Excluded from Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Summary of Number of Common Shares Outstanding", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Components Of The Provision For Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value of Term Loan", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Net Deferred Income Tax", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r142" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r921" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Reconciliation Of Company's Statutory Income Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r141" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share-based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r78" ] }, "engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Estimated Useful Life of Each Asset", "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]", "documentation": "Schedule of estimated useful lives of property, plant and equipment." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]", "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition." } } }, "auth_ref": [ "r93", "r149" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Loss Before Provision for Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r916" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Principal Payments Due Under the Loan Agreement", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r98", "r99", "r721", "r722", "r725" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r405", "r406", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r20", "r21", "r77" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r140" ] }, "engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Shares Reserved for Future Issuance Under the Plan", "label": "Schedule of Shares Reserved For Future Issuance Under The Plan Table Text Block", "documentation": "Schedule of shares reserved for future issuance under the plan." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r64", "r65", "r66", "r67", "r68", "r69", "r70", "r135", "r137", "r138", "r192", "r193", "r194", "r258", "r382", "r383", "r385", "r387", "r390", "r396", "r398", "r661", "r662", "r663", "r664", "r785", "r892", "r913" ] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesFinancingTransactionAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth_ref": [ "r150" ] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Domain]", "documentation": "Measurement of financing transaction securities held." } } }, "auth_ref": [ "r150" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r808" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r811" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r276", "r776" ] }, "engn_Series1ClassCRedeemableConvertiblePreferredMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "Series1ClassCRedeemableConvertiblePreferredMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series 1 Class C Redeemable Convertible Preferred", "label": "Series 1 Class C Redeemable Convertible Preferred [Member]", "documentation": "Series 1 class c redeemable convertible preferred." } } }, "auth_ref": [] }, "engn_Series2ClassCRedeemableConvertiblePreferredMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "Series2ClassCRedeemableConvertiblePreferredMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series 2 Class C Redeemable Convertible Preferred", "label": "Series 2 Class C Redeemable Convertible Preferred [Member]", "documentation": "Series 2 class c redeemable convertible preferred." } } }, "auth_ref": [] }, "engn_Series3ClassCRedeemableConvertiblePreferredMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "Series3ClassCRedeemableConvertiblePreferredMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series 3 Class C Redeemable Convertible Preferred", "label": "Series 3 Class C Redeemable Convertible Preferred [Member]", "documentation": "Series 3 class c redeemable convertible preferred." } } }, "auth_ref": [] }, "engn_Series4ClassCRedeemableConvertiblePreferredMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "Series4ClassCRedeemableConvertiblePreferredMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series 4 Class C Redeemable Convertible Preferred", "label": "Series 4 Class C Redeemable Convertible Preferred [Member]", "documentation": "Series 4 class c redeemable convertible preferred." } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Preferred Shares", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r903", "r904", "r937" ] }, "engn_SeveranceBenefitsEntitledToBaseSalary": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "SeveranceBenefitsEntitledToBaseSalary", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance benefits entitled to base salary", "label": "Severance Benefits Entitled to Base Salary", "documentation": "Severance benefits entitled to base salary." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Total share-based compensation expense", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options vesting service period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r789" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options vesting period", "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r789" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r434" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, Maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, Minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, Maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, Minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptions": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptions", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of common shares and exercise price of options", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options", "documentation": "Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of common shares and exercise price of options, Maximum", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Maximum", "documentation": "Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options maximum." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of common shares and exercise price of options, Minimum", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Minimum", "documentation": "Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options minimum." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r405", "r406", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized increased", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r791" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options remain available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r76" ] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionToPurchaseCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionToPurchaseCommonShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase common shares", "label": "Share Based Compensation Arrangement By Share Based Payment Award Option to Purchase Common Shares", "documentation": "Share based compensation arrangement by share based payment award option to purchase common shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited or expired", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total", "terseLabel": "Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r944" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r944" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares Granted", "label": "Granted", "terseLabel": "Number of stock option award issued during the period", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value per share of share options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares outstanding, Beginning balance", "periodEndLabel": "Number of shares outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r412", "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total", "terseLabel": "Increase in number of share reserved for future issuance in the beginning of the year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)", "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options." } } }, "auth_ref": [ "r944" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "periodStartLabel": "Weighted-Average Exercise Price Outstanding, Beginning balance", "periodEndLabel": "Weighted-Average Exercise Price Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r412", "r413" ] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options unvested", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Aggregate Intrinsic Value", "documentation": "Share based compensation arrangement by share based payment award options unvested aggregate intrinsic value." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options unvested", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price", "documentation": "Share based compensation arrangement by share based payment award options unvested weighted average exercise price." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Options unvested", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term1", "documentation": "Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Remaining options vesting", "terseLabel": "Shares Vesting", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r428" ] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options vested and not exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Aggregate Intrinsic Value", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Aggregate Intrinsic Value." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableNumber", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and not exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Number", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Number." } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options vested and not exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Exercise Price", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndNotExercisableWeightedAverageRemainingContractualTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Options vested and not exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and not Exercisable, Weighted Average Remaining Contractual Term." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental compensation cost", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r440" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price of options granted", "terseLabel": "Weighted-Average Exercise Price, Granted", "label": "Exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting Immediately Upon Grant Date", "terseLabel": "Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r404", "r411", "r430", "r431", "r432", "r433", "r436", "r446", "r447", "r448", "r449" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of shares", "label": "Share Price", "verboseLabel": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of vesting rights", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r938" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r790" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r432" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options unvested", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-Average Exercise Price, Options unvested", "terseLabel": "Exercise price", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r139" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r428" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Issued options were fully vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock value on date of grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued, price per share", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "engn_SharesReservedForFutureIssuanceUnderThe2023PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "SharesReservedForFutureIssuanceUnderThe2023PlanMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining shares reserved for future issuance under the 2023 Plan", "label": "Shares Reserved For Future Issuance Under The 2023 Plan [Member]", "documentation": "Shares Reserved For Future Issuance Under The 2023 Plan." } } }, "auth_ref": [] }, "engn_SharesReservedForFutureIssuanceUnderTheEquityPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "SharesReservedForFutureIssuanceUnderTheEquityPlansMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining shares reserved for future issuance under the equity plans", "label": "Shares Reserved For Future Issuance Under the Equity Plans [Member]", "documentation": "Shares reserved for future issuance under the equity plans." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term operating lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r558", "r794" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r127", "r212" ] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Software", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r177", "r192", "r193", "r194", "r215", "r242", "r243", "r250", "r252", "r258", "r259", "r309", "r340", "r342", "r343", "r344", "r347", "r348", "r382", "r383", "r387", "r390", "r398", "r526", "r661", "r662", "r663", "r664", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r694", "r718", "r741", "r758", "r759", "r760", "r761", "r762", "r892", "r913", "r920" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNumberOfCommonSharesOutstandingParentheticalDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r41", "r180", "r200", "r201", "r202", "r220", "r221", "r222", "r225", "r233", "r235", "r257", "r314", "r321", "r400", "r443", "r444", "r445", "r466", "r467", "r490", "r492", "r493", "r494", "r495", "r497", "r508", "r534", "r535", "r536", "r537", "r538", "r539", "r567", "r649", "r650", "r651", "r671", "r741" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r220", "r221", "r222", "r257", "r609", "r659", "r683", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r697", "r698", "r699", "r700", "r701", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r712", "r714", "r719", "r720", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r741", "r800" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r220", "r221", "r222", "r257", "r609", "r659", "r683", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r697", "r698", "r699", "r700", "r701", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r712", "r714", "r719", "r720", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r741", "r800" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r821", "r833", "r843", "r869" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "engn_StockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuanceCosts", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs", "label": "Stock Issuance Costs", "documentation": "Stock issuance costs." } } }, "auth_ref": [] }, "engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon cashless exercise of warrants (in shares)", "label": "Stock Issued During Period Shares Cashless Exercise Of Warrants", "documentation": "Stock issued during period shares cashless exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion and exchange of redeemable convertible preferred stock into common shares in connection with the Reverse Recapitalization (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r17", "r40", "r67", "r138", "r366" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of new stock issued during the period", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r17", "r107", "r108", "r138", "r661", "r741", "r759" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "verboseLabel": "Exercised", "terseLabel": "Exercise of stock options (in shares)", "label": "Stock options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r17", "r107", "r108", "r138", "r417" ] }, "engn_StockIssuedDuringPeriodSharesUponCashlessExerciseOfOptions": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuedDuringPeriodSharesUponCashlessExerciseOfOptions", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon cashless exercise of options (in shares)", "label": "Stock Issued During Period Shares Upon Cashless Exercise of Options", "documentation": "Stock issued during period shares upon cashless exercise of options." } } }, "auth_ref": [] }, "engn_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon exercise of warrants (in shares)", "label": "Stock Issued During Period Shares Warrants Exercised", "documentation": "Stock issued during period shares warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value issued", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r17", "r41", "r138" ] }, "engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon cashless exercise of warrants", "label": "Stock Issued During Period Value Cashless Exercise Of Warrants", "documentation": "Stock issued during period value cashless exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion and exchange of redeemable convertible preferred stock into common shares in connection with the Reverse Recapitalization", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r17", "r41", "r138" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares, value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r17", "r107", "r108", "r138", "r671", "r741", "r759", "r806" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r17", "r41", "r138" ] }, "engn_StockIssuedDuringPeriodValueUponCashlessExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuedDuringPeriodValueUponCashlessExerciseOfOptions", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon cashless exercise of options", "label": "Stock Issued During Period Value Upon Cashless Exercise of Options", "documentation": "Stock issued during period value upon cashless exercise of options." } } }, "auth_ref": [] }, "engn_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon exercise of warrants", "label": "Stock Issued During Period Value Warrants Exercised", "documentation": "Stock issued during period value warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "totalLabel": "Total shareholder's equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r108", "r111", "r112", "r129", "r696", "r713", "r742", "r743", "r795", "r807", "r915", "r927", "r967", "r990" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholder's equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonShares1" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r134", "r214", "r381", "r383", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r395", "r397", "r400", "r499", "r744", "r746", "r763" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share exchange ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r27" ] }, "engn_SubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "SubscriptionAgreementsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2024 Subscription agreements.", "label": "2024 Subscription Agreements [Member]", "terseLabel": "2024 Subscription Agreements" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r540", "r576" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r540", "r576" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r540", "r576" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r540", "r576" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r540", "r576" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r575", "r577" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "engn_SummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "SummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingTableTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing", "label": "Summary of Net Proceeds from Reverse Recapitalization and PIPE Financing [Table Text Block]", "documentation": "Summary of net proceeds from reverse recapitalization and pipe financing." } } }, "auth_ref": [] }, "engn_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "engn_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Table]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r862" ] }, "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity aggregate amount of redemption requirement", "label": "Temporary Equity, Aggregate Amount of Redemption Requirement", "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred shares value", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r340", "r342", "r343", "r344", "r347", "r348", "r450", "r633" ] }, "engn_TemporaryEquityNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "TemporaryEquityNoParValue", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity no par value", "label": "Temporary Equity No Par Value", "documentation": "Temporary equity no par value." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity shares authorized", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r106" ] }, "engn_TemporaryEquitySharesAuthorizedUnlimited": { "xbrltype": "stringItemType", "nsuri": "http://engene.com/20240430", "localname": "TemporaryEquitySharesAuthorizedUnlimited", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity shares authorized unlimited", "label": "Temporary Equity Shares Authorized Unlimited", "documentation": "Temporary equity shares authorized unlimited." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity shares issued", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r106" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity shares outstanding", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r106" ] }, "engn_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TermLoanMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term loan." } } }, "auth_ref": [] }, "engn_TheOldPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TheOldPlansMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Old Plans", "label": "The Old Plans [Member]", "documentation": "The old plans." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r922", "r973" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r854" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r861" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r882" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r884" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "engn_TrancheOneAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TrancheOneAdvanceMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 1 Advance", "label": "Tranche One Advance [Member]", "documentation": "Tranche one advance." } } }, "auth_ref": [] }, "engn_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TrancheOneMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche One", "label": "Tranche One [Member]", "documentation": "Tranche One." } } }, "auth_ref": [] }, "engn_TrancheThreeAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TrancheThreeAdvanceMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 3 Advance", "label": "Tranche Three Advance [Member]", "documentation": "Tranche three advance." } } }, "auth_ref": [] }, "engn_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TrancheThreeMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche Three", "label": "Tranche Three [Member]", "documentation": "Tranche three." } } }, "auth_ref": [] }, "engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 2 Advance Subject to Achievement of Specified Interim Milestone", "label": "Tranche Two Advance Subject to Achievement of Specified Interim Milestone [Member]", "documentation": "Tranche two advance subject to achievement of specified interim milestone." } } }, "auth_ref": [] }, "engn_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TrancheTwoMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche Two", "label": "Tranche Two [Member]", "documentation": "Tranche two." } } }, "auth_ref": [] }, "engn_TransactionCostWithheldFromProceedsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "TransactionCostWithheldFromProceedsReceived", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less transaction costs withheld from cash proceeds on Closing Date", "label": "Transaction Cost Withheld From Proceeds Received", "documentation": "Transaction cost withheld from rroceeds received." } } }, "auth_ref": [] }, "engn_TransactionCostsOfReverseRecapitalizationAndPipeFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "TransactionCostsOfReverseRecapitalizationAndPipeFinancing", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs as part of reverse recapitalization and pipe financing", "label": "Transaction Costs Of Reverse Recapitalization And PIPE Financing", "documentation": "Transaction costs of reverse recapitalization and pipe financing." } } }, "auth_ref": [] }, "engn_TransactionCostsRelatedToIssuanceOfNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "TransactionCostsRelatedToIssuanceOfNotes", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs related to issuance of notes", "label": "Transaction Costs Related To Issuance Of Notes", "documentation": "Transaction costs related to issuance of notes." } } }, "auth_ref": [] }, "engn_TransactionCostsWithheldFromProceedsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "TransactionCostsWithheldFromProceedsReceived", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less transaction costs withheld from cash proceeds on Closing Date", "terseLabel": "Transaction costs withheld from proceeds received", "label": "Transaction Costs Withheld From Proceeds Received", "documentation": "Transaction costs withheld from proceeds received." } } }, "auth_ref": [] }, "engn_TransactionsCostsDeferredAndNettedAgainstProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "TransactionsCostsDeferredAndNettedAgainstProceeds", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationSummaryOfNetProceedsFromReverseRecapitalizationAndPipeFinancingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less transaction costs previously deferred and netted against proceeds", "terseLabel": "Transactions costs deferred and netted against proceeds", "label": "Transactions Costs Deferred and Netted Against Proceeds", "documentation": "Transactions costs deferred and netted against proceeds.", "negatedLabel": "Less transaction costs previously deferred and netted against proceeds" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r374", "r396", "r498", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r643", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r923", "r924", "r925", "r926" ] }, "engn_TransitionServicesForConsultingFeePerHour": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "TransitionServicesForConsultingFeePerHour", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Transition services for consulting fee per hour.", "label": "Transition Services For Consulting Fee Per Hour", "terseLabel": "Transition services for consulting fee per hour" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r886" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r884" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r884" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r885" ] }, "engn_TwentyTwentyTwoNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TwentyTwentyTwoNotesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Notes", "label": "Twenty Twenty Two Notes [Member]", "documentation": "Twenty Twenty Two Notes Member." } } }, "auth_ref": [] }, "engn_TwoThousandTwentyFourPipeInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TwoThousandTwentyFourPipeInvestorsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2024 PIPE investors.", "label": "Two Thousand Twenty Four PIPE Investors [Member]", "terseLabel": "2024 PIPE Investors" } } }, "auth_ref": [] }, "engn_TwoThousandTwentyFourSubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TwoThousandTwentyFourSubscriptionAgreementsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty four subscription agreements.", "label": "Two Thousand Twenty Four Subscription Agreements [Member]", "terseLabel": "2024 Subscription Agreements" } } }, "auth_ref": [] }, "engn_TwoThousandTwentyThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TwoThousandTwentyThreeWarrantsMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Warrants", "label": "Two Thousand Twenty Three Warrants [Member]", "documentation": "Two thousand twenty three warrants." } } }, "auth_ref": [] }, "engn_TwoZeroTwoThreeFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TwoZeroTwoThreeFinancingMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Financing", "label": "Two Zero Two Three Financing Member", "documentation": "Two Zero Two Three Financing." } } }, "auth_ref": [] }, "engn_TwoZeroTwoThreePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "TwoZeroTwoThreePlanMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Plan", "label": "Two Zero Two Three Plan [Member]", "documentation": "Two zero two three plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r178", "r179", "r180", "r181", "r182", "r224", "r225", "r226", "r227", "r237", "r277", "r278", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r332", "r443", "r444", "r445", "r464", "r465", "r466", "r467", "r475", "r476", "r477", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r523", "r524", "r528", "r529", "r530", "r531", "r541", "r542", "r545", "r546", "r547", "r548", "r563", "r564", "r565", "r566", "r567", "r610", "r611", "r612", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r478" ] }, "engn_UnauditedInterimFinancialInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://engene.com/20240430", "localname": "UnauditedInterimFinancialInformationPolicyTextBlock", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Unaudited interim financial information policy.", "label": "Unaudited Interim Financial Information [Policy Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r881" ] }, "engn_UpfrontFees": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "UpfrontFees", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront fee", "label": "Upfront Fees", "documentation": "Upfront Fees" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://engene.com/20240430/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r55", "r56", "r57", "r163", "r164", "r167", "r168" ] }, "engn_ValueOfStockAndWarrantIssuedDuringThePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "ValueOfStockAndWarrantIssuedDuringThePeriod", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of stock and warrant issued during the period", "label": "Value of Stock and Warrant Issued During the Period", "documentation": "Value of stock and warrant issued during the period." } } }, "auth_ref": [] }, "engn_ValueOfStockAndWarrantIssuedPricePerUnits": { "xbrltype": "perShareItemType", "nsuri": "http://engene.com/20240430", "localname": "ValueOfStockAndWarrantIssuedPricePerUnits", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of stock and warrant issued price per units.", "label": "Value of stock and warrant issued price per units", "terseLabel": "Value of stock and warrant price per unit" } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable operating lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r559", "r794" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963" ] }, "engn_WallStreetJournalMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "WallStreetJournalMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wall Street Journal", "label": "Wall Street Journal [Member]", "documentation": "Wall street journal." } } }, "auth_ref": [] }, "engn_WarrantLiabilitiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantLiabilitiesNonCurrent", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liabilities", "label": "Warrant Liabilities Non-current", "documentation": "Warrant liabilities non-current." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://engene.com/20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants to purchase common shares", "terseLabel": "Warrant Liabilities", "label": "Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r797", "r798", "r801", "r802", "r803", "r804" ] }, "engn_WarrantTerm": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureRedeemableConvertiblePreferredSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Warrant Term", "documentation": "Warrant term." } } }, "auth_ref": [] }, "engn_WarrantToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantToPurchaseCommonStockMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails" ], "lang": { "en-us": { "role": { "label": "Warrant To Purchase Common Stock [Member]", "documentation": "Warrant To Purchase Common Stock.", "terseLabel": "Warrants to purchase common shares" } } }, "auth_ref": [] }, "engn_WarrantValueIssuedAsPartOfAmendedTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantValueIssuedAsPartOfAmendedTermLoan", "crdr": "debit", "presentation": [ "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Warrant value issued as part of amended term loan.", "label": "Warrant Value Issued as Part of Amended Term Loan", "terseLabel": "Warrant value issued as part of Amended Term Loan" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, maturity date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r966" ] }, "engn_WarrantsAndRightsOutstandingMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantsAndRightsOutstandingMaturityPeriod", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, maturity period", "label": "Warrants And Rights Outstanding Maturity Period", "documentation": "Warrants and rights outstanding maturity period." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average expected life (in years)", "terseLabel": "Warrants, contractual term", "label": "Warrants exercisable period", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r966" ] }, "engn_WarrantsIssuedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantsIssuedDuringPeriodValue", "crdr": "credit", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureReverseRecapitalizationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued during period, value", "label": "Warrants Issued During Period, Value", "documentation": "Warrants issued during period, value." } } }, "auth_ref": [] }, "engn_WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureCommonSharesScheduleOfSharesReservedForFutureIssuanceUnderThePlanDetails", "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants to Purchase Redeemable Convertible Preferred Shares", "terseLabel": "Warrants to purchase redeemable convertible preferred shares", "label": "Warrants to Purchase Redeemable Convertible Preferred Shares [Member]", "documentation": "Warrants to purchase redeemable convertible preferred shares." } } }, "auth_ref": [] }, "engn_WarrantsToPurchaseSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://engene.com/20240430", "localname": "WarrantsToPurchaseSharesOfCommonStock", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureConvertibleDebenturesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase shares of common stock", "label": "Warrants To Purchase Shares Of Common Stock", "documentation": "Warrants to purchase shares of common stock." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average number of common shares used in net loss per share, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "terseLabel": "Weighted-average common shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r241", "r252" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://engene.com/20240430/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails", "http://engene.com/20240430/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average number of common shares used in net loss per share, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted-average common shares outstanding, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r239", "r252" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "15", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481116/815-15-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5B", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480588/815-10-25-5B" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480526/815-10-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "SubTopic": "15", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481051/815-15-35-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.28)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r892": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 84 0000950170-24-073330-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-073330-xbrl.zip M4$L#!!0 ( #TZSEB7<&.82YOO\"JQZ9]L^ZY3R?I'=WD/3DIL[LJ26Y)Z9?=')2Z18TR# MK@(D<7[]1A1(BJ1X 46 *$KT\9$$5*(J*^/V161DQ$__Y^/>>/0>VJZ93O[R M9_&0_WD$DSPMS>3=7_Z\]7I[9^?/_^?G?_GI?S V^O7ISO/1<_@PVLJSYCW\ MVG1Y/.WF+8R^>_W[]Z.=R;B9P.@_?GGU;/3K-,_W8#(;L='N;+;_^-&C#Q\^ M/"RUF733\7R&S^H>YNG>HQ%CAS??;B'2]Z-?XPQ&CR67FG'+A'HCW&,9'@OW M4 =G_C?GCSD_\;/I_D';O-N=C;[+WX_H5_CLR03&XX/1TV82)[F)X]'KHX?^ M@+/,#T=;X_'H%?VJ&[V"#MKW4!XN[KD[P^7 )9ET?WEP8N8?U,-I^^Z1""$\ M^DAC'BP&/?Z8VG%ICL?2QWZDY-P^6EP\-71V[E"S&#H[.;0Y-8&3H]4C7,89 MOAH%_\_?#S^^=.H'.-\S/SC_=? WDG'%E#CZ98[C MPS7H3A-;JD=T;3[NV9V)A^+36L]8!Z=7#C\_?#=]?V*I'\W:..GJM-WK;T"4 M,(S[$X^&7%@W3ZA&AQ?/+LNY"W)JT'S67LABX1%>/5XS:,Y_-%XX=<>F MFVHIW&5\OAAQXL4N?*E3=P9D+7F>I$G^"#[.8-(U:0P,>@[LE[%C\B'_]/-W MD^-?XP>80*^M2+UPK?@)WKN FXZNG'[?C[/SW_4RXA)?22;L@Y__9?33+L2" M?X]^FC6S,?PL./O;3X\6_Z9O]V 6>WW+X)_SYOU?'FQ/)_BR,_8&Y_)@E!>? M_O)@AFOPJ-=BC^BNCPYO^U.:EH-1-SL8PU\>[,7V73-Y/(KSV?1_-'O[TQ;% M;O;C?BQD&AZ/_/[''Q_T3RW-^Z,?E:;;'\<#4@. 5W]J/CZF>T.[^&=3"DSZ M?W[2$Z,&:?KTK0O1&3# BG*!:2DY\PG?SW$+(1208.V#T23NT5.@>;R%UJ60 MA7DZCN\.7^WC[!54?.FW+G&>HG),I9*8#CJSR)5DTDFG(PB5 7EJL8!D M>5R;CU!8C6-4DC_W?_WTZ-0TSY]UC 992BF6G+9,*P4L1!%8#J$:J[PM7IR< M]9%9?(JF,XY?XIVFY2E^UWW1&_S\-[G4+(,K$+D5+#C4$QI"9$DFPPQ$J;P' M+FLZ.&#. MEOVRA0MM">3V;YG^\WHTM=%OSV>ZT;?X; MRA^H#/::&90OF__QSY>;?H[6* BL"EF8+@%969C P&IO@T,^EGQ5T\_<95,+ MLU4[E/":F3>BX-MH4[)!/0_AZND_;6/N8>*A '(%3L;(P%E UE:>^1 S$^!2 MQI=3'N+E\_][',_A[%Q]=%E47E"0/6HCC2P8=,*/V3AC33"!HP*93YK%#_YX M^\?K7U'+=\WC23-&_=KB+1]=,&4IE3,*Z19L%$SS@.N@\"E.0:HJI9@_Z8QK M3#D&+9.PD44A*],5M5 ,*.3X)B&BG@HRQ*6G?)I)I#>2NX2+C/J,:8,*&IFD M,"%-3L$X[6,].^/MZ=[>=+)Y!O>E""E=92HG01I%LIA0%6;G>/16AB+#2N:^ M$NX^/70YVV+IOJ7 MV#7='Y-I(C\G(NS9F>S/<=HX_]R,FX7"A-FO^.#WD?RZK:Z#V;,F)KPZ._@M M-I-GTZY[/4._C&S7BXHNU'0/GASCJ&=--SN['E*FHD(6S(J(M(3H6-1<,*DK MFJ/"'9=(RXLAUI^V=R-^NS,Y?J$7%=$,.JHS>N2OD' JZ'IV3U#5(ZPHG^9_ M-/4&NJ66F1L'12)3&U^116Q5:"BK9MEP%X-/.^#&29O*8M2R<.D18-F!+',"I5(@%LBHZ[3Q!@&)MXQTAG,2N3OY MH2IKG%V5$44/M1XJ/%]P[A6->^(J<8@!E^8S:SX492U!;["/_]>R[U;;$+,2=OQQ\&O(R'M!76Q]B6_H_ M7I&3U^$$7Z,H-!D6[H0X^[*\HN4 0PA0$9"(<(8I! M/"[S]@!B^^!G]=G;/SKMRO70!"89NI]_HLC1XZX/U.#31WTDZ3$YPG]YT*$/ M.::H3?_=;DN3(S^;'$8T6'PL^[./^N,G-['<@AV14FCU2,M/))Q;X.W0S5&M;'YON MP<^T'H^WQ['KMEZ31BMOD!-P6HN?__3HW+M>XV''6J]_QHO:2\UGCWX%!9" MJ)=.J*A/"+07LBMF].C,WX]7KI9;&<4^_V90HL,[82TQ_.6P41%3R7Y,O59)G7 ?UD;;U$/R]G'H?*1\>Q M[IU)AUB^UQ0G"'MM6_-TVE+LZ?ETAAIU4GXIN?_GZNF^B.?.?J9 &4. J,3Q MLAQ>^1)29J^D2J@(M")3&!SZM58B&O7HYY;,J^>P;E)>[^7UZEY>)6F<#P$Q M"KK"N *2T(ICZ':&E+7FU9:A\O%2*FI[,RKJ-*MJIO@JJ.6A!G"(%(!'!#V( MVUF2 ,BT53GGDX.YX\C&/YZA8GK;3/0(V\UF/ M:U[4)[&=H+'K$*DL<,W!^3=8T/OH(4\0.$P/ 'I6>+%/MUJO^4'J"H'BN(3Y M(;$]R0@W,C]+H=*-ZZQ3*R677RE<5'Y"P=UDI6P0*FC@#+T,$AF=6!\UCJ+H M"H#24P=GJ"&7QPCG:/,$ ?X)C?9J/@;!?S'B\.K+<;R*OY=ZV,ZD-.^;,H_C M$P]#>=N=3@ZV=V$^>;=6#=D+A@BKT)#!"K"0-"N*++HDKXKVAFKT@/2)UA8W M-'(?*:]%=.'8JCV;+G8H3FLXRD&(;=Y%H/4KO(?Q=)_&/OE(+N%5X/^FNH[W M=.++2/"9H3>18'1 T?>LB'@\:/26>66!9\Y"E-'5*IP#-522(H*>G8NRWT"[ M]VQZI?2N0*Y6@SR4E"@[WC-503+MK$&Y2H@813'"($9V9;#(@W:T7]03H9*3 M2H[VAJ$0*;;>M=!?7C]BD$S*)>W@R:$WDB+AHA):,YL $4.QB07 !_CB8P2= M731UJ 3\2J&CIFR-6X>.2AKOLD7M[)U'^T Z3Z=((?SY#R1)SWSGAVKG!CDT*KICG%)6G70'G&G:C)@]52KAW0?S%5 MYJE#\8KMP>LXAL_]\!?C\J3?Y^AZ<5S(UE^GXP+MNCWO4V[$3>CC:M;<(+ES M] KM7]4L5IF94MR*+)4)P0Z5/B_;*;[J[("\A1GB1A*>_<66 9G&T[+S#&(' MNTBU]EK 0A0DG! 8M: =-9!Q9YX"Q&58*5 MVNLT6.2SI,%[!;/83* <(9]!T5&L*)(#$LF%,LQ$)N'VHC"?T2/TR3KO$I2@ MAVLBKPA5O\9U@$XN$[&^*QXC>*X+6,=4G[E15& )/4@TH%DI;317;K 6 U5*=\+34-E?C7@KVOIW6& Q.Q%3O M"N@-/AJ3=&*@96 Z@F7X!6)@*P,:QIRB-$.ET<7QT0_3_P?M%/]ZLXO">9BR ML.9]"$6G"%T]G!=6N!D_'=&P4H%"]>$*]E\G(J>KU!&F"Y:B6QK%53+T)) MM389<,BSF%[OQW60YXRGP_7RD&ME(=H (BD*S&JH3"N9T'>UF1DOA#?)ZBP& MZ[%>*%N]RIB4P_#[P28OT*;YV/HMN-^,XOC M]?/+LB']%?*+$"F7$ ++&5E%5P$LA")8MJIR4@LN#I9?!N-JK0><62>\"\HS M1,L(SC(H%HLU2*0H@C76YN'F(RR57_?+$/+K5I4-676JWB* 3H&H12>1@BF9 M\61\R5"KTX.%TA=DAV_O3)I9$\?;XVEW-7Y>&6\L EIJ,P&M4RI9G ;UEZGD M,T-OHI*STL9YR$Q%B$Q+],>B1.5L:N*.5V>4]4/EI.'",4F*>3GS*E>70L@C MZFD?.9,E>#JY;YE'#XY5&734PE=;Q5!I>9DO=Q$BNTI=KT))' _I]<3VZ4/+ M*W,H%X_]]TBO/WO1]F5\3F],'\'#PS'KM51R=?$%*;V.5B3F-LPI9AVU_0'"6XIP;G/:Q5J M&>DZ,_1&05-O"H^JHD4'U,9& MS@WJT%*H6)5V+%II>2C5E3C8X-DW!X?6DR["BRI5AE#C8>.D3LN\*C)^"$=BXD5A#W,DV'HX/A2)J0A0E&%%D'ESEP7@I[ M_+A$"OOR=AWM^1FE_&877HP+75A9A'0HP(\*!SJ4S24@P]FA-X$,U0=I)2], M!:T1,J!"B +1>P[@M4M1V#C8*.97>BAQ,QD,14L;H H$#E0V-); DI292:_1 M-0#OA!MYOOK$*?'/10B3I$F[]"H*Y!2Z-U8L;Y2O*&<"P*1[7)78:0-'>#5;S7 MRNM>Z&!HCP?=E<2A+*,-O$3F,Q)'5_2B@E>"PEDF00*NT[WP7(,T#U87V9H6^*K/*L"TJ@<"C7!%2AW<V;75A@SV6B=8-!,,)ZGKR*K!A?**D/J"QO8-H8720W6<3!'K7^YG;0 M!K!O7G)(.51@G"J1:U,=\S5E9F4V/M>@NK] M#NT[:&^Q(M])W_"6*M.J;*2D&FR\K\C'HV+1!<>LIN@WSS[HP<4\J9':,W@7 MQT_Z^9R@V-,G6]OKCV(:)I:I]']VZ(W2&B 498UB)KK,=+:&Q:(]$]YDI)*S M4=_U0,Q6SO,]:C(*Y<5L%UH:U\(NW>T]+,+;=\6$IAI*D"4S59 )=!">)6K5 M9(W3)49=0QUL!;!+BB'@YX.C/Z=KZJYP@UHSJS)HOJ@8"R7<1BT0 #F+!LT@ M'LI9I"!=T&ZPIR5O93_P,":W?GNX@3IMOE"3(6F94<%MX-)+[@>;K+_9JN,K)(($B^YP=,P(A=;< M@$25 ,"\+R!*"M;;P4'DC3G$5P>Y%J'VJT]87?FH3?O>IT[PG3J? 2X18A4_*A6VC7[HZM1\J5J]XG-/<^4"O' M?C_5IXBFT&M0RB8-@]T:62OJZREYM W[9OIRWN;=V,'FF^YM""'*FFIR"B72 M2(J85 ))!ECEMF;T[HP:;IV;E9_26DI)OVEFA,C.GO'M]?=N _7)1V0Y8KW% MX93VJSP9)F7AQ23-P%-,P"I$V=$JU"\!.$^H;_A@]C(:QBL MW-X?]?J]KKL!,B9H3?*$7F.?(2^CO.^(CG^-@D_:^ M@8X=&]K7Y@F5ORNL9'+$J_;,EYQ93*4@EHO@8+ )M@/.3E\A:O/195%16'/P M@6F=T7#KA!^S<<::8 )?>[AZ8R]?-3H-@ELF3,"7=T:P6'$9?/91>&H%!8/= M8[S,#>V+K4_G79R4Q5[CT^F\I>!^;IO]4Z[IUQE>H$Z(5OK(E#*H=JCPI]=9 MLB)-K%6$Z/U@T>BUU,Z=.PPC8G$^)\5JH,V8A+)');*9KU6I+"%P.]@T;\4(@(,MWWH\OT)#WWM.]:;,,<$CD-F MSB?46]%REFS(#)RT@1M14.H<9PM]GN"+56F HL"$MPCM;$.I0MGSE#EXXC[J@ (01:YCM( MK1,Q[[WI9)D^#W?3B"CME1'4,M4C#M"*:II9*DML$LI<]-RJX9/OBO-"I?2I M2G'\,C9E9W);O=4VT77<"ZT@55[H6' #;G6&VBH:D4'- G2$S) MH&C'%.4S)3K:%:QUIK@8UAX[N;9*0F]F->C;UF#!%L8!N1:U$UH0J*B2AL'6C;PL]>$) AY*;IB\;*?O MFVX%*5N;V5*AK4[XYYP$]CW^\?GFRID!ZT\?,TPL4U7Z[-";I8]IJ1-:&Q.4 M9)J:-D:-3*J@(ERW+O/A[L MD^]_ I^O"3*LJ>ALJ"IK;UFUHE):7T7EX0HZ M:A0U+%[;.U[D>9/8?#/!#J=%K538&3$Z81M;60#CT!XDM!*(ZG@>;&+.$*O4 MKC#HJR-H3P4G;:5^E) 5"]S340L5G)2YPG [A%Y5I?9T9/>N%:I%Q)\HDYE) M3H4N%((H+Y-F,H1:#:!34-)0*7-1E_'K["3?C! K;-DJ*Z)67:E3D4>@X$1D M7NC J@NR"AX0Y [6('WCR3/HK:6@G&,&I$=7.A'&0Q\[J.@@5Y_JG8^RKW6C M9#UM-&50W =D"9<]VIPL+$N:>ITB2;A5Q8HR_)2F3<.! 1S T14=>H\@W5@J M+%F-9\$C7(]1R\*E=P7N7LAU\%745K5E9:TT/J):-$A%ACA0L@0ULY0AB8S> M\9"W^U=82^K*A]YN\90!'-JM JSG1C*5*)5?EF[?0/<%[E0+E5URB]WU[ MLV=-3%2&K('NZ;0ER>F)O34IZZ/[F@HT\N"X0Z-:C,U,!XFDI!8S4EE$MJA$ M71UL8L' '(X5'K8I*0N5763"2J1*$85%ER.3)MM$T12]_IV[U0/5PY8X'Z:' M#7'0]/T7Y-F;Z6%/#AJ/!G ?,DVAG.WJL:K-I/LN'IRK@6JGV0K@FK$T=IF M-/-IL"[R ^+KS"\[A+G*2I'3DY"2ZTSBURAF#KIT!E&>P&#.\6QH8('NN:" MJ\0,IQ.(6BM4.0!4>-VX&)U+=; \?)EQ^J*:%:MP1#\)&.%?RNS(:^I?HUU=4C&]#SBIXPTWQS!GJ M>6>L9"%J8% M6&Z$#GFPVY)#\'"&0$*#)D\XRXJE")$. 4D(E>7"T0QZB$4. M5J&O)%%N.(ZIA5*E$=0^ !;A@@3"LIB5"0HRZ#+8<,$0D]8WT/@I%ZDUQ,IX M=DC"E(%P)((EI:J/(6==!GOR9R!E55:9/)B@>! >Y3,C-*F)SK#6Q"JETEC# M73&#A2:78=6+ND&L#*X.HN/W )R=FH(M"L%L+#XS#3*A;D9X8[@R@.QDE1NL M1EZ^@E6/91>2?1M5K%9988Q3978>6$4"+>HF^90R$P6!I\\F1C_8JHI7';0\ M%*Q/+1SN8*@]YIJ#*=1%F JU0T'WP 5-S49Y0GBA&(BU25%4=79*L1VE>KW9FTS2!?=8$.+ MF]H%ORH]X,4$#M,#[O?=;Q3FH8KU0F<6."7V)%%8*+4R$[1/PJK@AMM4[))< MYU-!NMOJOGHJ]G:C(U(J(LB-2.9J#"J, -08R*"-<2)3GR!A!YL,<6<3YP:P M@1'0IU&B6*8C=16B@N-)9H^RR4'6[&NI@ZV5<:$P_AX/3K56N.7 ^=)$-"M* MC5'HJ.:(I', M'8M5G>-*LD17T!BZ0%6SLB;_*686:[6RJEH<'^QYCU/GQ(]%H$^TB1T4"A'A M3Q;N<;]7N;+>Y$/8 CW)/,+WY9>6*8)S=NA-F"=&4P&D91DH7(^\Q*+BE?$" M2'D^[%9S^NPOUZD\QTF8Z- 8?P?K F4MTIKM$ M8)X*V84BK$V"!V4&6T=DN0*HZJLJ@%JUMB" F4 G8H)R+"6%!BRE6+0!2'RP MGO.-(MBW;QBN?.*FVG9NR.1D:GT4M&=94*ED#97.ISID[)@2.H3)J<%JBONS M3DNXE2N+N88($9"(B&Q!(*<8RY(OU-2OHJ,9/6K$NP9.MC8(3C;>_D#T)4;E M2D*_Z-0(E23J):,*18\,\QXYST7M#/-Y9FLLK\5+H=-X%CL:[[D M+%GT2K)*ILZ0E99DDX7T6OI2U M9\M=U]9P8E:Q5 +.F:$WBD;7(E-,FE7Z0Z_ M(@Z6-<=1I3B:[&WF)=?U46O)2TWH+IU8WDQUH(8%P!A%LOU5AJV6HGASS2CE46#:Y M,%C+>B?(NAEIS94G:2*@Z0GXA[0%I34B:HK:1EE!YS38KKA+D/6V2@%LI#6Y M-E45F1FO(3.=:V;>.-2V)@0120VGP:;!;_2PY1)\L]ASVKZ6 E@>Z0[AL.=Z MXE-9(9[51C+MG:7:!HH%F1-S07#G."07![NQ=;^A?4[,>(4-V*5 %R,4$!NJ M%"VA7)\C*T])U&ZQ>/[**AP4Y<"8Q+)$E*2A( PNP; :2D3E9Y2I@]OX&&R MZ6LZ)',Z0G(R/'2C\_:N\MC7I5$.,9[!/V)4 ;62]C4'BWIBL%[7M[I;OQE' MSL9DK76.*4V522LXR@"K3%KN%$AT#,1@8VE+E;I<0.-:FPRO]^.5NN+&%N.D MW;\1[''.UV0KJX+ 3JB4G5\]8A\?=09>LAGQ?KUN"3VVI'#13&"520#;D_G MM.VUCXQP<";1\<@M7UOKY#/.![6W7JHQZYFA-TK["@4AAP9F>4(7OF3/(O>> M9:M2#IPC?PY.7PU0JVRB\3.O-IF24)\!]=35P2VRLA W(E)4J?+A5I;\.@[D M;J:7%+?*E%P42YIR>J-V+%$U&VUCI9(.1L3!EN.XLW0_?:9^9076B@FI1L>J MK8EIAS=.(1J6D_-LVA[@R+7"^K,"BKYY6,ZF MGAIZ$P$%ZJB=5$8FL05M*N5[Y.Q8$-K%DJL2<;![XIMRX_\>VX8"WZ]PT4]5 MZ1N/7\_P6;/_.YVWDRM!V I@[=>R-L]E/:7>J@Q2%O1M*N>4(28]"\'@ U!S1NMRE,-U1JZJT V?&IVN ML=3(69C"]6KH8B%%&UC*_5X>EX@XDV&.&PY&)NWS8$^173?:B$,0K*P_YKC" M/G@!0N8*"1Z]UH@BG6!!58Y2I#)U$'4#+DHP*/*Y,W+]??)6KB7N>Z=^)>DIR7#AE2@,W3"+ (47%F0%EI2OPD()40^6.R\C M_DMJ_["S/6XF38[C-VVS9C5_YB3MC=2\*,)ZJO]3M6&Z(*Q(W&FF+%@;=7( M=S)![5LM!KB>'I(J1)F5#ZP(0]L, EBPCGJ,EEA"EM6ZP<95GL:F_7L$3QMUU]I>67^O#/5>64,.O (";5- MGO7-U/AB4_3+_>(M:E9FX]^C\:B'K%H,4T);*HBN$^99WEX$)DMUO!YLL3&U;6 MOUU;R)XJS*M*9JH$P4(*'IVA:'+P1J;ABM@=.""^F=Q'K4WR2:,C2SU\=!(: MB9H4\T%S[91R40[6:;CJU-;&>LBM\(B+DKF8PCF#$-"I,\@C'E4C4[+8ZF31 M40\VX#R,/;=DP:?(A.1=H!\SE0=ON)<"D"R0KMP9X5L&.7T5IGU%1'7 M.UX$LUX)IE4R+!6+RM&&JG*I5?K!XOM?YETS 20(X9*N^63C%FTUH'V'6&7) M"-K=-&BQ*AT*H(3Y:I@6J"L# .V(^6"QXY)4>06SB+)7GL1V@H[SUVG)0%!K0>GPR8E2@!0" M1T6'J% YVI)CX6:PK;\&)ETK;'A;DT&GD$K&:%1\FM):?>$%73\E0.2H51@L M2+RJ_L9I$'$X;)%BOL@Q_RJMF'%&:(\>MG4R,!V21,08 X.<'4=E"BD/-A]A M"^]0FO&<7.?#W ,DTY./>3PO4)ZVTST2O?FL]\!?U"-]^1+:1;>3@_-OL.E3 M1)NI/N&LI'*9A44I*3&E]#D"@J7*.5I-9PK*:LX-3FW#,OD%.J-MY94#ZM_Y#Y=85H,WD;SGJGP7(&@JHA)5#,6\Z9":A M9JL@"C_8 Z-78.O#XX,]L.[I1^2"\F;ZLMF''53$W6S:WIFZ:@BGO7<20;:@ M V2.^O%%5"=55!%J0=4E!@NWAYO0O9F.@28X &,M1\H&?4=5.$NB:H:((R,>#,"BH6(WL1@1!UN;ZD[4 MCMY,Q A]'# B2!(]] :U @H44*\Z'T7QPY?A"AS"-Z '^R>[%JCV2?3E+I/ M>4J;[QBU(?F65CC/JV(!;1D:,53[48%DR@8I?(4 ZDZ>E_C*SB\- .Y41YTQ M$MXN12KDZ2T+"=&$ET8GQ1,"H,&F5&W*$JPIM4.G[&U&F2W4-\H)S9)%FJ3B MH[/1>S7<",J@HF$GR'.F8L&-LMF4,QRL8#8!-7,TF2&U BMH@!,WB'7Y8&WO M92IU.W:[AY;SR4=H<]-]I:D R>*Z\N*9RM2>WH)A@9?(K,Y>Y\)-'JZ_/@Q- MMZKBT=D))4-R#(U/)>\#-1T(RIJ76?.258C#*\^UJARC9#,B&"J31T??*-T+ MV5!GQKE,1B2.\#X/C0W77SG[OA[?UUR/+_I:>3:5!8.H!I6M9$&GQ)3$*[X6 M%=-@5>]5MG,,7?=-V,]00T;\HUAVDGHE*O0IG2K,.J5*+)9;/=C3U4,Z&;J9 MT)&P(>(?I"$[)F.TK%856154F).J$D,=Q?@&PTG;V:GST@Z7(FW*X6J^GF/KK.0 M@0DG9>!@,_CA)R8,KZ3P"KW*7&/.45%+1>J_XV)F7NK K%35@+$@_6 #_K=R MSN%V>B9O1CQC=J%*"M_3 0>MHZ,D%,5*UMI;K77B@Q7/0>SF;H9LR5.T*R86 M5#:+WL(^1>A2G4ZE M.+!^<-LSD,OCG4EIWC=E'LYTJ/D MI @B1FF9%*DOXNA9M+8P9U0&U(Z^K+\%Q)<*US?GW@P@NF6]\RH$QX(,?7%Y MQ:)$M9RY4#EPD:.]CVXM0;UKE).7JXMN&53!$-!U!1D2T\97%@MH9CPJY^IJ M+&FPIO0;]60W4W?!))$ _T.S0"?\M=(LE HL1Y&TT454-]A=_(N. >],D.!Q MO#V>=E<7FEPMPMO0.>"3C'3V)/ EC'1VZ(UV0_I4\)*8B."I^1EG*7F.(",6 M8606S@_V[-JJBY!GS01>U L#Q4^G;<+QO[73#[/=U_O323=MZ=S5SB]_ M7W<5\RQ!1>T5/13AT8/@@V6+:Q>J7O.ATP&T,PFU M:BUM11B(CKG.=!@+E&)%I*JK]S4-=^/Z0BF_E>ZAG/&PJM*-)GCCK$7/FWK- M@Z$&7=*C(D^([PR2PMWMMES')G=:9Q_08OX*[V$\W5_"LQO,QF6V7JB*GI,, MM$, B.Q#K4I6: [E*5$A34D]M MX2PKTL54O,X^#JY.]%5M6481L4:DXB:^5 40S/G M6'!]QPT-UF<()0PV=+;$P=;G2)HI<= M%JA;56]7G6,ME+XLC3 (+^DT?PA4 MG3]QD[4S:KBG^5>RTW/ET]:?JCJ8HZ.;,1T\VZ2H[A&O$1A51&1>YLPLE-G\"Z.G_3S67N'D[-]@<1*BB1:(S,NB651\L@T M=P@*!5A$G>"4A$0NP]!6_KIJ/^?YWGR,8\N+V2ZT-*Z%7;K;>U@T/EDWM5;E MCML2I/3%(687J-5]-"PHA/ ^5Y%U2D*KP6YS7"MD\G3>HMLW;^E$Z=/F(_WK MSM0I%$8JXXIA-1@4*&**M9P)D"APPP2#5A$ Q:E2M&9G(L9 MK+?RS:4!K:D<;. Y!A_16Z;4Z.@D2[%49J/447B3E1BL7 ZAU<(-RMFLJK@H MHLL@M>6L6D3\FHIS!X__$N!X,26&? W#3> D19&$NA Z:=1:'+E3.? M."769217U$8,."5]Z6(FS^'#LYBF;9Q-6ZH^NBANLOZR)K+WJ,,JM*.I+D"* M"J$G]44P(K'@.*I?;73PSE%L;ZB$6JH9)54XCVW>1?*\$H,_ Y4 !Y&6Z@5'OWPP>9 ':$L&!2HJA3S/!260 &.S9^5MW M(BZNK/+)ON)H^OJN^RMG$]_ETAU93@V]41\Y,"HJJKSK-;%F0ET?75]9108E MO2INL 4#[L@9LA6>TG7!6RTA,1#HA6H.@LY12^:\5L9)A&!QL-OWF[3,ZTFF M*$*64IQAH+2A;G_4@S$K5I2H*4F3>![<9M(GM=XV[_NFZI^4^ZNF^\=9XB0H M!F!NS,F+$B(K.BFF%8*4 MP!,@ZA4QEABD3G<3%GRTI!Q>1$"O*^#_K2 K>9O >+GI+A=%(@4[)N='\$RE342$+9OLCX4#5V33EA>D:'-DY+M>^ M>W W>-G4E%1!)*@='4V$5-&2V,BRL-6$E*4=WEF$]9\WVN3Q5.'[<*M9@A'. M#KU1^RI-)X:C83+1&:.J'#$"9T[R*GQ(/-7A*[5OY\ HU]K&#!+U6D($B.]$ M1TEJ2B([TBH$ IJK67HTH%3+X#;M:E MG87% "H1&:IY(9;9 CX[]$8Y([$ZR[U@NE3.-*^5>6^ 0985P &O;K#)D9>= MX*/NW[EM^BW%X^R$JTBX/%==W%O\1)[">R0*FMF\IISW(52XXRS]HH6,/*P:^ M:%\U[W9GY^34')44_"KWCJT"$:@10C!D+3T(EJ*+S"5\#&K;5,M@&UNO6"9N M[$6?//E[(XSI2Y0\!70&R=3%;%F(J+92%%&J7%,=;MF!2TZ,M\WXU);QLGLS M7^27-I,E_-(;;PV0(*Z"XDAO*TVU2&ST5+3BBFH4*>:BXTAO&X49;++4-W=T M:P!'3@(OI?"46;&*SIT8U!#!)R9SY045AH+AE2#[AJK5;&9SJD**.KH^[T%1 M44[%T+)SEGP"6[ES;KAG(>[A[5<(;]>SJ>=B3I+'R)2A'!];$HL2*@N0HR[=E5EJC:DD?_(NI[G_NHA4E_XXRL MT4)[F[5S5BB=$ H72B9F@*H6(1!A2;A$!])Y-IR[6^AW_:7T'G8UEE6J4"^Y MKE*P6!%#:H>4\BYIYG*U088M^H2"FJ4%\@L!RCII( MEA*."I/!I@#:::L'>R9O\.>6-X/5E@,"R;A1+@U-LEJ87@2 M>+OF:0"QT8!*,58.S+DB4>Z,8SZ 8VCWE5!6*%,&?&AJLZ4X^IKXRU'L3/G\ M&[G "9UM92#2RE:8]CXYCKG5'CWRLC>IZ$WXN ])EJOI)1%0* MN22F;"7B-2CWD>"A1()/R?&I<^XW,'W%@GQ M/Q_> _]Y=(.C*T>?Z0[GW&T[%NIG]\\YNB!/I]/9\9W[WJ5P\A?/49#Z@DMG M']YT4RV%>[R]]>ME3__L]_3EKS"9[C63\VX[G[6/NW_6V67W//7S1Z=G?OF+ MTYT_6\9E'GG>O7H'[@*B+"Y>\XY_X#_I:"0J[HYJ62-SY/CK=#R.;=>[BS>A MTQ^O5TJG95_SRVFU'2>QK.SU5\RFZW]]I-=GO+4D+?%#\_$QSFPZ;S-TBX^[ M$$NOS_#Q/__+:/03_CWJ9@=C5-#[L5"Q=#:;[C_F#TTS^1'GS':!PO6'7Z3I M1]8U_XVC'J=IBW=B^,V/.,/]HYM45%XT!!X+OC_[<2^V[_ F_2U_[*_5N->, M#QZ_097=C9[#A]&KZ5Z<' U,T]ELNH=C20.R.&Y078^ASN@9W7Z<'#WFPRX* M">NHZ-OC_1;8AS;N_WCFV9<^#I_UH2FSW<>UF;%>XT[H(?_K3\+R'W]Z1,_" M5=H_L5+'KWCXYO1.\J$T^[-1F<[3&'X\N8#B: (;7PNUJJ4XM0AK>+<,A)_. MOEV>CJ?MXS_Q_K\?+W[7#PL^3=-Q.;GP_@O?_H_G.V^>_#IZ_6;KS9/7W^HB MO'ZR_<>KG3<[3UZ/MI[_.GKR']M_W7K^VY/1]HO??]]Y_7KGQ?.[OC+R"U?F MW[=>_W7G^6]O7CS_8?3K]DARH\-%:W'X3B2ZCS7_UV,U:+&@!"KUR78\&!TZ&*\ M@MKOPB3.4U2.J502TT'C;[B23#KI= 2A,K@'HTDD+XX::_PZS;UC33[6,!94 M^^SVV_QB]F,#W9Y9@1IMW9\ ? M38=0,+X+767C>#"=S_".'Z'\N+B[X/PA4O/P!YD\F/T.'G>P']'' 'PBWASO MWA[=^GW3-:E/QGE\-/IP$(XJQ\3O;Z[_]<<'CRZX%NSQQ9\>S=JSCSD$]#T5 M/^#D6&HA_N-Q_R>C+\Y?\<]GGVPA_SSYQ^Z..E8AQJC7J19HTTETBGOVC?C 9XI M55VS(B!8!PE4$JO2K'^;QQ8%?WSP"O:G[>S!J$[;O3C[RX,&7[&#C#P_':O'KVGZ-73UZ^>/5F M]/*/5Z__V'K^9O3FQ0AQ]1L$SR.A1B]>C83YKGP_>O%T].:O3T8G(/6 2M _*2FGDRL VG;#H^D(3@T#;>KAH>\5, MLLJE>_-JZ_GKG1Y5#Q5PWR!*,BBM?02X9\=R@7*)2 M-#=5I$_Z+!AZF<6[#&.=J?J\%MY8P.BO>#OD MYVZT,\D/5^:2#&M;]TMUQG=//L8\&Q'-1M,Z^D3%4>Q&K_Z-;!V7G'D-B17G MHT63DHM3J[$T=*ZMW:=VJ T5/$=VZ!/1VX/M:8'/75DH[V*[WT[?Y\6HE41. M+Q**7UIT#[K=T?9TC,"PB3^,%NF<7^C@#I<%3BX@+3-K/K+=IA28/'[ZUH.5 MR?O")-=(5Y& A9HK@ZH4%8#3V?EUNL;/'VT=K^SIO\[Q:<^193(D?H,4^I?L+HO^9MTY4F]U[SM)ZDQ(K?\Z$C[^)67[8YJ8KZ=V[?Q4GS MW_WG[](*W8>OGKX^N'HL"!0^U-J'_V\?1\^O#<);O;1O=* MZ'@M)C[?]HHD*SBJ^&ZJ9F@Y$XLB119U2** 0#-;5V-[MTIIH>L._WK63$"L MD6NTMW[T:@ZC9_#^X(?1ZSG>;"3E59N-%^B6&]G"+Z(+V)QD3(&)H /33A?F M2Q4,O]))U^A+-BNERS;^\T7[9OIAG1CG=6QPY+,XIYWK->_[+K>9>\'&K/.Y MRBJ9\M91+]&^1*R)AF$5,9 +ITHE]94 PG8JC @N6B9I44#6;:FZ<-W&:ZQ? _G/H?XCXZ6=K1?U?*<8_ M-PV(:QNUK:QXJI[!DV9!HE!5HY-%RG+#;YQM?8JX+Z?=+([_7[/?>W?KH^%? M]:N1?"FN0<1[!V(]4/&0\!2.W&]1D3;[<3R"CY#GU%H8OT;$"-T]NCZQ9"@> M(Y*/2_'S-3=OKPRZWY$(]Z>0]O_ZDY?"_=B-9C"&_=WI!$:3?OONAQ&RV7A. MC#&***NHOPH\'GVWG@W*6#-7"$*8K(HR*;UD,7NTC]%RZI5JB[LQ6B<@N(5O MLB*EN0(R&''5MN0 )OG]NI)G*\_<(8VUR))I2XW4:LG,5>IE4ZB,V(T= :KO M-7Y)7#VD/6F%,];>^^%N27\%&TG]K)H)A5/H;))2_WK)ZEPS(+&JE*9^+N%+ MC^4NRM11_[=EWJ]]YS^U7+Z4>96KPSA8]ZE\F\C1$)X6_SF$URZ9@@KK-E, M46+^K<8S/W\0O>(%#AM/N5INJ):ZC.BU*<^2JY4%48(T4GLI/O/110;T\GAE MV5(G$)\Y0X^>LUHJ0 B!JOZ==-B.:C(*F7J3=GTFN2SA&CG@]6&9KE6$I2\F M5[CC&F+8C!BCKDX7RR!;:D\E/8LQ*Q:UB9*C]4S$3*720V"I!,X2<&]*359SO2HM^.30=/79XY\G\>'5 M+]W&NQ C[L+H>>Q*_.>H[V0PHG(H,!L]>W;5[NJ]"5U&<_EJ5#*!BBA+IAW^ M$4Q-#**WP2DC?/F,>7+E29J^&7N@+M*V, ]1LA2UC;*"S@ENQX0>M6;ZX0A8 M09N;K@]S5,KSFL#HI)7]811G(WSPX3B@G:O\R M4X.-Q@@AF4N.BHUE@H20F2F2YV)UC;;%43H8Y5W M1=RC&F\?=J%/QJ9-D?;3$:_OQ/>CW=B-:C.&,HKC,5ZD>@"TR]+WFBFTM9+@ M< #>\WB;15&V\^)8^>%FRXD]FB/>H0T8NDS'RD<%KT[>]4/QA3/TN^U"COJZ M-MWH.[P?6=9NCN:VVYW2.;.C4]:S7;2N9^;^(9Z>)4UQ\>/#=_@>;?*DC+Z3 MBW=,R*MX/?T7O@&-[X?BCV@6A_>AT@A=/XE^DK&;C0(?E7C0/1SU:N/2O>&K M2';1UG!&DP(0&7 $1UHAO X113P)H;P)16NYHH2JPUI#BY(/9&!F654XO9WZ\ZE[HT>?6D5D"O*SZU^-LLOQ.CY=%"KH5>S[_WUJW-2#ICM-AW...[3:>%UJ_[%?(\U.G3? MKU%? \]::52[-D:J^<4U\]%2(RU3)4(P5_QG'L"7GG,\IA61ZE!]W^OK>WU] MKZ^_"GV-*C*.QO@:,(HYH[ZFI)?2J["6P.NYWXY0^MBY%[H]5/3XE/8(X*$6 MVL,5./B!L#H%IU!FW]'W[]KIA]GNT>6'"-VAGUN!VDSZ^D9]]C7ERTK^XT4S M["^+'X^&73G@XOD=#22\?CCX@KD>C6PF"WLD9&+RR ,YZ78\O(@'O_;LJ[M3 M=$'XA^$+,ZV,>>@OJU(H'G)[R67)'UZ: ';93T_\W+,_K6%F(-$.2;6+=[!KIB(;;N5MY) M<>@']7HA'PY:Y=;6\_-\MAL6/?Y:Q/%>+ZU4+]E[Z/.M,M"%AP_2:N6BI!-EE/'>,*N=9SI6R1(E\VF%=KC$:H%_EG3R93:ZY]-?YETS M@:Y;>4^"U37\NE,@;YTBMX9\K/OWOW__^_>_(^]_DVS4\_=WOJKEN0OL<8> M2 [5(A11S&B@HB(VL6B-814@&>/ *;>B7@9'S/E;SYO;"]:\ X#D&\UYK9=L M;E-IIW/WY)MZ7OI4GS0%9329]CE/\VZQ,8YON>BM>4X'H&G;/VM\0 __T."C M\;&C"4Y[2B[7^Z;K SZ3.,E-'--6%U4EI,'=+$Y*;$LWHO+D3;FHI(GZ+GY_ M[A[W-3.BU820Z%SEC/HA>*Z1)QOB4'6S\[Q?.%0O?Q4UNR10/0 MTTTP^YUJ-FOG7UK0:N5)/]>L:?3U"^+ULU^Z71B/CV1U]!U*8)^#LN@XLV(-\K1SFD45 XLQ<>U$DM[*L]PM!0?I$)(J&5 B',+4 ME))C,01KG2DN!G_.D8S^"&E_VFE1K.'%?-:C H0'#T;S2;.X_1]O^Z.CW0/4 MCKG90Y;_RX.=YT]/R\-DOL?*=,8.ASSX6>L?A+4_"!..&/+H/3>8MGNJ-,4/ M"[PTF8[V8SMZ'\=S^'10]H?1]--B7)C.=ZW"@-=S;D[7C)$/)16-*=,Y(NPA MM5P:6&;C%U>*//?E2O/^^/7&\)&5IEV@8DHOG.]-?BQ-MS^.!X_IZMDJD?RA M:1;/.XS.+K[XKWDW:^K!T:/[GS*$]TCPC_0.E"5Y3/N/F_";;VV)?WJ$"]PO M]&[[2:+>P2)\S6*=0?LXCC_$@^XPZ?$D14X'(\Y=ZV]Y26_C$'%OL=!\O"6J M#:/BZYN8Q@,JZ=L78=A>?.QN474>:IF-:L^[FAA^>7JVEP^]O.2Z>\C]LH4X M4\S_>-=.YY/"#OES40_O9IMX)X&]?>BI<\P5=09.$N?P%R=OPD^PR*I*T]U2 MQ'KI @MW^[WVFE(0%UY<9_"<&=[INH,OT>!\2;>N]4C<[9?Q&)KXK/S%XFBW M)>?S3QUU 8[CMY/I#-ZBYQY;0GUOT??\$"^I,D\DO;#,%3JIAUWS'B,G0#MN M)G!Q_M++)]L[6\]&SU^\>3)Z]>2WK5>_[CS_;?3TQ:M_QW^R9R]>_!M]?OUF MZ\V3WY\\?_/Z>%'C=>N$GBM"ZUSMWF:N<%]5+BN3]W)X1^3P=E]L4'*PHM>] M9_][]K]G_V\2D:T4\6Z]>C/:>7@51YWTV\0B:GR5]W?R)^SH-T?1M=XG//KR M-O >.O6SM\W;XY2%M\UDL<^ :.TVX-[3G>=;SWO M_,<,=[O6V]V7CS_AB&= MOK=I:U']=U50[RWBO47<2,[NS@SV1N)* SB D 6^U-Y;<<*$==2:N:_O>"L6 M[#C;[_7Q?PJG;5C <0I]V%O.NW\-L4QB@.\[78! M;D< MZ=DHRGQ=OO$1$:_+"8R>MU/9!3[]*2M_;89CQ1?Y"?U-:A>Y-DT03M2 MHO]2W%G-_@.T(_^G7S3?W\OY-R#ME6.Y.QRB3W5LJI3L[>$N9][FYI,#L+8OZ*R@ >WT*"X[J%XW^ M_1+? %HJ_;M((EU(]HGW.6SS/OIU\3[W>N!+]("]UP/?@AXXA=./00!A@!R[ MW;=U//VP2[GV26A'IQ^IW&O()N/C[KEG_#PBS# MO32O5IK5G9%F]?:?5+>A0:/6O(<^;(9?C \_WX9,_^W$\WOQ_-NGY_?2/9YV M<_*7M])T/CMJKO>JZ?[Q#8NL7CI?]EYDEQ-9?6=$5A-4GK73\2+*O=].,Q22 MD%MR>/M']Y+Z\OC1W[(HJOL\I_L\I_L\I_L\IX%F_GXSJ;_-;1C %V_^^N35 M?8;OPO0MO>OZ-4OLO>F[-WWWIF\ +MS5*;YW5:[.)@B/X5T<+SR_OBGQK;A^ MS^BA"Y]O\=![RW:.^% M]A9W+;\.F95OYY-%[4]H*>$HCJ%/.%YD(-Z&"/]QXOFCU_1\VKY\TC^?*F[/ MVV;6'"85_M'UQ<,.+?4W+?'WZ8"WOK/Y=4C\1C=97NPULQF4>\&]%]Q;W-^\ M%]Q[P;T7W,$)KOGZ!7=*?39.EFMY*V]%6OOV'CN?'GLOM_=RNS*YM5^_W/8& MU[Z%C[M-:F[GA/R3PV?=B^IF117O07/XRP/YX*MAYPZ_C;/;PHJOCY_V+?/R MI0=)SNT+N,GMZS//OO1QRV[]TLO=F78A0E[UVA>O\LUJ>]]LU<5]\Y"OK'G( M%U;WOLT6'B?J?P^HL<@U2Y'?I/?;3;3%!7U(;D==;*.UC0T]]/@<-WZ:[38= MG4YID0O'!Z-7L#]M9Z/I9/04'/CZX:C[M+DSCA\6.SP7W/>$ M!WWYC;?C)):&5O7,S;^C)B=D>M[#^."'I>?__<,13'Z#"1P?R[OX)SC+/)X7 M^&&4YK-1;*%O6CMN]JC$W&@V_>'DV&/!/GO_3V<01S.(>\?%,^ CZH79XDC? M#Z/=Z3YU:TLP;J!VU%.7"+RX]FX:QQWUNJ6&?C-X1VOPZ7&T8'5.\.SA:&]1"+D,_:5HOFA0]>P$L^Z:]L>OF>_N' M3Z.%O'C1'X[>X L1LN^.B$JGKG*SCR-^.&*6HRO[^Q#;<[YMIQ^;O7-^T*_O M^\^^)GEJ)O-SOI^/R]DO 67FO'LO"'KV6UK;#CX;W-.W=&>_1JG\["O2J6>_ M1(@U^>R[:==1_9;/O^]9*8X_N]!":3Z?\2%KG/T:7^(?GWVW>]X"?: OC[XC M)="AR(QC2RR/B]'U[/3=87V)"3)R?X ._8;^;"SR63?/NX->PD7+426[A]3!U21;M'?MCMBK3)%(2)Q)EVSD(WXZ??4.IYQB!PL_\(RM^V1[R(ZZ?]V@\=,/G4'MZ:T.4OU_]MZ] MNXWDR!/]*G5Z[=WN/4@YWX_N\9S#EMBV]K9)74GMF?VK3SXEV"! XR%+]]/? MS"J ! F2HL ""%1%SU@$":"J(C/B%\^,4%Q1<4WZ<%R>'M4K\ #)Q2C,K'D] M2W9M8:^&<=V^ZO,H]X9_ZYE>A7\;Q5+0.\/UY,,X7[MA\2M\#%F!C&.^R&PU MS]DM9OGQ9[,R =H-QS66YP_-_QUC9LO3DY>#92^)9CYTW9MQ%%:W*K].XZB^ M'O?AA4>2VR\!8V=_G[*373WEU6T?9B4G3Z@C*"OO]!HU]5(^@Q=F?CLB7^YMOF+ MO7]M]8,4]4Z*;MM[5[T6+N.TMD*+>DC9FIS\>V5/W<7:$;/M4D:"UQ!ZN9AF(W\6;PZ,SE_\K^6'\G?RG\_L M+-A_%3O,CAOL;L0A\_Z:2Q8_YVN-/T1@8F#BNV$WV_2^X&)FXVR]3!?#>>,G M%@.C,'?^;5"[E#4?%0?W7XMA*2$=9N2=I#3TV3\85/^,7PINSR;C<1R5SSS:_%PUYJ[VLDCI\SY,UCT?IAX>=5B)_B M:')9O+9!,447Y:A$QL3,@W4Y5V:V&Q_)S^LSA24]5E_ZZI>U3U4Q9:MD?B4Q M:3$:-89Y;2-?F_KS3%A9KADP,3#QW4R\QKHAEJ1Q,6(S\F;^:0(SZRRV1,QX MS979@K7+!BJ-ZI_-L_T;F^:@Q_@: GKC:4&XB TNK^:+NPU5;&R4P_"GS5II.+FJ; MH,Y;_#*9A/HKKZ:+#]5)R \PK$/MJZA$P_R9=1+Z>2RQ!3_5H*K!9ZKDP]Q[+\,'I :X'+@\F_@\N+JQ6F)/Y00X-TLE?DR M+1F^CK^5UZ,,K*7!^]V<#$P(3+@6@ CQ0^GFGYVG!D KFVV%RSK5=QV,ON;3 MAQEPKJXT6/?9!B77$4M(;![K(%N=E%O> MRB[;]0ZN+=3,QH4WFBA&IO.?]L,R,G>W< #" A??EY1H*BONSDVLH'.V*&&P M83$F[V"R,DZB"2J4%R5ZEBW=N SVIL72+;L>/ 7,",RX!JF3Q;P>[949JZ2K M_CF>_+MQ?A;CYG5&P>&':Y]HS896':ZQAOJ4]:QH(?D;*KJT^ S8'-OQ8<&Y;(5QU\O1$YB'7Y M0BE.*N5:UV;%9#1[<0];]:S\]&0T6A5)5A76%!H.ZOK.T1:_K)Y<9 M]?\XG&5)K^VKI:XJ CZMB^7JTL$B5QF5+LO'\]?]8CJMH^;K M4<:RBY_L=#A9S-:S[2^J5;GL>@K^PH:RP24XG]V0JY+*KY:%0H$6($JCK88% M3$:KRJR2VUQ+;%;UE((TS$P[*\9;)GOHUVJ7:MBY2FD.JEA\CM$PVW W0^'5 M;+B*KU]F-B_?:AKM+ .5);IX5^3>^CJ1FGT:_W&<5Z4N'VYB_>76=OJE+F7. MWQ['D@PH?\C7&JSB2A^F]@*,1>#Y^WD^CK-&'%4V<]7'NN UK3AT614;JS=U MI0FM?CW]R^G9JR5#YZ]F'"XVV^E?D,+7/GRQ\*QODIXSF^+\RU7)8FWJO?P+ M&MO_^3\H,S]EW;R2ALO)9;%(UTL)RR>S8I@4C7'/QU8/?UTY7VOYG1%2%,WJ MFD4EUL]8>G;-LD8K,W8'^?W+X6B4Y1!-QJ,OU7O[I_9?*VK2XF3M?A[6VL7/JE^S@S;.O'K2I!QJ6;L8!D0Q ME0W3%U'ZY=5)K;2NLG)UJ5L=:J[Y<"5ROXV'5Y,J9YN,7:;A36-V*F\+4G7V MM]<_OP3.!\@6ZKC$5=,YX9V-MQ$Y.8QP_3NL F ^[%**/ZJ*#G,NU6 MHV&UF!96_[*TMS*0ERK>FED_V5D);_RCY-3J^$7-A&MX6SY7V#6&1W F'+'> M!1_LC@)7)94\CG4<9[*8SX9A=?;OY@W +@">O=^C7=;Y%JY9 MG8H=7M;;AO)%+%H:#ZM#KNOEN\M#VG40I>%92$, NSW(;HOY<+0ZS/GJU7]7 M'\K[(6_;IUC2:R,[+[G@IHJW9K3KS,2@&N<;9H.E&)=I>:;ZZJL9^,JUYD-? M75R5(Q8W:^$GL^)Q#6>S181D1K,Q_W>RJ)H3[?7A[[SN/I9S>XM2,3<:-I5/ MX^4Q\@?R \T1V-EE-B"K.H)CKX[CELJHJC@+D]0T.GC@,N7!;'WR]7%'RZ^3 M(Y?385[C3'KYP+T)DAM'%^N)M3?[.]1!M#KQM\S%5#^.6HB;L."U??KQ?:3F:%S6=^.G3- BUA M>GV Q J=R]OEB4_&XT5^R,VU^W^:,-AH%AM'[I'K/0ZK*S?/F=W(^D&O(ARW MNMV?+@_)U2?NALTD\.^7S_WN].6J0\D/Y5AT8<+E8B]WY79%2*E:*L;4C] M[ G9K]XKLL+B94!, P_W%6&4R/5T<5D ;8E$US7-U]5(:_T-Z@A?P];EKZ5) MT>+BPJX?Y7L;:Y[./[V]',Z+?P#'^8 Y'SA#_?B.&7!,%/CJ ;XJ@#=;/TQ1 M)T!O%!9=6T8WCP:5VN0F,[$LGELBFBWYQ](E<#Z[HZ[S^FKKS5)J7=Z8'?'S MJB5 2>'_.ROZI9=06X)-Y?'*F+/S6GD#/P,_W^3GV6SBAS4>7EFOF7?FC7]0 MUV'F+]0-]Q9-06?6W/,O@]O,NHZX=I@U]'I2O5'5-\J1&_Z,-P(HI/@XOERP^J>R\J?M?J\"9UX7011Q6938@ " :X9" MTSIOR63%F%V:HJLV5E6'.%G[K:F8OG*D&[:^:J=YK3@ PX&%[W;$2N'\^@G/97G%[*J# M:7-(NCZ4-ZV#A?9+X_B77V<+5Z)"=5ARO&XGK[%D?9MEC.*6:*P5\#=O 5,#4S=,O3QTWY@G]3F4]6#A+-;=.;.ILLP>SI:F2JE_FX]B>"@@ M^&SQP-.7$&IOYLZL-RJ^W:1XU48V5LMVO7?UDKW1>CD5PW35/'D961J.F[A2 MPQ[E9.ALGZYW7;V*G^?OK#6H7AU97N9J9K?#^*S5[R^?+S_O1?HHU^B]J),^L$C]_M(5[ZH,Q MI;J\*9"JB\BG\=,P;_\D#6J_]FK=UY[RGK4?CHNPE;3^M:PO?8#QISBKSW^5 MSWF[*%>)S9/7>BHL1K4W\.4Z/[/64;K?'>*_DF5:G7YY!, UG6";E%9=AMQL MW2UI&"_S7S4HW]SABAY,.W/'4= M_&L XI[&Y55=Y?6- EU;.->7+EG8=4%9>]BVSRUTM5)+KP>9/N*7:6_[B$C]A$TM>;Q2_[95\G^K(F]Z-)D^BI M5=-#/;.+K'UY7!+TX4O=%CDH:=RQD#,H:>S8U)A2QO;[\/>KD,'ZT,G#&!KS MYN3M^^IU'?JC/_WR^NR )L>0V4A[&3K^?Q@#8OZ]<7U2]7-27OOF[('2*>MST+Z>POIV>GU5_/?RWC MD-YEUGZYQ7*T TTE(S\9U5V>PN_.CHI-\/OL8XR'PL\OS\]>G9Z].WU5Y5?O MSG]]_>KD_>FK V+QZN>37S-&G5;O_GIZ>O\(JQUNY$$LP_Q]X>;J M_5_/?WMW#ZO2_7YZ^>5\F?^5E.GE[6N5WJS>GJ]_RGI[\ MT-N5^VUL%Z'X^/M<@GO\V+T.H*SG;-X5"[:+^>2GI3U:GJ68I_GIR\=1=BW* M1)TT_!S#3U=QSA?XCZLOE&%B]G(6?YR5'A 9V%;+4)]5:*[]W>VAM9^&JZ31 MCZOO_[0Y([JYG90OC&%_7!K<=WR O)#TH;H^^T)KAZ_\>_/!!/<,#LX#U MY9ZF=B\GU-[MO^A]NR_?X),\>OCN<9-VQP#GN\F\54;*M4*G^]X MZATN3'L:XUX_YW(Z'%4,#_[#3?_TGQ13OAV#/+!RCGN>(,[8*V;-9]I/;1*7] MAUAW#4MW\O0N*:^M_&=3-CTC%[BXD]O:*7*_7=NUX9BN%R34M_F*^EL/?]2? M7[\ ?J"88=_:\=Y [?)$F*V5XH^ )[T1L)[A"7!Q3[>U4^2V[ ,^0@'>^>"= MUXKW37+X&@L^9K6Z 3=W7'(\.2QR;S+ ?73^H<4]/0RL>0+C_\?P<][&\2_E M_%XIHBS%!K_\SJ6R#CN%0@@6\>0QG/W[W\ M75OE2<(9AXPVB'.?D.$N_^J%$E(88;#ZKAK;B_S BQGZ8.WECT7L3L:A_#B] MEKF3^4L[G9:Y[7^WHT7\KBH=(.N[_/;[;^]>96V7]R%?A7U7A>B'%W8T^_-W M*/_65&O]^;OAY_F/X\4%"I,Y6G[BN_^DD@\TP?_QIYL4_^R2PD8K1411)HVX]P1IPQ2*/F@N9=1$I]O890VGCDB++*$IXQTQR!HG4(8T M8ZT5AAK[G-BER4!0TG/H:CE !*;PW1OP-L[FTV%][JB<""JC,Y8G-$*\G,R& MCO:0XF>:PY I[YO94?1B3'"',LFJ^(9HKB+#CE"+%*$6Z$"#DJK-FS=G:*3 M[#DZ08AW+W;M->=6<_NY\M,8AG4G Q^S\^9&$31'I\4,-,>ZY@C!>FT(13K1 MD+6 I<@I(1 C1HE(G=1./,6NC>-,RK7(O;>?7S8"]_9*WEK2'V1 ">NY"@&8 MZOM6=A2FHDTDJHPVPDJ"N,_&JH[6(*R#C#([XL'$IQBX^X,I.F"\[S %$=R] M6+IORE3M86B:9'>YOC*LFZW)6W$!H+L M,)_XF(-:7984@$6 Q>[#(LUXIE,0R&-E$2>6(D,$1U;*&%V*CO*-&,(VT>?] MP2(9"+S#"K'.P.)>0]:T#4.>'J,A_WY2AC> \=XC%QG"/^L:AA",350N&]&X M5%\PB;1W!F7C.:L<; +=S&]N8WCO0I=0:082FYZ'? ":^KZ5'86FX!WGS&9# M-CF<888ZI(U)*#H2>#0F6\"X#>-W%]"DQ8#SOI^$V'DP>AN3]?!MTC?+.63- MO(Y_+8;U!+$R$QL*@[LM,(#_-X(?5"GJ&4?1:HYX=!X98A72 CM%K],[CKMVT6<^;F??C#]4HVED9W)A7K)X.5,;E M%@<+5$*GY094PHTS;:P4 JKYOY=$#U7*D5;\V&R*0VUES=4DK9,.A9@MJ MMKX]HXYC"#)ZI#B5B#.3D*:>9-<^8FNT,HZWTL]@K43K;#+VK::OS"X;&G2F M1@M@$& 08/ >&-1289P,RSZOTAG26$3.4XRH%3*X1!F)&R[P-E'1G<(@@U+5 M PB90JGJ=:DJ&.5M2AU]08O8A*.),&:MV*E=XJ%&HYR'@+2+C_ /B='->' 8>_#FT] M%'L89X-J&D.,%_7([OR)FMCR.E\UQ>Q^YF7X:*?YR4O];OWR8[YTG,[J%(SZ MJ1[1V6S9^K^ETG?^!>;L/$3G8:#P#I0VD M@82P,4]W=9.D0N]!/>B&D^\SVLXGU67]@LTR3ZRDD28*=;6(2KOO15> M(&9CF2DF,;+44Z2LQ,$'REJ:A[B2MC>-L+7FC#? R'(=4+!1JF!,=+B50OR;;5)6.N1+NS$53B'X"SC5[ZT\>IR" M+BD0"=UU#=SE9%KKP$FJQI-YA,0_M!B %@/[A>7.G+T'? !\ 'RXKX&\UU;+ M["!J1;*K:)5$1C*%I'(>&^&LLZF-<.59T>([R=,+2:$!R6&%+_O>@ 22]J"8 M0#$]43$1&TA@'LD4)>)&>>0P9HA8S[GD"E-&VHA[KF7+VM5+ET.C/3US3&0197A+"'.6H9%)X?&& M0_[$(H:V7&\^X I\;YBALB/;^MWFY).JF7%20>OW!^D\#*B$IMG0^AVXN)]< M#.&DK53>FUL3P ;5:G%W:H,F%3'EP2)ERZAMYDLA;4D/><>"DR0:1MOPP:_( M>S>?^'^>3=[8Z=_M:'&K]""_+)^P\S@[3R<7<9JW]-5D-++366T2K!NIK\]^ MN6&EHEGTQ5(M7#.+X_L(9CQBD43F-"]5)CB&3##!B,7HA95,*M9*G<4S$#R> MW&&1WV.BMQ94+S!P::?5IT+<3S>8]N9=RN.BX6?T<1A"'/^8W1_*'2$Z(J4R M_W&E(G+%'V[ KY[OK1ZN*N!@(NYA\GTXQ@84_(P+S/P, -DCSXO#U8(^?R0C/) MJ##,$ZDW3L ^'1EJKI^]GLT6,=P0E6896@ SRUSENH,^;8@G@E(8^\0\S0) MZX-PI)7&47?1=;Z8S^9V'(;C#[LACEN3$@\!A< S<29)9)QBB)' L?!C4J.RMU62>7T^&H8GA0T6Q*U#VZS_U\XN*T8J3^(WL!L>%.5ST> M92GO5RP+BUE4U%H4E8PE.JN1-M8C$I7SV>Q@.MH=EB?<_ %<=%"T 2#T$! H M94HP1K._: GBN+3<9]D<5"RZQ)RS7A, A /.GO0EE/1R>]QI&48U;3 M[&[(D-TD+K5"SE.'H@Z>19%"=J':\*H:VIX[B*0X5UY8@3 3%G%M&7**:.0M ME3P[6M'+#6JW<4?V3>V119"H%A0KETTT&;*W*Y0IP9^ "!7>&:'RQJ2O1I!T M"(12E1#S+L,Z<=FU=)(@KQ2V6E(3J($(TE;CSC#F5D>%1,RBDA6F0\[J;$$K MX:QD>?=\VYCP5(]]L]3AGN 8EH&*[!QPHG%Q#D3F/)5- RT(89GO2#MG*39( MVRK($N6Z$PJJM@UZ#*E_E,N;G_Q1'7R $UFU?Y2@]WATFCZ(SD1*4 M7>:,NM3%K/HC183[DNC#2;/8LGZ\PS;>?AZ'8(-LQO?\+#N@4]^WLJ/HI)A/ M4GN%8BB1O"09TMQQ9 SE5-H8 FME%MV.T(D*,V"[++\^"I:&.K/M9BJ',"S< M8D?5I1T&-!Q7WEX.YW8$*J#3\@(J8%T%X.(D,QZ0PL(A'JA!)G"&2HX'1RJT M=Z&5^^0W][.A/5^<;$8V7D,U:1,]LZ, M?Y&_]3&.9\-/L1I-9M",H]N2TU?M\/U^2O\9CQ)CB@R.$64[UR$G4E8?!%ML M8BB:J!7C^%J0SXLTIP".AP6.1G(E13FQ%DDVQ:F5R'I#$'?Y/TH#B9RU8HH# M.!X,.$*L^HAIZ(=S4#W0) J:1#VC^E*$J1AU0D$1BGCP]2D&BK+M+JT( M7%G62N#[;9S;X3B&4SL=#\:HFR\U!0E$2D97!("JY2D,(QVTKGD?TC+S%F(+0&Y-VE1_&$N>.DC;GC MY'CGCL_N;2<(2A&4(BC%;^G9+8BUQ%*D$L[N@]"EP4RB*"LI@SWQ!/-6W(!2>8"2IHQC8*3Y\XH^=D''9G_2LV$'1OD:I;K')*[#>0VWRT M7/G'N@$K#L1W[8WUC8,/UVM[BA^1F$X MC;7T_9A78'$Q_BD,9Y[GK9/UYY]I?V0VR<=F13?LH? M[>C?]LOLI^_^='M_5HM?R_/=*_^4!=Z]@;0+?+A>TEV2^#0&^G>S12YKSC;6 MX/3L+Z=GI]5?SW]]]?KL+^^JUV7W2?I]_^N.O]EV^9P MNWC>\S>G;T_>O\[/6IVQ,-^?_.W\ MM[)?K\^J]W\]_^U=7IYZ\[+M.:A.__OEZ9OWU2_G;ZMW?SUY>UHO7E[*Y6]Y MTT]^Z.W*_3:VBU#:@.YS"0[!>JSMY+NBUG8QGZQ<@_(L16OFIR\?1]GBF2RR MY3+\',-/S:T(QB_P'U=?\*7C[>4L_CB+V1;+(+A:AMH!;*[]W>TH_J?A;%C[ M4U]^7'W_KM+\^G9/!;2KB98RJ],L/RFQ/CJJ7>X,.UIO_M6[I?) MM/B_^7_3&*N+_/>/LRJ[F=GSO6J6NAW+/":5? BK"3($,M2.#,V>&"=C*" M%M0X0- W#*+N'P25=N8 ,B C(",/R@@#&0$9 1D!/0(R C(">N3Y'+IM:O#; M]N@.M:;^O$D CS]4\?-EJ4B9_=@F AU-3>>C(>@PZA/WIEAZ1BYP<2>WM6?D M A=WWM5/D0H^>O7@I;^,LVJG_6)_C#?%3'$TN2PTKG$G;]H#- MLWNI^SAO=AA0T_I9,D)8<)1&I%R0B#M-D!'>H."EBHQ8SLS&9'$E=13$4&0M MQXAS%I&C1B.LM"5!&TFUW.P2UTC=R3B\NI:YTR9.T-)!,C/0 H:H F(=Y%8" M8K6$6-PF0[!B6>ZQ0CRI@ SV"5%!-%984$[5;<0R%E/)3$+"E=;Y)F:4PRYC M%Y6>BXQ;0H?G0"PVH 00"Q#K(+<2$*LEQ)(A6!N#0B29;&-I:I'5OC0H2

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end XML 86 engn-20240430_htm.xml IDEA: XBRL DOCUMENT 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember engn:ClassASecondTrancheMember 2013-07-26 2013-07-26 0001980845 engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember 2023-01-31 0001980845 2024-01-31 0001980845 engn:ClassCRedeemableConvertiblePreferredSharesMember 2023-04-30 0001980845 us-gaap:EmployeeStockOptionMember 2023-11-01 2024-04-30 0001980845 2022-11-01 2023-10-31 0001980845 engn:AnthonyCheungMember engn:Rule10B51TradingPlanMember 2024-04-19 0001980845 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-10 2020-04-10 0001980845 engn:TermLoanMember 2024-04-30 0001980845 engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 us-gaap:EmployeeStockOptionMember 2024-02-01 2024-04-30 0001980845 us-gaap:CommonStockMember 2023-04-30 0001980845 engn:OldEngenesShareOptionHoldersMember 2023-10-31 0001980845 us-gaap:LeaseholdImprovementsMember 2023-10-31 0001980845 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-11-01 2024-04-30 0001980845 us-gaap:RetainedEarningsMember 2023-11-01 2024-01-31 0001980845 engn:Series2ClassCRedeemableConvertiblePreferredMember 2024-04-30 0001980845 us-gaap:RetainedEarningsMember 2022-11-01 2023-01-31 0001980845 engn:TermLoanMember engn:AmendedLoanAgreementMember 2024-04-30 0001980845 us-gaap:SoftwareDevelopmentMember 2023-10-31 0001980845 engn:TwoZeroTwoThreeFinancingMember 2023-06-30 0001980845 engn:TermLoanMember engn:TrancheThreeAdvanceMember engn:AmendedLoanAgreementMember 2023-12-22 0001980845 engn:OfficeAndLabSpaceMember 2023-04-01 2023-04-30 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2023-02-01 2023-04-30 0001980845 us-gaap:RetainedEarningsMember 2023-10-31 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember 2023-01-31 0001980845 engn:Series3ClassCRedeemableConvertiblePreferredMember engn:ClassCInitialClosingMember 2021-06-30 2021-06-30 0001980845 engn:OfficeAndLabSpaceMember 2022-10-01 2022-10-31 0001980845 engn:OldHerculesWarrantsMember us-gaap:SeriesCPreferredStockMember engn:LoanAndSecurityAgreementsMember 2022-06-30 0001980845 engn:ClassCWarrantsMember 2021-06-30 0001980845 engn:AnthonyCheungMember engn:Rule10B51TradingPlanOneMember 2024-04-19 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2021-12-30 2021-12-30 0001980845 us-gaap:RetainedEarningsMember 2024-01-31 0001980845 engn:CeoTransitionAgreementMember 2024-02-13 2024-02-13 0001980845 us-gaap:EmployeeStockOptionMember 2024-02-01 2024-04-30 0001980845 engn:OfficeSpaceMember 2024-01-01 2024-01-01 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2024-04-30 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember engn:ClassBThirdTrancheMember 2015-01-06 0001980845 us-gaap:RetainedEarningsMember 2023-04-30 0001980845 srt:MaximumMember us-gaap:EmployeeStockOptionMember engn:TheOldPlansMember 2018-07-05 2018-07-05 0001980845 us-gaap:EmployeeStockOptionMember 2023-02-01 2023-04-30 0001980845 us-gaap:GeneralAndAdministrativeExpenseMember 2023-02-01 2023-04-30 0001980845 us-gaap:RetainedEarningsMember 2024-04-30 0001980845 us-gaap:ComputerEquipmentMember 2023-10-31 0001980845 us-gaap:RetainedEarningsMember 2022-10-31 0001980845 engn:OldHerculesWarrantsMember 2024-04-30 0001980845 engn:TermLoanMember engn:TrancheThreeAdvanceMember engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember 2023-04-30 0001980845 engn:TermLoanMember engn:IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 engn:SharesReservedForFutureIssuanceUnderTheEquityPlansMember 2024-04-30 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2024-02-01 2024-04-30 0001980845 engn:MergerAgreementMember 2023-10-31 2023-10-31 0001980845 engn:FEACMember 2023-05-16 2023-05-16 0001980845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-30 0001980845 engn:TwentyTwentyTwoNotesMember 2022-11-01 2023-04-30 0001980845 us-gaap:WarrantMember 2023-11-01 2024-04-30 0001980845 2022-10-31 0001980845 engn:PIPEFinancingMember 2023-10-31 0001980845 engn:TermLoanMember 2023-10-31 0001980845 engn:HerculesCapitalMember engn:TrancheOneMember engn:LoanAndSecurityAgreementMember 2021-12-30 0001980845 engn:FEACMember 2023-10-31 0001980845 engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember 2023-11-01 2024-04-30 0001980845 srt:ChiefExecutiveOfficerMember engn:CeoTransitionAgreementMember 2024-02-13 2024-02-13 0001980845 engn:OldEngeneShareholdersMember 2024-04-30 0001980845 us-gaap:WarrantMember 2022-11-01 2023-04-30 0001980845 us-gaap:EmployeeStockOptionMember 2022-11-01 2023-10-31 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember engn:ClassBThirdTrancheMember 2015-01-06 2015-01-06 0001980845 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-02-01 2024-04-30 0001980845 us-gaap:ComputerEquipmentMember 2024-04-30 0001980845 2024-04-30 0001980845 engn:TwoThousandTwentyFourSubscriptionAgreementsMember 2023-11-01 2024-04-30 0001980845 us-gaap:EquipmentMember 2023-10-31 0001980845 engn:TheOldPlansMember 2024-04-30 0001980845 engn:OldEngenesWarrantHoldersMember 2023-10-31 0001980845 us-gaap:EmployeeStockOptionMember 2023-10-31 0001980845 us-gaap:EmployeeStockOptionMember engn:TwoZeroTwoThreePlanMember 2023-11-01 2024-04-30 0001980845 engn:Series1ClassCRedeemableConvertiblePreferredMember 2024-04-30 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember engn:ClassBSecondTrancheMember 2015-01-06 0001980845 engn:AprilTwoZeroTwoThreeNotesMember 2023-11-01 2024-04-30 0001980845 2020-09-01 2020-09-30 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember 2023-01-31 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember 2022-10-31 0001980845 us-gaap:CommonStockMember 2023-11-01 2024-04-30 0001980845 us-gaap:AdditionalPaidInCapitalMember 2023-11-01 2024-01-31 0001980845 engn:Series4ClassCRedeemableConvertiblePreferredMember 2024-04-30 0001980845 us-gaap:ResearchAndDevelopmentExpenseMember 2022-11-01 2023-04-30 0001980845 engn:AprilTwoZeroTwoThreeNotesMember 2023-04-01 2023-04-30 0001980845 2024-06-11 0001980845 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001980845 2023-07-07 2023-07-07 0001980845 engn:TwoZeroTwoThreePlanMember us-gaap:SubsequentEventMember engn:EvergreenProvisionMember 2024-05-15 2024-05-15 0001980845 engn:ConvertibleNotesMember 2024-04-30 0001980845 us-gaap:ResearchAndDevelopmentExpenseMember 2023-11-01 2024-04-30 0001980845 us-gaap:RetainedEarningsMember 2023-01-31 0001980845 engn:PreferredShareWarrantsMember 2024-04-30 0001980845 engn:ClassCSecondTrancheMember 2021-06-30 0001980845 us-gaap:EmployeeStockOptionMember 2023-11-01 2024-04-30 0001980845 us-gaap:CommonStockMember 2024-01-31 0001980845 us-gaap:RetainedEarningsMember 2024-02-01 2024-04-30 0001980845 engn:TwentyTwentyTwoNotesMember 2022-11-01 2023-01-31 0001980845 engn:FEACMember engn:PIPEFinancingMember 2022-11-01 2023-10-31 0001980845 engn:PIPEFinancingMember 2022-11-01 2023-10-31 0001980845 engn:BdcNotesMember 2023-02-01 2023-04-30 0001980845 engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember 2022-10-31 0001980845 us-gaap:CommonStockMember 2023-10-31 0001980845 engn:TermLoanMember engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 engn:TheOldPlansMember 2022-11-01 2023-10-31 0001980845 us-gaap:EquipmentMember 2024-04-30 0001980845 2023-11-01 2024-04-30 0001980845 us-gaap:PrivatePlacementMember engn:SubscriptionAgreementsMember 2024-02-13 0001980845 us-gaap:WarrantMember 2023-02-01 2023-04-30 0001980845 us-gaap:CommonStockMember 2023-02-01 2023-04-30 0001980845 engn:TwoZeroTwoThreePlanMember 2023-10-31 0001980845 engn:AprilTwoZeroTwoThreeNotesMember 2023-05-16 2023-05-16 0001980845 us-gaap:EmployeeStockOptionMember 2024-04-30 0001980845 engn:OldHerculesWarrantsMember engn:LoanAndSecurityAgreementsMember 2023-11-01 2024-04-30 0001980845 engn:OldEngenesShareOptionHoldersMember 2024-04-30 0001980845 engn:WarrantToPurchaseCommonStockMember 2023-10-31 0001980845 engn:FEACMember 2023-01-31 0001980845 engn:ClassCWarrantsMember 2021-06-30 2021-06-30 0001980845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-31 0001980845 engn:TheOldPlansMember 2023-10-31 0001980845 us-gaap:GeneralAndAdministrativeExpenseMember 2022-11-01 2023-04-30 0001980845 engn:TermLoanMember engn:TrancheOneAdvanceMember engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 engn:TwoZeroTwoThreeFinancingMember 2023-05-16 0001980845 engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember 2023-02-01 2023-04-30 0001980845 engn:MayTwoThousandTwoThreeNotesMember 2023-05-01 2023-05-31 0001980845 engn:ForbionGrowthSponsorFeacIBVMember 2023-06-01 2023-06-30 0001980845 us-gaap:PrivatePlacementMember engn:TwoThousandTwentyFourSubscriptionAgreementsMember 2024-02-13 2024-02-13 0001980845 2023-11-01 2024-01-31 0001980845 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-07-05 2018-07-05 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember engn:ClassBInitialClosingMember 2015-01-06 2015-01-06 0001980845 engn:Series3ClassCRedeemableConvertiblePreferredMember 2024-04-30 0001980845 srt:MinimumMember us-gaap:EmployeeStockOptionMember engn:TheOldPlansMember 2018-07-05 2018-07-05 0001980845 engn:TermLoanMember engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember engn:ClassAInitialClosingMember 2013-07-26 0001980845 engn:FEACMember 2024-04-30 0001980845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-31 0001980845 2020-04-10 2020-04-10 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember engn:ClassBSecondTrancheMember 2015-01-06 2015-01-06 0001980845 engn:TermLoanMember engn:IfInterimMilestoneAchievedAndNoDefaultMember engn:AmendedLoanAgreementMember 2023-12-22 2023-12-22 0001980845 2023-10-31 0001980845 us-gaap:GeneralAndAdministrativeExpenseMember 2024-02-01 2024-04-30 0001980845 us-gaap:RedeemableConvertiblePreferredStockMember 2022-11-01 2023-04-30 0001980845 us-gaap:RedeemableConvertiblePreferredStockMember 2024-02-01 2024-04-30 0001980845 us-gaap:WarrantMember 2023-11-01 2024-04-30 0001980845 engn:OldHerculesWarrantsMember us-gaap:SeriesCPreferredStockMember engn:LoanAndSecurityAgreementsMember 2024-04-30 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember engn:ClassBInitialClosingMember 2015-01-06 0001980845 2022-11-01 2023-04-30 0001980845 us-gaap:NonvotingCommonStockMember 2024-04-30 0001980845 engn:TermLoanMember engn:TrancheOneAdvanceMember engn:AmendedLoanAgreementMember 2023-12-22 0001980845 engn:TermLoanMember engn:AmendedLoanAgreementMember 2024-02-01 2024-04-30 0001980845 engn:OfficeSpaceMember 2024-01-01 0001980845 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-11-01 2024-04-30 0001980845 engn:HerculesCapitalMember engn:TrancheTwoMember engn:LoanAndSecurityAgreementMember 2022-06-15 2022-06-15 0001980845 us-gaap:EmployeeStockOptionMember 2023-07-07 2023-07-07 0001980845 engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember 2022-11-01 2023-01-31 0001980845 engn:ConvertibleDebenturesEmbeddedDerivativeLiabilitiesFor2022NotesAndBdcNotesMember 2023-04-30 0001980845 engn:NewLaboratoryAndOfficeSpaceMember 2022-12-29 2022-12-29 0001980845 engn:TermLoanMember engn:AmendedLoanAgreementMember engn:WallStreetJournalMember 2023-12-22 2023-12-22 0001980845 2023-07-07 0001980845 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0001980845 engn:AprilTwentyTwentyThreeNotesMember 2023-04-04 0001980845 engn:OfficeAndLabSpaceMember 2022-10-31 0001980845 engn:OfficeAndLabSpaceMember 2021-11-01 2021-11-30 0001980845 engn:TwoThousandTwentyFourSubscriptionAgreementsMember 2024-02-13 2024-02-13 0001980845 engn:HerculesCapitalMember engn:TrancheThreeMember engn:LoanAndSecurityAgreementMember 2022-12-15 0001980845 engn:ClassCSecondTrancheMember 2021-06-30 2021-06-30 0001980845 engn:TermLoanMember engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember engn:AmendedLoanAgreementMember 2023-12-22 0001980845 engn:PhaseIClinicalTrialMember 2020-04-10 0001980845 us-gaap:PrivatePlacementMember engn:TwoThousandTwentyFourSubscriptionAgreementsMember 2024-02-13 0001980845 us-gaap:FairValueMeasurementsRecurringMember 2023-10-31 0001980845 engn:TwoZeroTwoThreeFinancingMember 2023-05-31 0001980845 engn:TwentyTwentyTwoNotesMember 2023-02-01 2023-04-30 0001980845 engn:FEACMember 2022-11-01 2023-10-31 0001980845 us-gaap:GeneralAndAdministrativeExpenseMember 2023-11-01 2024-04-30 0001980845 engn:WarrantToPurchaseCommonStockMember 2024-04-30 0001980845 engn:AprilTwentyTwentyThreeNotesMember 2023-02-01 2023-04-30 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember 2023-04-30 0001980845 engn:MergerAgreementMember 2023-11-01 2024-04-30 0001980845 us-gaap:CommonStockMember 2024-04-30 0001980845 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-30 0001980845 us-gaap:CommonStockMember 2023-01-31 0001980845 engn:PreferredShareWarrantLiabillitiesMember 2023-11-01 2024-04-30 0001980845 us-gaap:EmployeeStockOptionMember 2022-11-01 2023-04-30 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember engn:ClassASecondTrancheMember 2013-07-26 0001980845 2021-06-30 2021-06-30 0001980845 2023-04-30 0001980845 engn:SharesReservedForFutureIssuanceUnderTheEquityPlansMember 2023-10-31 0001980845 engn:CommonSharesIssuedToPipeInvestorsMember 2024-04-30 0001980845 engn:OfficeAndLabSpaceMember 2023-11-01 2024-01-31 0001980845 engn:FeacShareholdersMember 2024-04-30 0001980845 engn:OldEngenesEquityAndConvertibleNoteHolderMember 2023-10-31 0001980845 engn:ClassBRedeemableConvertiblePreferredSharesMember 2022-10-31 0001980845 us-gaap:RedeemableConvertiblePreferredStockMember 2023-11-01 2024-04-30 0001980845 2024-02-01 2024-04-30 0001980845 us-gaap:EmployeeStockOptionMember 2022-11-01 2023-04-30 0001980845 engn:TwoZeroTwoThreePlanMember 2022-11-01 2023-10-31 0001980845 engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember 2022-11-01 2023-04-30 0001980845 engn:TermLoanMember engn:AmendedLoanAgreementMember 2023-11-01 2024-04-30 0001980845 engn:TwoZeroTwoThreePlanMember 2024-04-30 0001980845 engn:OfficeAndLabSpaceMember 2021-11-30 0001980845 engn:CashWarrantExercisesMember 2023-11-01 2024-04-30 0001980845 engn:TwoZeroTwoThreePlanMember 2024-01-01 0001980845 2023-01-31 0001980845 srt:MaximumMember engn:TermLoanMember engn:AmendedLoanAgreementMember engn:WallStreetJournalMember 2023-12-22 2023-12-22 0001980845 engn:CashlessWarrantExercisesMember 2023-11-01 2024-04-30 0001980845 engn:TwentyTwentyTwoNotesMember 2022-11-01 2023-10-31 0001980845 us-gaap:LeaseholdImprovementsMember 2024-04-30 0001980845 engn:HerculesCapitalMember engn:TrancheTwoMember engn:LoanAndSecurityAgreementMember 2022-06-15 0001980845 engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember 2024-02-01 2024-04-30 0001980845 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001980845 us-gaap:WarrantMember 2024-02-01 2024-04-30 0001980845 engn:TwoZeroTwoThreePlanMember 2024-02-01 2024-04-30 0001980845 engn:ClassCRedeemableConvertiblePreferredSharesMember 2022-10-31 0001980845 engn:AnthonyCheungMember 2024-04-19 2024-04-19 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2023-11-01 2024-04-30 0001980845 engn:TwentyTwentyTwoNotesMember 2021-11-01 2022-10-31 0001980845 engn:WarrantsToPurchaseRedeemableConvertiblePreferredSharesMember 2023-02-01 2023-04-30 0001980845 engn:ClassARedeemableConvertiblePreferredSharesMember engn:ClassAInitialClosingMember 2013-07-26 2013-07-26 0001980845 engn:TwoZeroTwoThreeFinancingMember engn:ForbionGrowthSponsorFeacIBVMember 2023-06-30 0001980845 engn:TwoThousandTwentyFourPipeInvestorsMember 2024-02-13 2024-02-13 0001980845 engn:BdcNotesMember 2020-09-30 0001980845 us-gaap:SoftwareDevelopmentMember 2024-04-30 0001980845 engn:TheOldPlansMember 2023-11-01 2024-04-30 0001980845 engn:Series3ClassCRedeemableConvertiblePreferredMember engn:ClassCInitialClosingMember 2021-06-30 0001980845 us-gaap:NonvotingCommonStockMember 2023-07-07 0001980845 srt:MaximumMember us-gaap:EmployeeStockOptionMember engn:TwoZeroTwoThreePlanMember 2023-11-01 2024-04-30 0001980845 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-30 0001980845 engn:TermLoanMember engn:AppliedToRefinanceOfAmountOutstandingMember engn:PriorLoanAgreementMember 2023-12-22 2023-12-22 0001980845 engn:FEACMember 2023-05-16 0001980845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-30 0001980845 us-gaap:FurnitureAndFixturesMember 2023-10-31 0001980845 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-04-30 0001980845 engn:LoanAndSecurityAgreementMember 2024-04-30 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2023-10-31 0001980845 us-gaap:CommonStockMember 2022-11-01 2023-01-31 0001980845 engn:BdcNotesMember 2022-11-01 2023-04-30 0001980845 engn:NewLaboratoryAndOfficeSpaceMember 2022-12-29 0001980845 us-gaap:ResearchAndDevelopmentExpenseMember 2023-02-01 2023-04-30 0001980845 us-gaap:EmployeeStockOptionMember 2023-02-01 2023-04-30 0001980845 us-gaap:CommonStockMember 2022-10-31 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember us-gaap:PrimeRateMember 2021-12-30 2021-12-30 0001980845 engn:ClassCRedeemableConvertiblePreferredSharesMember 2023-01-31 0001980845 us-gaap:EmployeeStockOptionMember 2023-07-07 0001980845 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-11-01 2024-04-30 0001980845 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001980845 engn:TwentyTwentyTwoNotesMember 2022-10-31 0001980845 us-gaap:RedeemableConvertiblePreferredStockMember 2023-02-01 2023-04-30 0001980845 2023-02-01 2023-04-30 0001980845 engn:MayTwoThousandTwoThreeNotesMember 2023-05-16 2023-05-16 0001980845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0001980845 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0001980845 us-gaap:FairValueMeasurementsRecurringMember 2024-04-30 0001980845 us-gaap:AdditionalPaidInCapitalMember 2022-11-01 2023-01-31 0001980845 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001980845 2022-11-01 2023-01-31 0001980845 srt:MaximumMember engn:TheOldPlansMember 2018-07-05 2018-07-05 0001980845 engn:Series3ClassCRedeemableConvertiblePreferredMember 2021-06-30 0001980845 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0001980845 engn:ClassB1RedeemableConvertiblePreferredSharesMember 2015-09-10 2015-09-10 0001980845 us-gaap:PrivatePlacementMember engn:SubscriptionAgreementsMember 2024-02-13 2024-02-13 0001980845 engn:HerculesWarrantsMember engn:TermLoanMember engn:TrancheOneAdvanceMember engn:AmendedLoanAgreementMember 2023-11-01 2024-04-30 0001980845 engn:AmendedLoanAgreementMember 2023-12-22 0001980845 srt:MinimumMember engn:AprilTwentyTwentyThreeNotesMember 2023-04-04 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2022-11-01 2023-04-30 0001980845 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-02-01 2024-04-30 0001980845 engn:HerculesWarrantsMember engn:TermLoanMember engn:TrancheOneAdvanceMember engn:AmendedLoanAgreementMember 2024-04-30 0001980845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-31 0001980845 engn:FEACMember engn:AmendedLoanAgreementMember 2024-04-30 0001980845 us-gaap:FurnitureAndFixturesMember 2024-04-30 0001980845 engn:ClassB1RedeemableConvertiblePreferredSharesMember 2015-09-10 0001980845 us-gaap:ResearchAndDevelopmentExpenseMember 2024-02-01 2024-04-30 0001980845 engn:FEACMember 2023-11-01 2024-04-30 0001980845 engn:BdcNotesMember 2020-09-01 2020-09-30 0001980845 2021-06-30 0001980845 engn:AprilTwentyTwentyThreeNotesMember 2023-04-04 2023-04-04 0001980845 engn:HerculesCapitalMember engn:LoanAndSecurityAgreementMember 2021-12-30 0001980845 engn:PhaseIiClinicalTrialMember 2020-04-10 pure iso4217:CAD utr:sqft utr:sqft shares iso4217:USD shares iso4217:CAD shares iso4217:USD false Q2 0001980845 00-0000000 Unlimited Unlimited Unlimited Unlimited http://engene.com/20240430#ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilities http://engene.com/20240430#ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilities http://engene.com/20240430#ChangeInFairValueOfConvertibleDebenturesEmbeddedDerivativeLiabilities Unlimited Unlimited P3Y 10-Q true 2024-04-30 --04-30 2024 false 001-41854 enGene Holdings Inc. A1 4868 Rue Levy, Suite 220 Saint-Laurent QC CA H4R 2P1 514 332-4888 Common Shares ENGN NASDAQ Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per share ENGNW NASDAQ Yes Yes Non-accelerated Filer true true true false 44166159 264810000 81521000 75000 76000 1213000 2343000 3511000 1500000 269609000 85440000 1107000 589000 1837000 975000 930000 273528000 86959000 211000 1156000 5667000 3539000 421000 562000 6299000 5257000 22730000 9216000 1533000 30562000 14473000 0 0 0 0 0 0 0 0 44158587 44158587 23197976 23197976 453405000 259373000 15860000 13717000 -1016000 -1016000 -225283000 -199588000 242966000 72486000 273528000 86959000 9855000 3215000 15493000 6886000 7455000 1522000 12590000 2484000 17310000 4737000 28083000 9370000 -17310000 -4737000 -28083000 -9370000 -625000 -318000 341000 1526000 2984000 149000 4009000 316000 728000 1177000 1291000 2352000 -366000 91000 199000 27000 -86000 2347000 -545000 2379000 -3330000 -14963000 -5282000 -25704000 -12700000 21000 -9000 -14984000 -5282000 -25695000 -12700000 1175000 2389000 -14984000 -6457000 -25695000 -15089000 0.38 0.38 9.3 9.3 0.82 0.82 22.19 22.19 39443768 39443768 694497 694497 31186238 31186238 680003 680003 266696 1899000 156036 1554000 5560607 49665000 665767 16390000 7683000 -1016000 -99671000 -76614000 1804 6000 -6000 20000 20000 -7418000 -7418000 266696 1899000 156036 1554000 5560607 49665000 667571 16396000 7697000 -1016000 -107089000 -84012000 18258 27000 -10000 17000 15494 11000 -11000 39000 39000 -5282000 -5282000 266696 1899000 156036 1554000 5560607 49665000 701323 16434000 7715000 -1016000 -112371000 -89238000 23197976 259373000 13717000 -1016000 -199588000 72486000 291000 291000 319000 319000 -10711000 -10711000 23197976 259373000 14327000 -1016000 -210299000 62385000 56974 207000 -156000 51000 1917000 1917000 20000000 187614000 187614000 520282 6114000 -131000 5983000 383355 97000 -97000 -14984000 -14984000 44158587 453405000 15860000 -1016000 -225283000 242966000 -25695000 -12700000 372000 1663000 -366000 1526000 318000 132000 -67000 -8000 -22000 2208000 59000 158000 83000 -1130000 722000 2057000 190000 -689000 2049000 2565000 -2271000 35000 -21532000 -10667000 685000 23000 -685000 -23000 200000000 12386000 5983000 51000 17000 22500000 9445000 585000 8000000 132000 613000 132000 205505000 7753000 1000 1000 183289000 -2936000 81521000 20434000 264810000 17498000 867000 676000 319000 1904000 1167000 <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div id="notes_to_consolidated_financial" style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">escription of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enGene Holdings Inc. (together with its consolidated subsidiaries “enGene” or the “Company”) formed in connection with the Merger Agreement (as defined below) was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. enGene Inc., its wholly owned subsidiary since October 31, 2023 (now known as “enGene Inc.” or “Old enGene”), is a biopharmaceutical company located in Montreal, Quebec, Canada, and incorporated pursuant to the Canada Business Corporations Act on November 9, 1999.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients, and its head office is located in Montreal, Quebec, Canada. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or “DDX”, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Merger with Forbion European Acquisition Corp.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forbion European Acquisition Corporation (“FEAC”) was a special purpose acquisition company (“SPAC”), incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the “Closing Date”), the Company, FEAC, and enGene Inc., consummated the merger (the “Reverse Recapitalization”) pursuant to a business combination agreement, dated as of May 16, 2023 (the “Merger Agreement”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transaction was accounted for as a “reverse recapitalization” in accordance with accounting principles generally accepted in the United States (“GAAP”). Under this method of accounting, FEAC was treated as the “acquired” company for financial reporting purposes. This determination is primarily based on the fact that subsequent to the Reverse Recapitalization, senior management of Old enGene continued as senior management of the combined company; Old enGene identified a majority of the members of the board of directors of the combined company; the name of the combined company is enGene Holdings Inc. and it utilized Old enGene’s current headquarters, and Old enGene’s operations comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Company is considered to be a continuation of Old enGene, with the net identifiable assets of FEAC deemed to have been acquired by Old enGene in exchange for Old enGene common shares accompanied by a recapitalization, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill or intangible assets recorded. The number of redeemable convertible preferred shares, number of common shares, net loss per common share, the number of warrants to purchase common shares, and the number of stock options and the related exercise prices of the stock options issued and outstanding prior to the Reverse Recapitalization, have been retrospectively restated to reflect an exchange ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.18048</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the “Exchange Ratio”) established in the Merger Agreement. Operations prior to the Reverse Recapitalization are those of Old enGene.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its ordinary shares and warrants on the Nasdaq Global Market under the symbols “ENGN” and “ENGNW,” respectively, commencing trading on November 1, 2023, with Old enGene, a subsidiary of the Company, continuing the existing business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Accounting Standards Codification (“ASC”) 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for developing non-viral gene therapies and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. The Company has not yet commercialized any product candidates and does not expect to generate revenue from sales of any product candidates or from other sources for several</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, if at all. The Company will need substantial additional funding to support its continuing operations and pursue its development strategy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three and six months ended April 30, 2024, respectively, and negative cash flows from operating activities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the six months ended April 30, 2024, and, as of that date, has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. To date, the Company has not generated any revenues and has financed its liquidity needs primarily through the 2024 PIPE financing, the Reverse Recapitalization and the PIPE financing conducted by the Company as part of the Reverse Recapitalization (the "PIPE Financing"), debt and convertible debentures, and issuance of redeemable convertible preferred shares and warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of outstanding loans. As of the issuance date of these condensed consolidated financial statements, the Company expects that its existing cash and cash equivalents as of April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements. Effective from the first quarter interim condensed consolidated financial statements, the Company has ceased its disclosure of the existence of a material uncertainty that raised substantial doubt about the Company’s ability to continue as a going concern due to the proceeds received from the 2024 PIPE Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 0 0 0.0018048 -15000000 -25700000 -21500000 -225300000 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s significant accounting policies are disclosed in the audited consolidated annual financial statements for the years ended October 31, 2023 and 2022 and notes thereto, as found in our Annual Report on Form 10-K for the year ended October 31, 2023. These interim condensed consolidated financial statements should be read in conjunction with the consolidated annual financial statements. Since the date of those annual financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated balance sheet at October 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These interim financial statements</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> include the accounts of the Company and its wholly owned subsidiaries, enGene, Inc. and enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements as of October, 31 2023 and 2022 and for the years ended October 31, 2023, and 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of April 30, 2024, the condensed consolidated statements of operations for the three and six months ended April 30, 2024 and 2023, the condensed consolidated statement of redeemable convertible preferred shares and shareholders' equity (deficit) for the three and six months ended April 30, 2024 and 2023, and condensed consolidated statements of cash flows for the six months ended April 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended April 30, 2024 and 2023 are unaudited. The results for the three and six months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, are not necessarily indicative of results to be expected for the year ending October 31, 2024, any other interim periods, or any future year or period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no changes from the financial statements for the year ended October 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated balance sheet at October 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These interim financial statements</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> include the accounts of the Company and its wholly owned subsidiaries, enGene, Inc. and enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements as of October, 31 2023 and 2022 and for the years ended October 31, 2023, and 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of April 30, 2024, the condensed consolidated statements of operations for the three and six months ended April 30, 2024 and 2023, the condensed consolidated statement of redeemable convertible preferred shares and shareholders' equity (deficit) for the three and six months ended April 30, 2024 and 2023, and condensed consolidated statements of cash flows for the six months ended April 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended April 30, 2024 and 2023 are unaudited. The results for the three and six months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, are not necessarily indicative of results to be expected for the year ending October 31, 2024, any other interim periods, or any future year or period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no changes from the financial statements for the year ended October 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse Recapitalization</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023 (the "Closing Date”), FEAC, Old enGene, and the Company consummated the merger pursuant to the Merger Agreement, dated as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 16, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As a result of the Reverse Recapitalization, the Company became a publicly traded company, with Old enGene, a subsidiary of the Company, continuing the existing business operations. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Reverse Recapitalization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each outstanding common share of Old enGene was exchanged for common shares of the Company at the Exchange Ratio;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each of Old enGene’s redeemable convertible preferred shares outstanding immediately prior to the close of the Reverse Recapitalization was exchanged for shares of the Company’s common shares based on the same Exchange Ratio, with no dividends or distributions being declared or paid on Old enGene’s redeemable convertible preferred shares;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the 2022 Notes and May 2023 Notes (each as defined in Note 9) of Old enGene’s existing convertible notes outstanding immediately prior to the close of the Reverse Recapitalization were converted to Old enGene common shares at the conversion ratio in place at the time of conversion and were exchanged for shares of the Company at the Exchange Ratio; </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each outstanding option to purchase old enGene common shares became fully vested and converted into an option to purchase a number of common shares of the Company equal to the number of common shares of old enGene subject to such option multiplied by the Exchange Ratio, rounded down to the nearest whole share, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio, rounded up to the nearest whole cent;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all of Old enGene’s outstanding warrants exercisable for common shares of Old enGene were exchanged for warrants exercisable for the Company’s common shares using the Exchange Ratio, with the warrants maintaining the same terms and conditions;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all of Old enGene’s existing outstanding Class C warrants outstanding at the time of the Reverse Recapitalization were terminated; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all outstanding shares of FEAC being </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,670,927</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, held by Forbion Growth Sponsor FEAC I B.V. ("FEAC Sponsor") and shareholders were converted into the same number of the Company’s common shares, and outstanding FEAC warrants of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,029,444</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> held by FEAC warrant holders were converted into the same number of warrants to purchase one of the Company’s common shares. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the close of the Reverse Recapitalization, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,091,608</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares of the Company were issued to Old enGene’s equity and convertible note holders, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,679,432</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share warrants of the Company were issued to Old enGene’s warrant holders, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share options of the Company were issued to Old enGene’s share option holders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Merger Agreement, FEAC, the Company, and investors under the PIPE Financing (the "PIPE Investors") entered into Subscription Agreements pursuant to which, the PIPE Investors agreed to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company’s shares and warrants for an aggregate commitment amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">56.9</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As part of the PIPE Financing, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,435,441</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company’s common shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,702,791</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants to purchase the Company’s common shares for an aggregate purchase price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on October 31, 2023. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The common shares and warrants issued as part of the PIPE Financing were determined to be equity classified. The proceeds were allocated between the common shares and warrants on a relative fair value basis, taking into consideration the quoted market price of the FEAC common shares and warrants on the close of the market on October 31, 2023, resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">56.1</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million being allocated to the common shares and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million being allocated to the warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Merger Agreement, FEAC, the FEAC Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A. and the other holders of Class B shares in the capital of FEAC ("FEAC Class B Shares"), Old enGene, the Company and the other parties named therein entered into the side letter agreements, pursuant to which the FEAC Sponsor agreed to surrender and in effect issue to PIPE Investors FEAC Class B Shares and FEAC private placement warrants, immediately prior to the closing of the Reverse Recapitalization. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately following the Reverse Recapitalization and the PIPE Financing, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,197,976</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,411,641</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023, as part of the close of the Reverse Recapitalization, the Company received proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the FEAC trust account, net of the redemption payment to FEAC’s public shareholders and cash paid from the trust for FEAC expenses. Additionally, the Company received proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the PIPE Financing. Upon the closing of the Reverse Recapitalization and PIPE Financing, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in transaction costs, which was withheld from the proceeds received. The Company incurred a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of transaction costs associated with the Reverse Recapitalization and PIPE Financing, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was previously deferred by the Company and netted against the proceeds upon close. The transaction costs were allocated to the common shares and warrants on a relative fair value basis and netted against the proceeds upon close.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the elements of the net proceeds from the Reverse Recapitalization and PIPE Financing transaction as of October 31, 2023:</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Recapitalization</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash – FEAC’s Trust Account and Cash (net of redemptions<br/>   and cash paid for FEAC expenses prior to close)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,363</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash – PIPE Financing</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less transaction costs withheld from cash proceeds on Closing<br/>   Date</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,024</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash proceeds received from the Reverse Recapitalization and<br/>   PIPE Financing on Closing Date</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less transaction costs previously deferred and netted against<br/>   proceeds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,086</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash proceeds from the Reverse Recapitalization and PIPE<br/>   Financing</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,145</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total transaction costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were related to third-party legal, accounting services and other professional services used to consummate the Reverse Recapitalization and the PIPE Financing incurred by Old enGene. These transaction costs are allocated between common shares and additional paid-in capital, based on the relative fair value of the common shares and warrants issued upon the close of the Reverse Recapitalization, on the Company’s consolidated balance sheet as the Company’s common shares have no par value.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the number of common shares outstanding immediately following the consummation of the Reverse Recapitalization and PIPE Financing transaction:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:16.3%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number<br/>of Shares</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Old enGene Shareholders (Excluding Convertible Notes)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,711,786</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FEAC Shareholders, including sponsor's and shareholder with<br/>   non-redemption agreement</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,670,927</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes - Common Shares issued</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,379,822</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Shares issued to PIPE Investors</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,435,441</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Common Shares outstanding immediately after the<br/>   Reverse Recapitalization and PIPE Financing</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,197,976</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> On October 31, 2023 (the "Closing Date”), FEAC, Old enGene, and the Company consummated the merger pursuant to the Merger Agreement, dated as of May 16, 2023. As a result of the Reverse Recapitalization, the Company became a publicly traded company, with Old enGene, a subsidiary of the Company, continuing the existing business operations. 2023-05-16 3670927 5029444 13091608 2679432 2706941 2706941 56900000 6435441 2702791 56900000 56100000 800000 23197976 10411641 7400000 56900000 6000000 11100000 5100000 <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the elements of the net proceeds from the Reverse Recapitalization and PIPE Financing transaction as of October 31, 2023:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Recapitalization</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash – FEAC’s Trust Account and Cash (net of redemptions<br/>   and cash paid for FEAC expenses prior to close)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,363</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash – PIPE Financing</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less transaction costs withheld from cash proceeds on Closing<br/>   Date</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,024</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash proceeds received from the Reverse Recapitalization and<br/>   PIPE Financing on Closing Date</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less transaction costs previously deferred and netted against<br/>   proceeds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,086</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash proceeds from the Reverse Recapitalization and PIPE<br/>   Financing</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,145</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 7363000 56892000 6024000 58231000 5086000 53145000 11100000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the number of common shares outstanding immediately following the consummation of the Reverse Recapitalization and PIPE Financing transaction:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:16.3%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number<br/>of Shares</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Old enGene Shareholders (Excluding Convertible Notes)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,711,786</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FEAC Shareholders, including sponsor's and shareholder with<br/>   non-redemption agreement</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,670,927</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes - Common Shares issued</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,379,822</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Shares issued to PIPE Investors</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,435,441</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Common Shares outstanding immediately after the<br/>   Reverse Recapitalization and PIPE Financing</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,197,976</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 6711786 3670927 6379822 6435441 23197976 <div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any financial assets or liabilities that required fair value measurement on a recurring basis as of April 30, 2024 or October 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and during the year ended October 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers or reclassifications between fair value measure levels of liabilities. The carrying values of all financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended April 30, 2023, and as of April 30, 2023, the Company had the following instruments which were measured at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">April 2023 Notes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the fair value option of accounting for the April 2023 Notes (see Note 8). The Company recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be the total cash proceeds received of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. No change in fair value was recorded on the April 2023 Notes during the three and six months ended April 30, 2023, given the close proximity between the issuance date of the notes and the period end.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Debentures Embedded Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Reverse Recapitalization, the Company’s convertible debentures contained equity conversion options, and certain repayment features, that have been identified as a single compound embedded derivative requiring bifurcation from the host contract for the convertible debentures for which the fair value has not been elected. The Company estimated the fair value of the convertible debenture embedded derivative liabilities on issuance using a probability weighted scenario expected return model. The estimated probability and timing of underlying events triggering the conversion and liquidity repayment features and probability of exercise of the extension features within the convertible debentures as well as discount rates, volatility and share prices are inputs used to determine the estimated fair value of the embedded derivative.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the close of the Reverse Recapitalization the 2022 Notes were converted and exchanged for common shares of the Company, resulting in an extinguishment of the 2022 Notes and related embedded derivative liability. Further the BDC Note (as defined below) was repaid in full. Refer to Note 3 and Note 9.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of the change in the estimated fair value of the Company’s convertible debentures embedded derivative liabilities for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of October 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,791</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of </span><span><span style="-sec-ix-hidden:F_61e81418-0d25-446d-9314-961bb90861fb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">convertible debenture embedded</span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>   derivative liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">307</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of January 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,103</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of </span><span><span style="-sec-ix-hidden:F_057ed279-58f1-46f3-97f4-c507a98bca21;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">convertible debenture embedded</span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>   derivative liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of April 30, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,474</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the consummation of the Reverse Recapitalization, Old enGene issued warrants to purchase redeemable convertible preferred shares as part of the issuance of certain redeemable convertible preferred shares, convertible debentures, and the term loan (the “Preferred Share Warrants”). Upon the close of the Reverse Recapitalization, the Preferred Share Warrants were surrendered for no consideration and the fair value was determined to be zero. The Company estimated the fair value of its Preferred Share Warrant liabilities using a Modified Black-Scholes option-pricing model, which included assumptions that are based on the individual characteristics of the Preferred Share Warrants on the valuation date, and assumptions related to the fair value of the underlying redeemable convertible</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preferred shares, expected volatility, expected life, dividends, risk-free interest rate and discount for lack of marketability (“DLOM”). Due to the nature of these inputs, the Preferred Share Warrants are considered a Level 3 liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average expected life of the Preferred Share Warrants was estimated based on the weighting of scenarios considering the probability of different terms up to the contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in light of the expected timing of a future exit event, which includes a SPAC transaction. The Company determines the expected volatility based on an analysis of reported data for a group of guideline companies that have issued instruments with substantially similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The risk-free interest rate is determined by reference to the Canadian treasury yield curve in effect at the time of measurement of the warrant liabilities for time periods approximately equal to the weighted average expected life of the warrants. The Company has not paid, and did not anticipate paying, cash dividends on its redeemable convertible preferred shares; therefore, the expected dividend yield is assumed to be zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because there was no public market for the underlying redeemable convertible</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preferred shares, the Company determined their fair value based on third-party valuations. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company’s various securities of its capital structure using an option pricing method, or “OPM”, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of redeemable convertible preferred shares include volatility, DLOM, and the expected timing of a future liquidity event such as an IPO, SPAC transaction or sale of the Company, in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to considering the results of these valuations, the Company considered various objective and subjective factors to determine the fair value of the Company's preferred shares as of each valuation date, including the prices at which the Company sold redeemable convertible preferred in the most recent transactions, external market conditions, the progress of the Company's research and development programs, the Company's financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company's redeemable convertible preferred shares, among other factors.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of the change in the estimated fair value of the Company’s warrant liabilities for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of October 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,185</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of January 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,858</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liabilities</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">341</span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">196</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of April 30, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,003</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 0 0 0 0 0 0 0 0 0 0 8000000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of the change in the estimated fair value of the Company’s convertible debentures embedded derivative liabilities for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of October 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,791</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of </span><span><span style="-sec-ix-hidden:F_61e81418-0d25-446d-9314-961bb90861fb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">convertible debenture embedded</span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>   derivative liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">307</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of January 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,103</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of </span><span><span style="-sec-ix-hidden:F_057ed279-58f1-46f3-97f4-c507a98bca21;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">convertible debenture embedded</span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>   derivative liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of April 30, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,474</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 3791000 307000 -5000 4103000 -625000 4000 3474000 P10Y <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of the change in the estimated fair value of the Company’s warrant liabilities for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of October 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,185</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of January 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,858</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liabilities</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">341</span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange (gain)/loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">196</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of April 30, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,003</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 11456 1185 217 12858 341 -196 13003 <div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024, and October 31, 2023, property and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,167</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,779</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">287</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">269</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">215</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,992</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,316</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,885</span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,727</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,107</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense related to property and equipment was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Depreciation and amortization expense related to property and equipment was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">158</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024, and October 31, 2023, property and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,167</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,779</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">287</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">269</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">215</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,992</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,316</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,885</span></p></td> <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,727</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,107</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 2167000 1779000 287000 269000 146000 70000 177000 69000 215000 129000 2992000 2316000 1885000 1727000 1107000 589000 78000 37000 158000 83000 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024, and October 31, 2023, accrued expenses and other current liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,427</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">759</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,427</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,708</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and related benefits</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,511</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">814</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued income tax payable</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,667</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,539</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024, and October 31, 2023, accrued expenses and other current liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,427</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">759</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,427</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,708</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and related benefits</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,511</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">814</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued income tax payable</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,667</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,539</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 2427000 759000 1427000 1708000 1511000 814000 30000 39000 272000 219000 5667000 3539000 <div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreement and Clinical Research Organization</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement – Nature Technology Corporation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 10, 2020, the Company entered into a Non-Exclusive License Agreement (the “License Agreement”) with Nature Technology Corporation (“NTC”) whereby the Company licenses certain rights to the technology of radiopharmaceutical products from NTC for commercialization. Under the terms of the License Agreement, NTC granted to the Company and its affiliates a non-exclusive, royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can voluntarily terminate the license agreement with prior notice to NTC.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company paid NTC an initial, upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> annual maintenance fee. The Company is also required to make a payment to NTC of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon assigning the License Agreement to a third party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The License Agreement provides for a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the first dose of a milestone product, as defined in the License Agreement, in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well as a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">450</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a milestone product, has not yet been achieved as of the period ended </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by the Company, its affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (“GMP”) lot of a product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During each of the three and six months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively of expenses related to the annual maintenance fee under the License Agreement, which is recorded within research and development expenses.</span></p> 50000 50000 50000 50000 450000 13000 13000 25000 25000 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes Payable</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 30, 2021, the Company entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. (“Hercules” or the “Lender”) for the issuance of a term loan facility with an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the “Prior Term Loan”). The Prior Loan Agreement provided for (i) an initial term loan advance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which closed on December 30, 2021, (ii) subject to the achievement of certain clinical milestones (“Clinical Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the achievement of the Clinical Milestone through June 15, 2022, which was drawn in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and (iii) subject to the achievement of certain financial milestones (“Financial Milestone”), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from achievement of the Financial Milestone through December 15, 2022, which was not achieved. The Company is required to pay an end of term fee (“Prior Term Loan End of Term Charge”) equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the Prior Term Loan advances upon repayment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Prior Term Loans were scheduled to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with no option for extension (the “Prior Term Loan Maturity Date”).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Prior Term Loan accrued interest at an annual rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% plus the prime rate of interest as reported in the Wall Street Journal minus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% provided, that, from and after the date the Company achieves the financial milestone, as defined within the agreement, the reference to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in clauses (i) and (ii) is reduced to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrowings under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term Loan are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the Prior Term Loan are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. At the Company’s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the closing date of the last draw down; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs after the first twelve months following the closing date of the last draw down, but on or prior to twenty-four months following the closing date of the last draw down; and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount outstanding at any time thereafter but prior to the Maturity Date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Prior Term Loan, the Company granted Hercules a security interest senior to any current and future debts and to any security interest, in all of the Company’s right, title, and interest in, to and under all of the Company’s property and other assets, and certain equity interests and accounts of Old enGene, subject to limited exceptions including the Borrower’s intellectual property. The Prior Loan Agreement also contains certain events of default, representations, warranties and non-financial covenants of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The debt discount and issuance costs under the Prior Term Loan were accreted to the principal amount of debt and being amortized from the date of issuance through the Maturity Date to interest expense using the effective-interest rate method. The effective interest rate of the outstanding debt under the Prior Loan Agreement was approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of October 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Prior Loan Agreement and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of debt discount and issuance costs inclusive of facilities fees, legal fees, Prior Term Loan End of Term Charge and initial fair value of the warrants under the Prior Term Loan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Old Hercules Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prior Loan Agreement, the Company agreed to issue to Hercules warrants (the “Old Hercules Warrants”) to purchase a number of shares of Old enGene’s redeemable convertible preferred shares at the exercise price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of the Prior Term Loans that are funded, as such amounts are funded. On the first tranche closing, Old enGene issued a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">84,714</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class C Preferred Shares which were determined to have a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon issuance. On the second tranche closing, in June 2022, Old enGene issued an additional warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">48,978</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class C Preferred Shares which were determined to have a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon issuance. The fair value of the Old Hercules Warrant values were initially recorded as a discount to the Prior Term Loan principal balance and are being amortized to interest expense using the effective interest method over the life of the Prior Term Loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Old Hercules Warrants were initially exercisable for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of the issuance of each warrant at a per-share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.632</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Canadian dollars, subject to certain adjustments as specified in the warrants. In addition, the Company has granted to the holders of the Old Hercules Warrants certain registration rights on a pari passu basis with the holders of outstanding preferred shares and warrants to purchase preferred shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounted for the warrants as a liability prior to the consummation of the Reverse Recapitalization since they were indexed to Old enGene’s redeemable convertible preferred shares that were classified as temporary equity. The Company remeasured the fair value of the warrants at each reporting date with changes being recorded as a change in the fair value of the warrant liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the close of the Reverse Recapitalization, the Old Hercules Warrants, along with all other warrants to purchase shares of Old enGene's redeemable convertible preferred shares, were surrendered for no consideration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amended Loan and Security Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 22, 2023 (the "Hercules Closing Date"), the Company entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement”), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the "Lenders”). The Amended Loan Agreement amends and restates in its entirety the Prior Loan Agreement with Hercules dated December 30, 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amended Loan Agreement provides for a term loan facility of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available in multiple tranches (the "Term Loan”), as follows: (i) an initial term loan advance (the "Tranche 1 Advance”) that was made on the Tranche 1 Advance closing of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the "Interim Milestone”), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of EG-70 in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances to us in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the date of achievement of the Interim Milestone through the earlier of (x) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days following the achievement of the Interim Milestone and (y) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and (iii) an uncommitted tranche subject to the Lenders’ investment committee approval and satisfaction of certain other conditions precedent (including payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (defined below) that the Lenders make additional term loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company is required to pay upon the earlier of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ( the “Maturity Date”) or payment in full of the Term Loans, an end of term fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the Term Loans (the "End of Term Charge"). The Company is also required to pay on July 1, 2025 or, if earlier, the date the Company prepays the Term Loans, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million representing the Prior Term Loan End of Term Charge (the Prior Term Loan End of Term Charge and End of Term Charge, collectively the "End of Term Charges").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loans mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with no option for extension.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the Wall Street Journal plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% (capped at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The Term Loan also bears additional payment-in-kind interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement are repayable in monthly interest-only payments through the "Amortization Date”, which is either: (x) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or (y) if the Interim Milestone is achieved and there has been no default, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or (z) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 1, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. After the Amortization Date, the outstanding Term Loans and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. The effective interest rate of the Term Loan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Amended Loan Agreement, the Borrowers granted Hercules a security interest senior to any current and future debts and to any security interest in all of the Borrowers’ right, title, and interest in, to and under all of the Company’s property and other assets, subject to limited exceptions including the Borrowers’ intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amended Loan Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict the Borrowers’ ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement also contains certain events of default and representations, warranties and non-financial covenants of the Borrowers. The Borrowers have been in compliance with the financial covenants since inception of the Term Loan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan. As a result of the extinguishment, the Company recorded a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a component within other income and expense in the Company's consolidated statement of operations during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024, which represented the difference between the reacquisition price of the debt, including fees and the initial fair value of the warrants paid directly to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Amended Loan Agreement and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hercules Common Share Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Amended Loan Agreement, the Company also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of the Company’s common shares, as shall be equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of such Term Loan advance divided by the Warrants per share exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adjustments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">138,696</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On the Hercules Closing Date, the Company issued to the Lenders </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62,413</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans (the "Closing Date Warrants”). </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Closing Date Warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815. Upon entering into the Amended Loan Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">22.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Tranche 1 Advance was allocated to the warrants, on a relative fair value basis, and recorded within additional paid in capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequently issued Hercules Common Share Warrants shall be substantially in the form of the Closing Date Warrants. Under the terms of the Amended Loan Agreement, the maximum number of Hercules Common Share Warrants and resultant underlying common shares of the Company that could be issued is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">138,696</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (i.e. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million total commitment amount divided by the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> price specified in the Closing Date Warrant), assuming no adjustments are made under the terms of the Hercules Common Share Warrants and further assuming the full amount of Term Loans are drawn.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024 and October 31, 2023, the carrying value of the term loans consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note payable, including End of Term Charge</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,530</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,144</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount, net of accretion</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,974</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">474</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note payable, net of discount</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,730</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,778</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of October 31, 2023, the Company classified $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the note payable as current, which represents the principal payments due and amortization of the debt discount between October 31, 2023 and the date the Prior Term Loan was amended in December 2023, as the debt was refinanced on a long-term basis in the subsequent period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of interest expense, respectively, related to the term loans, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was related to the amortization of the debt discounts, respectively. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of interest expense, respectively, related to the term loans, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was related to the amortization of the debt discounts, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and paid in kind interest are as follows as of April 30, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Note Principal<br/>Payments</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,285</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,254</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,047</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,617</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total principal payments, including End of Term Charge</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,203</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of April 30, 2024, based on borrowing rates available to the Company for loans with similar terms and consideration of the Company’s credit risk, the carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">April 2023 Notes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2023, Old enGene entered into a note purchase agreement (the “April 2023 Notes”) for a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Quebec), L.P., Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Fond de solidarité des travailleurs du Québec (F.T.Q.), and Forbion Capital Fund III Cooperatief U.A. (collectively the “April 2023 Investors”). The April 2023 Notes had an interest free period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of issuance, and commencing on the 46th day, began to accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum. The April 2023 Notes were classified as current as they matured on the earlier of (i) July 31, 2023; or (ii) the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the completion of the 2023 Financing (as defined below) in May 2023, Old enGene issued convertible debentures and warrants of Old enGene to the April 2023 Note investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, as repayment of the April 2023 Notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the fair value option of accounting for the April 2023 Notes. The Company recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Given the short period of time that the April 2023 Notes were outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> change in fair value was recorded during the three months ended April 30, 2023. The April 2023 Notes were extinguished in May 2023 as part of the issuance of the May 2023 Notes (see Note 9).</span></p> 20000000 7000000 4000000 2022-06 9000000 0.0635 2025-07-01 0.0825 0.0325 0.0825 0.0825 0.0815 0.03 0.02 0.01 0.183 11000000 1100000 0.025 84714 34 48978 23 P10Y 2.632 50000000 22500000 8600000 7500000 P60D 2025-03-31 0.0075 20000000 2028-01-01 0.055 0.7 2028-01-01 0.0075 0.0975 0.0925 0.0115 2025-07-01 2026-01-01 2026-07-01 0.1238 0.03 0.02 0.01 400000 400000 22500000 2100000 0.02 7.21 P7Y 138696 62413 300000 22500000 138696 0.02 50000000 7.21 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024 and October 31, 2023, the carrying value of the term loans consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note payable, including End of Term Charge</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,530</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,144</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount, net of accretion</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,974</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">474</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note payable, net of discount</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,730</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,778</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 24530000 10144000 1974000 474000 174000 108000 22730000 9778000 600000 700000 400000 100000 100000 1300000 900000 300000 200000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and paid in kind interest are as follows as of April 30, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Note Principal<br/>Payments</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,285</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,254</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,047</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,617</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total principal payments, including End of Term Charge</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,203</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 0 3285000 8254000 9047000 4617000 25203000 8000000 P45D 0.15 20000000 8000000 0 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Debentures</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Old enGene had issued convertible debentures to various investors. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding principal, accrued interest, and unamortized deferred financing costs of the convertible debentures recorded on the balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024 and October 31, 2023, as the convertible debentures were converted and exchanged for common shares of the Company or repaid upon the closing of the Reverse Recapitalization. Refer to Note 3.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BDC Notes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, Old enGene issued a convertible debenture to the Business Development Bank of Canada (“BDC”) in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the “BDC Notes”). The debt bears interest at rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum and had an initial maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 28, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In December 2021 Old enGene amended the agreement which resulted in the maturity date extending to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 29, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The BDC Notes were convertible at the option of the holder into Old enGene's Class B redeemable convertible preferred shares at a price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the price paid per share in qualified financing, as defined within the BDC convertible debenture agreement. The issuance of the Prior Term Loan in 2021 met the definition of a qualified financing per the BDC convertible debenture agreement. As the conversion option was not exercised upon the issuance of the Prior Term Loan, the conversion rights upon a qualified financing were waived. There were optional conversion options that existed if Old enGene is in default, or in the event of certain liquidation events, as defined within the BDC Notes, which allow for conversion of the BDC Note into the most senior share outstanding at the time of the event. If a liquidation event, as defined within the BDC Note agreement, and which included a SPAC transaction, is consummated after a qualified financing, and optional conversion is not elected, the Company is required to pay the investor in cash, the outstanding principal and the accrued but unpaid interest and in addition an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon issuance of the BDC Notes, Old enGene identified embedded derivatives related to the equity conversion features and liquidity event repayment features which required bifurcation as a single compound derivative instrument. Old enGene estimated the fair value of the embedded derivative liabilities upon issuance at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Old enGene remeasured the fair value of the embedded derivatives in effect at each reporting period, with the subsequent changes in the fair value of the derivative being recognized in changes in fair value of derivatives within the Company’s consolidated statements of operations and comprehensive loss. During the three and six months ended April 30, 2023, Old enGene recorded a change in fair value on the convertible debentures embedded derivative liability associated with the BDC Note of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Total interest expense for the BDC Notes, including the amortization of debt discounts, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three and six months ended April 30, 2023. As part of the issuance of the BDC Notes, Old enGene incurred an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the BDC Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. Upon the close of the Reverse Recapitalization the Company repaid the BDC Note, resulting in full settlement of the note.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Notes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended October 31, 2022, Old enGene issued convertible debentures for an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on October 20, 2022 (the “2022 Notes”). The 2022 Notes had an initial maturity that is the later of (i)</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of issuance; or (ii) the maturity date of the Prior Term Loan (see Note 8). The 2022 Notes bear interest at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum commencing on the date of issuance. The 2022 Notes are automatically convertible into common shares or redeemable convertible preferred shares of Old enGene upon certain events. Upon the close of the Reverse Recapitalization, the 2022 Notes were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,081,359</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon issuance of the 2022 Notes, Old enGene identified embedded derivatives related to the equity conversion features which required bifurcation as a single compound derivative instrument. Old enGene estimated the fair value of the embedded derivative liabilities upon issuance at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the three and six months ended April 30, 2023, the Company recorded a loss on the change in fair value associated of 2022 Notes </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cd969707-c528-4abf-9d1d-41289b3db04b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">embedded derivative liability</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Total interest expense for the 2022 Notes, including the amortization of debt discounts, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded for the three and six months ended April 30, 2023. As part of the issuance of the 2022 Notes, the Company incurred an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the 2022 Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023 upon the close of the Reverse Recapitalization, the 2022 Notes were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,081,359</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares of the Company. The Company accounted for the conversion as an extinguishment and recorded a loss on extinguishment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, relating to the difference between the fair value of the common shares issued and the carrying value of the 2022 Notes and fair value of the embedded derivative liability at the time of conversion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">May 2023 Notes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 16, 2023, concurrently with the execution and delivery of the Merger Agreement, Old enGene entered into agreements pursuant to which it agreed to issue new convertible notes and warrants (i) for cash in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and (ii) in repayment of the April 2023 Notes in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (collectively, the "May 2023 Notes” and, together with the warrants purchased concurrently, the "2023 Financing”; the 2023 Financing together with the Amended 2022 Financing, the "Convertible Bridge Financing”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 Financing occurred in two separate issuances with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million issued in May 2023 for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in repayment of the April 2023 Notes, and an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million issued in June 2023 for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, of which Forbion Growth Sponsor FEAC I B.V. funded an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The May 2023 Notes issued as part of the 2023 Financing, if not converted, have an initial maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 20, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are to accrue interest at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum, which is payable upon maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrants issued as part of the 2023 Financing were for the purchase of common shares of Old enGene. The 2023 Warrants were only to become exercisable upon the completion of the merger. Upon the close of the Reverse Recapitalization, the 2023 Warrants were exchanged for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,679,432</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants of the Company and have the same terms as the public warrants issued upon the FEAC initial public offering, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and which will expire five years after the completion of the merger.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrants issued as part of the 2023 Financing were concluded to be liability classified upon issuance, as they failed the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s own stock as prescribed by ASC 815. The terms of the warrants initially required the Company to issue a variable number of shares until the PIPE Financing was executed, at which time the number of warrants became fixed. The 2023 Warrants were initially and subsequently measured at fair value with any changes in fair value recorded as a component of other income and expense within the change in fair value of warrant liabilities. Refer to Note 3. Upon the execution of the PIPE Financing and consummation of the Reverse Recapitalization, the warrants were reclassified to equity as the number of warrants became fixed and it was determined that the warrants met the fixed for fixed criteria that is required for a contract to be considered indexed to the Company’s own stock as prescribed by ASC 815.</span></p> 0 0 2200000 0.08 2023-09-28 2025-09-29 0.80 0.20 200000 200000 100000 60000000 100000 36000 18400000 P3Y 0.10 2081359 3500000 800000 400000 600000 1300000 44000 2081359 3100000 30000000 8000000 28000000 20000000 8000000 10000000 10000000 20000000 38000000 2025-10-20 0.10 2679432 11.5 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Redeemable Convertible Preferred Shares</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of October 31, 2022, Old enGene’s Articles of Amendment had an unlimited number of authorized shares of each class of redeemable convertible preferred shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Class A Redeemable Convertible Preferred Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 26, 2013, Old enGene entered into a subscription agreement (the “Class A Agreement”) with multiple investors, whereby Old enGene agreed to sell to the investors an initial aggregate amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">610,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class A redeemable convertible preferred shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5929</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63845</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total aggregate proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the “Class A Initial Closing”). Included within the Class A Agreement were three additional future tranche obligations (the “Class A Second Tranche,” “Class A Third Tranche” and “Class A Fourth Tranche”) for Old enGene to issue and sell shares of Class A redeemable convertible preferred shares upon the achievement of certain milestone events. Only the Class A Second Tranche closed under the Class A Agreement. The Class A Second Tranche obligated Old enGene to sell and the Class A Investors to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,830,999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A redeemable convertible preferred shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.56967</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63845</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, upon the establishment of the Company’s headquarters in Montreal Quebec and completion of experiments required to bolster a patent application for dually-derivatized chitosan (the “Second Closing Milestone Event”), which occurred in 2013. Additionally, upon completing the Class A redeemable convertible preferred share financing, convertible notes of Old enGene held by multiple investors converted into Class A redeemable convertible preferred shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Class B Redeemable Convertible Preferred Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 6, 2015, Old enGene entered into a subscription agreement (the “Class B Agreement”) with multiple investors, where Old enGene agreed to sell to the investors an initial aggregate amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,758,221</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B redeemable convertible preferred shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.85032</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17532</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the “Class B Initial Closing”). Included within the Class B Agreement were two additional closings (the “Class B Second Tranche,” and the “Class B Third Tranche,” respectively) which obligated Old enGene to sell and Class B investors to purchase additional Class B redeemable convertible preferred shares upon certain events. The Class B Second Tranche obligated Old enGene to sell and the Class B Investors to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,838,815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B Shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63419</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17532</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Class B Third Tranche obligated Old enGene to sell and the Class B Investors to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,608,963</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B Shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63419</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17532</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Class B Second Tranche and Class B Third Tranche closed on March 1, 2017.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Class B-1 Redeemable Convertible Preferred Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 10, 2015, Old enGene entered into a Subscription Agreement (the Class “B-1 Agreement”), in which Old enGene was to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,523,809</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B-1 redeemable convertible preferred shares for a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.64367</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17532</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share, resulting in aggregate proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the year ended October 31, 2020, the Class B-1 redeemable convertible preferred shares converted to common shares on a 1:</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis. Therefore, as of each of the years ended October 31, 2020, October 31, 2021, and October 31, 2022, no shares of the Class B-1 redeemable convertible preferred shares remained outstanding. The Company has presented these shares within temporary equity as of October 31, 2019 within the consolidated statements of redeemable convertible preferred shares and shareholder deficit, as they contained the same redemption features as the Class B redeemable convertible preferred shares (further described above). Upon conversion to common shares, the carrying value of the Class B-1 redeemable convertible preferred shares was reclassified to additional paid in capital within shareholders’ deficit.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Class C Redeemable Convertible Preferred Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Class C redeemable convertible preferred shares are issuable in series, of which an unlimited number are designated as Series 1 Class C redeemable convertible preferred shares with an issue price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5929</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63845</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD); an unlimited number are designated as Series 2 Class C redeemable convertible preferred shares with an issue price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.85032</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.175315</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD); an unlimited number are designated as Series 3 Class C redeemable convertible preferred shares with an issue price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.12376</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD); and an unlimited number are designated as Series 4 Class C redeemable convertible preferred shares that is reserved for the potential conversion of the BDC Notes, and will each have an issue price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.69901</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2021, Old enGene entered into a subscription agreement (the “Class C Agreement”) with multiple investors, where Old enGene agreed to sell to the Investors an initial aggregate amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,662,813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series 3 Class C redeemable convertible preferred shares (the “Series 3 Class C Shares”) at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.12376</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the “Class C Initial Closing”). Included within the Class C Agreement was one additional closing (the “Class C Second Tranche”) which obligated Old enGene to sell and Class C investors to purchase additional Class C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class C Second Tranche obligated Old enGene to sell and the Class C investors to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,662,810</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series 3 Class C Shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.13192</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share for total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Class C Second Tranche closed on October 29, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of each of the Class C Initial Closing and Class C Second Tranche, each Class C investor received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,662,813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,662,810</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants, respectively, to purchase Class C redeemable convertible preferred shares (the “Class C Warrants”), resulting in an aggregate issued amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,325,623</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class C Warrants. The Class C Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.12376</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Class C Warrants were determined to be liabilities. The Company estimated the fair value of the warrant liabilities upon issuance and remeasured the fair value of the warrant liabilities at each reporting period, with the subsequent changes in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabilities within the Company’s consolidated statements of operations and comprehensive loss. Upon the completion of the Reverse Recapitalization, all existing Class C Warrants of Old enGene were extinguished.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Class C Agreement, certain convertible notes held by various Class C investors and other investors were exchanged for an aggregate amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,464,646</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B redeemable convertible preferred shares. Additionally, upon entering into the Class C Agreement, Old enGene also entered into a share exchange agreement (the “Share Exchange Agreement”) with the Class A investors and the Class B investors. As part of the Share Exchange Agreement, certain of the Class A redeemable convertible preferred shares issued to Class A investors were exchanged for Series 1 Class C redeemable convertible preferred shares and certain of the Class B redeemable convertible preferred shares issued to the Class B investors were exchanged for Series 2 Class C redeemable convertible preferred shares. This exchange resulted in the derecognition of Class A and B redeemable convertible preferred shares and the recognition of Class C redeemable convertible preferred shares at the fair value of the Class C redeemable convertible preferred shares. The difference between the carrying value of the Class A and Class B redeemable convertible preferred shares and the fair value of the Class C redeemable convertible preferred shares for which they converted into was recorded within additional paid in capital and no gain or loss on extinguishment was recorded within the consolidated statements of operations and comprehensive loss. Further, the February 2020 Warrants, June 2020 Warrants, and 2021 Warrants, which consisted of warrants to purchase Old enGene's Class B redeemable convertible preferred shares and were issued as part of the convertible debentures were cancelled and replaced by the terms of the Class C Warrants. The aggregate amount of outstanding warrants of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,242,130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the February 2020 Warrants, the June 2020 Warrants, and the 2021 Warrants converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,242,130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class C Warrants, which have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.12376</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD) per share and a term expiring on</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> February 14, 2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Immediately prior to conversion, the warrants were marked to fair value, with the change in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabilities within the Company’s consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon issuance of each series of Class A, Class B, and Class C Preferred Shares, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion of Redeemable Convertible Preferred Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, upon the consummation of the Reverse Recapitalization, each share of Old enGene’s redeemable convertible preferred shares issued and outstanding immediately prior to the close was exchanged for common shares of the Company using the Exchange Ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.18048</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. A retrospective adjustment has been applied to all periods presented to reflect the Reverse Recapitalization. Refer to Note 3 for additional discussion.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Undesignated Preferred Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue an unlimited number of preferred shares with no par value. The preferred shares are currently undesignated.</span></p> 610333 1.5929 1.63845 1000000 1830999 1.56967 1.63845 2900000 2758221 1.85032 2.17532 5100000 1838815 1.63419 2.17532 3000000 1608963 1.63419 2.17532 2600000 1523809 1.64367 2.17532 2500000 1 1.5929 1.63845 1.85032 2.175315 2.12376 2.632 1.69901 2.10559 3662813 2.12376 2.632 7800000 3662810 2.13192 2.632 7800000 3662813 3662810 7325623 2.12376 2.632 P10Y 16464646 10242130 10242130 2.12376 2.632 2030-02-14 0.18048 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_be33b9b0-4cb2-4585-b486-61bb7726f3b8;"><span style="-sec-ix-hidden:F_26ff2af4-1415-48d5-bfaa-b03b0ea9edda;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unlimited </span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">number of Common Shares authorized shares for issuance, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024 and October 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,158,587</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,197,976</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares outstanding, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares are entitled to one vote</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share held on all matters submitted to a vote of shareholders. Common shareholders are entitled to receive dividends, as may be declared by the board of directors, or the "Board", if any, subject to the preferential dividend rights of preferred shares. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends had been declared or paid.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 13, 2024, the Company entered into subscription agreements (collectively, the "2024 Subscription Agreements”) with the investors named therein, for the private placement (the "2024 PIPE Financing") of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of the Company,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The aggregate gross proceeds from the 2024 PIPE Financing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The 2024 PIPE Financing closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 20, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants to purchase Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and October 31, 2023, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,511,968</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,411,641</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants to purchase Common Shares outstanding, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the warrants to purchase Common Shares outstanding as of April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,449,555</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> have the same terms as the FEAC public warrants issued in connection with FEAC’s IPO, and have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and are exercisable beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the completion of the Reverse Recapitalization and which will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 31, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the completion of the Reverse Recapitalization. Through April 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">383,355</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares have been issued as a result of the exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,379,391</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants on a cashless basis and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">520,282</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares have been issued through cash exercises of warrants for proceeds totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of Common Shares to be issued upon the cashless exercise is equal to the quotient obtained by dividing (x) the product of the number of shares underlying the warrants, multiplied by the excess of the “Fair Market Value” over the warrant exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by (y) the Fair Market Value. The Fair Market Value is the volume weighted average price of the shares for the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Company’s Warrant Agent from the holder or its broker or intermediary. The warrants had a cashless exercise period until such time as the registration statement under the Securities Act with respect to the enGene Common Shares underlying the enGene Warrants was declared effective, which occurred on March 5, 2024. The Company may elect to call in the warrants for a redemption if the share price of the Company reaches redemption trigger price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">62,413</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the warrants to purchase Common Shares outstanding as of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, were issued as part of the Amended Term Loan on December 22, 2023, have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">7.21</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and are exercisable at any time beginning on December 22, 2023 expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 22, 2030</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the issuance date. The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company’s common shares as prescribed by ASC 815.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024, and October 31, 2023, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the Company's 2023 Plan ( as defined below):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30,</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31,</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase Common Shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,511,968</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,411,641</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase Common Shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981,433</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining shares reserved for future issuance under<br/>   the 2023 Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,222,703</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,607,943</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,716,104</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,726,525</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 0 44158587 23197976 Common Shares are entitled to one vote 0 20000000 10 200000000 12400000 2024-02-20 8511968 10411641 8449555 11.5 P30D 2028-10-31 P5Y 383355 1379391 520282 6000000 11.5 18 62413 7.21 2030-12-22 P7Y <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024, and October 31, 2023, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the Company's 2023 Plan ( as defined below):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 30,</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 31,</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase Common Shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,511,968</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,411,641</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase Common Shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981,433</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining shares reserved for future issuance under<br/>   the 2023 Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,222,703</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,607,943</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,716,104</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,726,525</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 8511968 10411641 3981433 2706941 3222703 2607943 15716104 15726525 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-Based Compensation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Reverse Recapitalization, upon the Closing Date, each outstanding option to purchase Old enGene’s common shares issued under the Old Plan’s was exchanged for an option to purchase common shares of the Company, and the number of shares and exercise price of each granted option was adjusted using the exchange ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.18048</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Further, the currency of all exercise prices of the options issued under the Old Plans were converted from CAD to USD using the exchange rate in effect on the day immediately prior to the Closing Date. A retrospective adjustment has been applied to the number of options and exercise price of stock options for all periods presented to reflect the Reverse Recapitalization as discussed further in Note 3.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Old Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Old enGene had an employee share option plan (the “ESOP”) and an equity incentive plan (the “EIP”) (collectively, the “ Old Plans”) which was adopted by the Board of Directors, and approved by the shareholders, effective July 5, 2018.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Old Plans, options to purchase non-voting common shares of Old enGene’s shares may be granted to directors, officers, employees, consultants and members of the scientific advisory board. The Old Plans provide for the issuance of stock options up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate issued and outstanding common shares and non-voting common shares of Old enGene calculated on an as converted and fully diluted basis. The Old Plans were administered by Old enGene’s Board of Directors. Old enGene’s Board of Directors determined the number of options to be granted, the vesting period and the exercise price of new options. It was Old enGene’s policy to establish the exercise price at an amount that approximates the fair value of the underlying shares on the date of grant as determined by Old enGene’s Board of Directors. The options vest in accordance with the vesting terms determined for each grant by Old enGene’s Board of Directors. The vesting terms of Old enGene’s granted stock options with service only conditions are typically </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting immediately upon grant date, or over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_17c40e14-c76d-417d-be4e-9c23142e8fd8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">- or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> service period. Upon the consummation of the Reverse Recapitalization, the Company recognized stock based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the acceleration of the vesting for the outstanding awards with service only vesting conditions under the Old Plan. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized compensation cost remains for the outstanding awards granted under the Old Plan with service only vesting conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 7, 2023, the Board of Directors approved the reservation of an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,046,764</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> non-voting common shares for issuance under the Company’s employee equity incentive plan, revising the number of shares reserved from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,775,729</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,822,493</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Also on July 7, 2023, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,046,764</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to employees at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> USD). These options are not exercisable unless and until the completion of the Reverse Recapitalization and there is an effective registration statement for the shares underlying such granted options and will terminate automatically in the event of the termination of the Merger Agreement. The Company has valued these awards at the grant date using Black-Scholes pricing model in which the fair value of the stock on the grant date was equal to the exercise price of the award. The expected term has been determined using management’s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers. Upon the grant date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">794,643</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the issued options were fully vested, and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">252,121</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options will vest over varying terms up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on a pro rata basis. The Company recognizes compensation expense when achievement of the performance condition is deemed probable using an accelerated attribution method, as if each vesting tranche was treated as an individual award. During the year ended October 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of stock based compensation expense was recorded associated with the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,046,764</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options granted in July 2023 because the Reverse Recapitalization was completed and the Company determined that the filing of the registration statement was probable to occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the consummation of the Reverse Recapitalization on October 31, 2023, all options outstanding under the Old Plans were exchanged for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares options to purchase common shares of the Company based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement. Further, all exercise prices were adjusted by the Exchange Ratio and the currency of the exercise prices was changed from CAD to USD based on the exchange rate in effect on October 30, 2023, the day immediately before the consummation of the Reverse Recapitalization. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> incremental compensation cost was recorded as a result of the change in underlying common shares from Old enGene to the Company, or as a result of the change of the exercise prices to reflect the adjustment for the Exchange Ratio and the change in currency from CAD to USD, as it was concluded that the fair value of the awards immediately before and immediately after the modifications did not change. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options remain available for grant under the Old Plans as of October 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The 2023 Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023, upon the completion of the Reverse Recapitalization, the shareholders approved and the Company adopted the enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which superseded the Old Plans. The 2023 Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Stock Units, Stock Appreciation Rights, or SARs, and other share-based awards including performance awards and share bonus awards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares initially reserved for issuance under the 2023 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,607,943</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares subject to the outstanding grants under the Old Plans, and shall automatically increase on January 1 of each calendar year beginning in 2024 by a number of shares equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,946,226</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Common Shares and such lesser number as may be determined by the Board. The Common Shares authorized under the 2023 Plan increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,946,225</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2024. As of April 30, 2024, the total number of Common Shares reserved for issuance under the 2023 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,261,110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,929,643</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remaining for issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board. The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the Common Shares on the date of grant and the term of stock option may not be greater than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Common Shares that are expired terminated, surrendered or cancelled under the 2023 Plan without having been fully exercised will be available for future awards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 15, 2024, the shareholders of the Company approved changes to the 2023 Plan. See Note 18 for additional information.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions that the Company used to determine the grant-date fair value of stock options during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024 and 2023 are summarized below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.642%;"></td> <td style="width:1%;"></td> <td style="width:1.82%;"></td> <td style="width:1%;"></td> <td style="width:10.042%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:7.001%;"></td> <td style="width:1%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:9.482000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.75 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.75</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81.39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.24</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81.39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.27</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.56</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.27</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.56</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares and exercise price of options (USD)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.80</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.55</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.80</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.55</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares and exercise price of options (CAD)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.11</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.11</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company’s stock option activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price (USD)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of October 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.40</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,192</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,331,700</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.49</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">56,974</span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.89</span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited or expired</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.89</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of April 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981,433</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.69</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,181</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable as of April 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,434,737</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,597</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options unvested as of April 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546,696</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.35</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.7</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,584</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company’s common share as of each reporting period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant-date fair value per share of share options granted during the three and six months ended April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The weighted-average grant date fair value per share of share options granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CEO Modification</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 13, 2024, the Company entered into a Transition and Modified Employment Agreement (the "Transition Agreement") with the Company's Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement dated November 8, 2023 (the “Amended Employment Agreement”). Under the terms of the Amended Employment Agreement the CEO will be entitled to:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months of continued health insurance benefits; </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of a prorated portion of his 2024 target annual bonus; </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceleration and vesting of any then unvested time-based equity awards that would have vested in the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period following such termination; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of the CEO’s vested equity awards extend beyond the respective applicable term thereof.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Transition Agreement further provides that, in the event the CEO resigns upon the appointment by the Company of a new chief executive officer, the CEO will be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of resignation (the “Consulting Period”) in exchange for a monthly fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the initial </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Consulting Period, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per hour thereafter, provided that the CEO need not devote more than fifteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) hours per week to providing such transition services.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the Transition Agreement, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,216,266</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock option awards issued to the CEO were modified to allow for an extended exercise period described above. The modification resulted in an incremental share-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which was recorded upon the effective date of the Transition Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Amended Employment Agreement, (a) upon the termination of Mr. Hanson’s employment by the Company without Cause (as defined in the Amended Employment Agreement) or by Mr. Hanson for Good Reason (as defined in the Amended Employment Agreement), in addition to the above severance benefits, Mr. Hanson will also be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">’ base salary continuation or, if such even occurs during a change of control period (as described in the Amended Employment Agreement), </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">’ base salary continuation.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.671%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:9.702%;"></td> <td style="width:1%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:7.782%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:8.002%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:8.522%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">530</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,580</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,678</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,208</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized compensation, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p> 0.0018048 0.15 1 P4Y 400000 0 1046764 1775729 2822493 1046764 5.87 4.24 794643 252121 P4Y 2600000 1046764 2706941 0 0 2607943 2706941 1946226000000 1946225 7261110 5929643 1 P10Y <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions that the Company used to determine the grant-date fair value of stock options during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024 and 2023 are summarized below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.642%;"></td> <td style="width:1%;"></td> <td style="width:1.82%;"></td> <td style="width:1%;"></td> <td style="width:10.042%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:7.001%;"></td> <td style="width:1%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:9.482000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.75 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.75</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81.39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.24</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81.39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.27</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.56</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.27</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.56</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares and exercise price of options (USD)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.80</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.55</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.80</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.55</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares and exercise price of options (CAD)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.11</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.11</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> P5Y9M P6Y29D P6Y29D P5Y9M P6Y29D P6Y29D 0.783 0.7892 0.8139 0.7824 0.7892 0.8139 0.0427 0.0466 0.0356 0.0427 0.0466 0.0356 14.8 17.8 1.55 7.66 17.8 1.55 2.11 2.11 <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company’s stock option activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price (USD)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of October 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,706,941</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.40</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,192</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,331,700</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.49</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">56,974</span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ccecff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.89</span></p></td> <td style="background-color:#ccecff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited or expired</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.89</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of April 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981,433</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.69</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,181</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable as of April 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,434,737</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,597</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options unvested as of April 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546,696</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.35</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.7</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,584</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 2706941 2.4 P8Y1M6D 52192000 1331700 12.49 56974 0.89 234 0.89 3981433 5.69 P8Y4M24D 41181000 2434737 2.1 P7Y7M6D 33597000 1546696 11.35 P9Y8M12D 7584000 11.6 8.87 1.5 1.5 P12M 25000 P6M 500 PT15H 1216266 1000000 P12M P18M <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.671%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:9.702%;"></td> <td style="width:1%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:7.782%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:8.002%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:8.522%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">530</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,580</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,678</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,208</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 337000 7000 530000 12000 1580000 32000 1678000 47000 1917000 39000 2208000 59000 11300000 P3Y7M6D <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the Reverse Recapitalization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:36.7%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:12.782%;"></td> <td style="width:1%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:10.656%;"></td> <td style="width:1%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:13.035%;"></td> <td style="width:1%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:13.769000000000002%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,984</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,282</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,695</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,700</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed dividend attributable to redeemable convertible<br/>   preferred shareholders</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,175</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,389</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common shareholders, basic and<br/>   diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,984</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,457</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,695</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,089</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares used in net<br/>   loss per share, basic and diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,443,768</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">694,497</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,186,238</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">680,003</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.38</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.30</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.82</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.19</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024 and 2023 because including them would have had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.392%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:16.323%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:16.323%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three and Six Months Ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redeemable convertible preferred shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,983,339</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase redeemable convertible preferred shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,194,756</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,511,968</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981,433</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,620,599</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493,401</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,798,694</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the Reverse Recapitalization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:36.7%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:12.782%;"></td> <td style="width:1%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:10.656%;"></td> <td style="width:1%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:13.035%;"></td> <td style="width:1%;"></td> <td style="width:1.266%;"></td> <td style="width:1%;"></td> <td style="width:13.769000000000002%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,984</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,282</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,695</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,700</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed dividend attributable to redeemable convertible<br/>   preferred shareholders</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,175</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,389</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common shareholders, basic and<br/>   diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,984</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,457</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,695</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,089</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares used in net<br/>   loss per share, basic and diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,443,768</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">694,497</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,186,238</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">680,003</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.38</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.30</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.82</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.19</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> -14984000 -5282000 -25695000 -12700000 1175000 2389000 -14984000 -14984000 -6457000 -6457000 -25695000 -25695000 -15089000 -15089000 39443768 39443768 694497 694497 31186238 31186238 680003 680003 0.38 0.38 9.3 9.3 0.82 0.82 22.19 22.19 <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024 and 2023 because including them would have had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.392%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:16.323%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:16.323%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three and Six Months Ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redeemable convertible preferred shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,983,339</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase redeemable convertible preferred shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,194,756</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,511,968</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981,433</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,620,599</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493,401</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,798,694</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 0 0 5983339 5983339 0 0 3194756 3194756 8511968 8511968 0 0 3981433 3981433 1620599 1620599 12493401 12493401 10798694 10798694 <div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in income tax provision. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended April 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in income tax benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of April 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has maintained a full valuation allowance against its remaining net deferred tax assets.</span></p> 21000 0 -9000 0 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s leases are comprised of operating leases for office and lab space.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into an office and lab space lease approximating </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,360</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of rentable square feet for designated office and lab spaces located at 7171 Frederick-Banting, City of Montreal, judicial district of Montreal, Province of Quebec. The leased commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and had an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months that would have expired on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 31, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and includes </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options to renew</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> periods </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon landlord consent at new lease rates. As the Company has elected</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not recognize leases with a lease term of 12 months or less on the balance sheet, this was considered a short-term lease, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating lease right of use assets and liabilities were recognized. In October 2022, the Company entered into a lease amendment to extend the lease for an additional term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the lease through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In April 2023, the Company extended the lease through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease was further extended through November 5, 2023, at which time the Company vacated the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 29, 2022, the Company signed a lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,620</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, beginning on the commencement date, and requires an annual initial base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAD per square foot, which is subject to annual increases of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2024, the Company entered into a lease agreement, in which the Company is sub-leasing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,450</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the initial term of the lease, which is set to expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 30, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and does </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024 and 2023, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.24%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.2%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.46%;"></td> <td style="width:1%;"></td> <td style="width:2.44%;"></td> <td style="width:1%;"></td> <td style="width:9.2%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.46%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease Cost:</span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable operating lease cost</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term operating lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease cost</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">244</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of the Company's operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024 are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.732%;"></td> <td style="width:20.408%;"></td> <td style="width:1%;"></td> <td style="width:33.86%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining)</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">468</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">303</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,722</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,545</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Lease liability</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,954</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 9360 2021-11 P12M 2022-10-31 true P12M 0 0 P6M 2023-04 true 2023-09 2023-09 10620 P10Y 36.5 0.02 2023-11 1400000 1400000 6450 500000 2026-12-30 false 400000 400000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended April 30, 2024 and 2023, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.24%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.2%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.46%;"></td> <td style="width:1%;"></td> <td style="width:2.44%;"></td> <td style="width:1%;"></td> <td style="width:9.2%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.46%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six months ended April 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease Cost:</span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable operating lease cost</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term operating lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease cost</span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">244</span></p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 119000 209000000 16000 24000000 32000000 106000 212000000 119000 122000 233000000 244000000 <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of the Company's operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2024 are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.732%;"></td> <td style="width:20.408%;"></td> <td style="width:1%;"></td> <td style="width:33.86%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining)</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">468</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">303</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,722</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,545</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Lease liability</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,954</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 223000 456000 468000 327000 303000 1722000 3499000 1545000 1954000 <div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of April 30, 2024, and October 31, 2023, there were no matters which would have a material impact on the Company’s financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended April 30, 2024 the Company had the following transactions with related parties:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 20, 2024, the Company completed the 2024 PIPE Financing, which provided for the private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and included both new and existing investors. One of the Company's director's, Mr. Gerry Brunk, is a managing director of Lumira Ventures ("Lumira"), and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares for a total price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the Company's 2024 PIPE Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended April 30, 2023 the Company had the following transactions with related parties:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2023, the Company entered into the April 2023 Notes for a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with the April 2023 investors, as described in Note 8. The April 2023 Notes had an interest free period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of issuance, and commencing on the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46th day, is to accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum. The April 2023 Notes had a maturity date which was the earlier of (i) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 31, 2023</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; or (ii) the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the completion of the 2023 Financing, which met the definition of a qualified financing as defined within the April 2023 Notes, the Company issued and aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of convertible debentures and warrants of the Company to the April 2023 Note investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, for the extinguishment and settlement of the April 2023 Notes.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 20000000 10 800000 8000000 8000000 P45D 0.15 2023-07-31 20000000 8000000 <div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Events </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated subsequent events through the date these financial statements were issued. Except as noted below, the Company concluded that no additional subsequent events have occurred that require disclosure.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 15, 2024, the shareholders of the Company approved changes to the 2023 Plan. The original 2023 Plan contained an evergreen provision (the “Evergreen Provision”) pursuant to which, commencing with the first business day of each calendar year beginning in 2024, the aggregate number of the Company’s Common Shares that could be issued or transferred thereunder (the “Plan Share Reserve”) and the number of Common Shares available for options intended to qualify as incentive stock options (the “ISO Sublimit”) each increased by a number of Common Shares equal to the lesser of (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,946,226</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Common Shares and (y) such lesser number of Common Shares as may be determined by the Compensation Committee. Pursuant to the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, on May 15, 2024, the Evergreen Provision was amended to provide for annual increases on the first business day of each calendar year of (i) the Plan Share Reserve by such number of Common Shares as equals </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate number of Common Shares outstanding on the final day of the immediately preceding calendar year (or such smaller number of shares as is determined by the compensation committee), and (ii) the ISO Sublimit by the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares and the increase in the Plan Share Reserve (or such smaller number of shares may be determined by the compensation committee of the Company’s board of directors).</span></p> 1946226000000 0.05 2500000 April 19, 2024 Anthony Cheung Chief Technology Officer true 250000 197060 true October 31, 2025 false false false false

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�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